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Summary 
Tissue resident macrophages are a highly heterogeneous cell type present in every 
mammalian tissue, where they have a critical role in innate immune defence and tissue 
homeostasis. Tissue-specific master regulators have been identified in different tissue-
resident macrophage populations, which regulate macrophage tissue-specific 
phenotype and function through the induction and maintenance of specific 
transcriptional programs. However, it is largely unclear how transcriptional master 
regulators control tissue-specific macrophage phenotype during the initiation of the 
inflammatory response and the resolution thereof. Genetic deletion of these tissue-
specific transcriptional regulators typically results in the ablation of the specific 
macrophage populations, such as the loss of splenic red pulp macrophages in of Spi-C 
deficient mice. Conversely, genetic deletion of Gata6 in macrophages does not 
completely ablate the population of peritoneal macrophages, albeit it leaves them at 
reduced numbers. Thus, Gata6-deficient pMϕs provide a unique tool to investigate 
how tissue-specific transcription factors regulate macrophage function during 
homeostasis and in response to environmental stimuli, such as those encountered 
during inflammation. As such, the work presented in this thesis aimed to characterise 
the role that Gata6 has during the inflammatory response of peritoneal macrophages, 
to identify mechanisms by which it regulates inflammatory processes, and to try and 
identify whether other GATA family members had analogous roles in other myeloid 
cells. Several key findings were generated during the studies presented in this thesis. 
Gata6-deficient macrophages were found to have dysregulated production of TNF, as 
well as the NLRP3- and caspase-1-dependent release of IL-1β in response to LPS 
stimulation alone. Interestingly, the aberrant release of pro-inflammatory cytokines 
from Gata6-deficient pMϕs was attenuated by co-culturing with pMϕs from Gata6-
WT mice, suggesting that Gata6 might release soluble factors that mediate the 
resolution of inflammation. I identified prostacyclin synthase to be highly expressed 
in resident pMϕs and show that it’s expression was greatly reduced in Gata6-deficient 
pMϕs. Consequently, the production of prostacyclin was severely diminished in 
Gata6-deficient pMϕs following LPS stimulation compared to those from Gata6-WT 
mice. Treatment of LPS-stimulated Gata6-deficient pMϕs with beraprost, a 
prostacyclin analogue, restored pro-inflammatory cytokine production comparable to 
pMϕs from Gata6-WT mice. The transcription factor GATA3 was found to be 
vi 
 
selectively up-regulated in Langerhans cells (LCs) generated in vitro from the MUTZ-
3 cell line compared to the precursors. However, the knockdown of GATA3 expression 
with shRNAs did not affect the development, maintenance, or phenotype of LCs in 
this model. 
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1.1 Macrophages 
1.1.1 Historical perspective 
Over a century ago, Élie Metschnikoff described the uptake of foreign material by specialised 
digestive cells in turbellarian worms (Metschnikoff, 1878). These observations provided the 
foundations for his seminal work showing the clearance of foreign particles from tissues by 
migratory devouring cells he named ‘phagocytes’ (from the Greek ‘phago’, meaning ‘devour’, 
and ‘cytos’ meaning ‘cell’(Metschnikoff, 1884). Although the description of phagocytosis had 
been described earlier, reviewed by (Stossel, 1999), Metschnikoff’s seminal work and 
proceeding experiments demonstrated that phagocytosis was critical in the host response 
against infectious agents such as bacteria (Metschnikoff, 1902, Metschnikoff, 1888, 
Metschnikoff, 1887). He later categorized phagocytes as macrophages and microphages (now 
called neutrophils) in multiple organs and noted the cellular heterogeneity. Furthermore, he 
showed that macrophages are not only important for host cell defence but also as scavengers 
of degenerating host cells (Metschnikoff, 1887). Metschnikoff is considered to be the father of 
natural immunity, and his work formulated the theory of immunity by phagocytosis (Gordon, 
2008). 
 
1.1.2 Macrophage ontogeny 
Over the last few years, the field of macrophage ontogeny has evolved rapidly. For decades, 
the prevailing dogma was that tissue-resident macrophage populations were derived from 
blood-circulating monocytes, arising from progenitors in the bone marrow (BM). This concept 
was the foundation of the ‘mononuclear phagocyte system’ (MPS), suggested by Van Furth 
and colleagues in the 1970s. This concept was supported by numerous studies which 
demonstrated: BM cells and monocytes could differentiate into macrophages in vitro and, 
adoptively transferred labelled monocytes migrated into tissue and differentiated into 
macrophages within tissues. However, this view has been challenged by the results of lineage-
tracing studies, which indicate that embryonic precursors give rise to many tissue-resident 
macrophage populations (Figure 1.1). In adulthood, some of these tissue-resident macrophages 
such as microglia and Langerhans cells (LCs) maintain themselves largely independent of 
blood-borne monocytes, through longevity and self-renewal (Ginhoux et al., 2010, Schulz et 
al., 2012, Hashimoto et al., 2013, Yona et al., 2013). Conversely, some tissue-resident 
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macrophage populations such as those of the dermis and lamina propria are thought entirely 
derived from circulating monocytes (Bain et al., 2014, Varol et al., 2009). In the steady state, 
most other tissues are composed of a mixture of embryonically-derived and monocyte-derived 
macrophages, which varies between tissues. Recent studies indicate that monocyte-derived 
macrophages slowly repopulate some tissues and displace the embryonically-derived 
population. For instance, Ly6C+ monocytes were shown to constitutively enter the peritoneal 
cavity, where they matured and subsequently replaced the embryonic population with age. 
Interestingly, this process was highly gender specific and demonstrated that the embryonic 
population were not proliferatively exhausted (Bain et al., 2016). Furthermore, the monocyte-
derived cells were found to acquire Gata6 and CD102, two markers of mature peritoneal 
macrophages (pMϕs) in adult mice (Gautier et al., 2014, Okabe and Medzhitov, 2014, Rosas 
et al., 2014). However, these cells failed to express the phagocytic receptor Tim4, which has 
been shown to be expressed by resident pMϕs. Thus, extensive transcriptional and functional 
studies are needed to determine whether monocyte-derived pMϕs are capable of adopting the 
full phenotype and function of the embryonic cells they replace. 
During the development of mammalian embryos, haematopoiesis consists of a tightly regulated 
stepwise process which begins in the yolk sac, passes through the fetal liver and eventually to 
the bone marrow, which is the location of haematopoiesis in adults (Figure 1.1). In developing 
mouse embryos, haematopoiesis begins in the yolk sac (primitive haematopoiesis), producing 
erythrocytes and macrophages. Primitive haematopoiesis is replaced by a transient wave of 
definitive haematopoiesis, which generates erythroid myeloid progenitors (EMPs) (McGrath 
et al., 2011, Bertrand et al., 2007). Furthermore, definitive haematopoiesis in the aorta-gonad-
mesonephros (AGM) region in the embryonic mesoderm generates haematopoietic stem cells 
(HSCs), which populate the fetal liver at around embryonic day 10.5 (E10.5). 
Thus, most tissue-resident macrophages develop locally and independently from those in other 
tissues, irrespective of their common lineage and embryonic-precursor origin. Furthermore, 
different tissues are composed of a mixture of embryonically-derived and monocyte-derived 
macrophages, for which recent studies suggest that in some tissues, monocyte-derived 
macrophages displace the embryonically-derived macrophages with age. However, it is 
currently unclear whether macrophages of different origin are functionally interchangeable and 
how this impacts tissue-resident macrophage identity and function at the steady state and during 
inflammation. Recent evidence suggests that environmental cues rather than ontogeny 
predominantly influence tissue-resident macrophage transcriptional programs and function 
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during the steady state (see 1.1.4 Macrophage transcription factors). However, whether BM-
derived macrophages can recapitulate all functions and homeostatic features of the pre-existing 
embryonic macrophages they replace, especially in response to chronic inflammation, remains 
to be fully investigated. 
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Figure 1.1 | Tissue-resident macrophage origin during steady state. 
Most tissue-resident macrophage populations in the steady state arise from embryonic 
precursors (embryonic-macrophages) independently of BM-derived monocytes, except for 
dermal macrophages and intestinal macrophages. Fate-mapping studies suggest that embryonic 
macrophages derive from yolk sac-derived erythro-myeloid precursors (EMPs). A wave of 
EMPs appear around embryonic day 7.5 (E7.5) in the yolk sac, which colonise the brain and 
other fetal tissues around E9 (fetal macrophages). In parallel, definitive haematopoiesis occurs 
in the aorta–gonads–mesonephros (AGM) from E10.5, that gives rise to haematopoietic stem 
cells (HSCs), which colonise the fetal liver at around E10.5. Haematopoiesis in the fetal liver 
generates monocytes (fetal liver monocytes) around E11.5–E12.5, which migrate to embryonic 
tissues around E13.5-E14.5, where they largely replace the fetal macrophages, with the 
exception of microglia. A late wave of EMPs is thought to contribute to fetal liver 
haematopoiesis from E8.5 and may also contribute to the generation of fetal liver monocytes. 
During adulthood, tissue-resident macrophages are thought to be maintained through self-
renewal and/or longevity (autonomous maintenance), as well as through conventional 
haematopoiesis. The requirement on blood monocytes for macrophage replenishment versus 
autonomous maintenance of tissue-resident macrophages is highly tissue-specific and is 
reported to be increasingly dependent on monocyte replenishment with age. 
  
Peritoneum
Lung
Spleen
Liver
Kidney
Yolk Sac
macrophage
Late EMP-derived 
fetal monocyte
Yolk Sac
EMPs
Early
Late
Fetal liver HSC-derived 
fetal monocyte
Bone marrow
‘Adult’ 
monocyte
HSC
Yolk sac 
macrophage
Microglia
Dermis
Lamina propria
6 
 
1.1.3 Macrophage function and development 
Tissue-resident macrophages are a highly heterogenous cell type, present in every mammalian 
tissue, where they play fundamental roles in development, homeostasis, tissue repair, and host 
defence (Gordon and Taylor, 2005, Wynn et al., 2013). In addition to these roles, macrophages 
perform numerous tissue-specific functions, depending on the tissue in which they reside 
(Davies et al., 2013, Gordon and Plüddemann, 2017). For instance, microglia, the brain-
resident macrophages play a role in synaptic pruning and the clearance of debris. Red pulp 
macrophages in the spleen phagocytose senescent erythrocytes and recycle heme to maintain 
iron homeostasis. pMϕs have been shown to regulate gut immunoglobulin (Ig) A production 
by interacting with peritoneal B-1 cells (Okabe and Medzhitov, 2014). Recently, tissue-resident 
pMϕs were shown to rapidly migrate to the liver following sterile injury via a non-vasculature 
route, whereby they promote repair after hepatic death (Wang and Kubes, 2016). Interestingly, 
it has been known for some time that following intraperitoneal injection of bacterial 
components, pMϕs “disappear”, a phenomenon commonly referred to as the “macrophage 
disappearance reaction” (Barth et al., 1995). This disappearance has been attributed to 
increased tissue adherence, cell death and tissue-emigration through draining lymphatics 
(Davies et al., 2011). Thus, these recent studies provide important functional insights into these 
earlier observations, whereby pMϕs are thought to act as a reservoir of mature macrophages to 
promote tissue repair after acute injury. 
Thus, despite common origins of most tissue-resident macrophages, each tissue-resident 
macrophage population performs distinct tissue-specific functions. Comprehensive 
transcriptional analysis of resident macrophage populations suggested macrophage populations 
from different organs exhibited considerable transcriptional diversity, underlying their tissue-
specific roles (Gautier et al., 2012, Okabe and Medzhitov, 2014). These studies suggest that 
local factors within the environmental niche of each specific tissue-resident macrophage 
population might govern the regulation, maintenance, and functional specialisation of tissue-
resident (Table 1.1). Indeed, earlier studies have demonstrated the importance of tissue-derived 
factors in the development and maintenance of macrophages. For instance, targeted ablation of 
colony stimulating factor 1 (CSF1) showed severe depletion of macrophages in many tissues 
including the skin, brain, bone, liver, and kidney (Cecchini et al., 1994). Furthermore, 
osteoporotic mice which have an inactivating mutation in Csf1, which encodes M-CSF (the 
cognate ligand of CSF1R), showed greatly diminished macrophage populations like those of 
CSF1R-deficient mice (Chitu and Stanley, 2006). However, the loss of M-CSF did not affect 
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LC (60% of wild-type mice) or microglia development to the extent of CSF1R loss, indicating 
that another ligand may be responsible for the maintenance or development of these 
populations (Witmer-Pack et al., 1993). IL-34, a stroma-derived cytokine was subsequently 
shown to bind to CSF-1R, suggesting that this alternative ligand may be responsible for the 
development of LCs and microglia (Lin et al., 2008). Accordingly, IL-34-/- mice were 
selectively deficient of LCs and microglia, but had little impact on BM, splenic, and liver 
macrophages (Wang et al., 2012). Furthermore, LC development is acutely dependent on 
transforming growth factor-beta 1 (TGF-β1), exemplified by the lack of epidermal LCs in TGF-
β1-deficient mice (Borkowski et al., 1996). 
 
1.1.4 Macrophage transcription factors 
Emerging evidence indicates that the phenotypic diversity and specialization of tissue-specific 
macrophages are governed by distinct transcriptional master regulators (Lavin et al., 2014). 
These tissue-specific factors are thought to co-ordinately regulate macrophage identity and 
function in tandem with lineage-specific transcription factors (Medzhitov and Horng, 2009). 
The coordinated action of these transcription factors specifies the tissue-specific gene 
expression of each tissue-resident macrophage population, allowing each subset to perform 
their niche specific functions (Figure 1.2). Furthermore, stimulus-induced transcription factors 
such as NF-κB coordinate the expression of genes that regulate the inflammatory responses. 
Interestingly, the accessibility of binding sites is imparted by tissue- and lineage-specific 
transcription factors (tissue-conditioning), thereby regulating the action of stimulus-induced 
transcription factors (Gosselin et al., 2014, Lavin et al., 2014). The molecular mechanisms 
underlying tissue-imprinting by tissue- and lineage-specific transcription factors are now 
starting to be unravelled, for reviews see (Glass and Natoli, 2016, Amit et al., 2016). 
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Figure 1.2 | Co-ordinate regulation of macrophage function and phenotype. 
Lineage-specific transcription factors together with tissue-specific transcription factors (which 
are influenced by environmental factors) are thought to co-ordinately regulate macrophage 
identity and function. Stimulus-dependent transcription factors such as those activated by 
microbial stimuli regulate a plethora of genes that coordinate immune response. Recent 
evidence suggests that lineage- and that tissue-specific transcription factors regulate the 
accessibility of binding sites, which in turn influences the ability of stimulus-dependent 
transcription factors to elicit gene expression. 
 
1.1.4.1 Lineage specific TFs 
The ETS family transcription factor PU.1 is a critical regulator of hematopoietic development, 
particularly in the myeloid lineage. In mice, complete disruption of Spi1, the gene encoding 
PU.1, results in embryonic and/or new-born lethality. The critical dependence on PU.1 for 
macrophage development is exemplified in knockout models, which have an absence of 
circulating monocytes and mature tissue macrophages (Scott et al., 1994, McKercher et al., 
1996, Iwasaki et al., 2005, Houston et al., 2007). PU.1 is further required by mature 
macrophages to respond to a variety of myeloid growth factors by modulating the expression 
of numerous genes, including those encoding M-CSFR and GM-CSFRα (Zhang et al., 1994, 
Zhang et al., 1996). 
 
1.1.4.2 Tissue-specific TFs 
Tissue-specific transcription factors have recently shown to play a critical role in determining 
the phenotype and function of the tissue-resident macrophages they control. Recent studies 
have identified and demonstrated the importance that tissue-specific transcription factors have 
on the phenotype and function of the tissue-resident macrophages they control (Table 1.1). For 
instance, the transcription factor Spi-C was found to be highly expressed in red pulp 
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macrophages and shown to be essential for their development; Spic-/- mice show a selective 
loss of red pulp macrophages. Similarly, the transcription factor Gata6 was identified to be 
selectively expressed in peritoneal macrophages (Gautier et al., 2012). Conditional knockout 
of the Gata6 gene in myeloid cells using the Cre-lox system (Gata6-KOmye) revealed that whilst 
peritoneal macrophages were still present, they were greatly reduced in number, supporting a 
role for Gata6 in pMΦ persistence under homeostatic conditions (Rosas et al., 2014, Okabe and 
Medzhitov, 2014). The dramatic reduction in the number of pMϕs was attributed to the 
dramatic reduction in aspartoacylase expression (Gautier et al., 2014), however, other reports 
attribute the reduction of peritoneal macrophages to their accumulation in the omentum (Okabe 
and Medzhitov, 2014). Furthermore, the surviving Gata6-deficient pMΦs exhibited gross 
transcriptional defects in a large number of genes, many of which were peritoneal macrophage-
specific genes (Rosas et al., 2014, Okabe and Medzhitov, 2014). As a result of these 
transcriptional defects, Gata6-deficient pMΦs were found to have defects in the control of IgA 
production by B-1 cells and defects in proliferative renewal during homeostasis and in response 
to inflammation (Okabe and Medzhitov, 2014, Rosas et al., 2014). 
 
Table 1.1 | Tissue-resident macrophage populations, environmental cues, and their 
master regulators 
Tissue-resident Mϕ  Transcription factor/s Environmental stimuli 
Alveolar Pparγ CSF2 
Intestinal Runx3 CSF2 
Kupffer LxrA (ID3) CSF1 
Langerhans cell Id2, Runx3 TGFβ, IL-34 
Splenic Marginal zone Lxrα Oxysterols, CSF1 
Microglia Sall1, Mef2C TGFβ, IL-34, CFS1 
Peritoneal Gata6 CSF1, Retinoic acid, 
omental factors 
Splenic Red Pulp SpiC Haem, CSF2 
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Recent studies have demonstrated that these tissue-specific master regulators can be induced 
by stimuli from the tissue microenvironment. Retinoic acid (RA) was found to stimulate Gata6 
expression in peritoneal macrophages and therefore contributes to the tissue-specific 
transcriptional program (Okabe and Medzhitov, 2014). Similarly, Spic expression was found 
to be selectively induced in RPM development by heme, a metabolite of erythrocyte 
degradation (Haldar et al., 2014). Supporting a critical role of the microenvironment on 
imparting tissue-specific transcriptional programs, BM-precursors adoptively transferred into 
irradiated mice acquired 90% of the transcriptional profile of their embryonic-derived 
peritoneal and alveolar macrophages. However, this was tissue-specific as BM-derived Kupffer 
cells acquired less than 50% of the tissue-specific enhancers of their embryonic counterparts 
(Lavin et al., 2014). However, upon conditional deletion of embryonic Kupffer cells, one study 
showed that BM-derived Kupffer cells acquired an almost identical transcriptional profile to 
their embryonic counterparts (Scott et al., 2016). Furthermore, adult tissue-resident peritoneal 
macrophages transplanted into the alveolar cavity of donor animals acquired the chromatin 
landscapes and gene expression similar to alveolar macrophages, although the recovery of 
transplanted pMϕs was low (Lavin et al., 2014). Overall, these results indicate that 
differentiated tissue-resident macrophages retain their plasticity and the critical importance of 
the tissue microenvironment on shaping the phenotype and function of macrophages (Lavin et 
al., 2014, Gosselin et al., 2014). 
 
1.1.4.2.1 The GATA family of transcription factors 
The GATA family of transcription factors are sequence-specific DNA-binding zinc finger 
proteins that are conserved in organisms from yeasts to mammals. The mammalian GATA 
family consists of six members, GATA1-GATA6, each of which displays a distinct and 
restricted pattern of tissue expression, exerting transcriptional control over a wide range of 
cellular processes. Members of the GATA family contain a highly-conserved DNA-binding 
domain composed of two adjacent Cys2/Cys2-type zinc finger motifs. The C-terminal zinc-
finger and its adjacent highly-conserved basic region mediates sequence-specific DNA binding 
to the consensus DNA sequence (A/T)GATA(A/G). The N-terminal zinc finger is responsible 
for the specificity and stability of DNA-binding, but is also capable of binding DNA 
independently, with a preference for GATC core motifs. Both zinc fingers participate in 
binding the palindromic GATA motif ATC(A/T)GATAAG (GATApal), resulting in markedly 
increased affinity (Trainor et al., 1996).  
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1.1.5 Macrophage activation 
In addition to lineage-specific and tissue-specific transcription factors determining macrophage 
phenotype and function, it has long been known that macrophages are able to adopt distinct 
functional phenotypes in response to extrinsic stimuli such as those from cytokines or microbial 
pathogens, which elicit dynamic changes in macrophage transcription, loosely known as 
macrophage activation (Gordon, 2003, Mosser, 2003, Benoit et al., 2008). Similar to 
lymphocyte activation, a dichotomous model for macrophage activation was proposed, the 
M1/M2 paradigm (Mills et al., 2000). These distinct phenotypes are induced by the actions of 
cytokines produced by two major classes of T lymphocyte populations: T helper 1 (Th1) and 
Th2 cells. Th1 cells produce interferon gamma (IFN-γ) whereas Th2 cells secrete interleukin 4 
(IL-4) and IL-13 to promote the M1 and M2 activation states respectively (Nathan et al., 1983, 
Doyle et al., 1994, Stein et al., 1992). Broadly speaking, M1 macrophages (also referred to as 
classical macrophages) are typically described to have important roles in host defence against 
bacterial, viral, and protozoal pathogens (O'Shea and Murray, 2008, Mackaness, 1962, Gordon, 
2007). They have enhanced antimicrobial, inflammatory and antigen-presenting properties, 
whereby they up-regulate and produce a plethora of pro-inflammatory mediators including pro-
inflammatory cytokines and nitric oxide (NO). Conversely, M2 macrophages (also referred to 
as alternatively-activated macrophages) are generally described to have a critical role in the 
resolution of inflammation, producing an array of anti-inflammatory mediators (Gordon and 
Martinez, 2010, Mantovani et al., 2004, Martinez et al., 2008). Furthermore, M2 macrophages 
are thought to be critical in the defence against helminths, drive allergic responses, regulate 
wound healing, and drive fibrosis (Anthony et al., 2006, Murray and Wynn, 2011). The M1/M2 
macrophage activation model has since formed the basis of research into macrophage activity 
ever since (Murray et al., 2014). The use of M1/M2 nomenclature has rapidly expanded, with 
the M1 designation restricted to classical activation, and M2 used to encompass various forms 
of macrophage activation other than M1 (Martinez et al., 2008). However, emerging studies 
have indicated that these macrophage populations may have marked differences in their 
physiology and biochemistry, both in vitro and in vivo. For instance, the M2 designation has 
been used to describe ‘type-II activated macrophages’, which like M2/alternatively activated 
macrophages, were shown to have reduced IL-12 secretion but higher levels of  IL-10 
production compared to M1 macrophages (Biswas et al., 2006, Mantovani et al., 2004). 
However, later studies have reported that type-II activated macrophages share more functional 
and biochemical similarities to M1 macrophages (Edwards et al., 2006). Similarly, one study 
12 
 
that analysed gene expression profiles of M2 populations elicited in a number of different 
murine disease models showed induction of a subset of genes in all populations irrespective of 
disease model, mouse strain, or source of cells (a common gene signature), they also had 
distinct differences in the expression of a large number of genes (Ghassabeh et al., 2006). 
Strikingly, further studies have reported that the phenotype and function of M2 macrophages 
induced by IL-4 stimulation were distinct in bone-marrow derived and tissue-resident 
macrophages (Gundra et al., 2014). Overall, it has become increasingly evident that the M1/M2 
activation paradigm is too simplistic and rigid, and that  macrophage activation most likely 
reflects a spectrum of functional states, which are both signal-dependent and plastic (Xue et 
al., 2014, Stout et al., 2005). Thus, a recent nomenclature system for macrophage activation 
that relates more specifically to the phenotype, function, and context of activation has been 
formally proposed to supersede the M1/M2 paradigm (Murray et al., 2014). 
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1.2 Inflammation 
The cardinal signs of inflammation first described by Celcius have persisted into modern times, 
comprising calor (heat), dolor (pain), rubor (redness), and tumor (swelling). Functio laesa 
(loss of function) was later added to the description of inflammation by Galen. Inflammation 
forms the basis of many physiological and pathological processes. Inflammation is a 
fundamental protective response to the loss of cellular and tissue homeostasis, which is critical 
for host defence, the clearance of detrimental stimuli, and, tissue repair (Medzhitov, 2008). 
Inflammation is triggered by the recognition of conserved motifs on pathogens known as 
pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns 
(DAMPs), endogenous molecules which are released in response to tissue injury by germline-
encoded pattern recognition receptors (PRRs) (see 1.3.1 Pattern recognition receptors) (Akira 
et al., 2006). PRRs are mainly expressed by myeloid cells including dendritic cells, 
macrophages, monocytes, and neutrophils, but are also expressed by epithelial cells, 
fibroblasts, and lymphocytes (Iwasaki and Medzhitov, 2004). Upon detecting PAMPs/DAMPs, 
PRR activation triggers the release of soluble factors including pro-inflammatory cytokines, 
chemokines, vasoactive amines, and lipid mediators including leukotrienes and eicosanoids. 
These soluble mediators have effects on local neighbouring cells (via autocrine and paracrine 
signalling), activating tissue-resident immune cells, as well as endothelial cells. The activation 
of endothelial cells increases vascular permeability and induces the expression of adhesion 
molecules such as VCAM-1 and ICAM-1. This allows the attachment of immune cells such as 
leukocytes to the endothelium and permit their subsequent transmigration into tissues at the 
site of infection/injury (Collins et al., 1995). Complement fragments C3a, C4a and C5a are 
produced by several pathways of complement activation, and promote the recruitment of 
monocytes and granulocytes, as well as inducing mast cell degranulation. The release of 
vasoactive amines such as histamine and serotonin by activated mast cells also serves to 
increase vascular permeability. When cytokines are released in larger quantities, they can exert 
endocrine effects such as the fever, fatigue, platelet activation, and the induction of acute-phase 
proteins in the liver,  (Gruys et al., 2005). These acute-phase proteins produced by the liver 
serve to inhibit microbial growth by binding to iron (e.g., Ferritin), and enhance the clearance 
of microbial pathogens by acting as opsonins to promote phagocytic clearance (e.g., C-reactive 
protein and complement). Additionally, some acute-phase proteins produced by the liver such 
as serpins promote the resolution of inflammation. The release of endogenous lipid mediators 
by macrophages such as leukotrienes together with chemokines and cytokines serve as 
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chemoattractants, which promote the recruitment of immune effector cells such as neutrophils 
and monocytes to the site of infection/tissue injury (Bonecchi et al., 2009, Luster et al., 2005). 
The infiltration of effector cells is time-dependent, with neutrophils the first to enter the 
afflicted site, followed by monocytes (Serhan et al., 2007). Once at the afflicted site, 
neutrophils are activated either the recognition of PAMPs/DAMPs, or through the action of 
cytokines secreted by resident cells. Once activated, neutrophils produce a host of antimicrobial 
mediators to combat microbial pathogens including reactive oxygen and nitrogen species, as 
well as various proteinases. However, these potent effectors also damage host tissues, 
necessitating the need for the resolution of inflammation and the restoration of tissue 
homeostasis (Serhan and Savill, 2005). Historically, it was widely accepted that the cessation 
of inflammation was a passive process, where the loss of pro-inflammatory mediators would 
be considered the ‘off signal’. However, it is now widely appreciated that the resolution of 
inflammation is an active and highly-regulated process, mediated by molecules that actively 
drive the termination of resolution, such as resolvins, prostaglandins and anti-inflammatory 
cytokines (Bannenberg et al., 2005, Serhan et al., 2000, Levy et al., 2001). 
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1.3 Innate Pathogen recognition 
1.3.1 Pattern recognition receptors 
Cells of the innate immune system express a large array of germline-encoded pattern 
recognition receptors (PRRs), which recognize and respond to a diverse array of highly-
conserved structural motifs expressed by microbes known as pathogen-associated molecular 
patterns (PAMPs) and damage-associated molecular patterns (DAMPs), endogenous 
molecules which are released in response to stress, tissue damage and necrotic cell death 
(Bianchi, 2007, Vance et al., 2009). The main functions of PRRs following pathogen 
recognition include phagocytosis, activation of pro-inflammatory signalling pathways, 
opsonisation, activation of the complement pathway, induction of apoptosis, and the activation 
of the adaptive immune response (Palm and Medzhitov, 2009, Gordon, 2002). PRRs can be 
defined as humoral (soluble) or cell-associated, with the latter group being further subdivided 
to cell surface and intracellular molecules (Figure 1.3). 
 
 
Figure 1.3 | Schematic representation of different groups of pattern recognition receptors. 
Abbreviations: ALR, AIM2-like receptor; CLR, C-type lectin receptor; NLR, NOD-like 
receptor; RLR, RIG-I-like receptor; TLR, Toll-like receptor. 
 
1.3.1.1 Humoral PRRs 
Humoral PRRs are key components of the innate immune response which include the 
collectins, ficolins, pentraxins, sCD14, milk fat globule-EGF factor 8 protein (MFG-E8), 
complement component 1q (C1q), and natural IgM. These receptors recognise PAMPs from a 
diverse array of pathogens of bacterial, fungal, and viral origin, as well as DAMPs on apoptotic, 
necrotic, and malignant cells (Rapaka et al., 2010, Palaniyar et al., 2004, Nauta et al., 2003). 
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The collectins (collagenous lectins) are a group of soluble PRRs belonging to the C-type lectin 
superfamily. The collectins, which include mannose-binding lectin (MBL), collectin 11, and 
surfactant protein A (SP-A) and D (SP-D) (Kawasaki et al., 1983, Haagsman et al., 1987, 
Benson et al., 1985, Hansen et al., 2010). The collectins share a similar structure consisting of 
an N-terminal collagen-like region which is involved in trimerization, and a ligand-binding C-
type lectin domain at the C-terminus, which selectively binds to carbohydrate moieties 
including mannose, fucose, and N-acetylglucosamine (GlcNAc), which are prevalent on the 
surface of a wide array of bacteria, fungi, and viruses (Neth et al., 2000, Sastry and Ezekowitz, 
1993, Holmskov and Jensenius, 1993, Drickamer, 1988). The ficolins (Ficolin-1, -2, -3) are 
another class of humoral PRRs that recognise N-acetylated carbohydrates present on microbial 
surfaces (Krarup et al., 2004). Ficolins consist of a collagen-like domain and a C-terminal 
fibrinogen-like domain that is responsible for carbohydrate recognition (Garlatti et al., 2007, 
Matsushita et al., 1996). Following recognition, humoral PRRs facilitate microbial clearance 
through complement activation, aggregation of microbial cells (agglutination), and 
opsonophagocytosis (Thiel, 2007, Endo et al., 2011, Ikeda et al., 1987, Matsushita et al., 1996). 
In addition, they also mediate apoptotic cell clearance and modulate inflammatory processes 
including cytokine production and chemotaxis (Schagat et al., 2001, Ogden et al., 2001, Taylor 
et al., 2000, Wright and Youmans, 1993, Gardai et al., 2003, Nadesalingam et al., 2005).  
 
1.3.1.2 Cellular PRRs 
Cellular PRRs encompasses a broad range of receptors and sensors that recognise a diverse 
array of PAMPs and DAMPs and can be divided into two groups based on their cellular 
localisation: cell surface or intracellular molecules. Cellular PRRs include Toll-like receptors 
(TLRs), C-type lectin receptors (CLRs), and Scavenger Receptors (SRs), which are 
transmembrane proteins which are located on the plasma membrane or endolysosomal 
membranes, whereas Retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), nucleotide-
binding oligomerization domain (NOD)-like receptors (NLRs) and absent in melanoma 2 
(AIM2)-like receptors (ALRs) reside in the cytoplasm. Cell surface PRRs may be either 
phagocytic/endocytic receptors or sensor molecules. Phagocytic receptors directly bind to and 
internalise ligands. Conversely, sensor molecules do not directly internalise ligands, but instead 
initiate pro-inflammatory signalling cascades that culminate in antimicrobial effector 
responses.  
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1.3.1.2.1 Toll-like receptors (TLRs) 
The Toll-like receptors (TLRs) are arguably the best-characterized group of PRRs (Kawasaki 
and Kawai, 2014, Beutler, 2009). To date, ten TLRs have been identified in humans and twelve 
in mice, with TLR1-TLR9 being conserved in both species, functional TLR10 present in 
humans (Mouse Tlr10 contains multiple sequence gaps and retroviral insertions), and TLR11, 
TLR12 and TLR13 present in mice but not humans. A number of genetic studies have 
demonstrated that different TLRs recognize distinct PAMPs and DAMPs in the extracellular 
space and in subcellular compartments including endosomes, lysosomes and endolysosomes 
(Table 1.2). 
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Table 1.2 | Toll-like receptors, cellular localisation, and their principal ligands 
TLR Species Localisation PAMPs DAMPs 
TLR1 Humans and mice Plasma membrane TLR1:TLR2: Triacyl lipopeptides  
TLR2 Humans and mice Plasma membrane TLR2: Lipoproteins 
TLR1:TLR2: Triacyl lipopeptides 
TLR2:TLR6: Diacyl lipoprotein, LTA, 
zymosan 
Biglycan, endoplasmin, histones, 
HMGB1, HSP60, HSP70, MSU 
crystals, Versican 
TLR3 Humans and mice Endolysosomal compartment dsRNA, tRNA, siRNA mRNA 
TLR4 Humans and mice Plasma membrane and 
Endolysosomal compartment 
Lipopolysaccharide, Mannan, Viral 
envelope proteins 
Amyloid-β, Biglycan, β-defensin 2, 
endoplasmin, fibrinogen, 
fibronectin, heparin sulphate, 
histones, HMGB1, HSP22, HSP60, 
HSP70, HSP72, MSU crystals, 
oxidised low-density lipoprotein,  
S100 proteins, surfactant protein A 
TLR5 Humans and mice Plasma membrane Flagellin  
TLR6 Humans and mice Plasma membrane TLR2:TLR6: Diacyl lipoproteins, LTA and 
zymosan 
 
TLR7 Humans and mice Endolysosomal compartment GU-rich ssRNA and short dsRNA ssRNA 
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TLR8 Humans and mice Endolysosomal compartment ssRNA, Imidazoquinolones ssRNA, Human cardiac myosin 
TLR9 Humans and mice Endolysosomal compartment CpG DNA, hemozoin Chromatin IgG complex, HMGB1, 
mtDNA 
TLR10 Humans Plasma membrane Unknown –Evidence to suggest that TLR10 
can form heterodimers with TLR1 and 
TLR2 
 
TLR11 Mice Endolysosomal compartment Profilin, flagellin, Uropathogenic bacteria  
TLR12 Mice Endolysosomal compartment Profilin  
TLR13 Mice Endolysosomal compartment Bacterial 23S rRNA with CGGAAAGACC 
motif 
 
Abbreviations: HMGB1, High-mobility group box 1 protein; HSP, Heat shock proteins; LTA, Lipoteichoic acid; MSU, Monosodium urate; 
mtDNA; Mitochondrial DNA 
TLR receptors and signalling reviewed by (Kawasaki and Kawai, 2014, Beutler, 2009).
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1.3.1.2.1.1 TLR signalling 
Engagement of TLRs with their respective ligands stimulates downstream signalling 
pathways, culminating in the transcriptional upregulation of distinct genes, which is 
both TLR-specific and cell-type specific. TLR signalling can be broadly divided into 
two distinct pathways, depending on the usage of one of two signalling adaptor 
proteins, MyD88 and TRIF. All TLRs signal through MyD88 except for TLR3, which 
uses the adaptor TRIF. TLR4 is unique because it can signal through both MyD88 and 
TRIF adaptor proteins to perpetuate downstream signalling (Yamamoto et al., 2003). 
The activation of TLR signalling originates from the Toll/IL-1 receptor (TIR) domain, 
which is associated with the MyD88 adaptor. MyD88 recruits IL-1R-associated kinase 
(IRAK)-4 to TLRs, which activates other IRAK family members, IRAK-1 and IRAK-
2 (Kawagoe et al., 2008). The IRAKs associate with the TNF receptor-associated 
factors (TRAFs), thereby activating the IKK complex, leading to the subsequent 
activation of Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
and the mitogen-activated protein kinases (MAPKs); p38 MAPK and JUN N-terminal 
kinase (JNK). Activation of the MAPK cascade leads to the activation of two 
transcription factor complexes; activator protein 1 (AP1) and cyclic AMP-responsive 
element binding proteins (CREB) (Figure 1.4). 
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Figure 1.4 | Mammalian TLR signalling pathways. 
TLRs signal through MyD88-dependent and MyD88-independent pathways. Upon 
respective ligand binding at the plasma membrane (TLR2/1, TLR2/6, TLR4/MD-2, 
and TLR5) or endocytic compartments (TLR7, TLR8, TLR9, and TLR13) recruit 
MyD88 to their TIR domains. TLR2/1, TLR2/6, and TLR4/MD-2 also recruit the 
adaptor protein MAL. MyD88 recruits IRAK proteins 1, 2 and 4, which recruit TRAF6 
to the complex. The complex serves as a platform to recruit TAK1, which mediates 
the activation of the IKK complex, leading to the subsequent activation of NF-κB and 
MAPKs (p38 and JNK). Activation of the MAPK cascade leads to the activation of 
two transcription factor complexes, AP1 and CREB. Conversely, TLR3 signalling is 
mediated through the TRIF-signalling pathway, which recruits TRIF and TRAM upon 
ligand binding. TRIF interacts with TRAF3, which activates TBK1 and IKKε, 
resulting in the activation of IRF3. IRF3 translocates into the nucleus, whereby it 
activates the transcription of genes including type I IFN. TLR4 is unique because it 
can signal through both MyD88- and TRIF-dependent pathways, requiring 
endocytosis for TRIF-dependent signalling. 
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1.3.1.2.1.2 Negative regulation of TLR signalling 
Dysregulation of TLR signalling can have severe consequences such as the cytokine 
storm associated with septic shock, autoimmunity, and lethality from ineffective 
defences against pathogens (Poltorak et al., 1998, Zacharowski et al., 2006, Stack et 
al., 2005, Roelofs et al., 2005, Leadbetter et al., 2002). Accordingly, a number of 
molecules that serve to negatively regulate TLR signalling have been identified, which 
have evolved to attenuate TLR signalling and prevent the deleterious effects of an 
overactive or prolonged innate immune response (Liew et al., 2005). Negative 
regulation of TLR signalling is achieved at multiple levels, ranging from soluble decoy 
receptors, membrane-associated protein regulators, regulation of adaptor complexes 
and signalling, as well transcriptional, post-transcriptional, and post-translational 
modulation, extensively reviewed by (Anwar et al., 2013, O'Neill et al., 2011, Murray 
and Smale, 2012, Kondo et al., 2012, Liew et al., 2005). Whilst some molecules that 
negatively regulate TLR signalling are constitutively expressed, most are induced 
downstream of TLR signalling, thereby attenuating TLR signalling in a negative 
feedback manner. Interestingly, mice deficient of constitutively expressed negative 
regulators of TLR signalling display spontaneous inflammatory or autoimmune 
diseases, suggesting that these molecules are important for controlling basal 
inflammatory responses to endogenous ligands. Soluble TLRs in blood and tissues, 
such as sTLR2 and sTLR4 have been reported to negatively regulate TLR signalling 
by functioning as decoy receptors, preventing direct interaction between bacterial 
ligands and cell-associated TLRs (Iwami et al., 2000, LeBouder et al., 2003). The 
regulation of TLR expression represents another mechanism through which TLR 
signalling is negatively regulated. TLR expression can be both downregulated by the 
actions of anti-inflammatory cytokines such as IL-10 and TGF-β1 which inhibit the 
transcription or stability of TLR-encoding mRNAs, or through the degradation of TLR 
proteins via ubiquitination, which promotes the proteasomal degradation of TLRs 
(Chuang and Ulevitch, 2004, McCartney-Francis et al., 2004, Muzio et al., 2000). In 
addition to soluble factors, a number of transmembrane receptors have been implicated 
in the negative regulation of TLR signalling, including IL-1 receptor-like 1 (IL1RL1, 
also known as T1 and ST2), single immunoglobulin IL-1R-related molecule 
(SIGIRR), radioprotective 105 (RP105), and tumor necrosis factor-related apoptosis-
inducing ligand receptor (TRAIL-R) (Brint et al., 2004, Wald et al., 2003, Diehl et al., 
2004). These molecules can negatively regulate TLR signalling through the 
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sequestration of transcription factors and adaptor proteins, or by interfering with the 
binding of TLR ligands to their respective TLRs. Following TLR:ligand ligation, TLR 
signalling can be further regulated by several intracellular negative regulators which 
include MyD88 short (MyD88s), IL-1 receptor-associated kinase M (IRAK-M), 
suppressor of cytokine signalling 1 (SOCS1), NOD2, phosphatidylinositol 3-kinase 
(PI3K), Toll-interacting protein (TOLLIP), A20, and activating transcription factor 3 
(ATF3) (Watanabe et al., 2004, Zhang and Ghosh, 2002, Boone et al., 2004, Gilchrist 
et al., 2006, Whitmore et al., 2007). SOCS1 is a member of the E3 ubiquitin ligase 
family, which negatively regulates TLR signalling through the targeted degradation of 
MAL and TRAF proteins (Yoshimura et al., 2007, Mansell et al., 2006). The IRAK 
family member, IRAK-M, lacks intrinsic kinase activity and negatively regulates TLR 
signalling by preventing the dissociation of IRAK4 and IRAK1 from MyD88. As such, 
IRAK-M deficient mice secrete more pro-inflammatory cytokines in response to 
various TLR ligands compared to their wild type counterparts (Kobayashi et al., 2002). 
ATF3, a member of the ATF/CREB family of transcription factors, is induced 
following LPS stimulation and serves as a negative regulator of TLR signalling. 
Accordingly, ATF3-deficient macrophages have enhanced pro-inflammatory cytokine 
production (Gilchrist et al., 2006). ATF3 dampens TLR signalling by recruiting 
histone deacetylases, which alter the chromatin structure in the promoter region of 
genes encoding IL-6 and IL-12, restricting access for NF-κB and AP1 transcription 
factors and thereby repressing expression (Whitmore et al., 2007). Overall, TLR 
expression and signalling are tightly controlled by numerous negative regulators, 
which serve to terminate inflammatory responses and prevent excessive inflammation. 
 
1.3.1.2.2 C-Type Lectin Receptors (CLRs) 
The term ‘C-type lectin’ was introduced to distinguish between Ca2+-dependent 
(CLRs) and Ca2+-independent animal lectins (Zelensky and Gready, 2005). The CLRs 
comprise a large family of soluble and transmembrane proteins that are defined by the 
presence of one or more C-type carbohydrate recognition domains (CRDs), a compact 
structural module that confers the carbohydrate recognition specificity of CLRs (Weis 
and Drickamer, 1996). The CLR family now includes members that contain one or 
more domains homologous to CRDs, but which do not bind to carbohydrates and are 
not calcium-dependent. Thus, “C-type lectin-like domain” (CTLD) is generally used 
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to refer to the structural module and “C-type lectin” consequently used to define 
proteins that contain one or more CTLDs, irrespective of carbohydrate recognition and 
dependency of calcium for binding. The CLRs encompass over 1000 members with 
diverse functions including cell adhesion, tissue remodelling, complement activation, 
platelet activation, regulation of natural killer function, endocytosis, phagocytosis, and 
activation of innate immunity (Weis and Drickamer, 1996, Osorio and Reis e Sousa, 
2011, Zelensky and Gready, 2005). 
The CLRs are highly expressed on myeloid cells where they have traditionally been 
associated with the recognition of fungi, but are now known to recognise a diverse 
array of microbial pathogens including viruses, mycobacteria, bacteria, and helminths 
(Rothfuchs et al., 2007, van Kooyk and Rabinovich, 2008, Robinson et al., 2006, 
Geijtenbeek and Gringhuis, 2009). Many of the PAMPs recognised by CLRs are 
carbohydrates: glucan structures present on mycobacteria and fungi; high-mannose 
structures expressed by fungi, mycobacteria, and viruses; and fucose structures on the 
surface of some bacteria and helminths. Following pathogen recognition CLRs elicit 
diverse signalling pathways, which is predominantly dependent on the signalling 
motifs in the cytoplasmic tails. Some CLRs, such as dectin-1, dectin-2 and mincle, 
induce signalling pathways that directly activate NF-κB (Hara et al., 2007). 
Conversely, other CLRs including DC-SIGN, DCIR and MICL, induce signalling 
pathways that modulate TLR-dependent gene expression, at both the transcriptional 
and post-transcriptional level. 
The phagocytosis of pathogens and their subsequent degradation in acidified 
phagolysosomes is an important mechanism of innate immune defence, recently 
reviewed by (Gordon, 2016). Whilst TLRs have not been shown to phagocytose 
pathogens, some studies have suggested that TLR signalling has a critical role in 
phagosomal maturation (Blander and Medzhitov, 2004). However, other studies have 
shown that phagosomal maturation is independent of TLR signalling (Yates and 
Russell, 2005). In contrast, many CLRs act as phagocytic receptors in myeloid cells, 
which upon recognition, internalise and subsequently degrade microbial pathogens. 
Distinct internalisation motifs are often contained within the cytoplasmic tails of 
CLRs, which both direct ligand uptake and subsequent sorting of receptors and cargo 
to endosomal compartments (Bonifacino and Dell'Angelica, 1999). 
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Dectin-1 is a transmembrane receptor that is highly expressed on myeloid cells (Taylor 
et al., 2002a), and is of particular relevance to this thesis. Dectin-1 is the major receptor 
for β-glucan, carbohydrate polymers found primarily in the cell walls fungi such as 
Saccharomyces cerevisiae and Candida albicans (Brown and Gordon, 2001). 
Zymosan is a β-glucan-rich preparation of cell wall from Saccharomyces cerevisiae 
that is recognised through receptors including, dectin-1, dectin-2, SIGNR1, mannose 
receptor, and TLR2/6 (Gantner et al., 2003, Brown and Gordon, 2001, Giaimis et al., 
1993, Taylor et al., 2004, McGreal et al., 2006). Recognition of β-glucan containing 
fungal organisms and yeast-derived particles (such as zymosan) by dectin-1 leads to 
phagocytosis, which is mediated through the ITAM-like motif in the cytoplasmic tail 
of dectin-1 (Herre et al., 2004). A salient feature of PRRs is their ability to couple 
microbial recognition to the activation of downstream signalling pathways that 
mediate innate responses, such as the expression of pro-inflammatory cytokines. 
Dectin-1 has been definitively demonstrated to stimulate cytokine production, which 
is dependent on spleen tyrosine kinase (Syk) (Rogers et al., 2005). Mutagenesis studies 
suggest that Syk recruitment is mediated through a single YxxL motif in dectin-1 
(where “x” is any amino acid). Once activated, Syk mediates the activation of the NF-
κB and the Erk, JNK, and p38 kinase cascades (Figure 1.5) (Robinson et al., 2006, 
Gross et al., 2006). Furthermore, dectin-1 and TLRs synergise in a Syk-dependent 
manner to produce optimal cytokine responses in macrophages (Dennehy et al., 2008), 
supporting a role for the recognition of pathogens simultaneously through different 
PRRs to control infections. 
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Figure 1.5 | Dectin-1 signalling. 
Zymosan stimulation initiates the activation of MAPKs and NF-κB (the latter via a 
complex containing CARD9, Bcl-10 and MALT1) in a Syk-dependent manner. The 
activation of these transcription factors leads to the expression of innate immune 
responsive genes such as pro-inflammatory cytokines. Zymosan is phagocytosed and 
subsequently degraded in phagolysosomes. The internalisation of zymosan in 
macrophages is independent of Syk activation, but the production of ROS is Syk-
dependent. 
 
1.3.1.2.3 NLRs 
The nucleotide-binding oligomerization domain receptors (NOD-like receptors, 
NLRs) are highly conserved cytosolic sensors of PAMPs and DAMPs. To date, 
twenty-two human and thirty-four mouse NLR family members have been identified 
(Kim et al., 2016b, Franchi et al., 2009). With few exceptions, NLR family members 
typically have a tripartite structure with a C-terminal leucine-rich-repeat (LRR) 
domain, a central NACHT domain, and an N-terminal caspase recruitment and 
activation (CARD) or pyrin (PYD) domain. The NLRs include NOD-1 and NOD-2, 
which recognise distinct ligands. NOD-1 recognises dipeptide γ-D-glutamyl-meso-
diaminopimelic acid, whereas NOD-2 detects muramyl dipeptide, a component of 
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peptidoglycan (Girardin et al., 2003a, Girardin et al., 2003b, Inohara et al., 2001). 
Upon ligand recognition by NOD-1 and NOD-2, signalling cascades activate NF-κB 
and MAPKs, which culminates in the production of pro-inflammatory cytokines. 
Some NLR family members oligomerise to form multimeric protein complexes called 
inflammasomes, following their activation by PAMPs or DAMPS (see 1.5   
Inflammasomes). 
1.3.1.2.4 Scavenger receptors (SRs) 
The Scavenger receptors are a diverse group of PRRs that were originally identified 
by their ability to recognise and remove modified lipoproteins. SRs have distinct but 
overlapping recognition of a diverse array of PAMPs and DAMPs, as well as apoptotic 
ligands. These promiscuous receptors include SR-A, MARCO, and CD36, and bind 
polyanionic ligands (Canton et al., 2013). Overall, SRs identify and remove unwanted 
entities such as apoptotic cells, damaged proteins, and a variety of microbial pathogens 
(Mukhopadhyay and Gordon, 2004). 
1.3.2 Phagocytosis 
Phagocytosis is a remarkably complex process that is critical in development, tissue 
homeostasis, and immunity, extensively reviewed in (Flannagan et al., 2012, Gordon, 
2016, Pauwels et al., 2017). Phagocytosis is the process by which cells recognise and 
internalise a variety of particulates (>0.5 µm) into membrane-bound vesicles known 
as phagosomes, including microorganisms, environmental debris, and altered-self such 
as apoptotic, necrotic, and senescent cells (Penberthy and Ravichandran, 2016). 
Phagocytes can be grouped into ‘professional’ and ‘non-professional’ phagocytes. The 
professional phagocytes include macrophages, mast cells, monocytes, and neutrophils. 
Non-professional phagocytes include epithelial cells, endothelial cells, fibroblasts, and 
mesenchymal cells, which are capable of phagocytosing during development and some 
pathological circumstances and can therefore be considered facultative phagocytes 
(Gordon, 2016). Furthermore, non-professional phagocytes typically phagocytose a 
smaller variety of particulates and have a lower efficacy for internalisation than 
professional phagocytes. 
Phagocytosis can be broadly broken down into a series of defined steps: recognition 
and binding of the target particle; actin-dependent ingestion of the target into a 
phagosome; the maturation of the phagosome into a phagolysosome via a series of 
28 
 
membrane fusion and fission events; and the degradation of the ingested particle in the 
acidic phagolysosome. However, the precise mechanisms of phagocytosis are 
remarkably heterogenous, owing to the various combinations of receptors that 
recognise and internalise particulates, as well as the nature of the particle, which may 
influence the maturation rate of phagosomes (Erwig et al., 2006). For example, 
phagocytosis mediated by Fcγ receptors (FcγRs) initiates ‘reaching’ phagocytosis that 
is typically characterised by membrane protrusions that extend to encapsulate the 
particulate, whereas particles internalised via complement receptors (CRs) are 
internalised without significant membrane protrusion, which is often referred to as 
‘sinking’ phagocytosis (Underhill and Goodridge, 2012). 
The Macrophage is considered the archetypal phagocytic cell; indeed, their name 
derives from the Greek for ‘big eaters’, owing to their phagocytic propensity. The 
phagocytic process is initiated by the recognition of particulates by plasma membrane 
receptors. The ability of macrophages to recognise, engage, and internalise a broad 
array of particulates therefore necessitates a vast repertoire of receptors and sensors 
(Freeman and Grinstein, 2014). Multiple receptors are co-expressed in single 
phagocytes, which collaborate in the detection and ingestion of particles. Furthermore, 
the activation of phagocytic receptors is generally dependent on lateral clustering, in 
which multivalent ligands on the surface of particles engage with multiple receptors 
on the phagocyte, which initiate cytoskeletal rearrangements and membrane 
trafficking leading to engulfment of the particulate (Gordon, 2016). 
Particulates may be recognised directly by non-opsonic receptors including CLRs 
(mannose receptor, dectin-1), integrins (e.g., CR3), and SRs. However, in many 
instances recognition of particulates is mediated by opsonins such as iC3b, 
immunoglobulin G (IgG), and MBL, which coat the particulates and are themselves 
recognised by cell surface receptors. These cell surface receptors are generally referred 
to as the opsonic receptors, of which CRs and FcγRs are the best characterised 
(Unkeless et al., 1988). CR3 has also been reported to mediate the recognition of 
particulates in the absence of opsonins, which is thought to be through macrophage-
derived complement deposition (Le Cabec et al., 2002). 
Although several types of receptor have been demonstrated to have roles in the 
phagocytic uptake of target particles, the definition of a bona fide phagocytic receptor 
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is complex. Only a few receptors have been reproducibly shown to be sufficient for 
phagocytosis upon ectopic heterologous in an otherwise non-phagocytic cell type. 
These include the FcγRs and dectin-1, which recognise antibody-opsonised particles 
and fungal β-glucan respectively (Brown and Gordon, 2001, Indik et al., 1991).  
However, whilst some receptors are unable to initiate target internalisation alone, a 
receptor that is necessary for the efficient binding of a particulate also participates in 
phagocytosis. A two-step model has been proposed to distinguish between receptors 
that ‘tether’ the particulate to the phagocyte, and receptors that provide a ‘tickle’ signal 
resulting internalisation of phagocytic targets: the ‘tether and tickle’ model (Hoffmann 
et al., 2001). Other receptors such as the TLRs may enhance phagocytosis by inducing 
the expression of phagocytic receptors such as FcγRs, as well as the inducing inside-
out activation of phagocytic integrins (Sendide et al., 2005). 
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1.3.3 Innate signalling pathways 
The recognition of microbial pathogens and the initiation of downstream effector 
functions are linked through the activation of transcription factors such as NF-κB, IRFs 
and MAPKs.  
1.3.3.1 NF-κB 
The NF-κB family of transcription factors have fundamental roles in innate immunity 
inflammation, cell proliferation, differentiation, and survival (Bonizzi and Karin, 
2004, Caamano and Hunter, 2002). Since its discovery in activated B cells in 1986, 
NF-κB has been found to be expressed in almost all cell types and tissues, and NF-κB 
binding sites (κB sites) are present in the promoters of a large number of genes. The 
NF-κB pathway has long been considered the prototypical proinflammatory signalling 
pathway, largely because the recognition of microbial products, antigens and cytokines 
lead to the activation of NF-κB. Furthermore, NF-κB induces the transcription of pro-
inflammatory cytokines, chemokines, and adhesion molecules, exemplifying its 
critical role in the innate and adaptive immune responses (Hayden and Ghosh, 2012). 
However, it has become increasingly evident that NF-κB signalling is critical for the 
resolution of inflammation, whereby it induces the expression of anti-inflammatory 
cytokines, pro-resolvins and induces apoptosis (Lawrence, 2009, Greten et al., 2007). 
In mammals, the NF-κB family is composed of five members; NF-κB1, NF-κB2, RelA 
(p65), c-Rel and RelB. In contrast to the other family members, NF-κB1 and NF-κB2 
are synthesized as pro-forms (p105 and p100), which are proteolytically processed to 
p50 and p52, respectively. These subunits form homodimer and heterodimers in the 
cytosol, which are determined by tissue-specific expression of different NF-κB 
subunits (Hayden and Ghosh, 2004). The NF-κB subunits all share a common 300 
amino acid long Rel homology domain (RHD), which is required for dimerization, 
nuclear translocation, and DNA-binding (Ghosh et al., 1995, Chen et al., 1998, Muller 
et al., 1995). However, only p65, c-Rel and RelB contain carboxy-terminal 
transactivation domains (TAD). Thus, not all NF-κB dimers are transcriptionally 
active, with some dimers (p50 and p52 homo- and hetero-dimers) demonstrated to 
repress κB-dependent transcription (Zhong et al., 2002). 
31 
 
1.3.3.1.1 NF-κB Signalling 
In resting macrophages, NF-κB dimers are retained in an inactive form in the cytosol 
through their interaction with one of seven inhibitor of NF-κB (IκB) family members. 
The binding of IκB family members to NF-κB dimers typically occludes the nuclear 
localization sequences (NLS) of NF-κB subunits, thereby preventing nuclear 
translocation and subsequent induction of gene expression (Beg et al., 1992). 
Accordingly, the activation of NF-κB is dependent on the degradation of IκB proteins 
bound to NF-κB dimers. However, more recent findings suggest that distinct IκB 
family members exert different functional characteristics on NF-κB responses, which 
is dependent on tissue-specific expression of IκB proteins and different cellular 
contexts (Oeckinghaus and Ghosh, 2009). 
Currently, two signalling pathways that lead to the activation of NF-κB have been 
described; the classical (canonical) and the alternative (non-canonical) pathway 
(Figure 1.6). The ‘canonical’ pathway is activated by microbial products, pro 
inflammatory cytokines such as IL-1 and TNF, and antigen receptor activation (Ghosh 
and Karin, 2002). Conversely, the non-canonical pathway is activated by TNF-family 
cytokines; CD40 ligand (CD40L and TNFSF5), B cell activating family (BAFF and 
TNFSF13B) and receptor activator of NF-κB ligand (RANKL and TNFSF11). These 
two pathways share a common regulatory step required for the activation of NF-κB; 
the activation of an IκB kinase (IKK) complex, which consists of catalytic kinase 
subunits (IKKα and/or IKKβ) and the regulatory non-enzymatic scaffold protein NF-
κB essential modulator (NEMO). Upon activation, an IKK complex phosphorylates 
IκB, leading to its polyubiquitination and proteasomal degradation. Unbound NF-κB 
dimers are consequently liberated, enabling them to translocate to the nucleus and 
modulate target gene expression. 
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Figure 1.6 | Canonical and non-canonical pathway of NF-κB activation. 
The canonical NF-κB pathway is induced by signals including antigens, TLR ligands 
and cytokines. This leads to the phosphorylation of the IKKβ subunit of the IKK 
complex (NEMO, IKKα, IKKβ). The IKK complex subsequently phosphorylates (P) 
IκB proteins bound to NF-κB dimers such as p50-p65 dimers, leading to 
polyubiquitination (Ub) and subsequent proteasomal degradation of IκB. Liberated 
NF-κB dimers can then translocate to the nucleus and bind specific DNA sequences 
(κB sites) and induce target gene expression. The non-canonical NF-κB pathway is 
activated by members of the TNF-like family of cytokines. This leads to NIK-mediated 
IKKα activation, which phosphorylates p100, initiating its proteasomal processing into 
p52. The p52 protein preferentially dimerizes with p65, translocates to the nucleus and 
induces target gene expression. 
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1.3.3.1.2 Regulation of NF-κB signalling 
Given the importance of NF-κB signalling in a wide range of key physiological 
processes, the NF-κB pathway is tightly regulated at multiple levels, extensively 
reviewed by (Oeckinghaus and Ghosh, 2009). Indeed, dysregulated NF-κB signalling 
has been attributed to the development of many human diseases including 
inflammatory diseases such as auto-immune diseases and atherosclerosis, as well as in 
neurodegeneration, and cancer (Hoesel and Schmid, 2013, Tilstra et al., 2011, 
Vallabhapurapu and Karin, 2009). 
The best characterised mechanism of NF-κB signalling termination involves the re-
synthesis of IκB proteins, the expression of which are induced by NF-κB signalling 
(Haskill et al., 1991, Sun et al., 1993, de Martin et al., 1993). Newly synthesised IκB 
proteins enter the nucleus, bind to NF-κB (removing it from DNA), and re-localise to 
the cytosol (Hayden and Ghosh, 2004). More recently, a number of additional 
mechanisms of NF-κB signalling have been identified that directly affect active NF-
κB subunits bound to DNA. These include a wide array of post-translational 
modifications such as ubiquitination, phosphorylation, and acetylation (Perkins, 
2006). These protein modifications alter cofactor binding or mediate the displacement 
and subsequent degradation of NF-κB dimers, resulting in the downregulation of NF-
κB signalling (Kiernan et al., 2003, Saccani et al., 2004). 
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1.4 Soluble mediators of the inflammatory 
response 
The release of soluble mediators following the recognition of PAMPs and/or DAMPs 
is a central component of the inflammatory response. PRR signalling typically 
culminates in the activation of transcription factors such as NF-κB, which regulates 
the expression of multiple genes essential for the immune response. Tissue-resident 
macrophages produce a plethora of soluble mediators including cytokines, 
chemokines, interferons (IFNs), and lipids, which amplify the inflammatory response, 
participate in the activation and recruitment of effector cells, enhance phagocytosis 
and antigen presentation, and coordinate the adaptive response. 
1.4.1 Lipid mediators 
The release of lipid mediators is a characteristic hallmark of the inflammatory 
response, which are required for both the initial inflammatory response and the 
resolution of inflammation. These lipid mediators are hydrophobic, which does not 
permit their storage, rather they are produced de novo as needed. In response to 
pathogen recognition, innate immune cells such as macrophages produce numerous 
lipid mediators including members of the prostanoid family, hydroxyeicosatetraenoic 
acids (HETEs), leukotrienes (LTs), lipoxins (LXs), and platelet-activating factor 
(PAF) (Samuelsson et al., 1987, Levy et al., 2001, Flower, 2006, Godson et al., 2000).  
1.4.1.1 Prostanoids 
Macrophages are an important source of prostanoids, which are produced rapidly in a 
multi-step process following microbial recognition (Peters-Golden et al., 2005, 
Alvarez et al., 2010). The prostanoid family, which includes prostaglandins (PGs), 
prostacyclins, thromboxanes (TXs) are synthesised from lipid membrane in a multi-
step process (Figure 1.7). Prostanoids are synthesised from arachidonic acid, which 
can either be taken up from the extracellular milieu or more commonly from 
arachidonic acid derived from phosopholipid bilayer, which is liberated downstream 
of microbial recognition. Arachidonic acid is liberated from lipid membranes by the 
phospholipase A2 (PLA2) enzyme, which associates with membrane phospholipids and 
cleaves fatty acid, releasing arachidonic acid, γ-homolinolenic acid and 
eicosapentaenoic acid. Free arachidonic acid is subsequently metabolised in a multi-
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step process by one of two key enzymes; cyclooxygenase (COX)-1 or COX-2. (These 
two proteins are encoded by two distinct genes, Ptgs1 and Ptgs2 respectively). Both 
proteins have comparable enzymatic functions, however COX-1 utilises extracellular 
sources of arachidonic acid, whereas COX-2 preferentially utilizes intracellular 
sources of arachidonic acid (Murakami et al., 1994). COX-1 and COX-2 consist of 
two distinct active sites that sequentially mediate the conversion of arachidonic acid 
to prostaglandin H2 (PGH2), a cyclooxygenase and a peroxidase site. Firstly, the 
cyclooxygenase catalyses the conversion of arachidonic acid to prostaglandin G2 
(PGG2), after which the peroxidise site mediates the conversion of PGG2 to PGH2. 
Lastly, downstream terminal prostanoid synthases metabolise PGH2 into members of 
the prostanoid family (Figure 1.7). The expression of these downstream synthases is 
tissue-specific, which consequently determines the profile of prostanoids produced. 
Resident pMϕs have been reported to produce mostly arachidonic acid cyclooxygenase 
(COX) products including prostanoids, but not metabolites from other pathways such 
as the anti-inflammatory lipoxins, protectins, and resolvins (Norris et al., 2011). 
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Figure 1.7 | Prostanoid synthesis pathway. 
Prostanoids are synthesised from arachidonic acid, which is either liberated from the 
lipid membrane by PLA2 or taken up from the extracellular milieu. COX 1/COX 2 
catalyse arachidonic acid into PGG2 and subsequently into prostaglandin H2 (PGH2), 
which is the common substrate for prostanoid synthesis. PGH2 is processed into 
individual prostanoids by the action of specific terminal synthases (red text). 
 
1.4.1.2 Prostanoid signalling 
Prostanoids typically exert their biological effects locally in an autocrine or paracrine 
manner through binding to their cognate receptors, which are G-protein-coupled 
receptors (GPCRs) (Table 1.3) (Hata and Breyer, 2004). More recently, intracrine 
signalling has been described to be an important signalling mechanism for 
prostacyclin, which signals via nuclear peroxisome proliferator-activator receptors 
(PPARs) (Forman et al., 1997, Lim and Dey, 2002, Wise, 2003). 
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Table 1.3 | Prostanoid synthesis and signalling/signal transduction 
Prostanoid Key enzyme Gene/s Receptor/s 
Prostacyclin (PGI2) Prostacyclin synthase  Ptgis IP 
PPARγ 
Thromboxane A2 (TXA2) Thromboxane-A synthase Tbxas1 TPα 
TPβ 
Prostaglandin D2 (PGD2) Prostaglandin D2 synthase 
(PTGDS) 
Ptgds DP1 
CRTH2 
Prostaglandin E2 (PGE2) Prostaglandin E synthase Ptges 
Ptges2 
Ptges3 
EP1 
EP2 
EP3 
EP4 
Prostaglandin F2 alpha 
(PGF2α) 
Prostaglandin F2 alpha 
synthase 
Akr1b3 FPA 
FPB 
Prostanoids and prostanoid receptors in signal transduction have been extensively 
reviewed (Bos et al., 2004, Woodward et al., 2011). 
 
1.4.1.3 Prostacyclin 
Prostacyclin (PGI2) is more widely recognised for its role as a potent vasodilator and 
inhibitor of platelet activation but its role in inflammation has become increasingly 
evident. The conversion of PGH2 into PGI2 is mediated by the enzyme prostacyclin 
synthase (PTGIS), which is widely expressed in vascular endothelial and smooth 
muscle cells, luminal epithelia, and tubal smooth muscle. Once synthesised, 
prostacyclin rapidly diffuses across the plasma membrane and exerts its effects 
through binding to its cognate receptor, the prostacyclin receptor (IP receptor). The IP 
receptor is a GPCR that upon activation, initiates a signalling cascade culminating in 
the activation of adenylyl cyclase and PLC, which subsequently increase intracellular 
cAMP and decreases Ca2+ levels. These two key secondary signalling molecules exert 
a wide array of effects responsible for the biological actions of PGI2. 
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1.4.1.4 Prostaglandin E2 (PGE2) 
Prostaglandin E2 (PGE2) is one of the major lipid mediators released by macrophages 
following TLR ligand or pro-inflammatory cytokine stimulation. It has been shown to 
regulate multiple aspects of inflammation and induce multiple functions in different 
immune cells (Phipps et al., 1991). At the early stages of inflammation, it is widely 
known for promoting local vasodilatation, chemoattraction, and activation of 
neutrophils, macrophages, and mast cells (Kalinski, 2012, Yu and Chadee, 1998). 
PGE2 also stimulates the production of IL-10, whilst inhibiting the transcription of pro-
inflammatory cytokines including TNF, enabling it to perturb non-specific 
inflammation (MacKenzie et al., 2013, Treffkorn et al., 2004). These pleiotropic 
effects are reflected by the existence of four different PGE2 receptors. 
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1.4.2 Chemokines 
During the initial inflammatory response, innate cells such as macrophages release 
chemokines. These small proteins, derived from ‘chemo’ (chemical) and ‘kine’ 
(movement) establish a chemo-attractant gradient, which enables the recruitment of 
(effector/immune) cells including neutrophils and monocytes and T lymphocytes (T 
cells) to sites of inflammation (Zlotnik and Yoshie, 2012). The recruitment is therefore 
important for acute effector responses and the initiation of the adaptive immune 
response (Ransohoff, 2009). The biological functions of chemokines are typically 
mediated by signalling through their cognate receptors, which are members of the 
GPCR family. 
Chemokines can also bind to members of the atypical chemokine receptor (ACKR) 
family, which are structurally homologous to chemokine GPCRs. However, ACKRs 
fail to initiate classical signalling pathways and downstream cellular responses 
characteristic of GPCRs upon chemokine binding (Graham et al., 2012, Hansell et al., 
2011). Furthermore, some ACKR family members have been shown to actively 
degrade bound chemokines. For instance, chemokines bound to ACKR2 are rapidly 
internalised, trafficked to endosomes where the low pH dislodges the chemokine from 
the receptor, and subsequently degraded in lysosomes. The unbound ACKR2 traffics 
back to the cell surface whereby it can re-acquire chemokines (Fra et al., 2003, Weber 
et al., 2004). ACKRs are therefore thought to have an important role in dampening 
inflammation and promoting the resolution of inflammation through the clearance of 
chemokines, diminishing the chemo-attractant gradient and thus influx of 
inflammatory cells (Griffith et al., 2014). 
 
1.4.3 Cytokines 
Cytokines are a diverse group of small, non-structural glycoproteins, which are 
produced by virtually all nucleated cells. They are key mediators of the inflammatory 
response, which amplify the initial inflammatory response, initiate the development of 
adaptive immunity, and promote antimicrobial effector functions (Dinarello, 2007, 
Arango Duque and Descoteaux, 2014, Iwasaki and Medzhitov, 2010, Turner et al., 
2014). The pattern of cytokine expression varies, with some cytokines being expressed 
by many hematopoietic and non-hematopoietic lineages, whilst others appear to be 
40 
 
highly restricted to specific lineages, and differentiation or activation state. Cytokines 
are usually not stored as pre-formed proteins, rather their synthesis is typically induced 
by complement- or immunoglobulin-mediated signalling, or by microbial pathogens 
detected by an array of PRRs such as TLRs (Takeuchi and Akira, 2010). Ordinarily 
the production of cytokines is tightly regulated, whereby they are transiently produced 
and then repressed by multiple mechanisms. The tight regulation of cytokine 
production is critical for the resolution of inflammation and subsequent tissue 
homeostasis. Indeed, many inflammatory diseases are characterised by elevated and 
prolonged cytokine production. 
Cytokines are predominantly short-lived and bind to specific cell surface receptors, 
which are differentially expressed by different cell types. Typically, they exert their 
effects locally in an autocrine and paracrine manner, although some including TGF-β 
and M-CSF are also capable of signalling in an endocrine fashion. Traditionally, 
cytokines were commonly classified into two broad groups, pertaining to their 
downstream biological effects: pro-inflammatory (e.g., IL-1β, IL-6, IL-12, IL-18, 
IFNγ and TNF); and anti-inflammatory (IL-4, IL-10, IL-13, IFNα, TGFβ). However, 
cytokines can be highly pleiotropic and as such, can exert different effects on target 
cells, which is dependent on several different determinants including: cell type 
(lineage), differentiation and/or activation states, and the presence or absence of other 
cytokines. With few exceptions, cytokines typically encode a signal peptide, allowing 
them to be synthesised, packaged, and secreted through the classical ER-Golgi 
secretary pathway (Stow et al., 2009). 
 
1.4.3.1 The IL-1 family 
IL-1 family members play a central role in mediating immune responses due to their 
diverse array of biological functions and the wide range of cell types they target. The 
IL-1 family of cytokines comprises 11 members: IL-1α, IL-1β, IL-18, IL-33, IL-36α, 
IL-36β, IL-36γ, IL-1Ra, IL-36Ra, IL-38, and IL-37 (Table 1.4). IL-1 family members 
are thought to have arisen from the duplication of a common ancestral gene, based on 
their highly conserved gene structure, preservation of amino acid sequence, and three-
dimensional structure (Dunn et al., 2001, Taylor et al., 2002b). 
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Typically, IL-1 family members are pro-inflammatory and mediate local and systemic 
inflammatory responses. Therefore, IL-1 family cytokines are tightly regulated at 
multiple levels by various mechanisms including receptor antagonists, decoy 
receptors, negative regulators, and control over the production and maturation of IL-1 
family cytokines (Garlanda et al., 2013). The importance of regulation of IL-1 
cytokines is exemplified in many autoimmune and inflammatory diseases to which 
dysregulated IL-1 signalling has been ascribed to play a critical role (Sims and Smith, 
2010, Gabay et al., 2010, Dinarello, 2010, Dinarello, 2009, Dinarello et al., 2012). 
 
Table 1.4 | IL-1 family members, their receptors, and main functions 
Cytokine Receptor Main function 
IL-1α IL-1R1 Agonist 
Pro-inflammatory 
IL-1β IL-1R1 Agonist 
Pro-inflammatory 
IL-18 IL-18Rα Pro-inflammatory 
IL-33 ST2 Pro-inflammatory 
IL-36α IL-36Rα Pro-inflammatory 
IL-36β IL-36Rα Pro-inflammatory 
IL-36γ IL-36Rα Pro-inflammatory 
IL-37 IL-18Rα Anti-inflammatory – in humans only 
IL-38 IL-36R Receptor antagonist 
Anti-inflammatory 
IL-1RA IL-1R1 Receptor antagonist 
IL-1R1 
IL-37RA IL-36R Receptor antagonist 
IL-36R 
IL-1 family members and signalling reviewed in (Dinarello, 2009) 
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1.4.3.2 IL-1 Signalling 
Most IL-1 family members share characteristics unlike that of other cytokines. First, 
IL-1 family members are predominantly synthesised as precursor proteins, with little 
or no biological activity, that require proteolytic processing to enable full biological 
activity (see 1.4.3.3 IL-1β processing). However, some family members have been 
shown to engage their receptors and initiate signalling cascades in target cells, which 
is evident with both IL-1α and IL-33 (Moussion et al., 2008, Dinarello, 1998). Another 
important feature of IL-1 family members is that except for IL-1 receptor antagonist 
(IL-1Ra), IL-1 family members lack a signal peptide required for conventional protein 
secretion, also known as leaderless proteins. However, the mechanisms governing the 
release of IL-1β are poorly understood. A multitude of non-classical secretory 
pathways have been proposed to mediate the secretion of IL-1β including: via 
exocytosis of secretory lysosomes, via exocytosis of exosomes, by shedding of plasma 
membrane microvesicles, and by export through plasma membrane transporters, 
reviewed in (Piccioli and Rubartelli, 2013, Eder, 2009). 
IL-1 family members signal through a group of closely related receptors, that consists 
of extracellular immunoglobulin domains, a short transmembrane region, and a 
cytoplasmic TIR domain (Sims, 2002). IL-1α and IL-1β share the same cognate 
receptor, type 1 IL-1 receptor (IL-1R1), which is ubiquitously expressed (Dinarello, 
1996). IL-1-receptor binding induces a conformational change in the extracellular 
domain of IL-1R1 that facilitates the recruitment of the co-receptor, IL-1R accessory 
protein (IL-1RAP). Formation of the trimeric complex initiates the recruitment of 
MyD88 and IRAK4, which perpetuate downstream signalling culminating in the 
activation of NF-κB and MAPK pathways (O'Neill, 2008). 
 
1.4.3.3 IL-1β processing 
The production and release of IL-1β is tightly controlled through the combination of 
two distinct signals: transcription as well as maturation and release. The first signal 
(commonly referred to as the ‘Priming’ signal) induces the expression of the 
biologically inactive precursor pro-IL-1β, which is generally mediated through NF-κB 
activity induced by TLR signalling. Typically, the priming signal alone (such as LPS) 
fails to induce the robust processing and secretion of mature IL-1β (Franchi et al., 
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2012). The second signal (‘Activation’ signal) is required for the assembly of a 
multimeric protein complex called the inflammasome (see 1.5   Inflammasomes). The 
assembly of inflammasomes leads to the activation of caspase-1, which subsequently 
proteolytically cleaves pro-IL-1β into the mature biologically active form (Thornberry 
et al., 1992). However, the requirement for two-signals for IL-1β release seems to be 
species-, ligand- and cell-type-dependent specific. With few exceptions, macrophages 
generally require two-signals for the release of IL-1β. Conversely, it has long been 
known that human blood monocytes stimulated with LPS alone secrete IL-1β (Danis 
et al., 1990, Lonnemann et al., 1989, Schumann et al., 1998, Hazuda et al., 1988). 
Similarly, porcine whole blood and PBMCs readily secrete IL-1β in response to LPS 
alone, whereas murine monocytes failed to secrete IL-1β (Gaidt et al., 2016, 
Thorgersen et al., 2009). Later studies showed that human monocytes stimulated with 
TLR2 or TLR4 ligands alone released mature IL-1β, which was attributed to 
constitutive caspase-1 activation and the release of endogenous ATP, which activates 
P2X7 receptors (P2X7R) through an autocrine loop culminating in caspase-1 activation 
(Netea et al., 2009, Piccini et al., 2008). Conversely, other studies indicate that IL-1β 
release from human monocytes is not strictly dependent on autocrine ATP acting on 
P2X7R (Ward et al., 2010, Grahames et al., 1999). Murine BMDCs have also been 
described to secrete mature IL-1β in response to LPS alone (He et al., 2013, Moriwaki 
et al., 2015), although the mechanisms governing human monocyte and murine BMDC 
IL-1β secretion in response to LPS alone are reportedly different (Gaidt et al., 2016). 
Thus, different cell-types have differential requirements for the processing and 
secretion of IL-1β, likely reflecting their separate functions in host defence and 
immunity. 
In addition to cell- and species-specific differential requirements for IL-1β secretion, 
some ligands can act as both a ‘Priming’ and ‘Activatory’ signal and thereby induce 
the processing and release of mature IL-1β. For instance, macrophages stimulated with 
zymosan which is recognised by both TLR2 and dectin-1 (Brown et al., 2002, 
Underhill et al., 1999), induce robust IL-1β processing and secretion via a non-
canonical caspase-8 inflammasome (Gringhuis et al., 2012). 
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1.4.3.3.1 Caspase-1 dependent processing 
In general, the activation of caspase-1 is critically required for the cleavage of pro-IL-
1β and pro-IL-18. Caspase-1 is synthesized as an inactive, monomeric precursor that 
is predominantly activated by inflammasomes (see 1.5   Inflammasomes). In addition 
to the cleavage of pro-IL-1β and pro-IL-18, caspase-1 has been demonstrated to 
mediate a form of cell death, termed pyroptosis, characterised by cell swelling and 
membrane rupture (see 1.6.4 Pyroptosis). 
 
 
Figure 1.8 | Processing sites of pro-IL-1β by caspase-dependent and -independent 
mechanisms. 
Schematic representation of pro-IL-1β protein and cleavage sites for different 
proteases. 
 
1.4.3.3.2 Caspase-1-independent processing 
Although caspase-1-depending processing is the best characterised mechanism of IL-
1β processing, caspase-1-independent cleavage of IL-1β has been reported to play a 
critical role in particulate-induced lung injury, host defence against pathogens, 
osteoarthritis, and other inflammatory diseases (Lukens et al., 2014). In support of 
caspase-1-independent IL-1 processing, genetic deletion of caspase-1 has been 
reported to not completely ablate the production of IL-1β in several IL-1-dependent 
disease models (Kono et al., 2012, Lukens et al., 2012). The caspase-1-independent 
processing of IL-1β has been reported to be mediated by numerous extracellular 
enzymes (Figure 1.8). This is particularly evident in sterile models of inflammation in 
vivo, where tissue-resident macrophages and infiltrating monocytes release pro-IL-1β 
into the extracellular space upon cell death, which is subsequently cleaved by 
macrophage- and neutrophil-derived serine proteases including cathepsin-G, chymase, 
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chymotrypsin, elastase, and proteinase 3 that can cleave pro-IL-1β to bioactive IL-1β 
(Fantuzzi et al., 1997, Joosten et al., 2009). 
Moreover, the proapoptotic enzyme caspase-8 has been reported to mediate IL-1β 
maturation after TLR3 or TLR4 ligation (Maelfait et al., 2008). Furthermore, 
recombinant caspase-8 was shown to cleave pro-IL-1β in vitro at the same site as 
caspase-1 (Asp116), suggesting a direct role for caspase-8 in the cleavage of IL-1β 
(Maelfait et al., 2008). Subsequent studies have shown that a range of stimuli can 
activate caspase-8 to cleave IL-1β in TLR- or TNF-primed cells including Fas death 
receptor ligation (Bossaller et al., 2012), and fungal recognition and binding by dectin-
1, which induce the formation of a CARD9-Bcl-10-MALT1 complex (Gringhuis et al., 
2012), as well as chemicals that induce ER stress, such as tunicamycin (Shenderov et 
al., 2014), proapoptotic chemotherapeutic compounds (for example, staurosporine and 
doxorubicin) (Antonopoulos et al., 2013), and histone deacetylase inhibitors 
(Stammler et al., 2015). Interestingly, TLR4 ligation alone can directly stimulate 
caspase-8 mediated IL-1β maturation, but this mechanism is restricted to BMDCs 
(Moriwaki et al., 2015). Additionally, recent studies have suggested that caspase-8 can 
also activate the NLRP3 inflammasome. For instance, in LPS-stimulated 
macrophages, the chemical or genetic loss of inhibitor of apoptosis (IAP) proteins 
mediated ripoptosome-mediated apoptotic and necroptotic signalling leading to the 
activation of caspase-8 (RIP1K-RIPK3-FADD-caspase-8 signalling), which can 
directly cleave IL-1β, but also induce the activation of the NLRP3 inflammasome 
(Lawlor et al., 2015, Vince et al., 2012, Yabal et al., 2014). The activation of the 
NLRP3 inflammasome by caspase-8 is suggested to be mediated by ROS activity 
(Vince et al., 2012), but further study is needed to fully address how RIP1K-RIP3K-
FADD-caspase-8 complexes activate the NLRP3 inflammasome. 
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1.5   Inflammasomes 
The inflammasomes are a group of multimeric protein complexes that typically consist 
of an inflammasome sensor molecule, the adaptor protein ASC (apoptosis-associated 
speck-like protein containing a CARD (caspase recruitment domain)), and caspase-1. 
To date, five inflammasome sensor molecules have been demonstrated to assemble 
inflammasomes including members of the NLR family (NLRP1b, NLRP3 and 
NLRC4), as well as the receptor proteins absent in melanoma 2 (AIM2) and pyrin 
(Table 1.5). 
Table 1.5 | Inflammasome sensor proteins and activators 
Inflammasome sensor Activators 
NLRP1b Bacillus anthracis lethal toxin 
NLRP3 Cholesterol, Monosodium urate (MSU), Amyloid β, 
Extracellular ATP, Asbestos, Silica 
NLRC4 Flagellin, TTSS rod component 
AIM-2 Cytoplasmic dsDNA (host or microbial) 
Pyrin Inactivation of RhoA 
Abbreviations: RhoA, Ras homolog gene family, member A; TTSS, type III secretion 
system. 
Activatory stimuli of inflammasomes have been extensively reviewed by (Latz et al., 
2013, Broz and Dixit, 2016). 
 
1.5.1 NLRP3 inflammasome and its activation 
1.5.1.1 Canonical NLRP3 inflammasome activation 
The NLRP3 inflammasome is the best characterized inflammasome to date, which has 
been demonstrated to be activated (canonical-activation) by a broad spectrum of 
endogenous and exogenous stimuli including ATP, pore-forming toxins, and 
particulates such as uric acid and crystals, silica, alum adjuvant, asbestos and amyloid 
beta (Latz et al., 2013). The diverse array of stimuli reported to activate the 
inflammasome are structurally and molecularly diverse, which make it unlikely that 
they (all) bind directly to and activate the NLRP3 inflammasome. Therefore, it is most 
likely that inflammasomes monitor cellular homeostasis, which is perturbed by 
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activatory stimuli, and activated when they detect a specific divergence from 
homeostasis, such as the recognition of DAMPs. Currently, three models through 
which diverse stimuli converge and activate the inflammasome have been proposed: 
lysosomal rupture (Hornung and Latz, 2010), cytosolic K+ efflux (Petrilli et al., 2007), 
and ROS generation (Tschopp and Schroder, 2010). However, reports on their relative 
contributions to NLRP3 activation have often been contradictory and a single unified 
model of inflammasome activation has yet to be determined. More recently, on the 
basis of re-examination of these mechanisms, it has been proposed that the release of 
potassium is the downstream convergence point for all NLRP3 activatory stimuli 
(Munoz-Planillo et al., 2013, Broz and Dixit, 2016). Indeed, low potassium medium 
alone is sufficient to activate the NLRP3 inflammasome. However, it is currently 
unknown whether intracellular potassium levels modulate the activation of NLRP3 
directly or whether another event correlates with low intracellular potassium 
concentrations is yet to be determined (Broz and Dixit, 2016). Interestingly, the 
activation and assembly of the apoptosome, a cytosolic molecular complex formed 
during apoptosis, is inhibited by physiological potassium concentrations (Cain et al., 
2001). As such, potassium may regulate the threshold for NLRP3 activation, 
safeguarding the cell against inappropriate formation of the inflammasome from the 
inadvertent release and/or detection of small amount of activatory ligand (analogous 
to cytochrome c in the activation of the apoptosome) (Kanneganti and Lamkanfi, 
2013). However, further work is needed to determine whether potassium efflux 
represents the secondary messenger specifically sensed by the NLRP3 inflammasome. 
 
1.5.1.2 Mitochondrial dysfunction and inflammasome activation 
Mitochondria are double-membrane-bound organelles that have critical metabolic 
functions including oxidative phosphorylation, fatty acid oxidation, and the Krebs 
cycle. In addition to their role in metabolism, mitochondria are complex regulators of 
cytosolic homeostasis. Perturbation of ROS, intracellular K+ concentration or 
lysosomal damage can induce mitochondrial dysfunction and apoptosis (Tschopp, 
2011, Johansson et al., 2010). The role of ROS in the activation of the NLRP3 
inflammasome is a topic of longstanding debate (Lawlor and Vince, 2014, Elliott and 
Sutterwala, 2015). Many studies implicated cytosolic ROS produced by NADPH 
oxidase as a critical mediator of NLRP3 activation. Furthermore, the generation of 
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ROS was one of the first intermediates discovered through which diverse NLRP3 
activatory stimuli converge to activate the inflammasome. Since then, there have been 
many conflicting reports regarding the role of ROS in the activation of the NLRP3 
inflammasome. Firstly, human PBMCs and mouse macrophages lacking NADPH 
oxidase activity (NADPH-dependent ROS production) showed normal NLRP3 
inflammasome activation in response to a range of activatory stimuli (Hornung et al., 
2008, van Bruggen et al., 2010, van de Veerdonk et al., 2010), suggesting that other 
cellular sources of ROS might be responsible for inflammasome activation. More 
recent studies implicated that mitochondrial ROS (mtROS) is responsible for 
inflammasome activation independent of NOX proteins. Dysfunctional mitochondria 
are thought to activate the inflammasome predominantly through the production of 
mtROS, and the release of mitochondrial DNA (mtDNA) and cardiolipin (Nakahira et 
al., 2011, Zhou et al., 2011, Iyer et al., 2013). Furthermore, oxidised mtDNA released 
into the cytosol during apoptosis was shown to directly bind to and activate the NLRP3 
inflammasome (Shimada et al., 2012). However, the release of mtDNA can occur 
downstream of NLRP3 activation and warrants further investigation (Nakahira et al., 
2011). Interestingly, in resting cells NLRP3 is associated with the ER but upon 
activation associates with mitochondria, dependent on the mitochondria anti-viral 
signalling protein (MAVS) (Subramanian et al., 2013, Zhou et al., 2011). However, 
the role of MAVS in inflammasome activation remains controversial. One report 
suggested a requirement for MAVS for NLRP3 activation in response to soluble 
stimuli (ATP, nigericin) but not particulates (alum, MSU) (Subramanian et al., 2013). 
However, several other reports demonstrated that MAVS was required for NLRP3 
activation induced by RNA viruses (which directly engage MAVS), but expendable 
for non-viral stimuli including ATP and nigericin (Franchi et al., 2014, Allam et al., 
2014, Park et al., 2013). 
To prevent cellular damage caused by dysfunctional mitochondria, the cell has adopted 
several mechanisms for controlling mitochondrial quality including mitochondrial 
fission and fusion, the proteolytic degradation of damaged proteins, and the selective 
clearance of dysfunctional mitochondria by autophagy (Park et al., 2015). Indeed, 
impaired removal of damaged mitochondria by autophagy has been implicated in the 
activation of the NLRP3 inflammasome (see 1.5.1.5 Autophagy: Regulation of NLRP3 
activity). 
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1.5.1.3 Non-canonical inflammasome activation 
In addition to the wide array of stimuli that activate the NLRP3 inflammasome 
(canonical), a non-canonical caspase-11 dependent mechanism of NLRP3 activation 
has been described (Kayagaki et al., 2011). Caspase-11 predominantly detects 
intracellular Gram-negative bacteria in the cytosol, but also vacuolar bacteria under 
delayed kinetics (Aachoui et al., 2013). Thus, caspase-11 is thought to mediate 
protection against bacteria that escape the vacuole. More recent studies have indicated 
that intracellular LPS is specifically detected by caspase-11 (Hagar et al., 2013). 
Furthermore, caspase-11 was shown to directly bind LPS via its CARD domain, which 
resulted in oligomerization and activation (Shi et al., 2014). Importantly, the caspase-
11 pathway is not responsive to intracellular LPS alone unless macrophages have been 
primed, which is necessary for the expression of caspase-11 and components of the 
non-canonical inflammasome (Hagar et al., 2013). The detection of Gram-negative 
bacteria activates the TLR4 MyD88- and TRIF-pathways, culminating in the 
activation of NF-κB and subsequent transcription of IL-1β, IL-18, and NLRP3 as well 
as IRF3 and IRF7 genes. IRF3-IRF7 complexes induce type I IFN signalling pathways, 
activating the JAK/STAT pathway and consequent the transcription of caspase-11 
(Schauvliege et al., 2002, Broz et al., 2012, Rathinam et al., 2012b, Aachoui et al., 
2013). In the second step, intracellular LPS binding to caspase-11 and/or unidentified 
scaffold proteins or receptors induce caspase-11 activation (Pellegrini et al., 2017). 
Once activated, caspase-11 induces pyroptosis through the cleavage of gasdermin D, 
as well as the activation of the NLRP3 inflammasome, culminating in the caspase-1-
dependent cleavage of pro-IL-1β and the release of mature IL-1β (Kayagaki et al., 
2015). Caspase-11 is thought to activate the NLRP3 inflammasome indirectly, as a 
result of K+ efflux through membrane pore induced by gasdermin D (Shi et al., 2015, 
Yang et al., 2015b). 
1.5.1.4 Negative regulation of NLRP3 inflammasome 
The NLRP3 inflammasome serves as a vital component to host cell defence against a 
number of microbial pathogens. However, emerging studies have implicated the 
aberrant activation of NLRP3 in a wide range of diseases, including inherited diseases 
(cryopyrin-associated periodic syndrome), as well as complex diseases such as 
multiple sclerosis, type 2 diabetes, Alzheimer's disease, atherosclerosis, obesity and 
gout (Wen et al., 2012, Masters et al., 2009). Accordingly, tight regulation of the 
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NLRP3 inflammasome at the transcriptional and post-translational levels is paramount 
to prevent the onset and progression of these various inflammatory and metabolic 
diseases, reviewed by (Rathinam et al., 2012a). Proteins composed of either a solitary 
CARD (CARD-only proteins; COPs) or a single pyrin domain (PYD-only proteins; 
POPs) have been reported to function as dominant negative molecules of 
inflammasome activation (Latz et al., 2013, Le and Harton, 2013). Accordingly, the 
expression of several COPS and POPS is induced during inflammation, suggesting 
that these molecules form part of the negative feedback loops that regulate the intensity 
and duration of the inflammatory response (Humke et al., 2000). The COP family 
includes COP/Pseudo-ICE (CARD16), INCA (CARD17), and ICEBERG (CARD18), 
caspase-12, and Nod2-S, each with varying degrees of similarity to the CARD of 
caspase-1. COP family members interact with the caspase-1 CARD, sequestering it 
from associating with ASC and thereby preventing IL-1β and IL-18 release (Saleh et 
al., 2006, Druilhe et al., 2001, Lamkanfi et al., 2004). The POP family includes POP1 
and POP2, which mediate their inhibitory effect on inflammasomes by interfering with 
the PYD-PYD interaction between NLRPs and the adaptor protein ASC (Dorfleutner 
et al., 2007, Bedoya et al., 2007). However, more recent studies showed that POP1 
neither inhibited ASC-dependent or NLRP3 inflammasome processing of IL-1β 
(Atianand and Harton, 2011). Interestingly, except for caspase-12, members of the 
COP and POP family are encoded by the human but not mouse genome (Chen and 
Sun, 2013). The presence COPs and POPs in humans suggests that they have more 
complexity with which inflammasomes are regulated. Alternative splicing of ASC 
gives rise to variants that negatively regulate inflammasome activity by inhibiting the 
assembly of inflammasomes (Bryan et al., 2010). Emerging evidence indicates that the 
tripartite-motif (TRIM) family of proteins regulate NLRP3 activity. TRIM30 was 
shown to suppress ROS production in response to a variety of ligands and thereby 
suppressing the activation of the NLRP3 inflammasome (Hu et al., 2010). The orphan 
nuclear receptor small heterodimer partner (SHP) was recently shown to negatively 
regulate NLRP3 activation, by competitively inhibiting the binding of NLRP3 to ASC 
(Yang et al., 2015a). Furthermore, NLRP3 activity has been reported to be regulated 
at the mRNA level. In one study, MicroRNA-223 (miR-223) which binds to the 3’ 
untranslated region (UTR) of NLRP3 mRNA, suppressed NLRP3 expression and 
thereby reduced NLRP3 inflammasome activity (Bauernfeind et al., 2012, Haneklaus 
et al., 2012). Similarly, the RNA-binding protein Tristetraprolin was recently 
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identified to negatively regulate NLRP3 activity by targeting elements in the NLRP3 
mRNA UTR and thereby repress its expression (Haneklaus et al., 2017). Type I IFNs 
have been shown to down-regulate the activity of NLRP3 in a STAT1-dependent 
manner (Guarda et al., 2011). Later studies showed that type I IFNs suppress NLRP3 
activity through the activation of inducible nitric oxide synthase (iNOS), leading to the 
production of NO inhibits the assembly of the NLRP3 inflammasome via thiol 
nitrosylation (Mishra et al., 2013, Mao et al., 2013). Finally, in addition to components 
of the immune system, the neurotransmitter dopamine was recently shown to 
negatively regulate NLRP3 activity via cAMP, which binds to NLRP3 and promotes 
its ubiquitination and subsequent degradation (Yan et al., 2015). Similarly, cAMP 
generated in response PGE2 signalling was demonstrated to inhibit NLRP3 
inflammasome activity (Mortimer et al., 2016).  
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1.5.1.5 Autophagy  
The term ‘autophagy’ (derived from the Greek words auto meaning ‘self’ and phagein 
meaning ‘to eat’) is a general term for the pathways by which cytoplasmic components 
are delivered to lysosome for degradation and has been extensively reviewed (Glick et 
al., 2010, Klionsky et al., 2016). To date, four different types of autophagy have been 
described, including microautophagy, macroautophagy, chaperone-mediated 
autophagy, and non-canonical autophagy. Macroautophagy (hereafter referred to as 
‘autophagy’) is a critically important homeostatic mechanism for the lysosomal 
degradation and recycling of intracellular constituents including macromolecules and 
organelles (Figure 1.9) (Shintani and Klionsky, 2004). Autophagy is highly conserved 
in eukaryotic organisms where it is most widely recognised for its central role in the 
bulk degradation of intracellular components such as long-lived proteins during 
nutrient deprivation (Yoshimori, 2004). However, in mammals, it is now appreciated 
that autophagy plays important roles in a wide array of physiological processes, 
including innate and adaptive immune cell responses (Deretic et al., 2013). Indeed, 
genetic abnormalities in various essential components of autophagy have been 
implicated in the development of diseases including cancer, neurodegeneration, non-
alcoholic fatty liver disease, and Crohn’s disease, reviewed in (Schneider and Cuervo, 
2014). 
1.5.1.5.1 Autophagy: Regulation of NLRP3 activity 
Given the importance of autophagy in various immune pathways, it is perhaps not so 
surprising that autophagic dysfunction perpetuates inflammatory responses, and 
microbial susceptibility and pathogenesis. For instance, the ablation or reduction of 
the autophagy proteins Atg5, Beclin1 and LC3B were demonstrated to have elevated 
NLRP3 inflammasome activation and IL-1β secretion in response to various stimuli 
(Zhou et al., 2011, Nakahira et al., 2011). These findings were corroborated by an 
earlier study where Atg16L1-deficient macrophages stimulated with LPS alone 
secreted IL-1β (Saitoh et al., 2008). Later studies further indicated that autophagy can 
regulate the activation of the NLRP3 inflammasome in multiple ways, from the 
removal of endogenous inflammasome activators such as mitochondrial-derived 
DAMPs, to the direct sequestering and degradation of IL-1β and inflammasome 
components. 
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Autophagy plays a central role in the clearance of dysfunctional mitochondria, in a 
process called mitophagy (Figure 1.9). As such, a deficiency in autophagy results in 
the accumulation of dysfunctional mitochondria, which is thought to contribute to the 
activation of the NLRP3 inflammasome through the production of ROS and release of 
mtDNA Therefore, the clearance of dysfunctional mitochondria by mitophagy is 
essential for preventing hyperactivation of inflammatory responses. Mitophagy is a 
multi-step process that is initiated by PTEN-induced kinase 1 (PINK1), a 
serine/threonine-protein kinase which accumulates on the outer membrane of 
dysfunctional mitochondria with decreased inner membrane potential (Narendra et al., 
2008, Okatsu et al., 2013). PINK1 subsequently recruits the E3 ubiquitin ligase 
(protein) Parkin from the cytosol to mitochondria. Once activated, Parkin 
polyubiquitinates many cytosolic and outer membrane proteins, however, the exact 
mechanism by which mitophagy is induced downstream of these modifications is 
currently unclear and widely debated. One initial report suggested that the autophagy 
receptor p62 (also known as SQSTM1 or sequestosome 1), was required for Parkin-
mediated mitophagy (Geisler et al., 2010). p62 is a highly-conserved ubiquitin- and 
LC3-binding adaptor protein that was shown to mediate the aggregation and 
autophagosomal clearance of mitochondria (Komatsu et al., 2012). However, later 
reports using p62-deficient mouse embryonic fibroblasts indicated that p62 was not 
essential for mitophagy (Narendra et al., 2010, Okatsu et al., 2010). Conversely, one 
recent study showed that myeloid-specific deletion of p62 strongly enhanced LPS-
induced inflammation, resulting from a deficiency in mitophagy (Zhong et al., 2016). 
Thus, it is most likely that these discrepancies arise from distinct cell-type and context-
specific roles of p62. Interestingly, p62 expression was shown to be induced by NF-
κB signalling, suggesting that one of the mechanisms by which NF-κB promotes the 
resolution of inflammation is through the induction of p62 expression, which in turn 
promotes the clearance of dysfunctional mitochondria by mitophagy (Zhong et al., 
2016). In addition to a role in mitophagy, p62 has been suggested to attenuate 
inflammasome activation by targeting inflammasome components to autophagic 
degradation (Shi et al., 2012). Of note, autophagy has also been reported to regulate 
IL-1β secretion by targeting pro-IL-1β for lysosomal degradation, thereby limiting the 
intracellular pro-IL-1β pool for NLRP3-mediated caspase-1 cleavage (Harris et al., 
2011).
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Figure 1.9 | Schematic of mammalian autophagy. 
(a) Cytosolic components are sequestered by an expanding membrane, the phagophore assembly (b) The phagophore is formed upon further 
nucleation. (c) Phagophore membrane elongation and autophagosome completion. (d) The resulting autophagosome fuses with endocytic and 
lysosomal compartments, leading to the formation of autolysosomes. (e) The autophagic cargo is ultimately degraded by lysosomal hydrolases. 
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1.6   Cell death 
In multi-cellular organisms, programmed cell death (PCD) plays a critical role in 
numerous biological processes including tissue remodelling during embryogenesis, the 
development of the immune system and during normal cell turnover. Historically, cells 
were thought to die by one of two modalities: apoptosis or necrosis. These cell death 
modalities were typically distinguished by morphological criteria such as nuclei 
condensation, membrane blebbing, and changes in cell size (Ziegler and Groscurth, 
2004). However, with the advancement of biochemical and genetic exploration of cell 
death, a number of distinct PCD modalities have been identified which have been 
extensively reviewed by (Galluzzi et al., 2012). These advancements have led to a 
greater understanding of the molecular mechanisms that mediate cell death subroutines 
and a switch from morphological criteria to molecular definitions to distinguish 
different modalities (Galluzzi et al., 2012). Relevant modalities of cell death, 
molecular mechanisms and characteristics for this thesis are summarized in (Table 
1.6). 
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Table 1.6 | Cell death subroutines: Molecular definitions, stimuli, and 
biochemical features 
Cell death Stimuli Main biochemical features 
Extrinsic 
apoptosis 
Extracellular stress 
signals: FasL/CD96L, 
TNF, and TRAIL 
Death receptor signalling: 
Caspase-8 (-10) activation 
BID cleavage and MOMP 
Caspase-3 (-6, -7) activation 
Dependence receptor signalling: 
PP2A activation 
DAPK1 activation 
Caspase-9 activation 
Caspase-3 (-6, -7) activation 
Intrinsic 
apoptosis 
Intracellular stress 
signals: DNA damage, 
oxidative stress 
Caspase-dependent: 
Irreversible Δψm dissipation 
MOMP 
Caspase-independent: 
Release of IMS proteins into the cytosol 
Respiratory chain inhibition 
Necrosis  Mitochondrial dysfunction; production 
of ROS, mitochondrial swelling 
ATP depletion 
Perturbed of Ca2+ homeostasis 
Physical characteristics: 
Lysosomal rupture 
Plasma membrane rupture 
Perinuclear clustering of organelles 
Necroptosis MLKL RIPK1 
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RIPK3 
Pyroptosis Stimuli that activate 
inflammasomes 
Caspase-1 activation 
Caspase-7 activation 
Cleavage of GSDMD 
Secretion of IL-1β and IL-18 
Abbreviations: DAPK1, death-associated protein kinase-1; GSDMD, gasdermin D; 
IMS, mitochondrial intermembrane space; MLKL, mixed lineage kinase like.; MOMP, 
mitochondrial outer membrane permeabilization; PP2A, protein phosphatase 2A; 
TRAIL, TNF-related apoptosis-inducing ligand; Δψm, mitochondrial transmembrane 
potential. 
Modalities and molecular mechanisms of cell death subroutines are extensively 
reviewed by the Nomenclature Committee on Cell Death (Galluzzi et al., 2012). 
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1.6.1 Apoptosis 
Apoptosis is a mode of PCD that occurs throughout life in multicellular organisms in 
which it has a critical role in development, homeostasis, and pathogenic responses. 
Broadly speaking, apoptosis is a form of PCD that is highly-regulated, energy-
dependent  and generally considered non-phlogistic (Elmore, 2007). A wide variety of 
physiological and pathological stimuli have been described to trigger apoptosis, for 
which two subroutines have been described: intrinsic and extrinsic apoptosis (Table 
1.6). These stimuli induce the release of ‘find-me’ signals including nucleotides (ATP 
and UTP), phospholipids, and chemokines from apoptotic cells, which help to recruit 
phagocytes (Elliott et al., 2009). The second stage of apoptosis is the expression of ‘eat 
me/phagocytic’ signals on the surface of apoptotic cells. The expression of these 
signals is critical for their specific recognition and clearance by phagocytes (Grimsley 
and Ravichandran, 2003). Many phagocytic signals have been proposed including 
phosphatidylserine (PS), intercellular adhesion molecule-3 (ICAM3), carbohydrates, 
and calreticulin (Gardai et al., 2006). The exposure of phosphatidylserine (PS), an 
anionic phospholipid that in healthy cells predominantly resides on the cytosolic side 
of the plasma membrane, but is exposed to the cell surface in apoptotic cells (Fadok et 
al., 1992, Martin et al., 1995). In one study, PS was masked by a PS-binding protein 
(annexin V) which was shown to inhibit the uptake of apoptotic lymphocytes by 
macrophages, further implicating PS as a strong ‘eat-me’ signal candidate (Krahling 
et al., 1999). However, the externalisation of PS is not strictly indicative of apoptosis, 
as PS exposure has been reported on the surface of endothelial cells of tumour 
vasculature and stressed tumour cells (Ran and Thorpe, 2002, Ran et al., 2002). 
Furthermore, macrophages are reported to have constitutive cell surface expression of 
PS, which is required for the apoptotic clearance of thymocytes (Callahan et al., 2000). 
Numerous membrane receptors have been implicated in the recognition of apoptotic 
cells which directly recognise apoptotic cells including members of the T cell 
immunoglobulin mucin domain (TIM) protein family, stabilin 2, and brain-specific 
angiogenesis inhibitor 1 (BAI1). Conversely, the recognition of apoptotic cells can be 
mediated by soluble bridging molecules including protein S, MFGE8, and GAS6, 
which bind to apoptotic cells and are subsequently recognised by phagocytes (see 
1.3.1.1 Humoral PRRs). However, it remains to be defined whether certain 
mechanisms of apoptotic recognition (membrane receptors vs soluble bridging 
60 
 
molecules) are only required under certain conditions (tissue development, 
inflammation, cell turnover), or whether these multiple mechanisms governing 
apoptotic cell recognition provide a degree of redundancy. Mechanisms of apoptotic 
recognition have recently been reviewed (Poon et al., 2014, Erwig and Henson, 2007). 
After phagocytosis, the apoptotic cell is processed via a phagolysosome pathway that 
results in the degradation of the apoptotic cell (Kinchen and Ravichandran, 2010, 
Kinchen et al., 2008). The final stage of apoptosis, commonly referred to as post-
engulfment consequences, involves the release of anti-inflammatory cytokines and 
pro-resolving factors. The release of these factors typifies the predominantly 
immunotolerant (pro-resolving) properties of apoptosis, although under certain 
contexts apoptotic cells have been reported to be highly immunogenic (Casares et al., 
2005, Zitvogel et al., 2004). Upon phagocytosis of apoptotic cells, macrophages 
release anti-inflammatory cytokines (TGF-β, IL-10) whilst concurrently inhibiting 
NF-κB signalling and production of pro-inflammatory cytokines (IL-1β, TNF, IL-12), 
granule enzymes, and lipids such as thromboxane B2 (Meagher et al., 1992, Fadok et 
al., 1998, Ipseiz et al., 2014, Voll et al., 1997). Furthermore, TLR ligands were shown 
to synergize with phagocytosed apoptotic cells, enhancing the production of pro-
inflammatory cytokines and chemokines at early time points, but suppressing the 
production of pro-inflammatory cytokines and increasing the production of TGF-β at 
later time points compared to stimulation with TLR ligands alone (Lucas et al., 2003). 
This combinatorial response to apoptotic cells and TLR ligands suggests that apoptotic 
clearance mediates the recruitment and activation of the innate response to clear 
pathogens, whilst promoting later resolution of inflammation. However, if the 
clearance of apoptotic cells is impaired or delayed, they may begin to lose their 
membrane integrity and progress to secondary necrosis following a sequence of 
molecular events that have been extensively described (Silva, 2010, Kim et al., 2003, 
Vanden Berghe et al., 2010). Secondary necrotic cells release intracellular components 
(DAMPs) that are thought to be recognised by PRRs and provoke an inflammatory 
response, which is thought to contribute to a range of autoimmune and inflammatory 
disorders including rheumatoid arthritis, systemic lupus erythematosus, and 
atherosclerosis (Poon et al., 2014, Gaipl et al., 2004, Rodriguez-Manzanet et al., 2010). 
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1.6.2 Necrosis 
Unlike apoptosis, necrosis was historically described as a form of premature cell death 
(non-programmed), usually triggered by external stimuli including toxins, infection, 
and trauma/sterile inflammation. Necrosis is characterised by a rapid loss of membrane 
integrity and the release of intracellular components into the extracellular space. In 
contrast to apoptosis, necrotic cell death in vivo almost invariably triggers local tissue 
damage and inflammation. Some of the intracellular components released by cells 
undergoing necrosis act as endogenous danger signals (DAMPs), that are recognised 
by PRRs and subsequently promote and exacerbate the inflammatory response. It has 
been proposed that necrosis constitutes a default cell death pathway (Golstein and 
Kroemer, 2007), which is supported by studies in which the inhibition of essential 
apoptotic machinery and autophagic proteins results in necrosis when stimulated with 
ligands that induce apoptosis (Shimizu et al., 2004, Degenhardt et al., 2006). 
Furthermore, inhibition of caspases can sensitize cells to the induction of necrosis by 
stimuli such as TNF; indicating that elements of the apoptotic signalling pathway 
might inhibit necrosis. Interestingly under these specific conditions, the spatiotemporal 
pattern of necrotic cell death follows that of apoptosis, indicating that necrosis simply 
substitutes for failed apoptosis (Golstein and Kroemer, 2007). 
1.6.3 Necroptosis 
Although necrosis has generally been considered a non-programmed cell death 
modality, in recent years, it has become increasingly evident that in some settings, 
necrotic cell death can be driven by defined molecular pathways, i.e., regulated 
necrosis. One such mechanism of regulated necrosis called ‘necroptosis’ has been 
described, which is characterised morphologically by organelle swelling and plasma 
membrane integrity loss (Pasparakis and Vandenabeele, 2015). Although TNF was 
reported to induce necrosis in cancer cells in the mid-1970s (Carswell et al., 1975), it 
was not until 25 years later than Holler and colleagues identified that receptor 
interacting protein kinase 1 (RIPK1 also referred to as RIP1) was the key regulatory 
molecule of necrosis induced by the death receptor ligands such as TNF (Holler et al., 
2000). Later studies have shown that necroptosis is initiated following activation by a 
number of stimuli including death receptor ligands, TLRs, IFNs, and intracellular RNA 
and DNA sensors (Pasparakis and Vandenabeele, 2015, Thapa et al., 2013, He et al., 
2011). These stimuli mediate the activation of RIPK1 and RIPK3, leading to the 
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formation of a pro-necrotic complex (the necrosome) through their RIP homotypic 
interaction motif (RHIM). The effector mixed lineage kinase like (MLKL) is recruited 
to the necrosome and binds to RIPK3 through its kinase-like domain. RIPK3 
subsequently phosphorylates MLKL at the T357 and S358 sites, inducing a 
conformational change in MKLK, exposing its N-terminal death effector domain 
(four-helix bundle domain) (Hildebrand et al., 2014). MLKL subsequently translocates 
to the plasma membrane and causes its permeabilization, and thus necroptosis (Cho et 
al., 2009, Zhang et al., 2009, He et al., 2009, Wang et al., 2014, Dondelinger et al., 
2014, Chen et al., 2013, Cai et al., 2014). 
1.6.4 Pyroptosis 
Pyroptosis is a lytic form of cell death that is important for host defence against 
pathogens but can also result in a potent and sometimes pathological inflammatory 
response (Jorgensen and Miao, 2015). The mechanism of IL-1β secretion is an 
enduring question since the discovery that IL-1β lacks a signal peptide, which is 
required for classical secretion. Pyroptosis was first characterised as an inherently pro-
inflammatory form of programmed cell death (PCD) that was dependent on caspase-1 
and correlated with IL-1β secretion (Fink and Cookson, 2005). However, it was 
typically argued that IL-1β release preceded cell death and/or that cell death was not 
intrinsically linked to the release of mature IL-1β. Later studies showed that non-
canonical inflammasome activation caused pyroptosis in a caspase-11-dependent 
manner (caspase-4/5 in humans) (Kayagaki et al., 2011, Shi et al., 2014). More 
recently, gasdermin D (GSDMD) was identified as the critical mediator of pyroptotic 
cell death (Shi et al., 2015, He et al., 2015, Kayagaki et al., 2015). When activated, 
inflammatory caspases (caspases-1, -11) cleave mouse GSDMD generating an N-
terminal cleavage product (GSDMD-NT), which oligomerises in membranes to form 
pores and ultimately trigger pyroptotic cell death and release of IL-1β (Liu et al., 
2016). Pyroptosis is thought to be critical for the release of mature IL-1β from the cell 
(Martín-Sánchez et al., 2016). Supporting this, an earlier study showed that in THP1 
cells all NLRP3 stimuli tested induced necrosis, with plasma membrane 
permeabilization (PI uptake) coinciding with the release of IL-1β (Cullen et al., 2015). 
Furthermore, viable cells stimulated with these NLRP3 activators retained mature IL-
1β, implicating membrane permeabilization as the mechanism by which mature IL-1β 
is released (Cullen et al., 2015). Supporting this, single-cell imaging showed that the 
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activation of caspse-1 exhibits all-or-nothing (digital) activation at the single-cell 
level. Furthermore, IL-1β release was only detected in dead macrophages containing 
active caspase-1 (Liu et al., 2014). However, this requirement is cell-type specific, as 
some cells release mature IL-1β without membrane rupture, notably human monocytes 
and murine neutrophils (Chen et al., 2014, Gaidt et al., 2016). Interestingly, the release 
of mature IL-1β from LPS-primed macrophages stimulated with different NLRP3 
stimuli was inhibited when treated with punicalagin, which stabilised plasma 
membranes and consequently inhibited plasma membrane permeabilization (induced 
by GSDMD-NT) (Martín-Sánchez et al., 2016). Furthermore, both active caspase-1 
and mature IL-1β were retained inside the cell, supporting a role for punicalagin in 
preventing the release of IL-1β and not by inhibiting the activation of the 
inflammasome and processing of IL-1β. Strikingly, when LPS-primed neutrophils 
(which release IL-1β independently of pyroptosis) were stimulated with NLRP3 
stimuli in the presence of punicalagin, the release of IL-1β was inhibited. These studies 
suggest an important common mechanism of IL-1β secretion (through membrane 
pores), but that cell-death is differentially regulated in different cell-types. 
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1.7   Hypothesis 
To date, limited studies have addressed how the loss of tissue-specific transcription 
factors effects the inflammatory responses of tissue-resident macrophage populations. 
As such, the work presented in this thesis aimed to identify whether Gata6 was 
important for the regulation of the inflammatory response and its resolution, and 
whether analogous factors control the development, phenotype or function of other 
myeloid cells. 
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2 Chapter Two - Materials and 
Methods  
Chapter Two 
Materials and Methods 
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2.1 Reagents 
2.1.1 Ligands 
Unless otherwise stated, Ultra-pure LPS-EB from E. coli O111:B4 (InvivoGen) was 
used for the work presented in this thesis. 
Ligand Target Source 
Pam3CSK4 TLR1/2 agonist InvivoGen 
Zymosan from Saccharomyces 
cerevisiae 
TLR2 and dectin-1 agonist Invitrogen 
Poly(I:C) (HMW) TLR3 agonist InvivoGen 
Ultra-pure LPS-EB from E. coli 
O111:B4 
TLR4 agonist InvivoGen 
LPS from E. coli O111:B4 TLR4 agonist Sigma 
Flagellin TLR5 agonist InvivoGen 
R848 (Resiquimod) TLR7/8 agonist InvivoGen 
CpG ODN 1826 TLR9 agonist InvivoGen 
 
2.1.2 Chemical compounds and their effects 
Compound Target/effect Source 
Ac-YVAD-cmk Selective and irreversible inhibitor of 
caspase-1 
Sigma 
Adenosine Binda adenosine receptors, which can 
down-regulate pro-inflammatory cytokine 
and increase anti-inflammatory cytokine 
production 
Sigma 
Apyrase Hydrolyses ATP to AMP Sigma 
ATP Binds to P2X receptors, triggering 
potassium efflux 
Sigma 
Bafilomycin A1 Inhibits vacuolar H+ ATPase, preventing 
the maturation of autophagic vacuoles by 
Sigma 
67 
 
inhibiting the fusion between 
autophagosomes and lysosomes 
BAPTA-AM Cell-permeant Ca2+ chelator, inhibiting 
Ca2+-dependent signalling 
Life-
technologies 
Chloroquine Lysosomotropic agent that prevents 
endosomal acidification, thereby 
preventing the maturation of autophagic 
vacuoles by inhibiting the fusion between 
autophagosomes and lysosomes 
Tocris 
Bioscience 
Dibutyryl-cAMP (DB) cAMP analogue Sigma 
Enbrel® (Etanercept) Soluble TNF receptor (blocks TNF 
signalling) 
Kind gift 
from Dr 
Gareth Jones 
(Cardiff 
University) 
Indomethacin COX1/2 inhibitor Cambridge 
Bioscience 
MCC950 Selective small molecule inhibitor of 
NLRP3 inflammasome activation 
Kind git from 
Dr Avril 
Robertson 
(University 
of 
Queensland) 
Mito-TEMPO Mitochondria-targeted antioxidant with 
alkyl and superoxide scavenging 
properties 
Enzo Life 
Sciences 
N-acetyl-L-cysteine 
(NAC) 
An antioxidant which scavenges ROS Sigma 
Nigericin Microbial toxin that acts as a potassium 
ionophore 
Invivogen 
Recombinant mouse 
IL-1ra 
Receptor antagonist which blocks IL-1 
signal transduction 
Recombinant 
mouse IL-1ra 
was from 
R&D 
systems and a 
kind gift 
from Dr 
Selinda Orr 
Rp-Adenosine 3′,5′-
cyclic 
monophosphorothioate 
triethylammonium salt 
(Rp-cAMPs) 
Specific membrane-permeable inhibitor of 
the activation of cAMP-dependent protein 
kinases I and II by cAMP 
Sigma 
Sodium Beraprost PGI2 analogue Cambridge 
Bioscience 
Torin2 Potent and selective mTOR inhibitor Tocris 
Bioscience 
Wortmannin Specific and potent PI3-K inhibitor. 
Inhibits autophagic sequestration 
Sigma 
  
68 
 
2.1.3 Solutions and buffers 
Ammonium-Chloride-Potassium (ACK) lysis buffer (pH 7.2) 
150 mM NH4Cl 
10 mM KHCO3 
0.1 mM Na2EDTA 
Annealing buffer (pH 7.5) 
10 mM Tris 
50 mM NaCl 
1 mM EDTA 
Cell-freezing medium 
90% FBS 
10% Dimethyl sulfoxide (DMSO) 
Cell-sorting buffer 
1X DPBS 
0.5% (w/v) Bovine serum albumin (BSA) 
2 mM EDTA 
FACS permeabilization buffer 
1X DPBS 
0.5 % (w/v) BSA 
5 mM EDTA 
2 mM NaN3 
0.5% (w/v) saponin 
FACS wash 
1X DPBS 
0.5% (w/v) BSA 
5 mM EDTA 
2 mM NaN3 
MACS buffer 
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1X DPBS 
0.5% (w/v) BSA 
2 mM EDTA 
Mammalian lysis buffer 
100 mM Tris (pH8.5) 
5 mM ethylenediaminetetraacetic acid (EDTA) 
0.2% (w/v) sodium dodecylsulphate (SDS) 
200 mM sodium chloride (NaCl) 
MUSE staining solution 
1X DPBS 
625 ng ml-1 Propidium iodide (PI) 
500 ng ml-1 LDS 751 
Lavage solution 
1X DPBS 
5 mM EDTA 
Radio-Immunoprecipitation Assay (RIPA) buffer 
150 mM NaCl 
1% Triton X-100 
0.5% sodium deoxycholate 
0.1% SDS 
50 mM Tris (pH 8.0) 
1 mM EDTA 
Running buffer (pH 8.3) 
25 mM Tris 
192 mM Glycine 
0.1% (w/v) SDS 
Stripping buffer (pH 6.7) 
100 mM βME 
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2% (w/v) SDS 
62.5 mM Tris-HCL 
Transfer buffer (pH 8.3) 
25 mM Tris 
192 mM Glycine 
20% (v/v) methanol 
Tris-buffered saline (TBS) (pH 7.6) 
137 mM NaCl 
20 mM Tris 
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2.2 Animals 
The animals used in this study were bred and maintained in Cardiff University’s Joint 
Biological Services Unit in specific pathogen-free (SPF) conditions. All experiments 
were performed in accordance with institutional and UK home office guidelines. 
Unless specified otherwise, mice were sacrificed by asphyxiation by rising CO2 
concentration, followed by cervical dislocation. 
2.2.1 Genotyping 
Genotyping of mice was performed on genomic DNA extracted from ear punch 
biopsies. Ear punch biopsies (performed by JBIOS staff for genotyping purposes) were 
placed into 1.5 ml microcentrifuge tubes (STARLAB) into which 50 µl mammalian 
lysis buffer supplemented with 100 µg ml-1 Proteinase K was added. The samples were 
incubated at 52°C for 1 hour in a Thermoshaker (Grant) with 1200 revolutions per 
minute (rpm). The proteinase K was inactivated by incubating samples at 72°C for 30 
minutes. The tubes were left to equilibrate to room temperature, after which 400 µl 
UltraPure™ DNase/RNase-free water (Life Technologies) was added to each sample; 
which were then vortexed for 5 seconds and incubated at room temperature (RT) for 
10 minutes. To distinguish Gata6Fl/Fl, Lyz2+/+ (‘Gata6-WT’) from Gata6Fl/Fl, 
Lyz2+/cre (‘Gata6-KOmye’) mice, 1 µl supernatant was used as a template in a standard 
PCR reaction (2.8.1), using primers specific for cre. The reaction was separated by 
agarose gel electrophoresis (2.8.1.1) and Gata6-KOmye mice were identified by the 
presence of an amplicon. 
2.2.2 Procedures 
2.2.2.1 Experimental peritonitis 
Experimental peritonitis was induced by a single 100 µl intraperitoneal injection of 
LPS O111:B4 (Sigma) in PBS (LPS dose and time-period as indicated in figure 
legend). Following sacrifice, total peritoneal cells were harvested by modified 
peritoneal lavage (see 2.3.7.2.1.1 Modified peritoneal lavage).  
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2.3 Mammalian cell culture 
2.3.1 General cell culture 
Mammalian cells were maintained in a humified incubator at 37°C with 5% CO2 unless 
otherwise stated. 
2.3.2 Cryopreservation of cells 
Sub-confluent cell lines were harvested and centrifuged at 350 x g for 5 minutes. The 
supernatant was aspirated and the cell pellet re-suspended (2-4x106 cells/ml) in cell 
freezing medium. A 1 ml aliquot was then transferred into a cryogenic storage vial 
(Greiner Bio-One) which was then placed in a ‘Mr. Frosty™’ Freezing container 
(Thermo Fisher Scientific), filled with 100% isopropanol alcohol (Thermo Fisher 
Scientific), and subsequently stored at -80°C. The Mr Frosty Freezing container is a 
rate-controlled freezer, which cools at a rate of approximately 1 °C/minute. 
2.3.3 Determination of cell number and viability 
Unless otherwise stated, all experiments in this thesis were performed with samples 
that had greater than 95% cell viability, as determined by Trypan Blue or propidium 
iodide exclusion. 
2.3.3.1 Haemocytometer 
Cells were counted using a Neubauer Bright-Line™ Hemocytometer. An aliquot of 
harvested cells were stained with 0.4% Trypan Blue Solution and mixed thoroughly. 
The stained cell suspension was applied to the haemocytometer. Viable cells were 
distinguished from non-viable cells by the differential uptake of Trypan Blue, which 
is a membrane-impermeant dye that is excluded from viable cells but is taken up by 
non-viable cells. The total number of viable cells in each of the four large corner 
squares of the haemocytometer were counted under a Nikon Eclipse TS100 inverted 
light microscope. After counting, the concentration of viable cells in the original 
sample was calculated using the following formula: 
Total viable cells/ml =
 Total viable cells counted x dilution factor
Number of large squares counted
 × 10000 
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2.3.3.2 Muse® Cell Analyser 
The Muse® Cell Analyser (Merck Millipore) was primarily used to determine both the 
total cell number and percentage viability of cells by differential staining of two dyes; 
Propidium iodide (PI) and LDS 751. PI is a membrane impermeant nucleic acid-
binding dye that is generally excluded from viable cells and can therefore be used to 
stain non-viable cells, whereas LDS 751 is a fluorescent cell-permeant nucleic acid 
stain that stains all nucleated cells. Cells were stained with MUSE staining solution 
and incubated at room temperature for 5 minutes. After incubation, the cells were 
analysed by the Muse® Cell Analyser to determine the total cell number and viability 
in the sample. 
2.3.4 Recovery of cryopreserved cells 
Cryopreserved cells were thawed rapidly by placing the cryogenic storage vial in a 
37°C water bath until approximately 80% thawed. The vial was then decontaminated 
by spraying with 70% isopropanol. The cells were then removed and added to a 50 ml 
falcon tube containing 9 ml pre-warmed growth medium and centrifuged at 350 x g 
for 5 minutes. After centrifugation, the supernatant, containing DMSO, was removed 
and the cells re-suspended in fresh growth medium and seeded into an appropriate 
culture vessel. Typically, 24 hours after seeding the medium was refreshed. 
2.3.5 Cell lines 
2.3.5.1 Human Embryonic Kidney 293T (HEK 293T, ‘293T’) cells 
The 293T cell line is a derivative of HEK 293 cell line that contains the SV40 large T-
antigen, which allows episomal replication of transfected plasmids which contain the 
SV40 origin of replication (DuBridge et al., 1987). 293T cells were cultured in 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% Foetal bovine 
serum (FBS), 100 U ml-1 penicillin, 10 µg ml-1 streptomycin and 400 µM L-glutamine 
(Gibco®, Thermo Fisher Scientific). Cells were sub-cultured at a ratio of 1:3 to 1:8 
every 2-3 days, when the cells were approximately 80% confluent. The growth 
medium was aspirated and the cells washed with DPBS, which was then removed. Pre-
warmed Trypsin-EDTA (Thermo Fisher Scientific) was added to the tissue culture 
flask and incubated at 37°C for 5 minutes. After incubation, the flask was carefully 
gyrated to assist cell-detachment and examined under an inverted microscope to ensure 
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the cells had detached from the tissue culture vessel. An equal volume of complete 
medium was added to the flask to neutralise the Trypsin-EDTA. The cell suspension 
was added to a 50 ml falcon tube and centrifuged at 350 x g for 5 minutes. The 
supernatant was aspirated, after which complete medium was added and the cells 
gently re-suspended by pipetting to achieve a single-cell suspension. Appropriate 
aliquots of the cell suspension were then added to new tissue culture vessels. 
2.3.5.2 Jurkat E6-1 
Jurkat cells are an immortalised line of human T lymphocytes, established from the 
peripheral blood of a 14-year-old boy with acute T cell leukaemia (Schneider et al., 
1977). Jurkat cells were maintained in Roswell Park Memorial Institute medium 
(RPMI) 1640 supplemented with 10% FBS, 100 U ml-1 penicillin, 10 µg ml-1 
streptomycin and 400 µM L-glutamine. The cell suspension was transferred into a 
sterile 50 ml falcon tube and centrifuged at 350 x g for 5 minutes. The supernatant was 
aspirated and the cells re-suspended in fresh growth medium and aliquoted into new 
tissue culture vessels. 
2.3.5.3 RAW 264.7 
RAW 264.7 are an immortalised murine macrophage cell line established from an 
ascites of a tumour induced in a male BALB/c mouse by intraperitoneal injection of 
Abelson murine leukaemia virus. Raw 264.7 cells were maintained in DMEM 
supplemented with 10% FBS, 100 U ml-1 penicillin, 10 µg ml-1 streptomycin and 400 
µM L-glutamine. Cells were sub-cultured at a ratio of 1:5 every 3-4 days. Subcultures 
were prepared by scraping sub-confluent monolayers with a plastic cell scraper to 
detach the cells from the tissue culture vessel. The cell-suspension was transferred to 
a 50 ml falcon tube and the cells pelleted by centrifugation at 350 x g for 5 minutes. 
The supernatant was aspirated and the cells re-suspended in fresh growth medium. The 
cell suspension was gently pipetted to attain a single-cell suspension, which was then 
aliquoted into new tissue culture vessels. 
2.3.5.4 Human bladder carcinoma cell line 5637 (5637) 
2.3.5.4.1 5637 cell culture 
Human bladder carcinoma cell line 5673 (5637) cells were maintained in RPMI 1640 
supplemented with 10% FBS, 100 U ml-1 penicillin, 10 µg ml-1 streptomycin and 50 
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µM beta-mercaptoethanol (βME). Cells were sub-cultured as in (2.3.5.1), at a ratio of 
1:6 every 2-3 days. 
2.3.5.4.2 Preparation of 5637 conditioned medium (5637-CM) 
5637 conditioned medium (5637-CM) was prepared by seeding 1.5 x 107 cells in 30 
ml complete medium in 180 cm2 tissue culture flasks, which were incubated overnight. 
The following day when the cells were confluent, the growth medium was aspirated, 
replenished with 30 ml fresh growth medium and incubated for 48 hours. After 
incubation, the medium was collected and centrifuged at 500 x g for 10 minutes. The 
cell-free supernatant was filtered through a 0.22 µm filter (Merck Millipore), aliquoted 
into sterile 7 ml bijou containers (Greiner Bio One) and stored at -20°C. 
2.3.5.5 MUTZ-3 
2.3.5.5.1 MUTZ-3 culture 
The MUTZ-3 cell line was established from the peripheral blood of a 29-year-old man 
with acute myeloid leukaemia (AML). MUTZ-3 wells were maintained in complete 
medium (Minimum Essential Medium α (MEM α) containing ribonucleosides and 
deoxyribonucleosides supplemented with 20% (v/v) FBS, 100 U ml-1 penicillin, 10 µg 
ml-1 streptomycin, and 50 µM βME supplemented with 10% (v/v) 5637-CM 
(2.3.5.4.2). MUTZ-3 cells were cultured in 12-well tissue culture plates by seeding 
cells at a concentration of 2 x 105 cells/ml in 2 ml medium. The medium was 
replenished after 3-4 days by adding 2 ml fresh medium. After another 3-4 days, the 
cells were transferred into a 50 ml falcon tube and pelleted by centrifugation at 350 x 
g for 5 minutes. The supernatant was aspirated and the cells re-suspended in fresh 
growth medium. The cells were counted (2.3.2) and re-seeded at 2 x 105 cells/ml in 2 
ml medium in 12-well tissue culture plates. 
2.3.5.5.2 Generation of MUTZ-3-derived LCs (MuLCs) 
To generate MUTZ-3-derived LCs (MuLCs), 2 x 105 MUTZ-3 precursors were seeded 
in 12-well tissue culture plates in 2 ml complete medium (2.3.5.5.1) supplemented 
with 100 ng ml-1 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), 10 
ng ml-1 Transforming Growth Factor-β2 (TGF-β2) and 2.5 ng ml-1 Tumor Necrosis 
Factor (TNF) (PeproTech) human recombinant proteins, and cultured for 10 days. The 
medium was refreshed on day 4 and 8 by exchanging 1 ml expended growth medium 
and with 1 ml fresh growth medium containing the appropriate concentration of 
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cytokines. On day 10, MuLCs were either harvested or stimulated to induce maturation 
(as outlined below). 
2.3.5.5.3 MuLC maturation 
To induce maturation of MuLCs, cells were stimulated with 1 µg ml-1 LPS O111:B4 
(Sigma) which was added directly into culture medium on day 10 for 24 hours. After 
incubation, immature and mature MuLCs were harvested by gentle pipetting. 
2.3.6 Primary human cells 
2.3.6.1 Isolation of Peripheral Blood Mononuclear Cells (PBMCs) 
and CD14+ Monocytes 
Buffy coats (50 ml) from anonymous healthy donors were obtained from the Welsh 
Blood Service. The blood was pipetted to a sterile 250 ml tissue culture flask into 
which sterile PBS was added to bring the total volume to 180 ml. Afterwards, 15 ml 
Ficoll (Ficoll-Paque Plus, GE Healthcare) was added to six 50 ml falcon tubes. The 
diluted blood (30 ml) was carefully pipetted on top of each Ficoll layer, after which it 
was centrifuged for room temperature 30 minutes at 800 x g without deceleration. The 
Peripheral Blood Mononuclear Cells (PBMC) was carefully collected and washed 
three times with sterile PBS. The cells were counted after which CD14+ monocytes 
were isolated using anti-CD14+ MACS® MicroBeads (Miltenyi Biotec), following the 
protocol outlined in (2.4.2.8.1 Direct magnetic labelling). 
2.3.6.2 Generation of monocyte-derived dendritic cells (MoDCs) 
To generate monocyte-derived dendritic cells (MoDCs) isolated CD14+ monocytes 
were cultured in complete medium (Iscove's Modified Dulbecco's Medium (IMDM) 
supplemented with 10% (v/v) FBS, 100 U ml-1 penicillin, 10 µg ml-1 streptomycin, 10 
mM HEPES Buffer (Sigma Aldrich), 1% minimum essential medium non-essential 
amino acids (Thermofisher Scientific), 1mM sodium pyruvate (Thermofisher 
Scientific), and 50 µM βME). The cells were seeded in 6 well plates at a density of 2 
x 106 cells per well in complete medium supplemented with 500 U ml-1 GM-CSF and 
500 U ml-1 IL-4 (Miltenyi Biotec). The medium was replenished every two days by 
exchanging a third of the expended medium with fresh medium containing the 
appropriate concentration of cytokines. On day 7 the differentiated MoDCs could be 
harvested. 
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2.3.6.3 Generation of Monocyte-derived Langerhans Cells 
To generate monocyte-derived Langerhans cells (MoLCs) isolated CD14+ monocytes 
were cultured in complete medium (RPMI 1640 supplemented with 10% FBS, 100 U 
ml-1 penicillin, 10 µg ml-1 streptomycin and 400 µM L-glutamine). The CD14+ 
monocytes were seeded at 1 x 106 cells/ml in complete medium supplemented with 
GM-CSF (500 U ml-1), IL-4 (500 U ml-1) and TGF-β (10 ng ml-1) (Peprotech). The 
expended medium was replenished on day 3 of differentiation. The differentiated 
MoLCs were harvested after 7 days of differentiation. 
2.3.7 Primary murine cells 
2.3.7.1 Bone marrow-derived macrophages (BMDMs) 
2.3.7.1.1 Isolation of bone marrow (BM) precursors 
After killing, the mice were sprayed with 70% isopropanol. A small incision was made 
to the ventral abdominal skin, anteriorly to the urethral opening. The posterior skin 
was then pulled down over each hind limb and over the foot. The foot was cut off just 
below the talocrural joint and at the acetabulofemoral joint with scissors, taking care 
to ensure that the femur and tibia remained intact. The soft tissue was carefully 
removed using scissors and forceps. Lint-free tissue was used to remove any remaining 
soft tissue. The bones were subsequently processed under aseptic conditions in a 
laminar flow hood. The bones were sterilized by placing them into a 30mm sterile 
plastic dish (Greiner Bio-One) containing 70% ethanol (EtOH) for 1 minute. The 
bones were washed twice with PBS to remove any traces of EtOH. Using sterile 
scissors and forceps, the epiphyses of individual femurs and tibia were removed. A 10 
ml syringe with a 25G needle containing 10 ml complete medium (DMEM 
supplemented with 10% FBS, 100 U ml-1 penicillin and 10 µg ml-1 streptomycin) was 
inserted into the bone marrow lumen and used to flush the bones, until the bone cavity 
appeared white. The bone marrow exudate was collected into a sterile 50 ml falcon 
tube. This process was repeated for the remaining bones. The pooled cell suspension 
was gently pipetted up and passed through a 70 µM cell strainer into a falcon tube. The 
cell suspension was centrifuged at 350 x g for 5 minutes, the supernatant aspirated and 
the cells re-suspended in 1 ml Ammonium-Chloride-Potassium (ACK) lysis buffer and 
incubated for 1 minute at room temperature. After incubation, 9 ml DPBS was added 
to the cell suspension and mixed by gentle pipetting. The cell-suspension was then 
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carefully underlaid with 1 ml FBS and subsequently centrifuged at 350 x g for 5 
minutes. The supernatant was aspirated and the cells washed twice with complete 
medium; the supernatant was aspirated, the cells re-suspended in complete medium 
and centrifuged at 350 x g for 5 minutes. After washing the cells were counted (see 
2.3.2), after which the cells could be either frozen and stored (2.3.2) or differentiated 
(see 2.3.7.1.2). 
2.3.7.1.2 Generation of BMDMs 
Bone marrow-derived macrophages (BMDMs) were differentiated from BM 
precursors by seeding 1x107 cells onto a 145 mm bacteriological plastic dish (Greiner 
Bio-One) in 25 ml DMEM supplemented with 10% (v/v) FCS, 100 U/mL penicillin, 
10 µg/mL streptomycin and 20 ng ml-1 murine M-CSF (Peprotech). After 3 days, 25 
ml complete medium was added to the cells. After another 3 days of culture, 25 ml 
medium was removed and replenished with 25 ml fresh complete medium. After 7 
days, the adherent BMDMs could be harvested. The growth medium was aspirated and 
the cells washed with ice-cold DPBS, which was then removed. The cells were 
harvested by adding 5 ml PBS supplemented with 5 mM EDTA and 8 mg ml-1 of 
lidocaine hydrochloride monohydrate (Sigma-Aldrich) and incubated for 5 minutes at 
37°C. After incubation, the cells were gently detached from the dish using a sterile cell 
lifter (Thermo-fisher Scientific). The cells were counted and seeded into an appropriate 
culture vessel for further experimentation in complete medium. The cells were counted 
and seeded into an appropriate tissue culture vessel for further experimentation. 
Typically, cells were not used for longer than 7 days after differentiation and were 
maintained in culture with complete medium supplemented with 20 ng ml-1 murine M-
CSF. 
2.3.7.2 Peritoneal macrophages (pMϕ) 
2.3.7.2.1 Peritoneal lavage 
After sacrifice, 5 ml ice-cold lavage solution was instilled into the peritoneal cavity 
with a 21G-needle, taking care to ensure no organs were punctured. The needle was 
then either left in the peritoneal cavity, or the needle entry site plugged by drawing 
abdominal fat into the needle entry site. The abdomen was then gently massaged to 
suspend the peritoneal cells in the lavage solution. The needle was drawn to the user’s 
left-hand side (right hand side of mouse) away from the viscera and with the bevel-
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side facing inwards, the lavage solution slowly withdrawn. The mouse was also rolled 
so that the lavage fluid accumulated near the needle. If necessary, the needle would be 
withdrawn and inserted to remove any remaining lavage solution. The lavage solution 
was ejected into a sterile 15ml falcon tube on ice. 
2.3.7.2.1.1 Modified peritoneal lavage 
The production of cytokines and chemokines in vivo was determined in lavage 
supernatants following a modified peritoneal lavage protocol. After sacrifice, 1 ml ice-
cold lavage solution was instilled into the peritoneal cavity with a 23G-needle and 
following the procedure outlined above, were aliquoted into 1.5 ml microcentrifuge 
tubes. The mouse was lavaged again, following the standard procedure (5 ml lavage), 
which was dispended into a 15 ml falcon tube. The 1.5 ml microcentrifuge tubes were 
centrifuged at 350 x g for 5 minutes and the supernatant transferred to clean 
microcentrifuge tubes, after which they were stored at -80°C. Concurrently, the cell 
pellet was pooled with the second lavage for that individual mouse. 
2.3.7.2.2 Phenotypic analysis of pMϕs from Gata6-WT and Gata6-KOmye mice  
To distinguish pMϕs from Gata6-WT and Gata6-KOmye mice, samples were analysed 
by flow cytometry (see 2.4.2 General flow cytometry) for the expression of the cell 
surface markers F4/80 and CD73, which are differentially expressed in pMϕs from 
Gata6-WT (F4/80highCD73high) and Gata6-KOmye (F4/80lowCD73low) mice (Rosas et 
al., 2014). Briefly, 50 µl lavage was added to V-bottom 96-well polystyrene microplate 
containing 50 µl FACS block and incubated on ice for 15 minutes. After incubation, 
FACS block containing anti-mouse PE anti-mouse F4/80 and V450 anti-mouse CD73 
antibodies was added directly to each well and incubated on ice for 15 minutes. After 
incubation, the cells were washed twice; the cells were pelleted by centrifugation at 
350 x g for 5 minutes, the supernatant aspirated, and the cells re-suspended in FACS 
wash. The samples were analysed by flow cytometry and pMϕs from Gata6-WT and 
Gata6-KOmye mice identified by F4/80highCD73high and F4/80lowCD73low expression 
respectively (Error! Reference source not found.). 
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Figure 2.1 | General gating strategy and phenotypic analysis of pMϕs from Gata6-
WT and Gata6-KOmye mice by flow cytometry. 
 
2.3.7.2.3 General pMϕ culture 
Total peritoneal exudate cells (PECs) or adherence-purified peritoneal macrophages 
(see below) were maintained in RPMI 1640 supplemented with 10% (v/v) FBS, 100 
U ml-1 penicillin, 10 µg ml-1 streptomycin and 400 µM L-glutamine unless stated 
otherwise. 
2.3.7.2.4 Adherence-purification of peritoneal macrophages and ex vivo 
microbial product stimulation 
The viability and total cell counts of PECs (or MACS-enriched pMϕs) were 
determined using the Muse® Cell Analyser. The percentage of pMϕs in each sample 
(% F4/80+ cells by flow cytometry) was used to ascertain the total number of pMϕs in 
each sample. Unless otherwise stated, lavages of the same genotype were pooled and 
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washed three times with complete medium. After washing, 1 x 105 pMϕs were seeded 
into each well of a 96-well tissue culture plate in 200 µl complete medium (or scaled 
up accordingly for larger multi-well plates at 5 x 105 cells/ml) and placed at 37°C, 5% 
CO2 for 3 hours. After incubation, non-adherent cells were removed by washing the 
wells three times with complete medium. The adherent peritoneal exudate cells 
(APECs) were then either unstimulated or stimulated with various ligands in the 
presence or absence of chemical compounds for the indicated time-points as described 
in each figure.  
2.3.7.2.5 Ex vivo microbial product stimulation of total PECs 
Flow cytometric experiments were performed with total PECs, unless otherwise stated. 
Total PECs were seeded at 4 x 105 cells into each well of a flat-bottomed 24-well ultra-
low attachment plate (Corning®) in 800 µl complete medium and treated as described 
in each figure legend. After the indicated time point, total PECs were harvested by first 
pipetting the cell suspension in each well into 15 ml falcon tubes stored on ice. The 
remaining cells were harvested by adding 400 µl Accumax™ solution (Sigma-
Aldrich) to each well and incubated at 37°C for 10-15 minutes. After incubation, the 
cells were pipetted gently to suspend any remaining adherent cells. The cell suspension 
was subsequently pooled with the corresponding sample stored on ice. 
2.3.7.2.6 Cell viability analysis 
Cell viability of ex vivo pMϕs was assessed by one of three methods, the Vybrant™ 
Cytotoxicity Assay, PrestoBlue™ Cell Viability, and propidium iodide (PI) flow 
cytometry (see 2.4.2.6 for PI viability staining). 
The Vybrant™ Cytotoxicity Assay Kit (Thermo Fisher Scientific) was used to assess 
cell viability through monitoring the presence of a cytosolic enzyme, G6PD, which is 
released by dying cells into the culture medium. The cells were plated (2.5 x 104) in 
each well of a 96-well plate in 200 µl complete RPMI (without phenol red) and left to 
adhere for 3 hours. After incubation, the non-adherent cells were removed by washing 
the cells three times with complete medium. The cells were treated as indicated in 200 
µl complete medium. In addition, separate wells reserved and lysed by adding the 
provided cell-lysis buffer (in triplicate) to determine the maximum G6PD release from 
the samples. After the indicated period, the cell supernatants were collected, 
centrifuged at 350 x g and the cell-free supernatants aliquoted into a fresh 96-well 
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plate. The supernatants were diluted in cell culture medium (1 in 10 dilution), and 50 
µl added to a 96-well black microplate (Greiner Bio-One). Cell culture medium was 
added in triplicate to separate wells as a no-cell control. The 2X reaction/resazurin 
mixture was prepared by adding 75 µl resazurin stock (4 mM), 400 µl reaction mixture 
and 9.52 ml 1X reaction buffer (scaled to accommodate a larger or smaller number of 
assays). The 2X reaction/resazurin mixture (50 µl) was added to each well and mixed 
thoroughly. The microplate was incubated at 37 °C for 10 minutes, after which 
fluorescence readings were taken at 5 minute intervals for 60 minutes to determine the 
optimal time point. The fluorescence readings were recorded with a FLUOstar Omega 
plate reader (BMG LABTECH) with a 570/10 nm excitation filter and a 612/10 nm 
emission filter. The average values for cell culture medium alone was subtracted from 
all values of experimental and fully lysed cells. The percentage cytotoxicity was 
subsequently calculated as: 
Percent cytotoxicity =
 Experimental G6PD (612 nm)
Maximum G6PD Release (612 nm)
 × 100 
2.3.7.2.7 PrestoBlue™ Cell Viability 
PrestoBlue™ Cell Viability reagent is a resazurin-based solution which is reduced by 
viable cells to quantitatively measure cell viability. Cells were plated in complete 
RPMI (no phenol red) in 96-well clear bottom black microplates (Greiner Bio-One) 
and left to adhere for 3 hours. After incubation, non-adherent cells were removed by 
washing the cells three times with complete medium. The cells were treated as 
indicated after which 10 µl PrestoBlue™ was added directly to each well and mixed 
by gentle pipetting. PrestoBlue™ was also added to no-cell control wells (medium 
alone). The cells were incubated for 60 minutes after which the fluorescence was 
recorded with a FLUOstar Omega plate reader (BMG LABTECH) with a 570/10 nm 
excitation filter and a 612/10 nm emission filter. The average fluorescence from the 
no-cell control wells was subtracted from the fluorescent value from the experimental 
cells. 
2.3.7.3 Thymocytes 
2.3.7.3.1 Isolation of murine Thymocytes 
The mouse was sprayed with 70% isopropanol. Surgical scissors were used to make a 
ventral incision in the abdominal skin. The incision was extended upwards towards to 
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the chin of the mouse. An incision was made in the sternum and the diaphragm cut. 
The rib cage was cut on each side and pinned. The thymus was carefully grasped with 
forceps and scissors used to gently detach from appendices. The thymus was placed 
into DPBS on ice. Under sterile conditions, the thymus was mechanically 
homogenized using a sterile 2 ml syringe plunger, which was used to push the thymus 
through a 40 µm cell strainer (BD Biosciences). Ice-cold DPBS was passed over the 
cell strainer intermittently to wash the cells through the strainer. After homogenisation, 
the cells were pelleted by centrifugation at 350 x g for 5 minutes. The supernatant was 
aspirated and re-suspended in 10 ml DPBS. The cell suspension was passed through a 
40 µm cell strainer, after which the cells were counted. 
2.3.7.3.2 Generation of apoptotic thymocytes 
Apoptotic thymocytes were generated by re-suspending 107 cells/ml in RPMI 1640 
supplemented with 10% (v/v) FBS, 100 U ml-1 penicillin, 10 µg ml-1 streptomycin and 
1 µM dexamethasone (Sigma-Aldrich). The cells were then incubated for 4 hours at 
37 °C with 5% CO2. After 4 hours, the thymocytes were analysed for apoptosis by 
flow cytometry for cleaved caspase-3, as well as cell cycle analysis with DAPI. 
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2.4 Flow cytometry 
Table 2.1 | Antibodies used for flow cytometry 
Antibody Reactivity Clone Isotype Supplier 
Anti-Human 
CD1a eFluor 450 Human Hl149 Mouse IgG1, κ eBioscience 
CD207 APC Human 10E2 Mouse IgG1, κ Biolegend 
CD80 PE Human 2D10 Mouse IgG1, κ Biolegend 
CD83 APC Human HB15e Mouse IgG1, κ BD Biosciences 
GATA3 Alexa 488 Human L50-823 Mouse IgG1, κ BD Biosciences 
HLA-DR APC-H7 Human L243 Mouse IgG2b, κ BD Biosciences 
Anti-Mouse 
CD11b Mouse 5C6 Rat IgG2b Homemade 
CD11b Mouse M1/70 Rat IgG2b BD Biosciences 
CD73 Mouse TY/11.8 Rat IgG1 eBioscience 
Cleaved Caspase-3 
(Asp175) 
Mouse D3E9 Rabbit IgG Cell Signalling 
Technology 
F4/80  Mouse CI:A3-1 Rat IgG2b AbD Serotec 
F4/80 Mouse BM8 Rat IgG2b eBioscience 
IL-1β Mouse NJTEN3 Rat IgG1,κ eBioscience 
IL-6 Mouse MP5-20F3 Rat IgG1 BD Biosciences 
MHCII Mouse M5.114.15.2 Rat IgG2b BioLegend 
Tim4 Mouse RMT4-54 Rat IgG2a BioLegend 
TNF Mouse MP6-XT22 Rat IgG1 BD Biosciences 
Anti-Rat 
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CD2 Alexa 488 Rat OX-34 Mouse IgG2a AbD Serotec 
CD2 Alexa 647 Rat OX-34 Mouse IgG2a AbD Serotec 
CD2 Biotin Rat OX-34 Mouse IgG2a AbD Serotec 
 
2.4.1 Multicolour flow cytometry 
Multicolour flow cytometry was carried out using a 9-colour Cyan™ ADP analyser 
(Beckman Coulter). Unstained and single-colour stained experimental cells were 
included as controls within each multicolour experiment. Acquisition parameters were 
established using unstained and single-colour stained cells. Compensation matrices 
and data analysis were performed post-acquisition using Summit Software (v4.3) 
(Beckman Coulter), unless stated otherwise. Appropriate isotype or fluorescence-
minus-one (FMO) controls were used as indicated. 
2.4.2 General flow cytometry 
Cells were aliquoted into V-bottom 96-well polystyrene microplates (Greiner bio-one) 
and fixed (if required) by adding ice-cold 4% formaldehyde (1X DPBS with 37% 
formaldehyde solution (Sigma-Aldrich)) to cells to obtain a final concentration of 1% 
(unless stated otherwise) and incubated on ice for 20 minutes. After fixation, cells were 
pelleted by centrifugation at 350 x g for 5 minutes, the supernatant removed and the 
cells washed with FACS wash. The cells were blocked by adding ice-cold FACS Block 
(FACS wash buffer supplemented with 5% serum (dependent on the host of antibody 
production) and 4 µg ml-1 rat anti-mouse FcγR II and FcγR III receptors (2.4G2) 
(murine cells only)). The cells were blocked for 20-30 minutes on ice. After 
incubation, fluorescent antibodies were added directly to the cells in the blocking 
buffer, mixed by gentle pipetting and incubated on ice for 30-60 minutes. After 
incubation, the cells were washed twice with FACS wash; the cells were pelleted by 
centrifugation at 350 x g for 5 minutes, the supernatant aspirated and the cells-pellets 
re-suspended in FACS wash. 
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2.4.2.1 Intracellular staining 
Intracellular staining was performed on fixed cells as described in (2.4.2), however 
FACS permeabilization buffer was used instead of FACS wash for the blocking and 
antibody staining steps. 
2.4.2.2 Intracellular cytokine staining (ICS) 
Intracellular cytokine (ICS) staining was performed as in (2.4.2.1), but cells were 
treated in the presence of GolgiPlug™ (BD Biosciences) for the duration of the 
experiment (maximum 12 hours). GolgiPlug™ prevents the release of cytokines 
containing a signal sequence (classically secreted cytokines) such as IL-6 and TNF, 
but not cytokines lacking signal sequences including most IL-1 family cytokines. 
2.4.2.3 Intranuclear staining (INS) 
Intranuclear staining was performed as in (2.4.2), however cells were instead fixed 
with 4% formaldehyde (final concentration). The cells were also permeabilised before 
blocking by re-suspending cells with methanol (stored at -20 °C) to obtain a final 
concentration of 90%, vortexed briefly and incubated on ice for 30 minutes. The cells 
were centrifuged at 350 x g, the methanol removed and the cells washed with FACS 
wash. The cells were pelleted by centrifugation, the supernatant was removed and the 
cells blocked and stained as described in (2.4.2). 
2.4.2.4 Nuclear Isolation Medium (NIM)-DAPI staining 
In a 1.5 ml microcentrifuge tube, 200 µl of cells (containing 1-3 x 105 cells) and 200 
µl NIM-DAPI reagent (Beckman Coulter) were added and mixed by gentle pipetting. 
This was incubated on ice (protected from light) for 30 minutes. After incubation, 600 
µl ice-cold DPBS was added and then centrifuged at 700 x g for 10 minutes. The 
supernatant was carefully removed, typically leaving 50 µl of supernatant to ensure 
that the nuclear pellet was not disturbed or lost. The nuclear pellet was then re-
suspended in an appropriate volume of ice-cold DPBS and analysed on the 9-colour 
Cyan™ ADP analyser (2.4.1). 
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2.4.2.5 Mitochondrial staining 
2.4.2.5.1 MitoTracker® staining 
MitoTracker® dyes (Thermo Fisher Scientific) were used to stain mitochondria in live 
cells (Table 2.2). MitoTracker® Deep Red FM is a far red-fluorescent dye that stains 
mitochondria in live cells, which is dependent on mitochondrial membrane potential. 
Thus MitoTracker® Deep Red FM only stains live mitochondria. Conversely, 
MitoTracker® Green stains mitochondria independent on the mitochondrial 
membrane potential, thereby staining all mitochondria in a cell (mitochondrial 
mass/volume). MitoTracker dyes were added directly to culture medium (No Phenol 
Red) at a final concentration of 250 nM and incubated for 30 minutes, unless otherwise 
stated. After staining, the cells were washed twice with complete medium, after which 
they could be stained for cell surface markers and subsequently analysed by flow 
cytometry. 
Table 2.2 | Mitochondrial dyes 
Mitochondrial dye Purpose Aldehyde fixable 
MitoTracker® Deep 
Red FM 
Mitochondrial dye that stains live 
mitochondria 
Yes 
MitoTracker® Green 
FM 
Mitochondrial mass/volume indicator No 
MitoSOX™ Red Mitochondrial superoxide indicator No 
Dihydrorhodamine 
123 (DHR123) 
ROS indicator No 
 
2.4.2.5.2 Reactive oxygen species (ROS) detection 
Mitochondrial ROS were detected in live cells with MitoSOX™ Red mitochondrial 
superoxide indicator (Thermo Fisher Scientific) or Dihydrorhodamine 123 (DHR123) 
(Invitrogen) for the detection of superoxide or hydrogen peroxide (H2O2) and 
hypochlorous acid respectively. Harvested cells were plated in 96-well low attachment 
plates, centrifuged at 350 x g for 5 minutes. The supernatant was removed and the cells 
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re-suspended in 100µl pre-warmed Hanks' Balanced Salt Solution (HBSS) or complete 
RPMI (No Phenol Red) containing 5 µM DHR123 or 5 µM MitoSOX red and 
incubated at 37°C for 20 minutes. After incubation, the cells were centrifuged at 350 
x g for 5 minutes, the supernatant aspirated and the cells washed with pre-warmed 
HBSS/RPMI. The cells were stained for cell surface antigens (see 2.4.2 General flow 
cytometry) and subsequently analysed by flow cytometry. 
2.4.2.6 Cell viability staining with propidium iodide 
Cell viability was determined by PI exclusion in non-fixed cells. Cell surface antigen 
staining was performed as in (2.4.2), however, all steps were performed with buffers 
without NaN3, which is toxic to cells. After staining of surface antigens, the cells were 
washed twice in FACS buffer. The cells were pelleted by centrifugation and re-
suspended in FACS buffer containing 3 µM PI (2 µg ml-1). The samples were analysed 
immediately by flow cytometry. 
2.4.2.7 Fluorescence-activated cell sorting (FACS) 
Harvested cells were centrifuged at 350 x g for 5 minutes to pellet the cells. The 
supernatant was then aspirated and the cells were re-suspended in ice-cold cell-sorting 
buffer and passed through a 40 µM nylon mesh cell strainer (BD Falcon) to obtain a 
single-cell suspension. The cell suspension was then centrifuged at 350 x g for 5 
minutes to pellet the cells. The supernatant was then aspirated and cells re-suspended 
at a concentration of 2 x 107 cells/ml in ice-cold blocking buffer (cell-sorting buffer 
supplemented with 5% rabbit serum (dependent on host of antibodies production) and 
4 µg ml-1 2.4G2 (murine cells only). The cells were then incubated on ice for 20 
minutes. After incubation, fluorescent antibodies were added directly to the cells in the 
blocking buffer and mixed by gentle pipetting. Unstained and single-stained cells were 
included for compensation set-up and voltage adjustment. The cells were then 
incubated on ice for 30 minutes protected from light. After incubation, the cells were 
centrifuged at 350 x g for 5 minutes to pellet the cells after which the supernatant was 
removed and the cells were washed with sorting buffer. This step was repeated. The 
cells were re-suspended at a concentration of 2 x 107 cells/ml in ice-cold cell-sorting 
buffer and transferred to a sterile 5 ml polypropylene round-bottom falcon tube (BD 
Biosciences) and sorted on a BD FACSAria™ III cell sorter (BD Biosciences). Cells 
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were sorted into a 5 ml a polypropylene falcon tube containing 500 µl FCS stored on 
ice. 
2.4.2.8 Magnetic-activated cell sorting (MACS) 
2.4.2.8.1 Direct magnetic labelling 
Cells were pelleted by centrifugation at 350 x g for 5 minutes, after which the 
supernatant was aspirated and the cells washed with ice-cold MACS buffer. The cell 
suspension was passed through a 40 µM nylon mesh cell strainer (BD Falcon) to obtain 
a single-cell suspension. The cells were then centrifuged, the supernatant removed and 
the cells re-suspended at a concentration of 1.25 x 108 cells/ml ice-cold MACS buffer. 
MACS® MicroBeads specific for the cell-surface antigen were added to the cells (125 
µl/ml), mixed by gentle pipetting and incubated at 4°C for 15 minutes. After 
incubation, the cells were washed with ice-cold MACS buffer and centrifuged at 350 
x g for 10 minutes. After incubation, the cells were washed with ice-cold MACS buffer 
and centrifuged at 350 x g for 10 minutes. In the meantime, a suitable MACS column 
was prepared by loading 500 µl MACS buffer (MS column) onto the column. After 
equilibrating the column, the supernatant was aspirated from the cells and which were 
re-suspended in 500 µl ice-cold MACS buffer (up to 108 cells). The cell suspension 
was applied to the MACS column and the flow-through collected into a sterile 15 ml 
falcon tube on ice. After the cell suspension had completely passed through the MACS 
column, the column was washed three times with ice-cold MACS buffer: 500 µl 
MACS buffer was applied to the column and allowed to completely flow through the 
column into the collection tube before applying subsequent washes. After washing, the 
column was removed from the magnet and placed into 15 ml falcon tube on ice. The 
positive selection cells were eluted from the column by applying 1 ml MACS buffer 
and using the plunger to push the buffer through the column.  
2.4.2.8.2 Indirect magnetic labelling 
Cell surface antigens for which there were no available MACS® MicroBeads were 
first stained with a biotinylated primary antibody to the cell surface antigen, using the 
cell surface staining protocol as previously described (2.4.2 General flow cytometry). 
After staining, the cells were sorted using the protocol outlined in (2.4.2.8.1) using 
MACS® Anti-Biotin MicroBeads. 
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2.5 Metabolic analyses 
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were 
determined using the XF24 Seahorse Metabolic Analyser (Seahorse Biosciences). 
TIM4-enriched pMϕs were plated at a seeding density of 2.5 x 105 cells/well in 200 µl 
complete RPMI into each well of a XF96 cell culture microplate (Seahorse 
Biosciences). After seeding, the cells were left to adhere for 2 hours in a 37°C 
incubator with 5% CO2. After incubation, the medium was removed and 180 µl XF 
Assay medium (Seahorse Biosciences) containing the indicated substrate (Table 2.3) 
was carefully added and placed into a 37°C incubator without CO2 supplementation 
for 60 minutes. Meanwhile, the Seahorse Bioanalyser was heated to 37°C and 
calibrated using the sensor cartridge. After calibration was completed, the cell culture 
plate was added and run using the appropriate program (Table 2.4). Mitochondrial 
stress testing was performed by injecting Oligomycin (10 µg ml-1), FCCP (12 µM) and 
Rotenone (2 µM) and antimycin A (10 µM). 
Table 2.3 | Mitochondrial Stress Test Substrate Conditions 
Substrate Final concentration 
No substrate n/a 
Glucose 25 mM 
Glutamate 2 mM 
Glucose + Glutamate  
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Table 2.4 | Seahorse Mitochondrial Stress Test Program 
Injection Step Duration (Minutes) Cycles 
 Mix 2 
5 
 Measure 3 
Oligomycin  
 Mix 2 
2 
 Measure 3 
FCCP  
 Mix 2 
3 
 Measure 3 
Rotenone/AA  
 Mix 2 
2 
 Measure 3 
2-DG  
 Mix 2 
4 
 Measure 3 
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2.6 Molecular cloning 
2.6.1 Restriction endonuclease digestion of lentiviral vectors 
Lentiviral vectors were linearized by digestion with an appropriate restriction 
endonuclease (New England Biolabs). Typically, 1 µg lentiviral plasmid, 1 µl (10 
units) restriction endonuclease (some restriction sites require more enzyme), 5 µl 10X 
NEBuffer and nuclease-free water up to a final reaction volume of 50 µl, were added 
to a 0.2 ml PCR tube and mixed by gentle pipetting. The reaction was incubated at 
37°C for 1 hour and then 65°C for 20 minutes to inactivate the restriction enzyme. The 
restriction digest was assessed for successful digestion by agarose gel electrophoresis 
(2.8.1.1), after which the linearized plasmid could be excised from the gel with a sterile 
scalpel and purified (2.6.2). 
2.6.2 DNA extraction/purification from agarose gels 
DNA was purified from agarose gels using the NucleoSpin Gel and PCR Clean-up kit 
(Macherey-Nagel). The excised agarose gel was solubilized with Buffer NTI (200 µl 
per 100 mg agarose) and incubated for up to 10 minutes with intermittent vertexing, 
until fully dissolved. The sample (up to 700 µl) was added to a NucleoSpin® Gel and 
PCR Clean-up Column and centrifuged at 11000 x g for 30 seconds. The flow-through 
was discarded and any remaining sample could be added and the centrifugation step 
repeated. The membrane was washed twice: 700 µl Buffer NT3 was added and 
centrifuged at 11000 x g for 30 seconds and the flow-through discarded. The 
membrane was dried by centrifugation at 11000 x g for 1 minute. The column was 
placed into a clean 1.5 ml microcentrifuge tube. Buffer NE or nuclease-free water (15-
30 µl) was added to the column and incubated for 1 minute at room temperature. The 
DNA was eluted from the column by centrifugation at 11000 x g for 1 minute. 
2.6.3 Small hairpin RNA (shRNA) 
2.6.3.1 shRNA design 
Validated shRNA sequences for target genes were obtained from Sigma, which were 
modified to incorporate a XhoI restriction site for the shRNA loop sequence, a U6 
promoter termination sequence, and 5’ and 3’ 15 base pair sequences complimentary 
to the lentiviral vector. If validated shRNA sequences were not available, shRNA 
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sequences were designed. Non-overlapping sequences were selected in coding and 
non-coding sequences containing 19-21 nucleotides (annealing sequence) beginning 
with a guanosine (G) base, and preferentially a GC content between 30-50%. 
Candidate sequences were subjected to a nucleotide BLAST search to eliminate 
candidate shRNAs with unwanted targets. 
2.6.3.2 shRNA oligonucleotide annealing 
The complimentary forward and reverse shRNA oligonucleotides were re-suspended 
to 100 µM in nuclease-free water. The complimentary shRNA constructs were 
annealed by adding 1 µl of each shRNA and 23 µl annealing buffer were added to a 
0.2 ml PCR tube. The tube was heated to 95°C for 5 minutes in the PCR thermocycler, 
and then subsequently allowed to cool to room temperature (approximately 45 
minutes) after which they could either be placed on ice or stored at -20°C for long term 
storage. 
2.6.3.3 Cloning shRNAs into lentiviral vectors 
The shRNA duplex (2.6.3.2) was cloned into the linearized lentiviral vector (2.6.1) 
using the In-Fusion® HD Cloning Kit (Clontech). 200 ng linearized vector, 1 µl of 
1:20 diluted annealed shRNA oligonucleotides, 2 µl 5X In-Fusion HD Enzyme Premix 
and nuclease-free water to a total reaction volume of 10 µl were added to a 0.2 ml PCR 
tube, mixed by gentle pipetting and incubated at 50 °C for 15 minutes. After 
incubation, the reaction was placed on ice or stored at -20 °C for long term storage. 
2.6.4 Transformation of chemically competent cells 
Transformation was performed using NEB 10-beta Competent E. coli (New England 
Biolabs). A vial of NEB 10-beta Competent E. coli was thawed in ice for 10 minutes, 
after cells were mixed by gentle pipetting and 50 µl per transformation added to a 1.5 
ml microcentrifuge tube on ice. 1 µl ligation product/reaction (2.6.3.3) or 1 pg-100 ng 
purified plasmid DNA was added to the cells and mixed by flicking the tube 5 times 
and placed on ice for 30 minutes. After incubation, the tube was added to a heat block 
set at 42 °C for 30 seconds, and subsequently placed on ice for 5 minutes. SOC medium 
or LB medium (950 µl) was added to the cells which were then placed in a 37 °C 
shaking incubator (250 rpm) for 60 minutes. Concurrently, LB agar plates 
supplemented with 100 µg ml-1 Ampicillin (Sigma-Aldrich) were placed at 37 °C for 
60 minutes. After incubation, 10-fold serial dilutions of the cells was performed in 
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Super Optimal broth with Catabolite repression (SOC) medium (New England 
Biolabs) of which 100 µl was added onto each selection plate, distributed evenly across 
the plate with a sterile cell spreader (Thermo Fisher Scientific) and incubated overnight 
at 37 °C (12-16 hrs). After incubation, plates were sealed with Parafilm (Sigma-
Aldrich) and stored at 4 °C for up to one month. 
2.6.5 Screening for specific transformants by colony PCR 
Colony PCR was used to determine whether individual transformants on the 
ampicillin-supplemented agar plates (2.6.4) contained the desired plasmid constructs. 
Individual colonies were picked by touching a sterile pipette tip onto a single colony, 
which was used to inoculate a PCR reaction mix with primers that enable the 
identification of plasmids with successful shRNA insert. The PCR reactions were then 
separated by AGE. 
2.6.6 Bacterial culture/E. coli culture 
Bacterial cultures for plasmid DNA purification (2.6.7) were grown from a single 
colony picked from an ampicillin-supplemented agar plate in a Stuart SI500 orbital 
shaking incubator at 37 °C with 225 rpm. A sterile pipette tip was used to pick a single 
colony, which was used to inoculate a starter culture of 5 ml lysogeny broth (LB) or 
2xYT media (Sigma-Aldrich) containing 100 µg ml-1 ampicillin (Sigma-Aldrich) and 
grown for 8 hours in a shaking incubator at 37 °C with 225 rpm. After incubation, the 
starter culture was diluted 1/500 to 1/1000 in 3 ml (minipreparation of plasmid DNA) 
or 100ml (maxipreparation of plasmid DNA) LB broth containing 100 µg ml-1 
ampicillin and cultured for 12-16 hours in a shaking incubator at 37 °C with 225 rpm. 
2.6.7 Plasmid DNA purification 
Plasmid DNA was purified from bacterial cultures (2.6.6) using the PureLink® Quick 
Plasmid Miniprep Kit (Thermo-Fisher Scientific) or Qiagen® Plasmid Maxi Kit 
(Qiagen). Plasmid DNA was eluted with UltraPure™ DNase/RNase-free water and 
stored at -20°C. 
2.6.8 Plasmid DNA sequencing 
Plasmid DNA was sequenced by sanger sequencing by Eurofins MWG Operon. 
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2.6.9 Preparation of bacterial glycerol stocks 
Bacterial glycerol stocks were prepared by adding 0.5 ml overnight bacterial culture 
and 0.5 ml sterile 50% Glycerol solution into a sterile 1.5 ml microcentrifuge tube. 
The solution was mixed gently by inversion and subsequently placed at -80 °C. 
2.6.10   Revival of bacteria from glycerol stocks 
To recover bacteria from the frozen glycerol stock, a sterile pipette tip was used to 
scrape off frozen bacteria from the top of the storage vial. The bacteria were streaked 
directly into LB broth supplemented with 100 µg ml-1 ampicillin (or appropriate 
selective antibiotic) and incubated overnight at 37 °C (12-16 hours). 
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2.7 Lentivirus production 
2.7.1 Lentiviral plasmid co-transfection 
Pseudovirus particles were produced using a second generation lentivirus plasmid 
packaging system (Burns et al., 1993). 293T cells were seeded in 75cm2 tissue culture 
flasks in DMEM supplemented with 10% FBS, 100 U ml-1 penicillin, 10 µg ml-1 
streptomycin and 400 µM L-glutamine the day before transfection, so that the cells 
were approximately 70-90% confluent on the day of transfection. The cells were co-
transfected with lentiviral plasmids using the Effectene transfection kit (Qiagen). The 
media from the 293T cells was aspirated and 5 ml ice-cold DPBS added to wash the 
cells. The PBS was then aspirated and 12 ml complete medium added. The lentiviral 
plasmid (1 µg), the vesicular stomatitis virus glycoprotein (VSV-G) envelope 
encoding plasmid pMD.G2 (500 ng) and the packaging plasmid pCMVΔ8.91 (750 ng) 
were aliquoted into a 1.5 ml microcentrifuge into which condensation buffer EC (up 
to 300 µl total volume) was added. Enhancer (18 µl) was then added to the solution, 
which was vortexed briefly and incubated at room temperature for 5 minutes. 
Effectene (60 µl) was then added to the solution, which was vortexed for 10 seconds 
and incubated at room temperature for 10 minutes. The solution was then added to a 
15 ml falcon tube and made up to 3 ml with complete media, which was then added 
drop-wise to the 293T cells, to make a total volume of 15 ml. The flask was then 
swirled to ensure sufficient distribution of the lentiviral plasmids across the cells. The 
supernatant was collected 48 hours after transfection, after which it was concentrated 
(2.7.2). Fresh medium was added to the cells and collected after 24 hours and 
concentrated. 
2.7.2 Lentivirus particle concentration 
Lentiviral supernatant (2.7.1) was added to a 50 ml falcon tube and centrifuged at 500 
x g for 10 minutes to pellet cells and large cell debris. The cell-free supernatant was 
further clarified by filtering through a 0.45 µm polyethersulfone syringe filter 
(Sartorius). The supernatant was subsequently concentrated either by 
ultracentrifugation or using Lenti-X concentrator. 
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2.7.2.1 Ultracentrifugation 
The clarified supernatant was carefully overlaid onto 3 ml 20% sucrose (Sigma-
Aldrich) in a 30 ml konical™ Polypropylene tube (Beckman Coulter). The supernatant 
was centrifuged in an Optima™ L-100 XF Ultracentrifuge (Beckman Coulter) at 
26000 rpm for 90 minutes at 4 °C. The tubes were carefully removed and under a tissue 
culture hood, the supernatant carefully removed. The tubes inverted on paper tissue 
and left for 10 minutes after which any residual supernatant was removed with tissue 
paper. The viral pellet was gently re-suspended in PBS or Aim V® Serum Free 
Medium and incubated at room temperature for 20 minutes. The virus solution was 
subsequently aliquoted into cryogenic storage vials and stored at -80 °C.  
2.7.2.2 Lenti-X™ Concentrator 
The clarified supernatant was added to a fresh 50ml falcon tube into which 4X Lenti-
X concentrator (Clontech) was added to give a final concentration of 1X. The solution 
was mixed thoroughly by inverting the tube and incubated at 4°C for 6-24 hours. After 
incubation, the solution was centrifuged at 1500 x g for 45 minutes at 4°C. After 
centrifugation, the supernatant was removed and the pellet re-suspended in appropriate 
medium/PBS (1 ml per T75cm2 flask), aliquoted into a cryogenic storage vial and 
stored at -80 °C. 
2.7.3 Lentiviral titre determination 
Lentiviral titres were determined by transduction of Jurkat E6-1 cells with different 
volumes of concentrated lentiviral supernatant (2.7.2) and determination of the 
expression of the eGFP or rat CD2 reporters by flow cytometry. Briefly, 2 x 105 Jurkat 
E6-1 cells were seeded into 24-well plates in 200 µl complete RPMI. Different 
volumes of concentrated lentiviral particles were then added into each well, after 
which the total volume per well was made up to 400 µl with complete medium. The 
following day, 600 µl complete medium was added to each well. 48 hours after 
transduction, 1ml complete medium was added to each well. 72 hours post-
transduction, the cells were harvested and fixed with 1% formaldehyde for 30 minutes 
on ice. After fixation, the cells were pelted by centrifugation at 350 x g for 5 minutes. 
The supernatant was removed and the cells washed with ice-cold FACS wash. After 
washing, the cells were prepared as in (2.4.2), and analysed by flow cytometry. 
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2.7.4 Lentiviral particle transduction 
2.7.4.1 In vitro/ex vivo transduction 
Typically, cells grown in vitro were transduced with lentiviral particles in 24-well 
plates. BMDMs were seeded into 24-well plates in 200 µl complete medium 
containing 2X M-CSF, after which lentiviral particles (suspended in AIM V® 
Medium) were added directly to each well (up to 200 µl). After overnight incubation, 
600 µl complete medium containing 1 x M-CSF was added to each well. Cells were 
typically harvested 72 post-transduction for flow cytometric analysis, RNA extraction, 
or western blot analysis. For functional assays (TLR stimulation and cytokine 
production) the medium was aspirated, the cells washed, and fresh medium added. 
2.7.4.2 In vivo transduction 
The transduction of pMϕs in vivo was achieved through intra-peritoneal (i.p.) injection 
(up to 300 µl volume) of lentiviral particles into mice. Unless stated otherwise, mice 
were sacrificed seven days after i.p. injection and the cells harvested by peritoneal 
lavage. 
2.7.4.3 Spinoculation 
The lentiviral transduction of cells in vitro has been reported to be substantially 
enhanced by centrifugal infection (‘spinoculation’), which is thought to enhance 
cellular susceptibility by increasing viral deposition on target cell surfaces (O'Doherty 
et al., 2000). Therefore, cell lines that were more difficult to transduce with lentiviral 
particles were spinoculated. Cells (2 x 105) were aliquoted into each well of a U-
bottom 96-well plate, centrifuged at 350 x g for 5 minutes and the supernatant 
aspirated. The cell pellets were subsequently re-suspended in complete medium and 
concentrated viral supernatant (up to 100 µl total volume) was added to each well. The 
plate was wrapped with saran wrap and centrifuged at 1200 x g for 2 hours at 25°C. 
After centrifugation, the cells were re-suspended and transferred to 24-well plates and 
300 µl complete medium added to each well. The cell culture medium was refreshed 
as in (2.7.4.1). 
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2.8 Polymerase chain reaction (PCR) 
2.8.1 Standard PCR 
The PCR reactions were carried out using the KAPA2G Fast PCR MasterMix (Kapa 
Biosystems) in a total reaction volume of 25 µl. The PCR reaction mixture (Table 2.5) 
was added into 0.2 ml PCR tubes (Starlab/STARLAB) (after which the template DNA 
was added) and the PCR reactions performed in a Mastercycler® nexus gradient 
(Eppendorf) using the program shown in (Table 2.6), unless stated otherwise. 
Table 2.5 | PCR reaction components per 25 µl reaction volume 
Component Volume (µl) Final concentration 
2X KAPA2G Fast Mastermix 
10 
1X (0.2 mM each dNTP, 0.5U 
DNA polymerase, 1.5 mM MgCl2) 
Forward primer (100µM) 0.125 0.5 µM 
Reverse primer (100µM) 0.125 0.5 µM 
Template DNA As required <100 ng 
Nuclease-free H2O Up to 25 — 
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Table 2.6 | PCR thermocycling conditions 
Step Temperature (°C) Duration Cycles 
Initial denaturation 95 2 minutes — 
Denaturation 95 15 seconds 
35 Annealing 60 15 seconds 
Extension 72 15 seconds/Kb 
Final extension 72 10 minutes — 
 
2.8.1.1 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate and visualise DNA fragments, 
including PCR products and plasmid DNA was digested with restriction enzymes 
(2.6.1). An appropriate percentage/size agarose gel (Table 2.7) was prepared by 
dissolving agarose powder (Thermo Fisher Scientific) in 1X Tris-acetate-EDTA 
(TAE) buffer (Invitrogen). The agarose powder was then dissolved by intermittent 
heating and swirling until the powder had fully dissolved. The solution was then 
allowed to cool to approximately 60 °C after which 0.5 µg ml-1 Ethidium Bromide 
(Thermo Fisher Scientific) was added and mixed by gently swirling. The solution was 
then poured into a gel casting tray (EmbiTech), after which an appropriate comb was 
placed into the gel solution and allowed to cool until set. After the gel had solidified, 
the comb was removed and the gel was placed into a gel tank (EmbiTech) and 
submerged in 1X TAE buffer containing Ethidium Bromide. Samples were loaded 
onto the gel along with an appropriate DNA ladder (Promega). The gel was run at a 
100 V and running dyes (xylene cyanol FF, bromophenol blue and orange G) contained 
within the DNA ladder were used to track migration during electrophoresis. After the 
products had been separated sufficiently, the gel was removed and visualized using the 
Bio-Rad Fluor-S MultiImager and analysed using Quantity One software (Bio-rad). 
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Table 2.7 .| Percentage agarose gel for resolution of DNA 
Percentage Agarose gel (w/v) Product size (Kb) 
0.50 1 - 30 
0.75 0.8 - 12 
1.0 0.5 - 10 
1.25 0.4 - 7 
1.5 0.2 - 3 
2.0 0.05 - 2 
 
2.8.2 Quantitative real-time PCR (qPCR) 
2.8.2.1 qPCR primer design 
Oligonucleotide primers for qPCR were designed using the NCBI Primer-BLAST 
suite, with criteria optimised for qPCR as outlined in the MIQE guidelines (Bustin et 
al., 2009). Unless stated otherwise, primer pairs for qPCR were designed to: yield a 
PCR amplicon of between 70-150 bp and be exon spanning or separated by an intron 
of at least 1kb to minimise amplification from genomic DNA contamination giving 
rise to false positives. 
2.8.2.2 qPCR primers 
Table 2.8 |. qPCR primers 
Gene Forward Reverse 
Mus musculus 
Casp1 CACAGCTCTGGAGATGGTGA CTTTCAAGCTTGGGCACTTC 
Il1a CGCTTGAGTCGGCAAAGAA
ATC 
CAGAGAGAGATGGTCAATGG
CA 
Il1b ATGAAGGGCTGCTTCCAAAC ATGTGCTGCTGCGAGATTTG 
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Il6 TCCGGAGAGGAGACTTCACA TTGCCATTGCACAACTCTTTT
CT 
Map3k
8 
GCCTTGGTTGGTCGACTCT TGCTGTCAGGTGGCTCTG 
Nlrp3 TGGGCAACAATGATCTTGGC TTTCACCCAACTGTAGGCTCT
G 
Ptgir ATGTACCGCCAACAGAGAC
G 
CCTCGGATCATGAGAGGCAG 
Ptgis TCCACTCAGCGGATGTTTTC ACAGGCGGTTTTTGACACTG 
Ptgs1 GAGATCTGGACCTGGCTTCG GTTGGACCGCACTGTGAGTA 
Ptgs2 AGCCAGGCAGCAAATCCTT CAGTCCGGGTACAGTCACAC 
Pycard ACTGTGCTTAGAGACATGGG
C 
TGGTCCACAAAGTGTCCTGTT 
Serpinb
2 
GGCTTTATCCTTTCCGTGTG AGGAGCATGCTGATGTTTCC 
Sqstm1 GCCAGAGGAACAGATGGAG
TC 
AGCTTGGCCCTTCCGATTC 
Tnf TAGCCCACGTCGTAGCAAAC ACAAGGTACAACCCATCGGC 
Ywhaz TTGAGCAGAAGACGGAAGG
T 
GAAGCATTGGGGATCAAGAA 
Homo sapiens 
CCND1 ATGCCAACCTCCTCAACGAC CGCAGACCTCCAGCATCC 
CCR6 GTCATCACATTGGTGAGCTG
G 
AAGTAGAGGTGACTCTCAGG
CA 
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CD207 AGGTCCAAAGTGTGAGGTTC
TG 
TCACATGGGGCATCATTCCA 
CD40 ACTGATGTTGTCTGTGGTCC
C 
TGATAAAGACCAGCACCAAG
AGG 
CD86 ACTAGCACAGACACACGGA
TG 
TCAGAGGAGCAGCACCAGAG
A 
CDH1 CGTCCTGGGCAGAGTGAATT
T 
ACACCATCTGTGCCCACTTT 
CDK6 CTGCAGGGAAAGAAAAGTG
CAA 
CTCCTCGAAGCGAAGTCCTC 
CLEC5
A 
CCCAACGGCTTCATTACCAC TCCTTTGCAAAAGTCCCTGCT 
GATA3 CGTCCCGCCCTACTACG CCGTCCAGCCAGGGTAG 
YWHA
Z 
CCCAGAGAAAGCCTGCTCT CCGATGTCCACAATGTCAAGT 
 
2.8.2.3 RNA extraction 
Total RNA was extracted from cells using RNeasy Plus Mini and Micro kits (Qiagen). 
The growth medium from adherent cells was aspirated after which 350 µl (≤5 x 106 
cells) or 600 µl (≤1 x 107 cells) lysis buffer (Buffer RLT supplemented with 1% (v/v) 
βME) was added. Non-adherent cells were pelleted by centrifugation at 350 x g for 5 
minutes, the medium completely removed and then re-suspended in lysis buffer. The 
cell lysate was loaded onto a QIAshredder homogenizer (Qiagen) and centrifuged at 
12 000 x g for 2 minutes. The cell lysate could then be stored at -80°C, or the RNA 
could be extracted immediately. The lysate was transferred to a genomic DNA 
(gDNA) Eliminator spin column and centrifuged at 8 000 x g for 30 seconds, to remove 
any contaminating gDNA. An equal volume of 70% ethanol was added to the eluate 
and mixed by gentle pipetting. The lysate-EtOH mixture (up to 700 µl) was transferred 
onto an RNeasy Mini (≤1 x 107 cells) or Micro (≤5 x 105 cells) spin column, 
104 
 
centrifuged at >8000 x g for 15 seconds and the flow-through discarded. Any 
remaining lysate-EtOH mixture could be subsequently added to the column, followed 
by centrifugation and the flow-through subsequently discarded. The column was 
washed with buffer RW1; 700 µl buffer RW1 was added to the column, the cap 
carefully closed, centrifuged at ≥8000 x g for 15 seconds and the flow-through 
discarded. The column was then washed twice with buffer RPE; 500 µl was added to 
the column, centrifuged at ≥8000 x g for 15 seconds and the eluate discarded. The 
column was washed with 500 µl 80% EtOH and centrifuged at ≥8000 x g for 2 minutes. 
The RNeasy spin column was placed into a new 2 ml collection tube and centrifuged 
with the lid open at ≥8000 x g for 5 minutes. The RNeasy spin column was transferred 
to an RNase/DNase free 1.5 ml microcentrifuge tube (Eppendorf). RNase/DNase free 
water was added to the centre of the RNeasy Mini (30-50 µl) or Micro (14 µl) spin 
column and incubated for 2 minutes at room temperature. After incubation, the column 
was centrifuged at ≥8000 x g for 1 minute to elute the RNA from the column, which 
was subsequently stored at -80°C.  
2.8.2.4 Analysis and quantification of RNA 
Total RNA (2.8.2.3) concentration and purity was determined by UV absorption in a 
NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific). This calculates the 
concentration of nucleic acids by absorption at 260 nm. The 260/280 ratio is used to 
assess nucleic acid purity. A ratio of ~1.8 and ~2 are generally considered pure for 
DNA and RNA respectively. The 260/230 ratio is used as a secondary measure of 
nucleic acid purity, with a ratio between 2-2.2 considered pure. 
2.8.2.5 First-strand cDNA synthesis 
First strand cDNA was synthesised from total RNA (2.8.2.3) using the Precision 
nanoScript™ 2 Reverse Transcription kit (Primer Design). Up to 2 µg total RNA could 
be reverse transcribed per reaction. Total RNA, 0.5 µl Oligo-dT primer, 0.5 µl Random 
nonamer primer and nuclease-free water to make a final reaction volume of 10 µl were 
added to a thin-walled 0.2 ml PCR tube (STARLAB). The samples were incubated at 
65 °C for 5 minutes, after which the samples were placed on ice for at least 1 minute. 
5 µl nanoScript2 4X buffer, 1 µl 10 mM dNTP mix, 3 µl nuclease-free water and 1 µl 
nanoScript2 enzyme were added to each sample and mixed by gentle pipetting. The 
samples were incubated at 25 °C for 5 minutes and then at 42 °C for 20 minutes. The 
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reaction was inactivated by incubating the samples at 75 °C for 10 minutes. Nuclease-
free water was added to the cDNA to make a final concentration of 5 ng µl-1 and 
subsequently stored at -20 °C. 
2.8.2.6 qPCR 
The qPCR reactions were performed in a ViiA™ 7 Real-Time PCR System (Applied 
Biosystems) using the Fast SYBR® Green technology to determine relative expression 
values of target genes. The qPCR reactions were performed in a 20 µl reaction volume. 
The qPCR reaction components (Table 2.9) were added to a MicroAmp® Fast optical 
96-well reaction plate (Applied Biosystems), which was sealed with MicroAmp® 
Optical Adhesive Film (Thermo-Fisher Scientific) and centrifuged at 350 x g for 5 
minutes. The qPCR reactions were performed in triplicate and run following a two-
step protocol (see Table 2.10). No-template control reactions were included for each 
primer pair and post-acquisition analysis of dissociation curves was used to determine 
the specificity of the qPCR reactions. 
Table 2.9 |. Components for qPCR reaction 
Component Volume (µl) Final concentration 
2X SYBR® green PrecisionFAST™ with 
Low ROX Master mix (PrimerDesign) 
10 1X 
Forward Primer (10 µM) 0.6 300 nM 
Reverse Primer (10 µM) 0.6 300 nM 
cDNA (5 ng µl-1) 5 25 ng 
RNase/DNase free water 3.8 — 
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Table 2.10 |. Thermocycling conditions for qPCR reactions 
Step Temperature Duration Cycles 
Enzyme activation 95°C 2 minutes — 
Denaturation 95°C 5 seconds 
40 
Annealing/extension/data acquisition 60°C 20 seconds 
Dissociation curve 
95°C 15 seconds 
— 60°C 1 minute 
95°C 15 seconds 
 
2.8.2.7 Analysis of qPCR data 
The comparative cycle threshold (CT) method (ΔΔCT) was used for the analysis of 
qPCR data (Livak and Schmittgen, 2001). The relative expression of the genes of 
interest were calculated using an appropriate reference gene (indicated in figure 
legends). 
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2.9 Enzyme-linked immunosorbent assay 
(ELISA) 
ELISAs were performed using the BD OptEIA™ kits (BD Biosciences) unless 
otherwise stated. All wash steps were performed in an automated Tecan HydroFlex™ 
microplate washer (Tecan). 100 µl PBS containing the appropriate capture antibody 
was added to each well of a flat-bottom 96-well EIA/RIA plate (Corning® 96 well 
EIA/RIA flat-bottomed), which was sealed and incubated overnight at 4 °C. Following 
the overnight incubation, the wells were washed twice with DPBS containing 0.05% 
(v/v) Tween-20 (Sigma-Aldrich). The wells were blocked by adding 200 µl blocking 
solution (DPBS with 10% FBS) for 1 hour at room temperature. Meanwhile, eight two-
fold dilutions of the appropriate cytokine standard, from 2000 to 15.625 pg ml-1, were 
performed in blocking solution. After blocking, the wells were washed 3 times and 
subsequently incubated with the cytokine standards, in triplicate and cell culture 
supernatants overnight at 4 °C. Following overnight incubation, the wells were washed 
5 times after which 100 µl blocking solution containing biotinylated detection antibody 
and streptavidin-horseradish peroxidase (HRP) were added and incubated at room 
temperature for 1 hour. Following incubation, the wells were washed 7 times. 
Meanwhile, The TMB substrate kit (BD Biosciences) were prepared: the working 
reagent (WR) was prepared by mixing equal parts of 3,3′,5,5′-Tetramethylbenzidine 
(TMB) and hydrogen peroxide. 100 µl of the WR was added to each well, the plate 
was then sealed and incubated at room temperature for 30-60 minutes. The reaction 
was terminated by adding 50 µl 2 M sulphuric acid (Fisher Scientific). The optical 
density (O.D.) at 450 nm with λ correction 570 nm was measured with a 
Multiskan®Spectrum microplate reader (Thermo Labsystems). A standard curve using 
the O.D. for the appropriate standard was plotted against the concentration of that 
standard from which linear regression analysis was used to interpolate the 
concentration of the unknown samples. 
2.10  Nitric Oxide (NO) assay 
The production of nitric oxide (NO) was determined using the Greiss test to measure 
nitrite (NO2-); which is one of two primary stable metabolites of NO. A nitrite 
standard reference curve was prepared by performing six two-fold serial dilutions of 
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sodium nitrite (Sigma-Aldrich) in triplicate from 65 µM to 1.01 µM in the appropriate 
matched media for the experimental test. 50 µl of each nitrite standard (in triplicate) 
and each sample was added to each well of a flat-bottom 96-well EIA/RIA plate 
(Corning® 96 well EIA/RIA flat-bottomed). 50 µl of modified Griess reagent (Sigma-
Aldrich) was added to the samples and nitrite standards, and incubated at room 
temperature (protected from light) for 15 minutes. Following the incubation, the 
spectrophotometric absorbance was measured at 540 nm with a Multiskan®Spectrum 
microplate reader (Thermo Labsystems). 
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2.11  Immunoblotting 
2.11.1   Preparation of whole cell lysates 
2.11.1.1   Preparation of whole cell lysates from adherent cells 
The culture medium was aspirated and cells were washed with ice-cold DPBS. The 
DPBS was removed and cells were lysed in ice-cold RIPA buffer supplemented with 
1X Halt™ Protease and Phosphatase Inhibitor Cocktail (1 ml lysis buffer per 107 cells), 
harvested using a plastic cell scraper and transferred to an ice-cold 1.5 ml 
microcentrifuge tube. The cell lysate was incubated on a roller at 4 °C for 30 minutes. 
After incubation, the lysate was centrifuged at 12000 x g for 20 minutes at 4 °C. The 
supernatant was carefully removed and added to a fresh pre-cooled 1.5 ml 
microcentrifuge tube and stored at -20 °C. 
2.11.1.2   Preparation of whole cell lysates from non-adherent 
cells 
Whole cell lysates were prepared from non-adherent cells by centrifuging the cell-
suspension at 500 x g for 10 minutes. The supernatant was aspirated, the cells washed 
with ice-cold PBS and then centrifuged at 500 x g for 10 minutes to pellet the cells. 
The supernatant was removed and the cells re-suspended in lysis buffer and processed 
as in (2.11.1.1). 
2.11.2   Preparation of cell culture 
supernatant/concentration 
Cell-free culture supernatants were prepared by collecting the cell culture supernatants 
and centrifuging at 500 x g for 10 minutes. The supernatants were aspirated and placed 
into 1.5 ml microcentrifuge tubes, after which they could be stored at -80 °C until use. 
Cell-free culture supernatants were concentrated using Methanol/Chloroform 
precipitation. One volume of methanol and one-quarter volume of chloroform were 
added to the supernatant, vortexed vigorously for 20 seconds and then centrifuged at 
20000 x g for 10 minutes. After centrifugation, the upper phase was aspirated, being 
careful not to disturb the interface. One volume of methanol was added, vortexed for 
20 seconds and then centrifuged at 20000 x g for 5 minutes. The supernatant was 
removed and the pellets briefly dried in a heat block set at 55 °C for 10 minutes. After 
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drying, the pellet was re-suspended in 1 x laemmli buffer (Bio-Rad), vortexed and 
heated to 99 °C for 5 minutes. After heating, the sample was centrifuged at 350 x g for 
1 minute to pellet insoluble components. 
2.11.3   Protein Quantification/Bicinchoninic acid (BCA) 
protein assay 
The BCA protein assay kit (Pierce) was used to determine the total protein 
concentration of whole cell lysate samples (2.11.1). The BCA Working Reagent (WR) 
was prepared by mixing 50 parts of BCA Reagent A with 1 part Reagent B. 100 µl 
WR was then added to each well of a flat-bottom 96-well EIA/RIA plate (Corning® 
96 well EIA/RIA flat-bottomed). 5 µl of each sample (samples could be diluted in 
RIPA lysis buffer) and BSA standards (Seven two-fold serial dilutions of BSA from 
2000 to 15.625 µg ml-1) were added to each well, after which the plate was sealed and 
incubated at 37°C for 30-60 minutes. After incubation, the O.D. at 562 nm was 
measured with a Multiskan®Spectrum microplate reader (Thermo Labsystems). 
Protein concentrations of the unknown samples are then determined by interpolation 
of the BSA standard curve. 
2.11.4   SDS-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed using the Mini-PROTEAN® Tetra Vertical Electrophoresis System (Bio-
Rad). SDS-PAGE resolving gels were made to the required percentage for resolving 
the protein of interest (see Table 2.11) by adding dH2O, 30% Acrylamide/Bis Solution 
(37.5:1 mixture), 1.5M Tris-HCl (pH 8.8), 10% (w/v) SDS, 10% (w/v) ammonium 
persulfate (APS) and N,N,N′,N′-Tetramethylethylenediamine (TEMED) (see Table 
2.12). The solution was mixed thoroughly and pipetted into a Mini-PROTEAN® Cell 
1.5 mm glass cassette (BioRad). Immediately after pouring the resolving gel, water-
saturated n-butanol was used to overlay the monomer solution. The gel was left to 
polymerise for approximately 60 minutes, after which the overlay solution was 
removed and the top of the gel washed with dH2O. The stacking gel was prepared, 
mixed thoroughly and added on top of the resolving gel. A 1.5 mm comb was carefully 
inserted to form wells and the gel left to polymerise for approximately 45 minutes. 
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After polymerisation, the comb was carefully removed and the wells washed with 
dH2O. The SDS-PAGE gel was inserted into a cassette and placed into the Mini-
PROTEAN® Tetra Vertical Electrophoresis tank (Bio-Rad). Running buffer was 
added to the tank until the cassette was completely submerged. The samples and ECL 
Full-Range Rainbow Molecular Weight Markers (Amersham) were loaded into each 
well. The gel was electrophoresed at 80 V until the samples had migrated to the 
resolving gel, after which the voltage was increased to 100 V and left until the size of 
interest bands had been sufficiently separated. 
 
Table 2.11 |. Percent of acrylamide in resolving gel for separation of different 
molecular weight proteins 
Resolving gel acrylamide percentage (%) Protein size (kDa) 
8 25-200 
10 15-100 
12.5 10-70 
15 12-45 
20 4-40 
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Table 2.12 |. Recipes for SDS-PAGE stacking and resolving gels 
Component 
Stacking Gel Resolving Gel 
4% 7.5% 10% 12% 15% 
dH2O 6ml 4.8ml 4ml 3.3ml 2.3ml 
30% Acrylamide/Bis Solution 
(37.5:1 mixture) 
1.3ml 2.5ml 3.3ml 4ml 5ml 
0.5M Tris-HCl, pH 6.8 2.5ml — — — — 
1.5M Tris-HCl, pH 8.8 — 2.5ml 2.5ml 2.5ml 2.5ml 
10% (w/v) SDS 100µl 100µl 100µl 100µl 100µl 
10% (w/v) APS 50µl 50µl 50µl 50µl 50µl 
TEMED 5µl 5µl 5µl 5µl 5µl 
 
2.11.5   Membrane transfer 
Proteins that had been separated by SDS-PAGE (2.11.4) were transferred onto 
nitrocellulose or PVDF membranes using either a wet transfer or semi-dry transfer 
procedure. The gel was removed from the glass cassette and washed with transfer 
buffer. PVDF membranes were soaked in 100% methanol for 5 minutes, after which 
they were washed in distilled water for 5 minutes. After washing, the membrane was 
equilibrated in transfer buffer for 10 minutes. 
2.11.5.1 Wet transfer 
Wet transfer was performed using the Mini Trans-Blot Electrophoretic Transfer Cell 
(Bio-Rad). The gel transfer cassette was assembled as followed from cathode to anode 
side: fibre pad, filter paper, gel, nitrocellulose or PDVF membrane, filter paper and 
fibre pad. After assembly, the cassette was placed into the transfer cell and completely 
submerged with transfer buffer. An ice pack was added to the transfer cell and the 
transfer carried out at 0.23Amps for 90 minutes. 
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2.11.5.2 Semi-dry transfer 
Semi-dry transfer was conducted using the Trans-Blot Semi-Dry Transfer Cell (Bio-
Rad). The gel sandwich was assembled as followed from the anode (bottom) to cathode 
(cathode top): pre-wet filter paper, membrane, gel, and pre-wet filter paper. The 
stainless-steel lid (cathode) and safety cover were secured in place. The blot was run 
at a constant voltage of 20 V for 25-40 minutes, depending on the size of the protein 
of interest.  
2.11.6   Immunoblotting 
After transfer, the membrane was washed with 1X Tris-buffered saline (TBS) for 5 
minutes at room temperature on an (orbital shaker). The membranes were then blocked 
with blocking buffer (TBS with 0.1% (v/v) Tween® 20 (TBST) supplemented with 
non-fat dry milk or BSA (dependent on antibody), see Table 2.13) for 1-2 hours at 
room temperature. The membrane was removed and washed three times for 5 minutes 
each with TBST. The membrane was incubated with the primary antibody in the 
appropriate blocking buffer and incubated overnight at 4 °C on a roller. The following 
day, the membrane was washed five times for 5 minutes with TBST. The membrane 
was incubated with the appropriate secondary antibody in blocking buffer and 
incubated at room temperature for 1 hour. The membrane was washed seven times for 
5 minutes with TBST. Amersham ECL Prime Western Blotting Detection Regent (GE 
Healthcare) was added to the membrane and incubated at room temperature (protected 
from light) for 5 minutes. After incubation, the membrane was removed, wrapped in 
plastic wrap and placed into an exposure cassette. The membrane was exposed to 
Super RX film (FUJIFILM) and developed using the Compact X4 imaging system 
(Xograph). 
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Table 2.13 |. Antibodies for immunoblotting 
Antibody Source Source Produ
ct code 
Dilutio
n 
factor 
Blockin
g 
buffer 
Stainin
g 
buffer 
Primary antibodies 
Anti-Mouse 
Ptgis 
Polyclon
al Rabbit 
IgG 
Abcam ab2366
8 
1:2500 5% 
(w/v) 
milk 
5% 
(w/v) 
milk 
Anti-Mouse IL-
1β 
Polyclon
al Goat 
IgG 
R&D 
Systems 
AF-
401-
NA 
1:500 5% 
(w/v) 
milk 
0.05% 
(w/v) 
milk 
Secondary antibodies 
Anti-Goat IgG-
HRP 
Rabbit Santa Cruz 
Biotechnolo
gy 
sc-
2922 
1:5000  0.05% 
(w/v) 
milk 
Anti-Rabbit 
Immunoglobuli
ns-HRP 
Polyclon
al Goat 
Dako P0448 1:2000  5% 
(w/v) 
milk 
 
2.11.7   Stripping and re-probing 
After film development, the membrane was washed three times for 5 minutes each 
with TBST. After washing, the membrane was incubated with stripping buffer 
(100mM βME, 2% (w/v) SDS and 62.5mM Tris-HCL pH 6.7) and incubated at 50°C 
for 30 minutes with gentle agitation. The membrane was washed five times for 5 
minutes each with TBST. To ensure the membrane had been sufficiently stripped, the 
membrane was incubated ECL Prime Western Blotting Detection Regent for 5 minutes 
and subsequently exposed to Super RX film and developed as in (2.11.6). If the 
stripping was effective, the membrane was washed for 5 minutes with TBST, after 
which it was suitable for immunoblotting as in (2.11.6).  
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2.12  Lipid extraction and analysis 
Cell-free culture supernatants (1 ml) were added to glass extraction tubes into which 
the appropriate deuterated internal standards were spiked. 2.5 ml extraction solvent (1 
M acetic acid/2-Isopropanol/Hexane (2:20:30, v/v/v) was added and vortexed 
thoroughly for 1 minute. 2.5 ml hexane was added and vortexed for 1 minute. The 
samples were centrifuged at 500 x g for 5 minutes at 4°C. After centrifugation, the 
upper layer was carefully removed with a glass Pasteur pipette and transferred to a 
clean glass vial. A further 2.5 ml hexane was added to the lower layer, vortexed 
thoroughly and centrifuged at 500 x g for 5 minutes at 4°C. The upper layer was 
removed as before and pooled with the previous layer. The samples were dried under 
a N2 vacuum extraction system, after which the samples were re-suspended in 100 µl 
methanol. The samples could then be stored at -80°C until further analysis. Standard 
curves were generated from internal standards and lipid products quantified by 
LC/MS/MS using a 4000 Q-Trap™ LC/MS/MS System (Applied Biosystems). 
LC/MS/MS was performed by Dr Victoria Tyrrell (Professor O’Donnell Laboratory). 
2.13  Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 6. Statistical significance 
was calculated using the appropriate statistical test (indicated in figure legend). A p 
value > 0.05 is indicated as not significant (ns). Significant results are indicated as 
follows: * (p ≤ 0.05); ** (p ≤ 0.01); *** (p ≤ 0.001). 
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3.1 Introduction 
Macrophages are key sentinels and mediators of the inflammatory response against 
invading pathogens. They detect a wide array of PAMPs through their broad array of 
PRRs, of which the TLRs are the best characterised. The bacterial cell-wall component 
LPS is recognised by TLR4, which results in the expression of several hundred genes 
that amplify the initial inflammatory response, initiate the development of adaptive 
immunity, and exert antimicrobial activities. The production and release of soluble 
mediators by macrophages upon microbial recognition is a critical component of the 
host inflammatory response to pathogen infection. Cytokines are a diverse group of 
glycoproteins that are key mediators of the inflammatory response, which amplify the 
initial inflammatory response, initiate the development of adaptive immunity, promote 
antimicrobial effector functions, and promote the resolution of inflammation 
(Dinarello, 2007, Iwasaki and Medzhitov, 2010).  
Members of the IL-1 family affect virtually all cells and organs and have a fundamental 
role in the initiation, amplification, and resolution of inflammation. Typically, IL-1 
family members are pro-inflammatory, inducing the expression and synthesis of many 
effector proteins including cytokines/chemokines, COX-2, PLA2, and inducible nitric 
oxide synthase (iNOS) (Dinarello, 2009). Unsurprisingly, dysregulated IL-1 
production has been implicated in the pathogenesis of many autoimmune, 
inflammatory diseases, and degenerative diseases (Dinarello et al., 2012, Carta et al., 
2017, Hoffman et al., 2001). IL-1β is a potent pro-inflammatory cytokine which 
mediates innate immunity and inflammation. As such, the production of IL-1β is 
tightly-controlled, and generally requires two distinct signals. The first signal induces 
the expression of the biologically inactive precursor pro-IL-1β, which is typically 
mediated through TLR signalling. Once synthesised, pro-IL-1β needs to be 
proteolytically cleaved to the mature form, before it can be released and thereby exert 
its biological effects through binding to its cognate receptor, IL-1R. Typically, the 
processing of pro-IL-1β is mediated by caspase-1, although numerous extracellular 
proteases have been reported to cleave pro-IL-1β in vivo (Joosten et al., 2009, Kono et 
al., 2012). Caspase-1 itself is generally inactive in resting cells and requires activation 
by multimeric protein complexes called inflammasomes, which sense a plethora of 
endogenous and exogenous stimuli. The diverse array of stimuli which activate 
inflammasomes are generally referred to as the ‘second signal’ for IL-1β processing 
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and release. Activation of the inflammasome and its subsequent assembly results in 
the auto-activation of caspase-1, which subsequently cleaves pro-IL-1β into its 
biologically active form, which exits the cell and mediates signalling via IL-1R. In 
addition to the processing of IL-1β (and IL-18), caspase-1 mediates a form of 
programmed cell death termed pyroptosis, characterised by cell swelling and plasma 
membrane rupture. Furthermore, recent studies have reported that in macrophages, 
pyroptotic cell death is required for the release of mature IL-1β (Martín-Sánchez et al., 
2016). 
 
3.1.1 NLRP3 inflammasome activation 
The NLRP3 inflammasome is the best characterised inflammasome to date, which has 
been demonstrated to be activated by a broad array of endogenous and exogenous 
stimuli (Latz et al., 2013). The diverse array of stimuli are structurally and molecularly 
diverse, which make it unlikely that they (all) bind directly to and activate the 
inflammasome. Therefore, the general consensus is that inflammasomes monitor 
cellular homeostasis (which is perturbed by activatory stimuli), and are activated when 
they detect a specific divergence from homeostasis, such as the recognition of DAMPs. 
Three models through which stimuli converge to activate the inflammasome have been 
proposed: lysosomal rupture, cytosolic K+ efflux, and ROS generation (Hornung and 
Latz, 2010, Petrilli et al., 2007, Tschopp and Schroder, 2010). However, reports on 
their relative contributions to NLRP3 activation have often been contradictory and a 
single unified model of inflammasome activation has yet to be agreed. More recently, 
it was reported that the release of potassium is the downstream convergence point for 
all NLRP3 activatory stimuli (Munoz-Planillo et al., 2013). However, it is currently 
unclear whether intracellular potassium levels modulate the activation of NLRP3 
directly or whether another event correlates with low intracellular potassium 
concentrations is yet to be determined (Broz and Dixit, 2016). 
Extracellular ATP is widely used in vitro as a potent activator of the NLRP3 
inflammasome, which binds to P2X7 receptors resulting in the processing and release 
of IL-1β. The release of ATP in resting macrophages is low, but substantially increased 
upon stimulation with TLR ligands (Cohen et al., 2013). Furthermore, both stressed 
and damaged cells release ATP into the extracellular space, which may lead to the 
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activation of the inflammasome. The release of IL-1β from primary human monocytes 
stimulated with LPS alone was proposed to result from their endogenous release of 
ATP, leading to constitutive caspase-1 activity (Netea et al., 2009), but ATP-
independent IL-1β release from human monocytes following LPS stimulation has 
since been reported (Ward et al., 2010), and these discrepancies likely arise from 
different purification protocols for monocytes and reflect differential responses of 
different monocytic subsets. Macrophages are reported to release ATP into the 
extracellular milieu via pannexin-1 channels following TLR stimulation (Cohen et al., 
2013). The extracellular ATP is catabolised by macrophages in a coordinated two-step 
process. First ATP is hydrolysed to AMP by the ectoenzyme CD39. AMP is 
subsequently dephosphorylated into adenosine by CD73. Thus, these ectoenzymes are 
thought to regulate anti-inflammatory signalling through the hydrolysis of 
extracellular ATP (which can activate the inflammasome), and through the sequential 
generation of adenosine, which is reported to terminate the synthesis of many pro-
inflammatory cytokines (Antonioli et al., 2013). The expression of these two 
ectoenzymes can therefore determine the degradation of extracellular ATP and 
generation of adenosine in the extracellular milieu. Macrophages deficient of CD39 
exhibit enhanced production of pro-inflammatory cytokines such as IL-1β, IL-6, and 
TNF (Levesque et al., 2010). It has been suggested that CD39 has more profound anti-
inflammatory effects than CD73, because the conversion of AMP to adenosine can 
occur in the absence of CD73 (Hamidzadeh and Mosser, 2016). However, recent 
studies suggest that the suppression of pro-inflammatory cytokine production through 
apoptotic cell clearance is dependent on CD73, and that CD73-deficient mice had 
enhanced neutrophil influx during a mild TLR4 peritonitis model (Murphy et al., 
2017). 
3.1.2 IL-1β drives neutrophil recruitment in vivo 
IL-1β has a key function in the recruitment of neutrophils, and the IL-1-dependent 
peritoneal accumulation of neutrophils has frequently been used as an in vivo assay for 
IL-1β production (Martinon et al., 2006, Guarda et al., 2009). Indeed, the influx of 
neutrophils into the peritoneum is markedly decreased in mice deficient of either IL-1 
or IL-R (Iyer et al., 2009). Furthermore, mice deficient of NLRP3 inflammasome 
components show similar perturbations to neutrophil recruitment, but noteworthy that 
the influx is less severely diminished compared to IL-1- or IL-1R-deficient mice 
120 
 
(Duewell et al., 2010). This differential response has largely been attributed to caspase-
1-independent processing of IL-1β and/or the contribution of IL-1α (Dinarello, 2009). 
3.1.3 Gata6 regulates the function and phenotype of pMϕ 
In the naïve mouse peritoneal cavity, mononuclear phagocytes can be subdivided by 
flow cytometry based upon the expression of F4/80 and CD11b, a major subset with 
an F4/80highCD11bhighMHCIIlow phenotype and a minor subset with an F4/80int-
lowCD11b+MHCIIhigh phenotype (Dioszeghy et al., 2008, Rosas et al., 2007). The 
former was the classical resident pMϕ, whereas the latter were tentatively called ‘DC-
like’ cells, owing to superior antigen processing and presentation, and stimulation of 
T cell proliferation. However, during inflammation, this minor population could not 
be distinguished from recruited inflammatory monocyte-derived (Inf) Mϕs due to a 
lack of definitive markers. The failure to identify these cells during inflammation led 
to ambiguity, and confusion of these cells with InfMϕs and DCs and as such, the 
composition of this population has been a source of controversy in recent years. The 
expression of CD11c in this population has led to some investigators to exclude this 
population (as CD11c is highly expressed in DCs), leading another group to describe 
two Mϕ subsets in the peritoneal cavity, a major population of ‘large peritoneal 
macrophages’ and a minor population, designated as ‘small peritoneal macrophages’ 
(Ghosn et al., 2010), corresponding to the classical resident pMϕs and DC-like cells 
described by our group. More recent studies have shown that classical DCs are found 
in the peritoneal F4/80lowMHCII+ subset (Bain et al., 2016). Transcriptional profiling 
of the F4/80int-lowCD11b+MHCIIhigh subset reveals that they have major differences to 
F4/80high resident pMϕs, likely reflecting their distinct functions in the peritoneal 
cavity. In addition to CD11c, gene expression analysis of the F4/80int-
lowCD11b+MHCIIhigh subset has shown that they selectively express the surface marker 
CD226, also known as DNAX accessory molecule-1 (Liao et al., 2016, Kim et al., 
2016a). This marker enables the F4/80lowMHCII+ subset to be reliably distinguished 
from InfMϕs (CD11c-CD226-). Studies from our lab demonstrated that mice deficient 
of Flt3l (an important growth factor for DC) have a marked deficiency in the 
CD226+F4/80int-lowCD11b+MHCIIhigh subset (Liao et al., 2016). 
Recent evidence suggests that distinct tissue-specific master regulators govern the 
phenotypic diversity and specialised functions of different tissue-specific 
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macrophages. Our research group as well as other groups identified the transcription 
factor Gata6 as a critical regulator of a peritoneal macrophage-specific transcriptional 
program (Gautier et al., 2014, Okabe and Medzhitov, 2014, Rosas et al., 2014). 
Genetic deletion of Gata6 in macrophages led to a dramatic reduction in the number 
of F4/80high resident pMϕs from approximately 50% in Gata6-WT mice to 20% in 
Gata6-KOmye mice. The loss in resident pMϕs in Gata6-KOmye is accompanied by an 
increase in the number of eosinophils and F4/80int-lowMHCIIhighCD226+ cells. 
However, studies in our lab indicate that the F4/80+Tim4+Gata6- resident pMϕs do not 
express CD226 or CD11c, suggesting that the remaining pMϕs in Gata6-KOmye mice 
are indeed resident macrophages corresponding to Gata6+F4/80high in Gata6-WT mice. 
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3.2 Chapter hypothesis and aims 
The hypothesis tested in this chapter is that Gata6 plays a fundamental role in the 
control of peritoneal macrophage inflammatory responses. 
Aims 
• To establish whether Gata6 regulates pro-inflammatory cytokine production 
• To determine differential responses to various TLR ligands 
• To evaluate the whether the release of IL-1β is mature and dependent on the 
NLRP3 inflammasome 
• To examine mechanisms of aberrant release of IL-1β 
• To determine whether Gata6-deficient pMϕs are predisposed to apoptosis both 
naïve and stimulated 
• To evaluate whether purinogenic signalling and soluble factors contribute to 
IL-1β release 
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3.3 Results 
3.3.1 Dose-dependent IL-1β release from LPS-stimulated 
Gata6-deficient pMϕs 
Macrophages express a broad array of PRRs that detect pathogens and tissue-injury 
(sterile inflammation) via conserved PAMPs and DAMPs respectively. The TLRs 
represent the best characterised PRRs by which macrophages detect pathogens. To 
determine whether Gata6-deficient pMϕs have dysregulated inflammatory responses, 
pMϕs were stimulated with the archetypal TLR4 ligand, lipopolysaccharide (LPS), and 
the production of soluble mediators determined. The focus of this chapter is the 
regulation of IL-1 family member cytokines (Figure 3.1), and the production of other 
prototypical pro-inflammatory cytokines (TNF and IL-6) are discussed in Chapter 
Four. 
In response to LPS, Gata6-deficient pMϕs secreted significantly more IL-1β and IL-
18 compared to pMϕs from Gata6-WT mice in a dose-dependent manner (Figure 3.1). 
The production of IL-1β was detectable in Gata6-deficient pMϕs stimulated with 10 
ng ml-1 LPS and reached peak production at 100 ng ml-1 LPS (Figure 3.1A). 
Conversely, IL-18 release from Gata6-deficient pMϕs was much lower than IL-1β and 
was only significantly produced after stimulation with 100 ng ml-1 LPS. Conversely, 
LPS-stimulated pMϕs from Gata6-WT mice did not produce significant amounts of 
IL-1β or IL-18 compared to unstimulated controls. 
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Figure 3.1 | Gata6-deficient pMϕs secrete IL-1β in response to LPS alone. 
Adherent peritoneal exudate cells (APECs) from Gata6-WT and Gata6-KOmye were 
stimulated with LPS at 0, 1, 10, 100 or 1000 ng ml-1 for 24 hours. Culture supernatants 
were collected and (A) IL-1β and (B) IL-18 release measured by ELISA. Data are 
expressed as mean ± S.D from three independent experiments. Statistical significance 
was determined by two-way ANOVA (Int, interaction statistic; Gata6, Gata6 effects; 
LPS, LPS concentration effects) with Tukeys multiple comparison post-test (*p < 0.05, 
**p < 0.01, ***p < 0.001, ns = not significant). 
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3.3.2 Aberrant IL-1β release from Gata6-deficient pMϕs is 
restricted to TLR4 stimulation 
To further characterise the effect that Gata6-deficiency has on the production of IL-
1β release and the inflammatory response, an array of TLR ligands were used to 
stimulate pMϕs from Gata6-WT and Gata6-KOmye mice (Figure 3.2). 
In contrast to LPS stimulation, which resulted in robust IL-1β release from Gata6-
deficient pMΦs (p < 0.0001), none of the other TLR ligands tested triggered a 
significant increase in IL-1β production compared to unstimulated pMϕs (Figure 3.2). 
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Figure 3.2 | IL-1β release from Gata6-deficient pMϕs is restricted to LPS/TLR4 
stimulation. 
APECs from Gata6-WT and Gata6-KOmye mice were unstimulated or stimulated with 
Pam3CSK4 (500 ng ml-1), Poly(I:C) (1 µg ml-1), LPS (100 ng ml-1), Flagellin (100 ng 
ml-1), R848 (1 µg ml-1), CpG ODN 1826 (5 µM) or CpG ODN 1826 control (5 µM) 
for 24 hours. Culture supernatants were collected 24 hours after stimulation and the 
release of IL-1β measured by ELISA. Data are shown as mean ± S.D from five 
independent experiments. Statistical significance was determined by two-way 
ANOVA (Int, interaction statistic; Gata6, Gata6 effects; Ligand, TLR ligand effects) 
with Tukeys multiple comparison post-test (*p < 0.05, **p < 0.01, ***p < 0.001, ns = 
not significant). 
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3.3.3 Gata6-deficient pMϕs exhibit enhanced and prolonged 
pro-inflammatory cytokine production in response to 
LPS 
The production of soluble mediators by immune cells is tightly regulated, with defects 
in regulation underlying causes of a range of inflammatory disorders including 
arthritis, autoimmune diseases, and neurodegeneration (Sedger and McDermott, 2014, 
Clark, 2007, Tanaka and Kishimoto, 2012, Dinarello et al., 2012, Arnardottir et al., 
2016). The resolution of inflammation is therefore a fundamental event of the immune 
response. To determine whether Gata6 controls the inflammatory responses of pMϕs 
the kinetics of pro-inflammatory cytokine and mediator production were investigated 
in response to LPS and zymosan, a TLR2/4 and dectin-1 ligand that has been reported 
to induce IL-1β release from macrophages (Figure 3.3). 
In accordance with earlier observations, Gata6-WT pMΦs stimulated with LPS 
resulted in only limited detection of IL-1β in the culture supernatants, whereas Gata6-
deficient pMϕs stimulated with LPS resulted in robust secretion of IL-1β (Figure 3.3). 
The stimulation of pMϕs from Gata6-WT mice with zymosan (a ligand that can signal 
through MyD88-dependent and MyD88-independent pathways) resulted in robust 
secretion of IL-1β, with peak production detected at 24 hours, at which point IL-1β 
release was significantly higher than that from Gata6-deficient pMϕs (p = 0.0228). 
(Figure 3.3). The kinetics of IL-1β release from LPS stimulated Gata6-KOmye pMΦs 
was comparable to both Gata6-WT and Gata6-KOmye pMΦs stimulated with zymosan 
(Figure 3.3). 
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Figure 3.3 | Gata6-deficient pMϕs have aberrant IL-1β release when stimulated 
with LPS. 
APECs from Gata6-WT and Gata6-KOmye mice were stimulated with 100 ng ml-1 LPS 
(A) or a 1:1 ratio zymosan (B) for the indicated time points. Supernatants were 
collected and analysed by ELISA for IL-1β release. Data are expressed as mean 
percentage of maximum release ± S.E.M of three independent experiments (Release 
of IL-1β from LPS-stimulated cells is expressed as a percentage of IL-1β released from 
Gata6-KOmye APECs stimulated with LPS for 18 hours, and the release of IL-1β from 
zymosan-stimulated cells was expressed as a percentage of Gata6-WT APECs 
stimulated with zymosan for 24 hours). Statistical significance was determined by two-
way ANOVA (Int, interaction statistic; Gata6, Gata6 effects; Time, Ligand stimulation 
time effects) with Tukeys multiple comparison post-test (*p < 0.05, **p < 0.01, ***p 
< 0.001, ns = not significant). 
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3.3.4 IL-1β released by LPS-stimulated Gata6-deficient 
pMϕs is mature and caspase-1- and NLRP3-dependent 
The production and release of IL-1β is tightly regulated and typically requires two 
distinct signals (Martinon et al., 2002). The first signal induces the expression of pro-
IL-1β and NLRP3, whereas the second signal is required for the activation of the 
NLRP3 inflammasome. Activation of the inflammasome and subsequent assembly 
results in the activation of caspase-1, which then cleaves pro-IL-1β into the mature 
biologically active form (Franchi et al., 2012, Mariathasan et al., 2006, Agostini et al., 
2004). 
Typically, the processing of pro-IL-1β into the biologically active form requires 
cleavage by caspase-1. To test whether capase-1 is critical for the processing and 
release of IL-1β from Gata6-deficient pMϕs stimulated with LPS, pMϕs from Gata6-
WT and Gata6-KOmye were stimulated with LPS in the presence or absence of the 
caspase-1 inhibitor, Ac-YVAD-cmk (YVAD), for 24 hours and the release of IL-1β 
into culture supernatants measured by ELISA (Figure 3.4). The activation of caspase-
1 is typically mediated by inflammasomes, of which the NLRP3 inflammasome is the 
best characterised to date. To determine whether the release of IL-1β from Gata6-
deficient pMϕs stimulated with LPS was dependent on the NLRP3 inflammasome, 
pMϕs from Gata6-WT and Gata6-KOmye were stimulated with LPS in the presence or 
absence of MCC950, a small molecule inhibitor of NLRP3 inflammasome activation 
(Figure 3.4). To address whether the IL-1β release from LPS-stimulated Gata6-
deficient pMϕs was the mature, processed form (p17), the cell culture supernatants 
from unstimulated or LPS-stimulated pMϕs were analysed by immunoblotting for IL-
1β (Figure 3.4). 
The release of IL-1β from LPS-stimulated Gata6-deficient pMϕs was significantly 
reduced when treated with 10 µM and 40 µM YVAD (p < 0.0001 and p < 0.0001 
respectively). Similarly, the release of IL-1β was significantly lower in Gata6-deficient 
pMϕs treated with LPS and MCC950 compared to stimulation with LPS alone (p < 
0.0001). Immunoblotting showed that the IL-1β detected in culture supernatants was 
mature, and that treatment with MCC950 attenuated the release of mature IL-1β in 
LPS-stimulated pMϕs from Gata6-WT and Gata6-KOmye mice. 
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Figure 3.4 | The release of mature IL-1β from LPS-stimulated Gata6-deficient 
pMϕ is caspase-1- and NLRP3-dependent. 
(A, B) APECs from Gata6-WT and Gata6-KOmye mice were stimulated with 100 ng 
ml-1 LPS and either (A) Ac-YVAD-cmk or DMSO (vehicle control) or (B) DMSO or 
1 µM MCC950 for 24 hours. Culture supernatants were collected and IL-1β release 
measured by ELISA. Data are expressed as mean ± SD from five independent 
experiments. (C) Immunoblot analysis of IL-1β from concentrated supernatants of 
APECs from Gata6-WT and Gata6-KOmye stimulated with 100 ng ml-1 LPS with or 
without 1 µM MCC950 in serum-free medium for 18 hours. For a positive control 
(+ve) of mature IL-1β, pMϕs were primed with 100 ng ml-1 LPS for 3 hours followed 
by a 30 minute pulse with 5 mM ATP. (A, B) Data shows mean ± S.D from five 
independent experiments. Statistical significance was determined by two-way 
ANOVA with Tukeys multiple comparison post-test (*p < 0.05, **p < 0.01, ***p < 
0.001, ns = not significant). 
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3.3.5 Canonical inflammasome activation is comparable 
between Gata6-WT and Gata6-KOmye pMϕs 
TLR4 mediated activation of NF-κB is required for the expression of both pro-IL-1β 
and NLRP3. Therefore, the role of Gata6-deficiency on the expression of pro-IL-1β 
and NLRP3 was determined in unstimulated and LPS stimulated pMϕs from Gata6-
WT and Gata6-KOmye mice (Figure 3.5). To address whether Gata6-deficient pMϕs 
have altered responses to conventional inflammasome activation, pMϕs from Gata6-
WT and Gata6-KOmye mice were primed with LPS for 3 hours, followed by treatment 
with either ATP or nigericin (Figure 3.5 C). 
Western blot analysis of NLRP3 expression in unstimulated or LPS-stimulated pMϕs 
showed that LPS treatment greatly enhanced the expression of NLRP3. Furthermore, 
there was no obvious difference in NLRP3 expression detected by immunoblotting in 
LPS-stimulated pMϕs from Gata6-WT and Gata6-KOmye mice. The production of IL-
1β after LPS-primed pMϕs were treated with ATP or Nigericin was comparable 
between Gata6-WT and Gata6-KOmye pMϕs (p = 0.9914 and p = 0.7993 respectively). 
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Figure 3.5 | Gata6-deficient pMϕs have normal inflammasome function and 
NLRP3 expression. 
(A) APECs from Gata6-WT and Gata6-KOmye were unstimulated or stimulated with 
100 ng ml-1 LPS for 3 hours. The expression of Il1b and Nlrp3 were determined by 
qPCR relative to the endogenous control gene Ywhaz. Error bars indicate the 95% 
confidence interval of three technical replicates. (B) Immunoblot analysis of NLRP3 
and pro-IL-1β expression in pMϕs from Gata6-WT or Gata6-KOmye unstimulated or 
stimulated with 100 ng ml-1 LPS for 6 hours. Data representative of two independent 
experiments. (C) APECs from Gata6-WT and Gata6-KOmye were unstimulated or 
primed with 100 ng ml-1 LPS for 3 hours, followed by a 30-minute pulse with vehicle 
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control (Vh), 5 mM ATP, or 20 µM nigericin. Culture supernatants were collected and 
IL-1β release measured by ELISA. Data shows mean ± S.D from six independent 
experiments. Statistical significance was determined by two-way ANOVA (Int, 
interaction statistic; Gata6, Gata6 effects; Treatment, Treatment effects) with Tukeys 
multiple comparison post-test (*p < 0.05, **p < 0.01, ***p < 0.001, ns = not 
significant).  
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3.3.6 Gata6-deficient pMϕs exhibit no perturbations of 
NLRP3 inflammasome activatory pathways 
Having established that mature IL-1β release from LPS-stimulated Gata6-deficient 
pMϕs was dependent on the NLRP3 inflammasome, I investigated possible 
mechanisms through which the loss of Gata6 might promote aberrant inflammasome 
activation. Deficiencies in autophagy have been described to promote the processing 
and release of IL-1β in response to LPS alone (Saitoh et al., 2008). Additionally, 
intracellular cyclic AMP (cAMP) and Ca2+ levels have been shown to modulate 
inflammasome activation (Lee et al., 2012). Furthermore, intracellular cAMP and Ca2+ 
levels are modulated by prostanoids, lipid mediators that are secreted by macrophages 
following TLR-signalling. Therefore, LPS-stimulated pMϕs from Gata6-WT and 
Gata6-KOmye mice were treated with chemical inhibitors targeting autophagy, cAMP 
and Ca2+ signalling pathways, and lipid signalling (Figure 3.6). 
The release of IL-1β from LPS-stimulated pMϕs was not significantly affected by 
treatment with Dibutyryl-cAMP (DB), a cAMP analogue (p = 0.2551). Similarly, the 
release of IL-1β from LPS-stimulated Gata6-deficient pMϕs treatment with Rp-
cAMPS (RP), an inhibitor of the activation of cAMP-dependent protein kinases by 
cAMP (cAMP signalling) was comparable to LPS treatment alone (p = 0.9389). 
Treatment of LPS-stimulated Gata6-deficient pMϕs with the selective calcium 
chelator, BAPTA-AM, significantly reduced the secretion of IL-1β compared to LPS 
treatment alone (p = 0.0388). The secretion of IL-1β from LPS-stimulated Gata6-
deficient pMϕs treated with the prostacyclin analogue, beraprost, was significantly 
reduced by over 60% compared to LPS stimulation alone (p = 0.0366). Conversely, 
there was an almost two-fold increase in IL-1β secretion from LPS-stimulated Gata6-
deficient pMϕs treated with the COX-1/2 inhibitor, indomethacin, compared to LPS 
stimulation alone (p = 0.0010). IL-1β release from LPS-stimulated Gata6-deficient 
pMϕs treated with Torin2, a compound that enhances autophagy, was significantly 
lower than LPS treatment alone (p = 0.0110). The secretion of IL-1β from Gata6-
deficient pMϕs was comparable between LPS stimulation alone and treatment with 
either chloroquine or wortmannin (p = 0.2838 and p = 0.1705 respectively), which 
inhibit autophagy. 
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Figure 3.6 | Gata6-deficient pMϕs exhibit no perturbations of NLRP3 
inflammasome activatory pathways. 
(A-C) APECs from Gata6-WT and Gata6-KOmye were stimulated with LPS in the 
presence or absence of: (A) DMSO (vehicle control), 10 µM Torin2, 50 µM 
chloroquine, or 2.5 µM wortmannin; (B) LPS, 25 µM BAPTA-AM, 10 µM Dibutyryl-
cAMP (DB), or 10 µM Rp-cAMPS (RP); (C) DMSO, 10 µM sodium beraprost, or 10 
µM Indomethacin for 24 hours. Culture supernatants were collected and IL-1β release 
measured by ELISA. Data shows mean ± S.D from (A, C) five or (B) three 
independent experiments. Statistical significance was determined by two-way 
ANOVA (Int, interaction statistic; Gata6, Gata6 effects; Time, Ligand stimulation time 
effects) with Tukeys multiple comparison post-test (*p < 0.05, **p < 0.01, ***p < 
0.001, ns = not significant). 
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3.3.7 Gata6-deficient pMϕs have dysfunctional mitochondria 
and enhanced reactive oxygen species generation 
The NLRP3 inflammasome is activated by a wide array of endogenous and exogenous 
ligands. Dysfunctional mitochondria have been linked to the activation of the 
inflammasome, although this remains highly controversial. To examine whether 
Gata6-deficient pMϕs have dysfunctional mitochondria, that might contribute to 
inflammasome activation and the release of mature IL-1β, pMϕs from Gata6-WT and 
Gata6-KOmye were analysed by flow cytometry for DHR123 and MitoSOX to 
determine the production of ROS and mitochondrial superoxide production 
respectively (Figure 3.7). Gata6-deficient pMϕs had a significant increase in both 
DHR123 and MitoSOX staining compared to pMϕs from Gata6-WT mice (p = 0.0039 
and p = 0.0078 respectively). Furthermore, functional metabolic analyses on Tim4+-
sorted pMϕs showed that Gata6-deficient pMϕs had enhanced basal oxidative 
phosphorylation but a lower spare respiratory capacity compared to pMϕs from Gata6-
WT mice (Figure 3.7 B). To test whether an increase in mitochondrial ROS was 
accounted for by the accumulation of dysfunctional mitochondria, pMϕs from Gata6-
WT and Gata6-KOmye were stained with two mitochondrial-selective fluorescent dyes 
to distinguish total mitochondrial mass (MitoTracker Green) and respiring 
mitochondria (MitoTracker Red). Gata6-deficient pMϕs that were either unstimulated 
or stimulated with LPS for 16 hours showed an increase in the frequency of 
dysfunctional mitochondria (MitoTracker Greenhigh, MitoTracker Redlow) compared to 
pMϕs from Gata6-WT mice (Figure 3.7 D). Treatment of LPS-stimulated Gata6-
deficient with MitoTempo, a ROS scavenger, pMϕs significantly decreased the 
secretion of IL-1β release (p < 0.0001) (Figure 3.7 C). 
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Figure 3.7 | Gata6-deficient pMϕs have dysfunctional mitochondria and enhanced ROS. 
(A) Scatter plots showing naïve DHR123 and MitoSOX MFI from naïve pMϕs (CD11b+F4/80+MHC-) from Gata6-WT and Gata6-KOmye mice. 
Each point shows DHR123 and MitoSOX MFI from individual mice (minus FMO control) expressed relative to Gata6-WT pMϕs from two 
independent experiments. (B) Oxygen consumption rate (OCR) of pMϕs from Gata6-WT and Gata6-KOmye treated sequentially with oligomycin, 
FCCP, and Rotenone and antimycin A (Rot/AA) (mitochondrial stress test). OCRs were normalised to total protein in each well. Data representative 
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of two independent experiments. (C) APECs from Gata6-WT and Gata6-KOmye mice were stimulated with 100 ng ml-1 LPS and either DMSO 
(vehicle control) or MitoTempo for 24 hours. Culture supernatants were collected and IL-1β release measured by ELISA. Data are expressed as 
mean ± S.D from six independent experiments. (D) Bivariate plot showing MitoTracker Green (binds to the lipid membrane of the mitochondria) 
and MitoTracker Red (accumulates in respiring mitochondria) in pMϕs (CD11b+F4/80+) from Gata6-WT and Gata6-KOmye mice that were 
unstimulated or stimulated with 100 ng ml-1 LPS for 16 hours. For a positive control of mitochondrial depolarization (loss of MitoTracker Red 
staining), pMϕs were treated with 100 µM FCCP or 5 mM ATP. Statistical analysis was determined by (A) Wilcoxon matched-pairs signed rank 
test or (C) two-way ANOVA with Tukeys multiple comparison post-test (*p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant). 
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3.3.8 LPS induces cell death in Gata6-deficient pMϕs 
Recent studies have indicated that the release of mature IL-1β from macrophages is 
coupled with the loss of plasma membrane integrity and cell death (Cullen et al., 2015, 
Liu et al., 2014). To address whether the release of IL-1β in LPS-stimulated Gata6-
deficient pMϕs is accompanied by cell death, pMϕs from Gata6-WT and Gata6-KOmye 
were unstimulated or stimulated with LPS for 16 hours and the uptake of propidium 
iodide (PI) determined by flow cytometry (Figure 3.8). 
The percentage of PI+ pMϕs was comparable between unstimulated pMϕs from Gata6-
WT and Gata6-KOmye mice (p = 0.4193). Conversely, stimulation with LPS 
significantly increased the percentage of PI+ pMϕs from Gata6-KOmye compared to 
unstimulated Gata6-deficient pMϕs (p = 0.0265), and both unstimulated and LPS-
stimulated pMϕs from Gata6-WT mice (p = 0.0033 and p = 0.0033 respectively). 
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Figure 3.8 | LPS-stimulation induces cell death in Gata6-deficient pMϕs. 
(A) Representative flow cytometry bivariate plot showing the uptake of propidium 
iodide (PI) in pMϕs (gated by CD11b+F4/80+) from Gata6-WT or Gata6-KOmye mice 
that were either unstimulated or stimulated with 100 ng ml-1 LPS ex vivo for 16 hours. 
Numbers indicate percentage PI+ pMϕs. (B) Percentage PI positive pMϕs were 
determined using FMO controls. Data are expressed as mean ± S.D from three 
independent experiments. Statistical significance was determined by two-way 
ANOVA (Int, interaction statistic; Gata6, Gata6 effects; LPS, LPS effects) with 
Tukeys multiple comparison post-test (*p < 0.05, **p < 0.01, ***p < 0.001, ns = not 
significant). 
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3.3.9 Inhibition of Caspase-1 and NLRP3 fails to prevent cell 
death 
Pyroptosis is typically mediated by caspase-1, which cleaves gasdermin d leading to 
the formation of plasma membrane pores and subsequent plasma membrane rupture. 
LPS induces a significant increase in cell death of Gata6-deficient pMϕs, I next sought 
to determine whether inhibition of caspase-1 and the NLRP3 inflammasome (which 
inhibit the release of IL-1β) would prevent cell death, pMϕs from Gata6-WT and 
Gata6-KOmye were unstimulated or stimulated with LPS for 16 hours in the presence 
or absence of Ac-YVAD or MCC950 (Figure 3.9). 
Interestingly, inhibition of caspase-1 or inhibition of NLRP3 inflammasome activation 
did not attenuate cell death in LPS-stimulated Gata6-deficient pMϕs (Figure 3.9). 
Preliminary experiments suggest that the inhibitors themselves did not induce cell 
death as unstimulated Gata6-deficient pMϕs in the presence or absence of inhibitors 
had comparable cell death (Supplementary Figure 1). 
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Figure 3.9 | Inhibition of caspase-1 and NLRP3 inflammasome activation does 
not prevent cell death. 
(A) Bivariate plot showing the uptake of propidium iodide (PI) in pMϕs (gated by 
CD11b+F4/80+) from Gata6-WT or Gata6-KOmye mice that were either unstimulated 
or stimulated with 100 ng ml-1 LPS with the presence of DMSO (vehicle control), 40 
µM YVAD or 1 µM MCC950 ex vivo for 16 hours. Numbers indicate percentage PI+ 
pMϕs. Data is representative of two independent experiments. (B) Scatter plot showing 
percentage PI+ pMϕs from two independent experiments.  
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3.3.10   Naïve Gata6-deficient pMϕs are not apoptotic 
The dramatic reduction of peritoneal macrophages in Gata6-KOmye mice has been 
attributed to increased apoptosis under homeostatic conditions (Gautier et al., 2014), 
whereas another study attributed the reduction to increased accumulation of pMϕs in 
the omentum (Okabe and Medzhitov, 2014). 
To investigate whether naïve Gata6-deficient pMϕs have elevated apoptosis during 
the steady state, freshly isolated pMϕs from Gata6-WT and Gata6-KOmye were 
analysed by flow cytometry for cleaved caspase-3 (active), which is indicative of cells 
undergoing terminal apoptosis (Figure 3.10). Furthermore, naïve pMϕs from Gata6-
WT and Gata6-KOmye were stained with Annexin V (Figure 3.10). 
In contrast with previous findings (Gautier et al., 2014), the percentage of caspase-3 
positive Gata6-deficient pMϕs was comparable to those of Gata6-WT mice (p = 
0.8514) (Figure 3.10 C). Similarly, Annexin V staining showed no discernible 
difference between naïve pMϕ from Gata6-WT and Gata6-KOmye mice (Figure 3.10 
D-E). 
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Figure legend on next page 
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Figure 3.10 | Naïve pMϕs from Gata6-KOmye mice are not significantly predisposed to apoptosis. 
(A) Representative bivariate plots showing cleaved caspase-3 in naïve pMϕs (CD11b+F4/80+) from Gata6-WT or Gata6-KOmye mice. Thymocytes 
treated with dexamethasone for 4 hours are included as a positive control for apoptosis. (B) Representative overlay histograms showing cleaved 
caspase-3 in pMϕs (CD11b+F4/80+) (shaded histogram: isotype control). Number indicates percentage positive cells. (C) Bar chart shows mean 
percentage caspase-3 positive pMϕs ± S.D from 10 Gata6-WT and 11 Gata6-KOmye mice from two independent experiments. Caspase-3 positive 
pMϕs was determined using subtraction histograms of isotype control and stained cells. (D) Bivariate plot showing Annexin V staining in naïve 
pMϕs (CD11b+F4/80+) from Gata6-WT or Gata6-KOmye mice from one experiment. (E) Histogram showing cleaved Annexin V in naïve Gata6-
WT or Gata6-KOmye pMϕs (CD11b+F4/80+) (Grey, WT; Red, KO; shaded, stained; empty, FMO). Statistical significance was determined by 
unpaired t test with Welch’s correction (*p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant). 
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3.3.11   LPS induces apoptosis in Gata6-deficient pMϕs 
Having determined that cell death in LPS-stimulated Gata6-deficient pMϕs was 
independent of caspase-1 and NLRP3 activation and that freshly isolated Gata6-
deficient pMϕs were not apoptotic, I next sought to determine whether LPS-
stimulation would induce apoptosis in Gata6-deficient pMϕs. To address this, pMϕs 
from Gata6-WT and Gata6-KOmye were either unstimulated or stimulated with LPS 
and analysed by flow cytometry for cleaved caspase-3 (Figure 3.11). 
The percentage of caspase-3+ pMϕs was comparable between unstimulated pMϕs from 
Gata6-WT and Gata6-KOmye mice (p = 0.9983). Conversely, stimulation with LPS 
significantly increased the percentage of caspase-3+ pMϕs from Gata6-KOmye 
compared to unstimulated Gata6-deficient pMϕs (p = 0.0003), and both unstimulated 
and LPS-stimulated pMϕs from Gata6-WT mice (p = 0.0003 and p = 0.004 
respectively). 
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Figure legend on next page 
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Figure 3.11 | Caspase-3 activation is increased in LPS-stimulated Gata6-deficient pMϕs. 
(A) Representative bivariate plots showing cleaved caspase-3 in pMϕs (CD11b+F4/80+) from Gata6-WT or Gata6-KOmye mice that were 
unstimulated or stimulated with 100 ng ml-1 LPS ex vivo for 16 hours. Starved macrophage precursors (MϕPs) were included as a positive control 
for apoptosis. (B) Representative overlay histograms showing cleaved caspase-3 in pMϕs (CD11b+F4/80+) (shaded histogram: isotype control) (C) 
Percentage cleaved caspase-3 positive pMϕs was determined using subtraction histograms of isotype control and stained cells. Data are expressed 
as mean ± S.D from three independent experiments. Statistical significance was determined by two-way ANOVA (Int, interaction statistic; Gata6, 
Gata6 effects; LPS, LPS effects) with Tukeys multiple comparison post-test (*p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant). 
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3.3.12   Differential TLR signalling required for 
aberrant IL-1β release 
The release of IL-1β from Gata6-deficient pMϕs was restricted to stimulation with the 
TLR4 ligand LPS (Figure 3.2). The production and release of mature IL-1β requires 
both the induction of pro-IL-1β expression and the activation of inflammasomes, 
which culminate in the cleavage and release of IL-1β. Therefore, the incapacity of 
Gata6-deficient pMϕs stimulated with other TLR ligands to secrete IL-1β may be a 
consequence of their failure to induce pro-IL-1β expression, or that downstream 
signalling cascades fail to activate the inflammasome (either directly or indirectly). 
Understanding how LPS differentially induces IL-1β release from Gata6-deficient 
pMϕs may provide insight into the molecular mechanisms governing aberrant release. 
The selective expression of different TLR receptors in pMϕs may account for the 
failure to induce IL-1β secretion in Gata6-deficient pMϕs (Supplemental Figure 3), 
which is supported by the failure of some ligands to induce the production of other 
pro-inflammatory cytokines. Microarray expression analysis indicated that both TLR2 
and TLR4 were highly expressed in pMϕs from Gata6-WT and Gata6-KOmye. 
Furthermore, pMϕs stimulated with the TLR1/2 ligand Pam3CSK4 resulted in robust 
secretion of IL-6 (Chapter 4). Consequently, Pam3CSK4 was selected for further 
investigation into the differential mechanisms of LPS-induced secretion of IL-1β from 
Gata6-deficient pMϕs. To ascertain whether Pam3CSK4 can induce the expression of 
pro-IL-1β, pMϕs from Gata6-WT and Gata6-KOmye were either unstimulated or 
stimulated with either LPS or Pam3CSK4 for 6 hours and the expression of pro-IL-1β 
determined by flow cytometry (Figure 3.12). 
The percentage of pMϕs from Gata6-WT mice expressing pro-IL-1β was comparable 
when cells were stimulated with either LPS or Pam3CSK4 (p > 0.9999). Similarly, 
there was no significant difference in the percentage of Gata6-deficient pMϕs 
expressing pro-IL-1β stimulated with either LPS or Pam3CSK4 (p = 0.4356). The 
percentage of LPS-stimulated pMϕs expressing pro-IL-1β was significantly lower in 
pMϕs from Gata6-KOmye compared to Gata6-WT mice (p = 0.0014). Likewise, there 
was a significant reduction in the percentage of unstimulated pMϕs from Gata6-KOmye 
expressing pro-IL-1β compared to those from Gata6-WT mice (p = 0.005). 
Conversely, there was no significant difference in the percentage of Pam3CSK4-
150 
 
stimulated pMϕs expressing pro-IL-1β from either Gata6-WT or Gata6-KOmye (p = 
0.0821).  
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Figure 3.12 | Pam3CSK4 induces robust pro-IL-1β production. 
Total PECs from Gata6-WT and Gata6-KOmye mice were unstimulated or stimulated 
with either 100 ng ml-1 LPS or 500 ng ml-1 Pam3CSK4 for 6 hours. (A) Representative 
bivariate plot showing pro-IL-1β expression in F4/80+Tim4+ pMϕs. The percentage 
pro-IL-1β positive cells is indicated on each plot. (B) Representative overlay 5% 
contour plots with outliers of IL-1β-expressing F4/80+Tim4+ pMϕs from Gata6-WT 
(black contours, F4/80high) and Gata6-KOmye (red contours, F4/80low). (C) Bar chart 
shows percentage pro-IL-1β positive pMϕs. Data shows mean ± S.D from four 
independent experiments. Statistical significance was determined by two-way 
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ANOVA with Tukey’s multiple comparisons post-test (*p < 0.05, ** <0.01, ns = not 
significant).   
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3.3.13   Cell death is restricted to LPS stimulation in 
Gata6-deficient pMϕs 
The capacity of Pam3CSK4 to induce the expression of pro-IL-1β but not secretion of 
mature IL-1β from Gata6-deficient pMϕs, indicated that downstream pathways 
differentially induced by Pam3CSK4 and LPS were responsible for the specific release 
of IL-1β from Gata6-deficient pMϕs stimulated with LPS but not Pam3CSK4. In 
response to LPS, the percentage of necrotic (PI+) Gata6-deficient pMϕs was 
significantly higher compared to both unstimulated pMϕs and unstimulated or LPS-
stimulated pMϕs from Gata6-WT mice (Figure 3.8). Consequently, I hypothesized 
that as Pam3CSK4 does not induce the secretion of IL-1β in Gata6-deficient pMϕs, 
cell death will be comparable to unstimulated cells. To address this, pMϕs from Gata6-
WT and Gata6-KOmye were either unstimulated or stimulated with either LPS or 
Pam3CSK4 for 16 hours and the percentage of dead cells determined by flow 
cytometry (Figure 3.13). 
There was a marked increase in cell death in Gata6-deficient pMϕs stimulated with 
LPS compared to unstimulated pMϕs, in accordance with previous observations (p = 
0.0009). Conversely, pMϕs stimulated with Pam3CSK4 had comparable cell death to 
unstimulated controls (p = 0.9537) (Figure 3.13). Similarly, the percentage of PI+ 
pMϕs from Gata6-WT mice was comparable between unstimulated and either LPS or 
Pam3CSK4 stimulation (p > 0.9999 and p = 0.9998 respectively).  
  
154 
 
 
Figure 3.13 | Cell death of Gata6-deficient pMϕs is restricted to stimulation with 
LPS. 
(A) Bivariate plot showing the uptake of propidium iodide (PI) in pMϕs (gated by 
Tim4+F4/80+) from Gata6-WT or Gata6-KOmye mice that were either unstimulated or 
stimulated with 100 ng ml-1 LPS or 500 ng ml-1 Pam3CSK4 for 16 hours. The 
percentage PI+ cells is indicated on each plot. (B) Bar chart shows mean PI+ pMϕs ± 
S.D from three independent experiments. Percentage PI+ pMϕs was determined using 
FMO controls. Statistical significance was determined by two-way ANOVA (Int, 
interaction statistic; Gata6, Gata6 effects; Stimulation, Stimulation effects) with 
Tukeys multiple comparison post-test (*p < 0.05, **p < 0.01, ***p < 0.001, ns = not 
significant).  
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3.3.14   Cell death and IL-1β release from Gata6-
deficient pMϕs are significantly reduced when co-
cultured with pMϕs from Gata6-WT mice 
To investigate whether the release of IL-1β from LPS-stimulated Gata6-deficient 
pMϕs was a cell autonomous defect, or whether the release of soluble factors or 
contact-dependent mechanisms could modulate the release of IL-1β, co-cultured pMϕs 
from Gata6-WT and Gata6-KOmye were stimulated with LPS and the release of IL-1β 
determined by ELISA (Figure 3.14). Additionally, cell death was determined by PI 
staining in monocultures and co-cultures unstimulated and LPS-stimulated pMϕs from 
Gata6-WT and Gata6-KOmye mice. 
The secretion of IL-1β from LPS-stimulated Gata6-KOmye monocultures seeded 1 x 
105 cells was significantly higher than those containing 0.5 x 105 Gata6-deficient 
pMϕs or co-cultured pMϕs (p = 0.0275 and p < 0.0001 respectively). Co-cultured 
pMϕs released significantly less IL-1β than monocultures containing 0.5 x 105 Gata6-
deficient pMϕs (p = 0.0181). Conversely, the release of IL-1β from co-cultured pMϕs 
was not significantly different to monocultures containing 0.5 x 105 pMϕs from Gata6-
WT mice (p = 0.4843) (Figure 3.14). 
Similar to previous observations, the percentage of PI+ Gata6-deficient pMϕs was 
significantly higher than unstimulated Gata6-deficient pMϕs and both unstimulated 
and LPS-stimulated pMϕs from Gata6-WT mice. Strikingly, the percentage of PI+ 
Gata6-deficient pMϕs stimulated with LPS was significantly reduced when co-
cultured with pMϕs from Gata6-WT mice. 
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Figure legend on next page 
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Figure 3.14 | Cell-intrinsic release of IL-1β from LPS-stimulated Gata6-deficient pMϕs is attenuated when co-cultured with pMϕs from 
Gata6-WT mice. 
(A) Bivariate plot showing the uptake of propidium iodide (PI) in pMϕs (gated by Tim4+F4/80+) from Gata6-WT or Gata6-KOmye mice that were 
cultured separately (monoculture) or co-cultured (1:1 total PECs) and either unstimulated or stimulated with 100 ng ml-1 LPS for 16 hours. The 
percentage PI+ cells is indicated on each plot. Data representative of two independent experiments. (B) APECs from Gata6-WT and Gata6-KOmye 
were cultured separately (1 x 105 and 0.5 x 105) or co-cultured at a 1:1 ratio (1 x 105 total cells) after which they were stimulated with 100 ng ml-1 
LPS for 24 hours. After stimulation, IL-1β release was determined in cell-free culture supernatants by ELISA. Data shows mean ± S.D from four 
independent experiments. nd = not detectable. Statistical significance was determined by one-way ANOVA with Tukeys multiple comparison post-
test between co-cultured cells and monocultures containing 0.5 x 105 cells (*p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant). 
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3.3.15   Soluble Factors 
Interestingly, a distinguishing difference between LPS and Pam3CSK4 was the 
capacity to induce the production of TNF. The secretion of TNF from LPS-stimulated 
Gata6-deficient pMϕs was significantly higher than pMϕs from Gata6-WT mice (p < 
0.0001). Conversely, the secretion of TNF from Gata6-deficient pMϕs stimulated with 
Pam3CSK4 was comparable to secretion from Gata6-WT mice (p = 0.0773) (Figure 
3.16). TNF signalling can induce the activation of NF-κB as well as pro-apoptotic 
signalling cascades in macrophages (Parameswaran and Patial, 2010). Therefore, the 
differential IL-1β secretion and cell death in Gata6-deficient pMϕs may be mediated 
by TNF produced by LPS-stimulated but not Pam3CSK4.  
To address this, pMϕs from Gata6-WT and Gata6-KOmye mice were unstimulated or 
stimulated with LPS in the presence or absence of etanercept, which functions as a 
decoy receptor thereby inhibiting TNF signalling (Figure 3.15). Additionally, pMϕs 
were stimulated with LPS with or without recombinant IL-1 receptor antagonist (rIL-
1Ra) to determine whether autocrine or paracrine IL-1 signalling exacerbates IL-1β 
production. 
The secretion of IL-1β from LPS-stimulated Gata6-deficient pMϕs treated with 
etanercept was reduced by over 30% compared to LPS stimulation alone (p = 0.0049). 
However, the release of IL-1β from Gata6-deficient pMϕs stimulated with 
recombinant TNF was comparable to unstimulated pMϕs (p > 0.9999) (Figure 3.15 C). 
The secretion of IL-1β from LPS-stimulated Gata6-deficient pMϕs treated with 
recombinant IL-1RA was comparable to LPS stimulation alone (p = 0.0214). 
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Figure 3.15 | IL-1β release is reduced from LPS-stimulated Gata6-deficient pMϕs 
when TNF signalling is inhibited. 
APECs from Gata6-WT and Gata6-KOmye mice were unstimulated or stimulated with 
100 ng ml-1 LPS in the presence or absence of 25 µg ml-1 etanercept, 2.5 µg ml-1 
recombinant mIL-1RA, or 1 µM MCC950 for 24 hours. Culture supernatants were 
collected and (A) IL-1β and (B) TNF release measured by ELISA. Data are expressed 
as mean ± S.D from five independent experiments. (C) APECs were unstimulated or 
stimulated with either 100 ng ml-1 LPS or 100 ng ml-1 recombinant murine TNF 
(recTNF) for 24 hours, after which the supernatant was collected and IL-1β release 
measured by ELISA. Data are expressed as mean ± S.D from three independent 
experiments. (D) Bivariate plot showing the uptake of propidium iodide (PI) in pMϕs 
(gated by Tim4+F4/80+) from Gata6-WT or Gata6-KOmye mice that were stimulated 
with 100 ng ml-1 LPS in the presence or absence of 25 µg ml-1 Etanercept for 16 hours. 
The percentage PI+ cells is indicated on each plot. Experiment is representative of two 
independent experiments. Statistical significance was determined by two-way 
ANOVA (Int, interaction statistic; Gata6, Gata6 effects; Treatment, Treatment effects) 
with Tukeys multiple comparison post-test (*p < 0.05, **p < 0.01, ***p < 0.001, ns = 
not significant). 
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3.3.16   Purinogenic signalling 
Our group has previously reported that CD73 expression is greatly diminished in 
Gata6-deficient pMϕs (Rosas et al., 2014), which may alter purinogenic signalling and 
consequently the production of pro-inflammatory cytokines. Adenosine generated 
through the processing of extracellular ATP by CD39 and CD73 is reported to mediate 
the down-regulation of pro-inflammatory cytokines and induce the production of IL-
10 (Cohen et al., 2013, Hamidzadeh and Mosser, 2016). 
To examine whether Gata6-deficient pMϕ produce less IL-10 than those from Gata6-
WT mice, pMϕs from Gata6-WT and Gata6-KOmye were either unstimulated or 
stimulated with either LPS or Pam3CSK4 and the production of IL-10 determined by 
ELISA (Figure 3.16). The release of IL-10 was significantly lower in pMϕs from 
Gata6-KOmye stimulated with LPS compared to those from Gata6-WT mice (p = 
0.0101). Conversely, IL-10 production of pMϕs from Gata6-WT and Gata6-KOmye 
were comparable (p = 0.0533). 
To examine whether dysregulated purinogenic signalling is responsible for the release 
of IL-1β from Gata6-deficient pMϕs upon LPS stimulation, pMϕs from Gata6-WT 
and Gata6-KOmye mice were unstimulated or stimulated with LPS in the presence or 
absence of apyrase or adenosine and the release of IL-1β determined (Figure 3.16). 
The release of IL-1β from Gata6-deficient pMϕs was not significantly reduced by 
treatment with apyrase (which hydrolyses extracellular ATP) compared to LPS-
stimulation alone (p = 0.7090). Similarly, treatment with adenosine had no discernible 
effect on the release of IL-1β from Gata6-deficient pMϕs stimulated with LPS alone 
(p = 0.9816). Furthermore, the secretion of IL-1β from LPS-stimulated pMϕs from 
Gata6-WT and Gata6-KOmye mice treated with adenosine 5′-(α,β-methylene) 
diphosphate (AMP-CP), a CD73 inhibitor, was comparable to LPS-stimulation alone 
(p = 0.9858 and p = 0.8468 respectively).  
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Figure 3.16 | LPS-stimulated Gata6-deficient pMϕs secrete less IL-10 but IL-1β 
release is unaffected by purinogenic signalling. 
(A) APECs from Gata6-WT and Gata6-KOmye mice were unstimulated or stimulated 
with either 500 ng ml-1 Pam3CSK4 or 100 ng ml-1 LPS for 24 hours. Culture 
supernatants were collected and IL-10 release measured by ELISA. Data are expressed 
as mean ± S.D from five independent experiments. (B, C) APECs from Gata6-WT 
and Gata6-KOmye mice were unstimulated or stimulated with 100 ng ml-1 LPS in the 
presence or absence of 20 U ml-1 apyrase, 100 µM adenosine, or 10 µM AMP-CP for 
24 hours. Culture supernatants were collected and IL-1β release measured by ELISA. 
Data are expressed as mean ± S.D from three independent experiments. Statistical 
significance was determined by two-way ANOVA (Int, interaction statistic; Gata6, 
Gata6 effects; Treatment, Treatment effects) with Tukeys multiple comparison post-
test (*p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant). 
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3.3.17   Loss of Gata6 may enhance neutrophil 
recruitment in vivo 
IL-1β has a key function in the recruitment of neutrophils, and the IL-1-dependent 
peritoneal accumulation of neutrophils has frequently been used as an in vivo assay for 
IL-1β production (Martinon et al., 2006, Guarda et al., 2009, Duewell et al., 2010). 
Furthermore, macrophages secrete a plethora of soluble factors that can drive 
neutrophil recruitment including cytokines such as CCL3, CXCL2, and CXCL1 (Sadik 
et al., 2011). 
To determine whether Gata6-deficient pMϕs would drive a significant increase in 
neutrophil recruitment and/or retention, Gata6-WT and Gata6-KOmye were injected 
with either 1 ng or 10 ng LPS for 4 hours and the number of neutrophils determined 
by flow cytometry (Figure 3.17 A). The number of neutrophils recruited to the 
peritoneal cavity of Gata6-KOmye was significantly higher than Gata6-WT mice 
injected with 1 ng LPS (p = 0.0161). Conversely, mice injected with 10 ng LPS had 
comparable numbers of neutrophils recruited into the peritoneal cavity of Gata6-WT 
and Gata6-KOmye (p = 0.1534). To determine what cytokines and chemokines might 
drive the differential influx of neutrophils, peritoneal lavage supernatants from mice 
injected with 1 ng and 10 ng LPS were analysed by ELISA (Figure 3.17 B). However, 
no significant differences in cytokine and chemokine production were observed 
between Gata6-WT and Gata6-KOmye, and many of the cytokines and chemokines 
analysed were non-detectable or very low. To further investigate what factors might 
enhance the recruitment of neutrophils in vivo, pMϕs from Gata6-WT and Gata6-
KOmye stimulated with LPS ex vivo for 3 hours and the production of chemokines 
determined by ELISA (Figure 3.17 D). The production of CXCL1 and CXCL2 from 
LPS-stimulated Gata6-deficient pMϕs is comparable to those from Gata6-WT mice 
(p = 0.065 and p = 0.477 respectively). Conversely, the production of CCL3 was 
significantly higher in pMϕs from Gata6-KOmye stimulated with LPS higher compared 
to Gata6-WT pMϕs (p = 0.0006). 
To establish whether Gata6-KOmye had increased retention or recruitment of 
neutrophils at later time points, mice were injected with LPS and the recruitment of 
neutrophils determined by flow cytometry. Unlike at 4 hours, there was no significant 
difference in the number of neutrophils recruited after 24 or 48 hours into the 
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peritoneal cavities of Gata6-WT and Gata6-KOmye mice following the intraperitoneal 
injection of 1 ng LPS (p = 0.9922 and p = 0.8005 respectively). 
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Figure legend on next page 
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Figure 3.17 | Gata6-deficiency may enhance neutrophil influx. 
(A) Gata6-WT and Gata6-KOmye mice were either not injected (control) or injected intraperitoneally with either 1 ng or 10 ng LPS. Peritoneal 
lavage cells were analysed by flow cytometry for neutrophil recruitment after 4 hours. Scatter plot shows the number of neutrophils with each 
symbol representing one mouse. (B) Bar charts show cytokine and chemokine in peritoneal lavage supernatant from (A) was determined by ELISA. 
nd = not detectable. (C) Gata6-WT and Gata6-KOmye mice were either not injected (control) or injected intraperitoneally with 1 ng LPS. Peritoneal 
lavage cells were analysed by flow cytometry for neutrophil recruitment after 24 or 48 hours. Scatter plot shows the number of neutrophils with 
each symbol representing one mouse. (D) APECs from Gata6-WT and Gata6-KOmye were unstimulated or stimulated with 100 ng ml-1 LPS for 3 
hours. Culture supernatants were collected 3 hours after stimulation and CCL3, CXCL2, and CXCL1 release measured by ELISA. Data are shown 
as mean ± S.D from five independent experiments. Statistical significance was determined by two-way ANOVA with Tukeys multiple comparison 
post-test (*p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant). (A, C) Injections and flow cytometry were performed by Dr Natacha Ipseiz. I 
assisted with peritoneal lavages and cell counting, experimental design, and measuring cytokines and chemokines in peritoneal lavage supernatants 
by ELISA. 
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3.4 Discussion 
The aim of this chapter was to investigate whether Gata6 controls the inflammatory 
response in peritoneal macrophages. 
 
3.4.1 LPS-induces IL-1β and IL-18 secretion 
The production of IL-1β is tightly-regulated and in macrophages, requires at least two 
distinct signals. The first signal (typically TLR ligands) induces the expression of pro-
IL-1β, which is biologically inactive. The second signal is required for the activation 
of caspase-1, which cleaves pro-IL-1β (and IL-18) into the biologically active mature 
forms, which then exit the cell and exert their biological effects through their cognate 
receptors. The activation of caspase-1 is generally mediated through multimeric 
protein complexes termed inflammasomes, of which the NLRP3 inflammasome is the 
best characterised. 
Strikingly, Gata6-deficient pMϕs stimulated with LPS alone secreted mature IL-1β 
and IL-18, whereas pMϕs from Gata6-WT mice did not secrete IL-1β or IL-18 (Figure 
3.1). Although the release of mature IL-1β in response to LPS alone (‘Priming’ signal) 
has been well described for murine BMDCs and human monocytes (Gaidt et al., 2016, 
He et al., 2013), secretion from macrophages is generally strictly dependent on two 
distinct signals. Conversely, genetic defects that lead to spontaneous IL-1β secretion 
by macrophages have been reported. BMDMs deficient of all three inhibitor of 
apoptosis proteins (cIAP1, cIAP2, and XIAP) exhibited spontaneous NLRP3 
inflammasome activity and IL-1β secretion in response to LPS alone (Vince et al., 
2012). Similarly, ablation of Atg16l1 resulted in IL-1β secretion in response to LPS 
stimulation alone (Saitoh et al., 2008). More recently, LPS-stimulated BMDMs 
deficient of Tnfaip3 (which encodes the NF-κB inhibitor A20) were shown to 
spontaneously secrete IL-1β (Duong et al., 2015). However, the molecular 
mechanisms governing the secretion of IL-1β from LPS-stimulated Gata6-deficient 
pMϕs is likely to be distinct from these reported studies. For example, Gata6-deficient 
pMϕs primed with LPS and stimulated with soluble NLRP3 stimuli (ATP and 
nigericin) responded normally, secreting comparable levels of IL-1β as pMϕs from 
Gata6-WT mice (Figure 3.5). Conversely, macrophages deficient of all IAP proteins, 
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A20 or Atg16L1 primed with LPS and activated with ATP secreted significantly more 
IL-1β compared to wild-type macrophages. Another distinguishing feature is the 
specificity of LPS to induce the secretion of IL-1β, but not any of the other TLR 
ligands tested, whereas macrophages deficient of all IAP proteins or A20 secreted 
mature IL-1β in response to a range of TLR ligands. 
 
3.4.2 IL-1β release is restricted to LPS stimulation 
Having established that LPS-stimulated Gata6-deficient pMϕs secreted mature IL-1β, 
I investigated whether stimulation with other TLR ligands alone would induce the 
release of mature IL-1β. Somewhat surprisingly, none of the other TLR ligands tested 
induced a significant release of IL-1β from Gata6-deficient pMϕs (Figure 3.2). To 
investigate the mechanisms governing the differential release of IL-1β in response to 
different TLR ligands, pMϕs from Gata6-WT and Gata6-KOmye mice were stimulated 
with LPS or Pam3CSK4 and the expression of pro-IL-1β determined. The expression 
of pro-IL-1β was comparable between LPS- and Pam3CSK4-stimulated Gata6-
deficient pMϕs, indicating that Pam3CSK4 was an effective priming stimulus. 
Supporting this, studies have shown that pMϕs primed with Pam3CSK4 and 
subsequently treated with ATP release mature IL-1β (Levesque et al., 2010). Thus, 
Pam3CSK4 stimulation induces the expression of pro-IL-1β and NLRP3 expression, 
but is ordinarily incapable of inducing the release of mature IL-1β, consistent with the 
two-signal hypothesis. Based on these observations, the release of IL-1β from LPS-
stimulated but not Pam3CSK4-stimulated Gata6-deficient pMϕs suggest that 
downstream molecular mechanisms are differentially induced by LPS and Pam3CSK4 
which mediate the activation of the inflammasome. However, for the studies carried 
out in this thesis, a dose-response curve for IL-1β and IL-18 release from Gata6-WT 
and Gata6-KOmye pMϕs was only performed with the TLR4 ligand LPS. As such, it is 
possible that the concentrations of TLR ligands used to stimulate pMϕs from Gata6-
WT and Gata6-KOmye pMϕs were sub-optimal. As such, it is possible that the release 
of IL-1β and IL-18 from Gata6-deficient pMϕs may not be restricted to LPS 
stimulation alone and that the failure of other TLR ligands to induce the release of IL-
1β and TNF from Gata6-KOmye is an experimental artefact. 
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3.4.3 Mitochondrial dysfunction 
Having established that the secretion of IL-1β from LPS-stimulated Gata6-deficient 
pMϕs was mature, the underlying molecular mechanisms of NLRP3 inflammasome 
activation were investigated. Given the structural and molecularly diverse array of 
NLRP3 activatory stimuli, it is unlikely that they all bind directly to the NLRP3 
inflammasome, as such, it has been suggested that inflammasomes most likely monitor 
cellular homeostasis which is perturbed by activatory stimuli. In addition to their role 
in metabolism, mitochondria are complex regulators of cellular homeostasis. 
Perturbation of ROS, intracellular K+ concentration or lysosomal damage have been 
reported to induce mitochondrial dysfunction (Tschopp, 2011), which are also 
implicated in the activation of the NLRP3 inflammasome. As such, mitochondrial 
dysfunction has been strongly linked to the activation of the NLRP3 inflammasome, 
predominantly through the generation of mtROS and the release of mtDNA and 
cardiolipin (Nakahira et al., 2011, Zhou et al., 2011, Iyer et al., 2013). However, the 
role of mitochondria in the activation of the NLRP3 inflammasome is contentious 
(Lawlor and Vince, 2014). Naïve Gata6-deficient pMϕs had enhanced mtROS 
compared to pMϕs from Gata6-WT mice. Consistent with increased mtROS, Gata6-
deficient pMϕs had a higher basal rate of OXPHOS than pMϕs from Gata6-WT mice, 
although the spare capacity of Gata6-deficient pMϕs was lower. Furthermore, both 
unstimulated and LPS-stimulated Gata6-deficient pMϕs had significantly more 
dysfunctional mitochondria that pMϕs from Gata6-WT, as determined by MitoTracker 
deep red (selective for respiring mitochondria) staining relative to MitoTracker Green 
(Figure 3.7). 
 
3.4.4 Gata6 restricts LPS-induced cell death 
In addition to the cleavage of IL-1β and IL-18, caspase-1 mediates pyroptotic cell 
death in macrophages. To investigate whether LPS-stimulation induces cell death in 
Gata6-deficient pMϕs, unstimulated and LPS-stimulated pMϕs from Gata6-WT and 
Gata6-KOmye mice were analysed by flow cytometry for propidium iodide (PI+), a 
membrane impermeant dye that is generally excluded from viable cells. Gata6-
deficient pMϕs stimulated with LPS had a significant increase in the number of PI+ 
pMϕs, whereas unstimulated Gata6-deficient pMϕs and both unstimulated and LPS-
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stimulated pMϕs from Gata6-WT mice had comparable numbers of PI+ cells (Figure 
3.8). Furthermore, the PI+ pMϕs exhibited a marked decrease in forward scatter profile, 
indicative of dead cells. Interestingly, the number of PI+ Gata6-deficient pMϕs 
stimulated with Pam3CSK4 was comparable to unstimulated pMϕs and both 
unstimulated and Pam3CSK4-stimulated pMϕs from Gata6-WT mice (Figure 3.13). 
Thus, the restriction of cell death and IL-1β secretion to LPS stimulation but not 
Pam3CSK4 stimulation indicates that the mechanisms governing the secretion of IL-
1β in LPS-stimulated Gata6-deficient pMϕs also mediated cell death. 
Inhibition of caspase-1 and NLRP3 activation resulted in a significant reduction of IL-
1β secretion from LPS-stimulated pMϕs, consistent with a requirement of NLRP3 
mediated activation of caspase-1 and the processing of pro-IL-1β by caspase-1 to the 
mature biologically active form (Figure 3.4). However, inhibition of caspase-1 or 
NLRP3 activation failed to inhibit LPS-induced cell death in Gata6-deficient pMϕs 
(Figure 3.9). The failure of caspase-1 and NLRP3 inhibition to prevent LPS-induced 
cell death was unexpected, as caspase-1-dependent cleavage of gasdermin d was 
recently shown to mediate pyroptotic cell death (He et al., 2015, Kayagaki et al., 2015, 
Shi et al., 2015). Alternative mechanisms of caspase-1-independent pyroptosis have 
been shown to be mediated by caspase-11, which detects intracellular LPS (Kayagaki 
et al., 2015). After activation, caspase-11 directly mediates pyroptosis and activation 
of the NLRP3 inflammasome. The NLRP3 inflammasome subsequently leads to the 
activation of caspase-1, which cleaves pro-IL-1β. As such, further study is needed to 
investigate whether the cell death is mediated through the cleavage of gasdermin d, or 
whether the induction of cell death by LPS is independent from the molecular events 
regulating the release of IL-1β. 
Alternatively, LPS-stimulation might induce another mode of cell death in Gata6-
deficient pMϕs. The marked reduction pMϕs in Gata6-KOmye was recently attributed 
to a significant increase apoptosis of naïve Gata6-deficient pMϕs (Gautier et al., 2014), 
although an alternative explanation for reduced numbers was provided by another 
study indicating that Gata6-deficient pMϕs are retained in the omentum (Okabe and 
Medzhitov, 2014). In contrast to the observations of Gautier and colleagues, there was 
no significant difference in the percentage of caspase-3+ pMϕs freshly isolated from 
Gata6-WT and Gata6-KOmye mice (Figure 3.10). Similarly, annexin V staining was 
comparable between naïve pMϕs from Gata6-WT and Gata6-KOmye, which both 
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exhibited a comparable shift in staining compared to FMO controls. The background 
staining of annexin V can be attributed to the constitutive cell surface expression of 
Annexin V binding phospholipids in macrophages (Callahan et al., 2000). The increase 
in apoptosis of Gata6-deficient pMϕs was attributed to the marked reduction in Aspa 
expression, although it is noteworthy that approximately 10% of pMϕs from Aspa-
deficient mice were apoptotic, compared to over 20% reported for Gata6-deficient 
pMϕs (Gautier et al., 2014). Furthermore, apoptotic cells in vivo are typically cleared 
rapidly, unless the phagocytes have an impairment in the phagocytosis of apoptotic 
cells (Taylor et al., 2000, Elliott and Ravichandran, 2016, O'Brien et al., 2006). 
Conversely, LPS stimulation induced a significant increase in the percentage of 
caspase-3+ pMϕs from Gata6-KOmye compared to unstimulated pMϕs and both 
unstimulated and LPS-stimulated pMϕs from Gata6-WT mice (Figure 3.11). 
Interestingly, the percentage of PI+ pMϕs was lower in Gata6-deficient pMϕs co-
cultured with those from Gata6-WT mice (Figure 3.14). Furthermore, the release of 
IL-1β from LPS-stimulated co-cultured cells was significantly reduced compared to 
monocultures of Gata6-deficient pMϕs (Figure 3.14). This suggests that Gata6 may 
regulate cell-contact dependent mechanisms or release of soluble factors that modulate 
cell death and inflammatory responses. 
 
3.4.5 IL-1β secretion is enhanced by TNF signalling, but not 
strictly dependent 
Having established that co-cultured pMϕs release significantly less IL-1β than 
monocultures of Gata6-deficient pMϕs, I sought to establish whether soluble factors 
released from Gata6-WT pMϕs may attenuate the aberrant inflammatory responses of 
Gata6-deficient pMϕs. Gata6-deficient pMϕs stimulated with LPS had significantly 
higher and prolonged production of TNF compared to pMϕs from Gata6-WT mice. 
Intriguingly, the production of TNF was comparable between pMϕs from Gata6-WT 
and Gata6-KOmye mice stimulated with Pam3CSK4, which was undetectable at 24 
hours (Figure 4.4). TNF signalling can induce the activation of NF-κB as well as pro-
apoptotic signalling cascades in macrophages. Therefore, the differential IL-1β 
secretion and cell death in Gata6-deficient pMϕs may be mediated by TNF produced 
by LPS-stimulated but not Pam3CSK4. Blocking TNF signalling with Etanercept 
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significantly reduced the secretion of IL-1β from LPS-stimulated Gata6-deficient 
pMϕs by approximately 30%. Conversely, the production of IL-1β from Gata6-
deficient pMϕs stimulated with recombinant TNF was comparable to unstimulated 
pMϕs and both unstimulated and TNF-stimulated pMϕs from Gata6-WT mice. TNF 
may therefore synergise with LPS and induce the secretion of IL-1β from Gata6-
deficient pMϕs. In contrast to the reduction of IL-1β secretion, the percentage of PI+ 
pMϕs from Gata6-KOmye mice stimulated with LPS alone was comparable to those 
treated with etanercept (Figure 3.15), suggesting that TNF signalling does not play a 
prominent role in the cell death of LPS-stimulated Gata6-deficient pMϕs. Overall, 
these findings suggest that TNF may exacerbate the production of IL-1β but does not 
mediate cell death following LPS treatment. Blocking IL-1 signalling with IL-1RA 
had no discernible effect on the release of IL-1β. 
In addition to TNF, the production of IL-10 was significantly down-regulated in LPS-
stimulated Gata6-deficient pMϕs compared to those from Gata6-WT mice (Figure 
3.16). Interestingly, adenosine signalling can down-regulate the expression of pro-
inflammatory cytokines including TNF and increase the expression of anti-
inflammatory cytokines such as IL-10. Our group previously reported that CD73 was 
significantly downregulated in Gata6-deficient pMϕs (Rosas et al., 2014), an 
ectoenzyme that catalyses ADP to adenosine. Upon stimulation with TLR ligands, 
macrophages release ATP into the extracellular space, where CD39 converts ATP to 
ADP, which is subsequently dephosphorylated by CD73 to adenosine. These 
ectoenzymes thereby mediate inflammatory signalling in two ways: the removal of 
ATP from the extracellular space which can otherwise activate the NLRP3 
inflammasome, and the generation of adenosine, which upon binding to its receptor 
induces the expression of IL-10 and the down-regulation of pro-inflammatory 
cytokines including TNF. The release of IL-1β was comparable between Gata6-
deficient pMϕs stimulated with LPS alone and in the presence of adenosine (Figure 
3.16). Supporting this, inhibition of CD73 in pMϕs from Gata6-WT and Gata6-KOmye 
did not significantly affect the release of IL-1β from LPS stimulation alone, suggesting 
that adenosine generated through CD73 does not have a prominent role regulating the 
release of IL-1β. Treatment with extracellular apyrase (CD39) did not significantly 
reduce IL-1β release from LPS-stimulated Gata6-deficient pMϕs, suggesting that 
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extracellular ATP does not activate the NLRP3 inflammasome and subsequent release 
of IL-1β.  
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3.4.6 Gata6 may restrict neutrophil recruitment and 
retention 
One of the major functions of IL-1β in vivo is the recruitment of neutrophils (Martinon 
et al., 2006, Duewell et al., 2010). Since ex vivo LPS-stimulated Gata6-deficient pMϕs 
secrete significant amounts of mature IL-1β, attention was directed to determine 
whether Gata6-deficiency would enhance the recruitment and/or retention of 
neutrophils in vivo after administration of LPS intraperitoneally. Gata6-KOmye 
exhibited a significant increase in the number of neutrophils in the peritoneal cavity 4 
hours after intraperitoneal injection of LPS compared to Gata6-WT mice, although 
these results are from one independent experiment, and thus further repeats are needed 
to establish whether Gata6-deficient does promote enhanced neutrophil recruitment 
and retention (Figure 3.17). Gata6-deficient pMϕs stimulated with LPS ex vivo 
secreted detectable levels of IL-1β around 12 hours, so it is currently unclear whether 
IL-1β secretion mediates the significant increase in neutrophils 4 hours post LPS 
administration. On the other hand, LPS injected in vivo may induce the production of 
cytokines, chemokines, and lipid mediators with different kinetics to those of ex vivo 
stimulated pMϕs. IL-1β signalling has been shown to drive the influx of neutrophils 
through the secondary production of CXCL1 and CXCL2 (Biondo et al., 2014). In 
contrast to earlier time points, there was no significant difference in the number of 
neutrophils in the peritoneal cavities of Gata6-WT and Gata6-KOmye mice following 
intraperitoneal administration of LPS for 24 hours. At 48 hours post LPS 
administration, no neutrophils were detectable in the peritoneal cavities of Gata6-WT 
mice, whereas some neutrophils were detected in the cavities of Gata6-KOmye mice, 
albeit in low numbers (Figure 3.17). Peritoneal lavage supernatant was collected after 
4 hours and the production of cytokines and chemokines measured by ELISA. 
However, no significant differences were observed between Gata6-WT and Gata6-
KOmye, and many of the cytokines and chemokines analysed were non-detectable or 
very low. The limited detection of cytokines and chemokines may reflect the time point 
in which peritoneal lavage supernatant was collected. One study looking at the 
production of chemokines in the peritoneal cavity following challenge with 
Staphylococcus epidermidis supernatant showed that chemokines are produced 
transiently and not detectable after 3 hours (CXCL1 and CXCL2), or detectable in very 
small quantities (CCL3) during the time points analysed (Perks et al., 2016). However, 
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ex vivo stimulated Gata6-deficient pMϕs secreted significantly more CCL3 than those 
from Gata6-WT mice, which could drive neutrophil influx. However, CCL3 
production is comparatively much lower than both CXCL1 and CXCL2, which are 
reported to be the major chemoattractant responsible for attracting neutrophil 
migration (De Filippo et al., 2013, Ritzman et al., 2010). Therefore, the relative 
contribution of increased CCL3 driving a significant increase in neutrophil migration 
into the peritoneum remains to be investigated. Interestingly, Gata6-deficient pMϕs 
stimulated ex vivo with LPS for 16 hours had sustained production of CCL3 compared 
to pMϕs from Gata6-WT mice. 
 
3.4.7 Conclusions 
Collectively, these results suggest that Gata6 exerts critical control, either directly or 
indirectly, on the control of peritoneal macrophage inflammatory responses. 
Specifically, Gata6-deficient pMϕs have perturbed inflammatory responses where 
they secrete mature IL-1β in response to LPS alone. Ordinarily, macrophages require 
two-signals for the release of mature IL-1β, so these observations are particularly 
striking.  
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4.1 Introduction 
 
Soluble mediators in inflammation 
Soluble mediators play a critical role in the acute inflammatory response, and are 
released by both immune and non-immune cells upon pathogen recognition. When 
released, they orchestrate a wide array of functions such as the recruitment of effector 
cells, the polarisation/priming of both resident and infiltrating cells to enhance 
pathogen killing and direct antimicrobial activity. Furthermore, soluble mediators are 
critical for the resolution of inflammation, promoting tissue repair and ultimately the 
restoration of tissue homeostasis. Therefore, the spatiotemporal release of a diverse 
array of soluble mediators must be tightly regulated. Lipid mediators are potent 
signalling molecules that regulate an array of cellular responses, including in 
inflammation and immunity. Furthermore, dysregulated lipid signalling has been 
implicated in an array of inflammatory diseases (Ricciotti and FitzGerald, 2011). 
Supporting this, dysregulated control of soluble mediators is a major contributing 
factor to the onset and maintenance of several inflammatory and autoimmune diseases 
such as rheumatoid arthritis, peritonitis, diabetes, and inflammatory bowel disease 
(Funk, 2001). 
Tissue-specific  
Studies in our lab showed that Gata6-deficient pMϕs had perturbed inflammatory 
responses (data unpublished), suggesting that Gata6 may regulate, directly or 
indirectly, the expression of genes in pMϕs involved in host defence and inflammation. 
Microarray analysis of pMϕs from Gata6-WT and Gata6-KOmye mice revealed that a 
large number of pMϕ-specific genes were downregulated in Gata6-deficient pMϕs 
(Rosas et al., 2014, Gautier et al., 2014). Interestingly, one of the most down-regulated 
genes identified in the array was prostacyclin synthase (Ptgis), which was over 16-fold 
down-regulated in Gata6-deficient pMϕs. Ptgis is a key enzyme required for the 
synthesis of prostacyclin (PGI2), a member of the eicosanoid family. 
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Prostacyclin (PGI2) expression in homeostasis and disease 
The eicosanoids comprise a large family of bioactive lipids derived from arachidonic 
acid, which have diverse roles in regulating homeostatic processes and in regulating 
inflammation and immune responses (Funk, 2001). Macrophages are important 
sources of eicosanoids, which are produced rapidly in a multi-step process upon 
recognition of bacterial and fungal ligands (Peters-Golden et al., 2005, Alvarez et al., 
2010, Norris et al., 2011, Suram et al., 2013). Upon stimulation, arachidonic acid from 
phospholipids are released into the intracellular space, which is subsequently 
metabolised through the 5-lipoxygenase pathway to leukotrienes and the COX 
pathway to prostanoids (Figure 4.1).  
PGI2 is perhaps best known for its role within the cardiovascular system as a potent 
vasodilator and inhibitor of platelet aggregation (anti-thrombotic). However, it has 
become increasingly evident that PGI2 is important in the inflammatory responses. The 
key roles of prostanoids in inflammation were first demonstrated in 1971, in which the 
mechanism of action of aspirin was shown to be through the inhibition of prostanoid 
biosynthesis (Vane, 1971). Further work since has demonstrated both pro- and anti-
inflammatory roles of different prostanoids, which are largely dependent on receptor 
expression and cell-type specific signalling pathways, reviewed by (Narumiya et al., 
1999). 
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Figure 4.1 | Prostanoid synthesis pathway. 
Prostanoids are synthesised from arachidonic acid, which is either liberated from the 
lipid membrane by PLA2 or taken up from the extracellular milieu. COX 1/COX 2 
catalyse arachidonic acid into PGG2 and subsequently into prostaglandin H2 (PGH2), 
which is the common substrate for prostanoid synthesis. PGH2 is processed into 
individual prostanoids by the action of specific terminal synthases (red text). NSAIDs 
such as indomethacin inhibit the action of COX1/2 thereby preventing the production 
of downstream prostanoids. 
 
Prostacyclin signalling 
Once synthesised, PGI2 rapidly diffuses across the plasma membrane and exerts its 
effects through binding to its cognate receptor, the prostacyclin receptor (IP receptor). 
The IP receptor is a GPCR that upon activation, initiates a signalling cascade 
culminating in the activation of adenylyl cyclase and PLC, which subsequently 
increase intracellular cAMP and decreases Ca2+ levels. These secondary signalling 
molecules exert a wide array of effects, which is cell-type specific and responsible for 
the biological actions of PGI2. More recently, intracellular PGI2 has also been reported 
to signal via nuclear peroxisome proliferator-activator receptors (PPARs), activating 
intracrine nuclear pathways (Figure 4.2). 
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Figure 4.2 | Prostacyclin signalling: autocrine, paracrine, and intracrine 
mechanisms. 
Autocrine and paracrine signalling by PGI2 is mediated through the prostacyclin 
receptor (IP). Receptor binding predominantly activates Gs, though it can activate Gq. 
Gs activates adenylyl cyclase, which leads to increased cAMP. The cAMP mediates 
the activation protein kinase A (PKA). Intracrine PGI2 signalling is mediated through 
PPARβ/δ, located on nuclear membranes. PPARs heterodimerise with RXRs in the 
presence and absence of ligand. After ligand binding, these heterodimers undergo 
conformational changes, resulting in the dissociation of co-repressors and the binding 
of coactivators. These heterodimers bind to DNA sequences called PPAR response 
elements (PPRE), leading to the transcription of target genes. 
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4.2 Chapter hypothesis and aims 
The hypothesis tested in this chapter is that prostacyclin synthase plays a fundamental 
role in the control of peritoneal macrophage host defence and inflammation. 
Aims 
• To establish whether prostacyclin influences pro-inflammatory cytokine 
production. 
• To determine the expression pattern of Ptgis across immune cell populations. 
• Determine the expression of Ptgis in pMϕs from Gata6-WT and Gata6-KOmye 
mice 
• To evaluate the impact of prostacyclin analogues on pro-inflammatory 
cytokines production in Gata6-deficient pMϕs 
• Design lentivirus construct expressing Ptgis transgene and evaluate whether it 
can modulate pro-inflammatory cytokine production in BMDMs 
• Determine whether the in vivo reconstitution of Ptgis expression in Gata6-
deficient pMϕs restores pro-inflammatory cytokine production to pMϕs from 
Gata6-WT mice 
• To evaluate whether the in vivo knockdown of Ptgis expression in C57/BL6 
mice recapitulates the proinflammatory cytokine production defects observed 
in Gata6-deficient pMϕs  
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4.3 Results 
4.3.1 LPS-stimulated Gata6-deficient pMϕs have altered 
pro-inflammatory cytokine production 
Preliminary studies in our lab showed that the loss of Gata6 enhanced the production 
of pro-inflammatory cytokines, suggesting that tissue-specific transcription factors 
may mediate the acute inflammatory response and resolution of inflammation. TNF 
and IL-6 are the prototypical pro-inflammatory cytokines produced by pMϕs upon 
recognition of microbial ligands and their dysregulated production has been implicated 
in a variety of human inflammatory diseases. To ascertain whether the loss of Gata6 
affected the production of these cytokines, pMϕs from Gata6-WT and Gata6-KOmye 
were either unstimulated or stimulated with LPS for 3 and 16 hours, after which the 
expression of Tnf and Il6 were determined by qPCR (Figure 4.3). Furthermore, the 
kinetic release of TNF and IL-6 in response to LPS and zymosan was determined by 
ELISA (Figure 4.3). 
The expression of both Tnf and Il6 in unstimulated pMϕs from Gata6-WT and Gata6-
KOmye was very low, in accordance of their typical requirement of induction by 
microbial ligands. However, stimulation with LPS for 3 hours resulted in greatly 
increased Tnf and Il6 expression, which were both higher in pMϕs from Gata6-KOmye 
mice compared to Gata6-WT mice (Figure 4.3). After 16 hours, Tnf expression was 
undetectable in pMϕs from Gata6-WT mice. Conversely, Tnf expression was higher 
in pMϕs from Gata6-KOmye mice compared to Gata6-WT mice (Figure 4.3). 
Remarkably, the expression of Tnf in Gata6-deficient pMϕ stimulated with LPS for 16 
hours was comparable to peak Tnf expression in pMϕs from Gata6-WT mice. 
Similarly, the expression of Il6 was greatly increased in Gata6-deficient pMϕs 
compared to pMϕs from Gata6-WT mice. 
Having established that Gata6-deficient pMϕs have enhanced transcription of pro-
inflammatory genes in response to LPS stimulation, the secretion of these cytokines 
was assessed by ELISA (Figure 4.3). In response to LPS or zymosan, Gata6-deficient 
pMϕs secreted significantly more TNF compared to pMϕs from Gata6-WT mice (p = 
0.0002 and p < 0.001 respectively) (Figure 4.3). Furthermore, TNF production by 
Gata6-deficient pMϕ stimulated with LPS or zymosan was sustained, with significant 
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TNF production detected 24 hours post-stimulation. Conversely, in response to LPS 
or zymosan, TNF production by pMϕs from Gata6-WT mice (stimulated with LPS or 
zymosan) was transient, peaking at 3 and 6 hours and undetectable 12 hours post 
stimulation. The significant increase in TNF secretion was consistent with the 
expression changes detected by qPCR. In contrast to the marked increase in Il6 
expression in Gata6-deficient pMϕs stimulated with LPS for 3 hours detected by 
qPCR, the secretion of IL-6 detected by ELISA at 3 hours after stimulation with either 
LPS or zymosan was not significantly different between pMϕs from Gata6-WT and 
Gata6-KOmye mice (p = 0.9999 and p = 0.9816 respectively). The secretion of IL-6 
Gata6-deficient pMϕs stimulated with LPS for 24 hours was significantly higher than 
pMϕs from Gata6-WT mice (p = 0.0366). At all other time points, the secretion of IL-
6 detected in supernatants was not-significantly different between pMϕs from Gata6-
KOmye compared to those from Gata6-WT mice stimulated with LPS or zymosan 
(Figure 4.3). 
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Figure 4.3 | Gata6-deficient pMϕs have enhanced and sustained TNF production 
upon stimulation with LPS or zymosan. 
(A, B) APECs from Gata6-WT and Gata6-KOmye were unstimulated or stimulated 
with 100 ng ml-1 LPS for 3 or 16 hours. The expression of Tnf and Il6 were determined 
by qPCR relative to the endogenous control gene Ywhaz. Data is mean ± 95% 
confidence interval from 3 technical replicates. (C-F) APECs from Gata6-WT and 
Gata6-KOmye mice were stimulated with 100 ng ml-1 LPS (C-D) or a 1:1 ratio zymosan 
particles: cells (E-F) for the indicated time points. Supernatants were collected and 
analysed by ELISA for TNF (C, E) and IL-6 (D, F) release. Data are expressed as 
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mean ± S.E.M as a percentage of release at 6 hours (TNF) and 24 hours (IL-6) from 
three independent experiments. Statistical significance (C-F) was determined by two-
way ANOVA with Tukeys multiple comparison post-test (Int, interaction statistic; 
Gata6, Gata6 effects; Time, Treatment time effects) with Tukeys multiple comparison 
post-test (*p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant). 
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4.3.2 Aberrant TNF release is restricted to TLR4 stimulation 
Gata6-deficient pMϕs stimulated with LPS or zymosan produced significantly more 
TNF and for a sustained time-period compared to pMϕs from Gata6-WT mice. To 
explore whether other TLR ligands could result in sustained TNF production, pMϕs 
from Gata6-WT and Gata6-KOmye mice were either unstimulated or stimulated with 
different TLR ligands for 24 hours after which the release of TNF and IL-6 were 
determined by ELISA (Figure 4.4). 
In contrast to LPS stimulation alone which resulted in significant TNF release from 
Gata6-deficient pMΦs after 24 hours (p < 0.0001), none of the other TLR ligands 
tested resulted in significant differences in TNF release from Gata6-WT and Gata6-
KOmye mice (Figure 4.4). The production of IL-6 was not significantly different 
between pMϕs from Gata6-WT and Gata6-KOmye stimulated with different TLR 
ligands. 
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Figure 4.4 | Aberrant TNF release from Gata6-deficient pMϕs is restricted to 
TLR4 stimulation. 
(A, B) APECs from Gata6-WT and Gata6-KOmye mice were unstimulated or 
stimulated with Pam3CSK4 (500 ng ml-1), Poly I:C (1 µg ml-1), LPS (100 ng ml-1), 
Flagellin (100 ng ml-1), R848 (1 µg ml-1), CpG ODN 1826 (5 µM) or CpG ODN 1826 
control (5 µM) for 24 hours. Culture supernatants were collected 24 hours after 
stimulation and (A) TNF and (B) IL-6 release measured by ELISA. Data are shown as 
mean ± S.E.M from five independent experiments. Statistical significance was 
determined by two-way ANOVA (Int, interaction statistic; Gata6, Gata6 effects; 
Treatment, Treatment effects) with Tukeys multiple comparison post-test (*p < 0.05, 
**p < 0.01, ***p < 0.001). 
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4.3.3 Intracellular cytokine staining reveals that IL-6 is 
significantly decreased in Gata6-deficient pMϕs 
stimulated with LPS 
The composition of cells within the peritoneal cavity of Gata6-KOmye mice is 
markedly different to that of Gata6-WT mice. The number of resident pMϕs is 
dramatically reduced from approximately 50% in Gata6-WT mice to 20% in Gata6-
KOmye mice (Rosas et al., 2014, Okabe and Medzhitov, 2014). The loss in resident 
pMϕs in Gata6-KOmye is accompanied by an expansion/increase in the number of 
eosinophils and MHCIIhighCD226+ DC-like cells. 
To determine the contribution of pMϕs to inflammatory cytokine production, and 
exclude the possibility of other cell subsets contributing to the differences in cytokine 
production detected by ELISA, the production of TNF and IL-6 in unstimulated and 
LPS-stimulated pMϕs from Gata6-WT and Gata6-KOmye was determined by 
intracellular flow cytometry (Figure 4.5). 
In accordance with the gene expression and ELISA, TNF production was significantly 
increased pMϕs from Gata6-KOmye compared to Gata6-WT mice stimulated with LPS 
for 3 hours (p < 0.0001) (Figure 4.5). Surprisingly, the production of IL-6 in LPS-
stimulated pMϕs from Gata6-KOmye was significantly lower compared to Gata6-WT 
mice (p < 0.0001), which is in stark contrast to the expression and release of IL-6 
detected by ELISA (Figure 4.5). 
Interestingly, the production of TNF by LPS-stimulated pMϕs from Gata6-WT and 
F4/80high pMϕs from Gata6-KOmye mice was comparable (p = 0.9977), whereas the 
TNF production was markedly higher in F4/80low pMϕs from Gata6-KOmye (p < 
0.0001). Furthermore, the production of IL-6 in F4/80high pMϕs was significantly 
higher than in F4/80low pMϕs (p < 0.0001), however, this was lower than pMϕs from 
Gata6-WT mice (p = 0.0027) (Figure 4.5). 
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Figure 4.5 | Gata6-deficient pMϕs have enhanced TNF and reduced IL-6 in 
response to LPS.  
(A-C) Total PECs from Gata6-WT and Gata6-KOmye mice were unstimulated or 
stimulated with 100 ng ml-1 LPS for 3 hours in the presence of GolgiBlock. (A) 
Representative density/bivariate plot of IL-6 and TNF production by pMϕs (gated by 
F4/80+Tim4+) was measured by intracellular cytokine staining. (B, C) Bar chart shows 
mean MFI (minus isotype control) of TNF and IL-6 production in Tim4+F4/80high 
pMϕs from Gata6-WT mice and Tim4+F4/80high and Tim4+F4/80low pMϕ populations 
within the same Gata6-KOmye mice. Data shows mean ± S.D from 2-4 individual mice 
per group from two independent experiments. Statistical significance was determined 
by two-way ANOVA (Int, interaction statistic; Gata6, Gata6 effects; Treatment, 
Treatment effects) with Tukeys multiple comparison post-test (*p < 0.05, **p < 0.01, 
***p < 0.001). 
  
IL
-6
 (
M
F
I)
U n s tim u la te d L P S
0
1 0
2 0
3 0
4 0
5 0
**
T w o -w a y  A N O V A
In t: p  <  0 .0 0 0 1
G a ta 6 : p  <  0 .0 0 0 1
T re a tm e n t : p  <  0 .0 0 0 1
***
T
N
F
 (
M
F
I)
U n s tim u la te d L P S
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
T w o -w a y  A N O V A
In t: p  <  0 .0 0 0 1
G a ta 6 : p  <  0 .0 0 0 1
T re a tm e n t : p  <  0 .0 0 0 1
n s
***
***
G a ta 6 -W T
G a ta 6 -K O
m y e
F 4 /8 0
h ig h
G a ta 6 -K O
m y e
F 4 /8 0
lo w
B C
A
R5 R5
R5 R5
0.51% 0.64%
58.77% 89.97%
Gata6-WT Gata6-KOmye
R5
R5
R5
R5
0.08% 0.33%
98.75% 9.88%
Gata6-WT Gata6-KOmye
F4
/8
0
TNF
F4
/8
0
IL-6
St
ai
n
ed
Is
o
ty
p
e
189 
 
4.3.4 Co-cultured Gata6-WT pMϕs prevent aberrant TNF 
release from Gata6-deficient pMϕs 
The release of IL-1β from LPS-stimulated Gata6-deficient pMϕs was significantly 
reduced when co-cultured with pMϕs from Gata6-WT mice. To determine whether 
the aberrant production of TNF could be restored by pMϕs from Gata6-WT mice, the 
release of TNF from monocultured cells and co-cultured was determined in LPS-
stimulated pMϕs from Gata6-WT and Gata6-KOmye mice (Figure 4.6). 
The secretion of TNF from LPS-stimulated Gata6-KOmye monocultures seeded 1 x 105 
cells was not significantly different to those containing 0.5 x 105 Gata6-deficient pMϕs 
(p = 0.7506). Co-cultured pMϕs released significantly less TNF (not detectable) than 
monocultures containing 0.5 x 105 Gata6-deficient pMϕs (p = 0.0003). Conversely, 
the release of IL-1β from co-cultured pMϕs was not significantly different to 
monocultures containing 0.5 x 105 pMϕs from Gata6-WT mice (p > 0.9999) (Figure 
3.14). 
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Figure 4.6 | Aberrant LPS-induced TNF release from Gata6-deficient pMϕs is 
attenuated when co-cultured with pMϕs from Gata6-WT mice. 
APECs from Gata6-WT and Gata6-KOmye were cultured separately (1 x 105 and 0.5 
x 105) or co-cultured at a 1:1 ratio (1 x 105 total cells) after which they were stimulated 
with 100 ng ml-1 LPS for 24 hours. After stimulation, TNF release was determined in 
cell-free culture supernatants by ELISA. Data shows mean ± S.D from four 
independent experiments. nd = not detectable. Statistical significance was determined 
by one-way ANOVA with Tukeys multiple comparison post-test between co-cultured 
cells and monocultures containing 0.5 x 105 cells (*p < 0.05, **p < 0.01, ***p < 0.001, 
ns = not significant). 
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4.3.5 Prostacyclin synthase expression is selectively 
expressed in pMϕs and is dependent on Gata6 
Having established that the release of TNF from LPS-stimulated Gata6-deficient 
pMϕs was attenuated when co-cultured with pMϕs from Gata6-WT mice, the 
mechanisms through which Gata6 may modulate inflammatory responses were 
investigated. Analysis of microarray data showed that one of the most highly down-
regulated genes in Gata6-deficient pMϕs was prostacyclin synthase (Ptgis), the key 
enzyme required for PGI2 production (p = 0.003502) (Figure 4.7). Furthermore, 
western blotting showed that Ptgis expression was greatly reduced in Gata6-deficient 
pMϕs (Figure 4.7). The expression of Ptgis was analysed in different immune cell 
populations, which revealed that it was predominantly restricted to resident pMϕs 
(Figure 4.7). 
To determine whether the Gata6 regulates the expression of other terminal synthases 
in pMϕs (which would influence the balance of prostanoids produced) microarray 
expression data from Gata6-WT and Gata6-KOmye mice was analysed (Figure 4.7). 
Interestingly, whilst the expression of other terminal synthases was not significantly 
different, thromboxane synthase (Tbxas1) was significantly increased in Gata6-
deficient pMϕs (p = 0.005213) (Figure 4.7). Thromboxane synthase is the critical 
enzyme mediating the synthesis of thromboxane (TXA2), which exerts biologically 
effects opposing the actions of PGI2 (Caughey et al., 1997). PGI2 has been reported to 
signal via two receptors; autocrine and paracrine signalling through the prostacyclin 
receptor (IP); and intracrine signalling mediated through peroxisome proliferator 
activated receptors (PPARs) on nuclear membranes (Lim and Dey, 2002, Li et al., 
2012, Hertz et al., 1996, Forman et al., 1997). Microarray analysis of pMϕs from 
Gata6-WT and Gata6-KOmye showed that the expression of PPARβ/δ, PPARγ, and IP 
receptor expression were unaffected by Gata6-deficiency (Figure 4.7). 
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Figure 4.7 | Ptgis is highly expressed in resident peritoneal macrophages and 
dependent on Gata6. 
(A) Heatmap showing the expression of Gata6 and Ptgis across different immune cell 
populations. Data was generated and provided by the ImmGen consortium. (B, C) 
Microarray expression of terminal prostanoid synthases (B) Ptgis, thromboxane 
synthase (Tbxas1), prostaglandin E synthase 2 and 3 (Ptges1 and Ptges2) and PGI2 
receptors (C) PPARβ/δ, PPRRγ and Ptgir in pMϕs from Gata6-WT and Gata6-KOmye. 
Data is expressed as mean ± S.D from three biological replicates. (D) Immunoblot 
showing Ptgis and β-actin in pMϕs from Gata6-WT and Gata6-KOmye mice. Image 
representative of two independent experiments. Statistical significance (B, C) was 
determined using an empirical Bayesian statistic corrected for false discovery rate by 
the Benjamini-Hochberg procedure. Not significant (ns) p ≥ 0.5, *p < 0.05, **p < 0.01, 
***p < 0.001. 
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4.3.6 Prostacyclin analogues modulate TNF and IL-6 
production in pMϕs. 
To examine how prostanoids effected the production of pro-inflammatory cytokines, 
pMϕs from Gata6-WT and Gata6-KOmye mice were either unstimulated, stimulated 
with LPS alone, or stimulated with LPS in the presence of beraprost or indomethacin 
and analysed by flow cytometry for TNF and IL-6 (Figure 4.8). 
In accordance with my previous findings, Gata6-deficient pMϕs produced 
significantly more TNF and significantly less intracellular IL-6 compared to pMϕs 
from Gata6-WT mice (Figure 4.8). Upon treatment with the PGI2 analogue beraprost, 
the production of TNF was significantly reduced in pMϕs from Gata6-WT mice and 
F4/80low and F4/80high pMϕs from Gata6-KOmye mice (Figure 4.8). The production of 
TNF by pMϕs from Gata6-WT and F4/80high pMϕs from Gata6-KOmye mice was 
greatly increased when cells were stimulated with LPS and indomethacin compared to 
LPS alone (p = 0.0023 and p = 0.0342 respectively). Conversely, the increase in TNF 
production from F4/80low pMϕs treated with LPS and indomethacin was comparable 
to LPS treatment alone (p > 0.9999) (Figure 4.8). 
The production of IL-6 was significantly increased in Gata6-deficient pMϕs treated 
with LPS and beraprost compared to LPS treatment alone (p = 0.0048). Conversely, 
pMϕs from Gata6-WT mice treated with LPS and beraprost had no significant effect 
on the production of IL-6 compared to treatment with LPS alone (p = 0.8177). The 
production of IL-6 by pMϕs from Gata6-WT mice was significantly reduced when 
treated with LPS and indomethacin compared to LPS treatment alone (p = 0.0005). 
Treatment of Gata6-deficient pMϕs with LPS and indomethacin had no discernible 
effect on IL-6 production compared to LPS treatment alone (p > 0.9999). The 
production of IL-6 in F4/80high pMϕs from Gata6-KOmye was comparable to treatment 
with LPS alone (p = 0.2407). 
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Figure 4.8 | Prostacyclin analogues regulate TNF and IL-6 expression. 
(A, B) Total PECs from Gata6-WT and Gata6-KOmye mice were unstimulated or 
stimulated with 100 ng ml-1 LPS for 3 hours in the presence of DMSO (vehicle), 10 
µM Beraprost or 10 µM Indomethacin. Scatter plots shows mean MFI (minus isotype 
control) of TNF and IL-6 production in Tim4+F480+ pMϕs from Gata6-WT and 
Tim4+F4/80high and Tim4+F4/80low populations within the same Gata6-KOmye mice. 
Data shows MFI from two independent experiments. Statistical significance was 
determined by two-way ANOVA between LPS stimulation alone and with the 
indicated compounds (Int, interaction statistic; Gata6, Gata6 effects; Treatment, 
Treatment effects) with Tukeys multiple comparison post-test (*p < 0.05, **p < 0.01, 
***p < 0.001, ns = not significant). 
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4.3.7 Prostacyclin synthase (Ptgis) transgene expression 
The restoration of normal inflammatory responses in LPS-stimulated Gata6-deficient 
pMϕs through treatment with beraprost supported the hypothesis that the loss of Ptgis 
expression in pMϕs led to dysregulated cytokine production upon stimulation with 
LPS. 
To determine how Ptgis expression effects the inflammatory response, the next aim 
was to reconstitute Ptgis expression in Gata6-deficient pMϕs through Ptgis-expressing 
lentiviral constructs. To address this, Ptgis (accession NM_008968) was cloned from 
the cDNA of WT pMϕs and inserted into a lentiviral vector containing the reporter 
rCD2 and T2A peptide (T2A-rCD2 (Figure 4.9). To assess the functionality of the 
Ptgis transgene, BMDM were non-transduced (WT) or transduced with lentivirus 
expressing Ptgis or the T2A-rCD2 (empty vector control) constructs. The expression 
of Ptgis was determined 72 hours post transduction by qPCR and immunoblotting 
(Figure 4.9). 
The expression of Ptgis in BMDMs was undetectable by either qPCR or 
immunoblotting, supporting microarray data from the ImmGen consortium showing 
that Ptgis expression is largely restricted to pMϕs (Figure 4.9). Similarly, BMDMs 
transduced with empty vector control (T2A-rCD2) had limited detectable Ptgis 
expression, whereas transduction with the Ptgis transgene greatly increased the 
expression of Ptgis (Figure 4.9). 
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Figure 4.9 | Ptgis transgene expression in BMDMs. 
(A) Schematic of Ptgis-expressing and empty vector control (T2A-rCD2) lentiviral 
constructs. (B, C) BMDMs were either non-transduced (WT) or transduced with Ptgis 
or T2A-rCD2 control expressing lentiviruses. (B) Ptgis expression was determined by 
qPCR relative to the endogenous control gene Ywhaz. Scatter dot plot shows Log2 
expression from five biological replicates (individual points) from three independent 
experiments. (C) Immunoblot of showing Ptgis expression in BMDMs unstimulated 
or stimulated with LPS for 24 hours. Peritoneal macrophages (pMϕs) were used as a 
positive control for Ptgis expression. Image representative of two independent 
experiments. 
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4.3.8 BMDM expressing Ptgis transgene constructs produce 
PGI2  
Having established that the Ptgis transgene was expressed by BMDMs, the 
functionality of the protein was assessed. Therefore, BMDMs either non-transduced 
(WT) or transduced with T2A-rCD2- or Ptgis-expressing lentiviruses were either 
unstimulated or stimulated with LPS for 24 hours. The supernatants were analysed by 
mass spectrometry for PGD2, PGE2, TXB2 and 6-keto-PGF1α release (Figure 4.10). 
The production of prostanoids in unstimulated BMDMs was very low/undetectable 
and comparable between WT BMDMs and those transduced with either T2A-rCD2- 
or Ptgis-expressing lentiviruses (Figure 4.10). However, upon stimulation with LPS, a 
marked increase in 6-Keto-PGF1α (a stable metabolite of PGI2) was detected in 
supernatants of BMDMs transduced with Ptgis-expressing compared to WT and T2A-
rCD2 transduced BMDMs (Figure 4.10). Furthermore, the production of PGD2, PGE2 
and TXB2 (a stable metabolite of TXA2) were reduced in LPS-stimulated BMDMs 
expressing Ptgis compared to WT and T2A-rCD2 BMDMs (Figure 4.10). 
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Figure 4.10 | Prostacyclin release is greatly enhanced in LPS-stimulated BMDMs 
transduced with Ptgis transgene. 
BMDMs either non-transduced (WT) or transduced with either T2A-rCD2- or Ptgis-
expressing lentiviral constructs and either unstimulated or stimulated with 100 ng ml-
1 for 24 hours. The supernatants were analysed by mass spectrometry for PGD2, PGE2, 
TXB2 and 6-keto-PGF1α release. Data are representative of two independent 
experiments. 
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4.3.9  Pro-inflammatory cytokine production by BMDMs is 
greatly reduced by PGI2 analogue but not Ptgis 
transgene  
To examine whether the production of pro-inflammatory cytokines is modulated by 
the expression of Ptgis transgene, BMDMs that were non-transduced or transduced 
with T2A-rCD2 or Ptgis-expressing lentiviruses were unstimulated or stimulated with 
LPS and the production of TNF and IL-6 determined by intracellular flow cytometry 
(Figure 4.11). 
The production of IL-6 was barely detectable in both unstimulated and LPS-stimulated 
BMDMs that were non-transduced or transduced with T2A-rCD2 or Ptgis (Figure 
4.11). Conversely, the production of TNF was significantly increased in BMDMs 
stimulated with LPS for 3 hours compared to unstimulated controls (Figure 4.11). The 
expression of the Ptgis transgene did not significantly affect the production of TNF 
compared to non-transduced or T2A-rCD2 transduced BMDMs (Figure 4.11). 
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Figure 4.11 | Pro-inflammatory cytokine production is unaffected by Ptgis 
transgene expression. 
BMDMs were non-transduced (WT) or transduced with lentivirus expressing Ptgis or 
T2A-rCD2 (empty vector control). BMDMs were subsequently untreated (medium) or 
treated with 100 ng ml-1 LPS for 3 hours (in the presence of GolgiBlock), after which 
the production of TNF was assessed by flow cytometry. Data shows MFI (minus 
isotype control) from two biological replicates. 
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The production of TNF in BMDMs stimulated with LPS for 3 hours was unaffected 
by Ptgis transgene expression. To examine whether Ptgis transgene can modulate pro-
inflammatory cytokine production over extended time periods, BMDMs that were 
non-transduced or transduced with either T2A-rCD2 or Ptgis were unstimulated or 
stimulated with LPS for 6 hours and the production of IL-6 and TNF determined by 
intracellular flow cytometry (Figure 4.12). 
The production of TNF by BMDMs stimulated with LPS for 6 hours was not 
significantly different between BMDMs that were non-transduced or transduced with 
either T2A-rCD2 or Ptgis (p = 0.2270 and p = 0.1384 respectively) (Figure 4.12). 
Furthermore, IL-6 production from BMDMs after 6 hours stimulation with LPS was 
very low. 
  
202 
 
 
Figure 4.12 | Ptgis transgene expression doesn’t attenuate pro-inflammatory 
cytokine production.  
A) Representative bivariate plots showing intracellular cytokine of TNF and IL-6 in 
BMDMs that were non-transduced (WT) or transduced with lentivirus expressing 
T2A-rCD2 (empty vector) or Ptgis that were either unstimulated or stimulated with 
100 ng ml-1 LPS for 6 hours. (B, C) Scatter plots show mean MFI (minus isotype 
control) of TNF and IL-6 production from two independent experiments. Statistical 
significance was determined by two-way ANOVA (Int, interaction statistic; Ptgis, 
Ptgis effects; LPS, LPS effects) with Tukeys multiple comparison post-test (*p < 0.05, 
**p < 0.01, ***p < 0.001, ns = not significant).  
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To determine whether the production of pro-inflammatory mediators can be modulated 
by prostanoids, BMDMs were either unstimulated or stimulated with LPS alone or 
LPS in the presence of indomethacin or beraprost for 3 hours and the production of 
IL-6 and TNF determined by intracellular flow cytometry (Figure 4.13). 
The production of TNF in BMDMs was significantly lower in response to treatment 
with LPS and beraprost compared to treatment with LPS alone (Figure 4.13 B). 
Interestingly, the production of TNF by BMDMs treated with LPS and indomethacin 
was not significantly different to LPS treatment alone (Figure 4.13 B). The production 
of IL-6 treated with LPS alone and in the presence of either indomethacin or beraprost 
was not significantly different from unstimulated BMDMs (Figure 4.13 C). 
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Figure 4.13 | PGI2 analogues reduce TNF production in BMDMs. 
(A-C) BMDMs were unstimulated or stimulated with 100 ng ml-1 LPS with or without 
10 µM indomethacin or 10 µM beraprost for 3 hours in the presence of GolgiBlock 
and the production of TNF and IL-6 measured by intracellular cytokine staining. (A) 
Representative bivariate plot of TNF and IL-6 production. (B, C) Scatter plots show 
TNF and IL-6 MFI (minus isotype control) from two independent experiments. 
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4.3.10   In vivo transduction of resident peritoneal 
macrophages with PTGIS-expressing lentivirus 
To elucidate how PGI2 regulates the production of pro-inflammatory cytokines in 
pMϕs, Gata6-WT and Gata6-KOmye mice were injected intraperitoneally with 
lentivirus expressing T2A-rCD2 or Ptgis. The cells were unstimulated or stimulated 
with LPS ex vivo and the production of TNF and IL-6 determined by intracellular flow 
cytometry (Figure 4.14). 
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Figure 4.14 | Reconstitution of Ptgis expression in Gata6-KOmye fails to attenuate 
inflammatory cytokine production. 
Gata6-WT Gata6-KOmye mice were transduced with T2A-rCD2 or Ptgis by 
intraperitoneal injection with lentivirus. After 7 days, total peritoneal cells were 
harvested and either (A) unstimulated or (B) stimulated with 100 ng ml-1 LPS for 3 
hours. The production of TNF was determined by intracellular flow cytometry in 
CD11b+F4/80+ pMϕs that were either transduced (rCD2+) or non-transduced (rCD2-). 
Data shows MFI TNF expression from one experiment. 
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4.3.11   Does the knockdown of Ptgis expression result in 
dysregulated pro-inflammatory cytokine production? 
To corroborate the Ptgis reconstitution experiments, resident pMϕs were transduced 
in vivo by intraperitoneal injection of lentiviral shRNA constructs targeting Ptgis 
(shPtgis #1 and #2) and a non-silencing control (shNSC) construct. The expression of 
Ptgis was determined by qPCR in FACS-sorted pMϕs (F4/80+CD11b+MHCII-) that 
were transduced (rCD2+) and non-transduced (rCD2-) with lentiviral constructs 
(Figure 4.15). 
The expression of Ptgis was not significantly different between non-transduced and 
shNSC transduced pMϕs. However, the expression of Ptgis was down-regulated by 
approximately 78% and 85% by shPtgis #1 and #2 respectively compared to the non-
transduced pMϕs isolated from the same mouse (Figure 4.15). 
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Figure 4.15 | In vivo lentiviral knockdown of Ptgis in pMϕs. 
C57BL/6 mice were injected intraperitoneally with two lentiviral shRNA constructs 
targeting Ptgis (shPtgis #1 and #2) and a non-silencing control (shNSC). After 7 days, 
peritoneal cells were harvested and sorted by FACS. pMϕs (CD11b+ F4/80+ MHCII-) 
cells were sorted into two populations, non-transduced (rCD2-) and transduced cells 
(rCD2+). The expression of Ptgis in each population was determined by qPCR relative 
to the endogenous control Ywhaz. Error bars represent mean ± S.D from 3 technical 
replicates. (n = 1). 
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4.3.12   Ptgis knockdown doesn’t affect pro-
inflammatory cytokine expression 
To investigate how PGI2 controls the production of pro-inflammatory cytokine 
production, pMϕs were transduced in vivo with lentivirus expressing shNSC or shPtgis 
constructs. Total peritoneal cells were either unstimulated or stimulated with 100 ng 
ml-1 LPS ex vivo and the production of IL-6 and TNF determined by intracellular 
cytokine staining (Figure 4.16). 
The production of TNF by pMϕs stimulated with LPS for three hours was not 
significantly different between pMϕs transduced (rCD2+) with shNSC- or shPtgis-
expressing lentivirus (p = 0.8468). The production of TNF between transduced and 
non-transduced pMϕs stimulated with LPS for three hours was not significantly 
different in mice injected with either shNSC- or shPtgis-expressing lentivirus (p = 
0.8232 and p = 0.2192 respectively). Similarly, the production of IL-6 was comparable 
between pMϕs transduced with shNSC- and shPtgis-expressing lentivirus stimulated 
with LPS for three hours (p = 0.9267) (Figure 4.15). Likewise, IL-6 production from 
transduced and non-transduced pMϕs stimulated with LPS for three hours was not 
significantly different in mice injected with either shNSC- or shPtgis-expressing 
lentivirus (p = 0.8102 and p = 0.9932 respectively) (Figure 4.15). 
The production of both IL-6 and TNF were drastically reduced after 6 hours 
stimulation with LPS (GolgiBlock added at 3 hours) compared to stimulation with LPS 
for 3 hours. The production of TNF by pMϕs stimulated with LPS for six hours was 
not significantly different between pMϕs transduced (rCD2+) with shNSC- or shPtgis-
expressing lentivirus (p > 0.9999). Similarly, TNF production between transduced and 
non-transduced pMϕs stimulated with LPS for six hours was comparable in mice 
injected with either shNSC- or shPtgis-expressing lentivirus (p > 0.9999 and p > 
0.9999 respectively). Conversely, pMϕs transduced with shPtgis and stimulated for 6 
hours with LPS had significantly less IL-6 production than pMϕs transduced with 
shNSC (p = 0.0084). IL-6 production from transduced and non-transduced pMϕs 
stimulated with LPS for six hours was not significantly different in mice injected with 
either shNSC- or shPtgis-expressing lentivirus (p = 0.2349 and p = 0.9805 
respectively). 
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Figure 4.16 | Ptgis knockdown doesn’t modulate pro-inflammatory cytokine 
production. 
(A – D) C57BL/6 mice were injected intraperitoneally with lentiviral shRNA 
constructs targeting Ptgis (shPtgis) and a non-silencing control (shNSC). After 7 days, 
total peritoneal cells were harvested and either unstimulated or stimulated with 100 ng 
ml-1 LPS for (A, B) 3 or (C, D) 6 hours. The production of TNF and IL-6 was 
determined by intracellular flow cytometry in non-transduced (rCD2-) and transduced 
(rCD2+) pMϕs (F4/80+CD11b+) from the same mouse. Scatter plots show MFI (minus 
isotype control) of TNF (A, C) and IL-6 (B, D). (n = 3-4 mice per group). Data 
representative of one independent experiment. Statistical significance was determined 
by two-way ANOVA (Int, interaction statistic; Ptgis, Ptgis effects; LPS, LPS effects) 
with Tukeys multiple comparison post-test (*p < 0.05, **p < 0.01, ***p < 0.001). 
  
M e d iu m L P S  (3  h o u rs )
0
5 0
1 0 0
1 5 0
2 0 0
T
N
F
 (
M
F
I)
T w o -w a y  A N O V A
In t: p  =  0 .2 0 0 3
P tg is: p  =  0 .1 5 9 1
L P S : p  <  0 .0 0 0 1
n s
n s
M e d iu m L P S  (3  h o u rs )
0
1 0 0
2 0 0
3 0 0
IL
-6
 (
M
F
I)
T w o -w a y  A N O V A
In t: p  =  0 .5 9 0 3
P tg is: p  =  0 .5 9 4 9
L P S : p  <  0 .0 0 0 1
n s
n s
M e d iu m L P S  (6  h o u rs )
0
1 0
2 0
3 0
4 0
5 0
T
N
F
 (
M
F
I)
T w o -w a y  A N O V A
In t: p  =  0 .3 4 6 1
P tg is: p  =  0 .4 2 7 3
L P S : p  <  0 .0 0 0 1
M e d iu m L P S  (6  h o u rs )
0
1 0
2 0
3 0
4 0
IL
-6
 (
M
F
I)
T w o -w a y  A N O V A
In t: p  =  0 .0 2 7 4
P tg is: p  =  0 .0 0 9 1
T re a tm e n t : p  <  0 .0 0 0 1
**
n s
n s
**
A B
C D
s h N S C  rC D 2
-
/rC D 2
+/
s h P tg is  rC D 2
-
/rC D 2
+/
211 
 
4.4 Discussion 
4.4.1 Gata6-deficient pMϕs have perturbed production of 
pro-inflammatory cytokines 
Preliminary experiments by Dr Marcela Rosas suggested that Gata6-deficient pMϕs 
may have perturbed inflammatory responses. To elucidate the role Gata6 has on the 
inflammatory response, pMϕs were stimulated with an array of microbial ligands and 
the expression of pro-inflammatory genes determined by qPCR and the production 
determined by ELISA and intracellular flow cytometry. Strikingly, the expression and 
release of TNF was significantly increased in Gata6-deficient pMϕs (Figure 4.3). TNF 
is a potent cytokine, whose dysregulation has been implicated in numerous 
inflammatory conditions. Interestingly, whilst the expression and release of TNF was 
transient in pMϕs from Gata6-WT mice, Gata6-deficient pMϕs exhibited sustained 
TNF expression and secretion, implicating a role for Gata6, directly or indirectly, in 
promoting the resolution of inflammation. Stimulation with various TLR ligands 
revealed that the aberrant pro-inflammatory cytokine production was predominantly 
TLR4-dependent, although zymosan, also induced robust defects similar to LPS 
stimulation. The selectivity of TLR ligands may be due to restricted TLR expression, 
which was apparent flagellin in particular, which did not produce IL-6 at a range of 
concentrations (Supplementary Figure 2 and Supplementary Figure 3 ). Alternatively, 
other ligands may induce significant pro-inflammatory cytokine production at earlier 
time points, for which this experiment only analysed supernatants after 24 hours of 
stimulation. 
Conversely, whilst qPCR and ELISA data suggested that IL-6 production was 
significantly enhanced in LPS-stimulated Gata6-deficient pMϕs, intracellular flow 
cytometry showed that they have reduced production compared to pMϕs from Gata6-
WT mice (Figure 4.5). These discrepancies may arise from distinct differences in the 
composition of peritoneal cells in Gata6-WT and Gata6-KOmye. The composition of 
cells within the peritoneal cavity of Gata6-KOmye has been reported to be markedly 
different, with a drastic reduction in the number of pMϕs and a significant increase in 
the number of eosinophils and MHCIIhighCD226+ DC-like cells compared to Gata6-
WT mice (Rosas et al., 2014). Generally, ex vivo assays such as ELISAs were 
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performed using pMϕs purified by adherence, termed APECs. Typically, this method 
has been reported to yield a population of cells consisting of approximately 90-95% 
pMϕs. However, given the drastic differences in composition of peritoneal cells 
between the Gata6-WT and Gata6-KOmye, it is possible that APECs from Gata6-
KOmye contain a population of cells that are a potent source of IL-6, which accounts 
for the significant increase in IL-6 detected by ELISA but not intracellular flow 
cytometry. 
 
4.4.2 PTGIS is selectively expressed in pMϕs and GATA6-
dependent 
Having established fundamental changes in the production of pro-inflammatory 
cytokines by Gata6-deficient pMϕs, I sought to identify downstream mechanisms that 
may be responsible and modulate those to restore the inflammatory phenotype to that 
of pMϕs from Gata6-WT mice. Microarray analysis revealed that one of the most 
down-regulated genes was Ptgis, the key enzyme required for PGI2 synthesis. 
Historically, prostanoids have been regarded as pro-inflammatory mediators, but they 
are now widely recognised for their role in suppressing inflammation and immune 
responses. Prostanoids regulate the immune responses by modulating cytokine and 
chemokine production, migration, phagocytic potential, and cellular differentiation. 
The profile of prostanoids produced is tissue-specific, which is attributed to the 
expression of prostanoid terminal synthases such as Ptgis. Therefore, the expression 
of terminal prostanoid synthases was analysed in pMϕs from Gata6-WT and Gata6-
KOmye. Apart from the significant decrease in Ptgis expression, Gata6-deficient pMϕs 
were found to have enhanced expression of Tbxas1, the enzyme responsible for the 
synthesis of TXA2. Accordingly, analysis of prostanoid production in pMϕs after 
stimulation with LPS showed that Gata6-deficient pMϕs produced significantly less 
PGI2 and more TXA2 compared to pMϕs from Gata6-WT mice (Error! Reference s
ource not found.). PGI2 and TXA2 are best known for their prominent roles in the 
maintenance of vascular homeostasis. PGI2 and TXA2 have opposing roles and their 
imbalance has been implicated in various cardiovascular disorders and pulmonary 
hypertension (Tuder et al., 1999, Christman et al., 1992). Interestingly, there are 
reports which suggest that these opposing functions can be extended to inflammatory 
213 
 
responses, including the regulation of cytokine production. For instance, the inhibition 
of thromboxane synthase was shown to dramatically reduce TNF secretion by 
zymosan-stimulated human monocytes (Caughey et al., 1997). Conversely, PGI2 
analogues have been demonstrated to reduce the production of pro-inflammatory 
cytokines including TNF, IL-6 and IL-12 in BMDCs (Zhou et al., 2007). Interestingly, 
PGI2 analogues promoted differential modulatory effects on IL-6 production 
depending on the specific cell type. Whereas the production of IL-6 in LPS-stimulated 
pMϕs treated with PGI2 analogues was greatly increased, alveolar Mϕs did not increase 
the production of IL-6 to the same extent (Aronoff et al., 2007).  
The production of prostanoids in pMϕs after stimulation with TLR4 agonists or 
infection with C. albicans has been reported to predominantly consist of PGI2 and 
PGE2 (Suram et al., 2013, Norris et al., 2011). Furthermore, these prostanoids are 
produced rapidly, with significant amounts detected 30 minutes post stimulation 
(Suram et al., 2013). Therefore, the dramatic loss of PGI2 and increase in TXB2 
production by LPS-stimulated Gata6-deficient pMϕs may contribute to the 
dysregulated pro-inflammatory cytokine production. 
 
4.4.3 Analogues restore ‘normal’ pro-inflammatory cytokine 
production in Gata6-deficient pMϕs 
Previous studies have strongly implicated PGE2 as the critical prostanoid produced 
upon LPS stimulation that inhibits the production of TNF in pMϕs (Katakami et al., 
1988). However, many of these studies utilized elicited Mϕs, which have very low 
Ptgis expression (Kuwamoto et al., 1997, Tripp et al., 1985, Wenzel et al., 1993). 
Furthermore, the prostanoid profile produced by resident pMϕs and elicited Mϕs has 
more recently been shown to be markedly different, which is likely to impart different 
effects on the inflammatory response (Norris et al., 2011). Indomethacin is an NSAID 
that targets COX1/2, thereby inhibiting the synthesis of downstream prostanoids. 
Interestingly, pMϕs from Gata6-WT mice treated with indomethacin had significantly 
increased TNF but decreased IL-6 production compared to LPS alone (Figure 4.8). 
This suggests that prostanoids produced upon microbial recognition are critical 
regulators of cytokine production. Similarly, the production of TNF in F4/80high pMϕs 
from Gata6-KOmye mice after treatment with indomethacin paralleled those of pMϕs 
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from Gata6-WT mice. Conversely, the production of TNF and IL-6 production in LPS-
stimulated F4/80low pMϕs treated with indomethacin was comparable to treatment with 
LPS alone, suggesting that the critical prostanoid regulating TNF and IL-6 production 
(in pMϕs stimulated with LPS) is PGI2, rather than PGE2. However, this does not 
exclude that TXA2 may contribute to cytokine regulation, which was found to be 
significantly higher in Gata6-deficient pMϕs stimulated with LPS compared to pMϕs 
from Gata6-WT mice. To address the contribution of PGI2 in the regulation of TNF 
and IL-6 production, LPS-stimulated pMϕs were treated with beraprost, a stable PGI2 
analogue. Beraprost significantly reduced TNF and increased IL-6 production in 
Gata6-deficient pMϕs to levels comparable to pMϕs from Gata6-WT mice treated 
with LPS alone. Beraprost treatment completely attenuated TNF production in pMϕs 
from Gata6-WT and F4/80high pMϕs from Gata6-KOmye mice, which is likely additive 
to the endogenous PGI2 produced by these cells after LPS-stimulation. The use of PGI2 
analogues to investigate the function of native PGI2 is contentious. Whilst endogenous 
PGI2 has a high binding affinity to its cognate receptor and not for other prostanoid 
receptors, many PGI2 analogues show equivalent binding to IP receptor and other 
prostanoid receptors including DP, EP, and, FP (Wise, 2003, Hata and Breyer, 2004, 
Wilson et al., 2011). Beraprost and cicaprost have been demonstrated to have higher 
binding affinity for IP receptor and are therefore considered better pharmacologic tools 
to investigate IP receptor-mediated biological responses (Tanaka et al., 2004). 
However, much of the ascribed functions of PGI2 has been investigated using other 
analogues, which may occlude the function of native PGI2. Furthermore, endogenous 
PGI2 is unstable at physiological pH and has a very short half-life (< 2 minutes), 
rapidly forming the inactive 6-keto-PGF1α (Smyth and FitzGerald, 2002, Lewis and 
Dollery, 1983). Conversely, the half-life of PGI2 analogues is considerably longer, 
which will undoubtedly prolong its biological effects (Toda, 1988). Another limitation 
of PGI2 analogues is that they do not compete for PGH2, which may thereby alter the 
production of other prostanoids. Indeed, analysis of supernatants of LPS-stimulated 
pMϕs showed a significant increase in TXB2 in Gata6-deficient pMϕs (Supplementary 
Figure 4Error! Reference source not found.). 
Overall, these results indicate that the loss of endogenous PGI2 production by LPS-
stimulated Gata6-deficient pMϕs leads to dysregulated cytokine production. 
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Furthermore, this effect is intrinsic to Gata6-deficient pMϕs, as F4/80high pMϕs from 
Gata6-KOmye mice responded similarly to those from Gata6-WT mice. 
4.4.4 Ptgis transgene expression 
To address the limitations of using PGI2 analogues outlined above, the next aim was 
to reconstitute the expression of Ptgis in Gata6-deficient pMϕs and evaluate whether 
this restored pro-inflammatory cytokine production to that of pMϕs from Gata6-WT 
mice. 
BMDMs do not express Ptgis, so were selected to validate the Ptgis-expressing 
lentiviral construct. The expression of the Ptgis transgene was greatly upregulated in 
BMDMs transduced with Ptgis-expressing lentivirus, as detected by qPCR and 
western blotting. Furthermore, upon LPS stimulation, BMDMs transduced with Ptgis-
expressing lentivirus produced significantly more PGI2 than BMDMs transduced with 
the T2A-rCD2. Furthermore, PGD2, PGE2 and TXB2 were reduced in BMDMs 
transduced with Ptgis-expressing lentivirus. Since prostanoids are synthesised from 
the same common substrate PGH2, the decrease in other prostanoids is likely because 
of increased competition for PGH2, which has limited bioavailability. Having 
established that the Ptgis transgene could produce PGI2, functionality was assessed. 
BMDMs that were non-transduced or transduced with ether T2A-rCD2 control or Ptgis 
were stimulated with LPS and the production of TNF and IL-6 determined by 
intracellular flow cytometry. Interestingly, BMDMs did not produce IL-6 in response 
to LPS after 3 or 6 hours stimulation with LPS (Figure 4.11 and Figure 4.12). However, 
BMDMs produced significant amounts of TNF when stimulated with LPS for either 3 
or 6 hours but this was unaffected by Ptgis transgene expression (Figure 4.11 and 
Figure 4.12). Early prostanoid production in pMϕs (0 -2 hours after stimulation) has 
been demonstrated to be dependent on COX-1, which is constitutively expressed in 
pMϕs (Rouzer et al., 2004). Conversely, COX-2 is basally expressed at low levels but 
strongly induced by growth factors and pro-inflammatory stimuli including LPS, and 
is reported to be responsible for late prostanoid production (Barrios-Rodiles et al., 
1999). It was noted that the quantity of prostanoids produced by BMDMs was 
considerably lower than that of pMϕs (Norris et al., 2011). The expression of Ptgs1 
(COX-1) and Ptgs2 (COX-2) have been reported to be substantially lower in BMDMs 
compared to peritoneal macrophages (von Moltke et al., 2012, Norris et al., 2011). Of 
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note, the expression of Ptgs1 is over 1.5 fold down in Gata6-deficient pMϕs compared 
to pMϕs from Gata6-WT mice (Supplementary Figure 5). Furthermore, the induction 
of COX-2 expression after stimulation with LPS is also much lower in BMDMs 
compared to pMϕs. Therefore, the Ptgis transgene may not be effective as the 
availability of PGH2 (which is produced by the action of COX1/2) may be very low. 
Supporting this, LPS-stimulated BMDMs treated with indomethacin had comparable 
levels of TNF production compared to stimulation with LPS alone, suggesting that 
early endogenous prostanoids produced by BMDMs either don’t regulate TNF 
production, or more likely that insufficient quantities of early prostanoids are produced 
by BMDMs because COX1/2 are not abundantly expressed, which are required for the 
generation of PGH2. To exclude the possibility that BMDMs do not respond to PGI2, 
LPS-stimulated BMDMs were treated with beraprost, which significantly reduced 
TNF production compared to LPS alone. 
Resident pMϕs from Gata6-WT and Gata6-KOmye mice were transduced in vivo with 
T2A-rCD2- or Ptgis-expressing lentivirus, after which they were unstimulated or 
stimulated with LPS. Despite being injected with the same lentiviral preparation, the 
number of recoverable rCD2+ pMϕs transduced with lentivirus was significantly 
reduced in Gata6-KOmye mice compared to Gata6-WT mice (2.14% ± 0.04 and 
19.85% ± 0.99 respectively). 
4.4.5 Knockdown Ptgis in WT mice 
To compliment the Ptgis reconstitution experiments in Gata6-deficient pMϕs, shRNAs 
targeting Ptgis expression were designed and evaluated in C57BL/6 mice. The 
previous experiments showing that F4/80high pMϕs from Gata6-KOmye mice had TNF 
and IL-6 production comparable to pMϕs from Gata6-WT mice suggested the 
dysregulated production in Gata6-deficient pMϕs was intrinsic. Given the relatively 
small population of F4/80high pMϕs within Gata6-KOmye, the production of PGI2 is 
unlikely to affect neighbouring F4/80low cells, whereas autocrine and intracrine PGI2 
signalling is likely to modulate its own TNF and IL-6 production. 
The production of TNF was not significantly different between pMϕs transduced with 
shNSC- or shPtgis-expressing lentivirus. Furthermore, the production of TNF between 
transduced and non-transduced pMϕs from the same mouse was comparable. 
Similarly, IL-6 production after 3 hours stimulation was not significantly different 
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between shNSC and shPtgis, and transduced and non-transduced cells. However, after 
6 hours stimulation the production of IL-6 was significantly decreased in pMϕs 
transduced with shPtgis.  
However, there are a number of distinct differences between the non-transduced and 
Ptgis-transduced pMϕs from the same mouse compared to F4/80high and F4/80low pMϕs 
from the same mouse. Firstly, the relative percentage of F4/80high is approximately 5%, 
whereas the non-transduced population is approximately 70-80% (in this experiment). 
The large population of non-transduced cells are likely to produce large quantities of 
PGI2 that will likely saturate the culture medium and induce signalling in the 
transduced cells. Alternatively, the transduced population will not produce PGI2 and 
will therefore mean the culture medium will have less total PGI2 than pMϕs transduced 
with shNSC. 
 
4.5 Conclusion 
Overall, Gata6 controls the expression of Ptgis, the key enzyme that synthesises PGI2. 
As such, the release of PGI2 from Gata6-deficient pMϕs following stimulation with 
LPS was significantly reduced compared to pMϕs from Gata6-WT mice. Treatment 
of LPS-stimulated Gata6-deficient pMϕs with a PGI2 analogue restored the 
dysregulated production of TNF and IL-6, suggesting that PGI2 may be a critical 
mediator released by pMϕs to control inflammatory responses. Furthermore, the 
release of TNF from Gata6-deficient pMϕs co-cultured with pMϕs from Gata6-WT 
was comparable to monocultured pMϕs from Gata6-WT mice. To establish whether 
PGI2 is the critical mediator modulating inflammatory responses, Gata6-deficient 
pMϕs were transduced with Ptgis-expressing lentivirus, which was technically 
challenging as the recovery of transduced Gata6-deficient pMϕs was significantly 
lower than pMϕs from Gata6-WT mice. Given the perturbed inflammatory responses 
of Gata6-deficient pMϕs, it is possible that the poor recovery was due to increased cell 
death, or increased migration away from the peritoneal cavity and further experiments 
are needed to clarify the role of PGI2 in mediating inflammatory responses. The design 
of shRNAs to knockdown Ptgis expression in Gata6-WT pMϕs provided an alternative 
mechanism to study this, but poor transduction efficiency in these preliminary 
experiments has confounded conclusions regarding the role of PGI2. Lentiviral 
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production protocols in our lab have since been optimised, which should enhance the 
transduction efficiency of future experiments.  
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5 Chapter Five – Do other GATA 
factors regulate the development of 
Mϕs? 
  
Chapter Five 
Do other GATA factors regulate the 
development of Mϕs? 
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5.1 Introduction 
Langerhans cells (LCs) are resident myeloid cells of the epidermis, which were first 
described in 1868 by Paul Langerhans, a medical student who thought they were part 
of the nervous system due to their stellate processes. LC have long been considered 
the archetypal DC, based primarily on morphological features and their proficiency 
for antigen capture, processing, and subsequent migration to draining lymph nodes 
whereby they present antigen to naïve T cells via MHC molecules, reviewed by 
(Romani et al., 2010, Villadangos and Schnorrer, 2007). However, it has become 
increasingly evident, aided by cell tracing and transcriptional profiling studies that LCs 
exhibit specific developmental and homeostatic features, distinct from other DC 
populations (Hoeffel et al., 2012). The development of cDCs and pDCs is critically 
dependent on the cytokine fms-like tyrosine kinase 3 (Flt3) ligand (Flt3L) and its 
receptor (Flt3) (Waskow et al., 2008, Tussiwand et al., 2005, McKenna et al., 2000); 
knockout mice have a ten-fold reduction in pDCs and cDCs , whereas LC numbers 
were unaffected (Merad et al., 2008, Onai et al., 2007, Waskow et al., 2008). Similarly, 
GM-CSF is important for the development and differentiation of DCs, whereas GM-
CSF-deficient mice have only a modest reduction of LCs in vivo (Kingston et al., 
2009). In contrast, LC development is acutely dependent on CSF1R and transforming 
growth factor-beta 1 (TGF-β1), exemplified by the lack of epidermal LCs in TGF-β1- 
and CSF1R-deficient mice (Borkowski et al., 1996). The strict dependency of CSF1R 
for LC development is similar to tissue-resident macrophage populations, which are 
greatly diminished in CSFR1-deficient mice (Dai et al., 2002). However, the loss of 
CSF1, the cognate ligand for CSF1R, did not affect LC (Witmer-Pack et al., 1993, 
Takahashi et al., 1992) or microglia development (Ginhoux et al., 2006). IL-34, a 
stroma-derived cytokine was subsequently shown to bind to CSF-R1, suggesting that 
this alternative ligand may be responsible for the development of LCs and microglia 
(Lin et al., 2008). Accordingly, IL-34-/- mice showed the same developmental defects 
as CSF-1R-deficient mice which were selectively deficient of LCs and microglia 
(Wang et al., 2012). 
Another notable difference between cDCs/pDCs and LCs lies in their homeostasis and 
the control thereof. DCs are relatively short-lived and replenished throughout life from 
BM-precursors. Conversely, LCs are very long-lived and under steady state conditions 
are maintained throughout life by self-proliferation of LC or LC precursors seeded 
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during embryogenesis, independent of BM-derived precursor input (Hoeffel et al., 
2012, Merad et al., 2002). Further studies suggest that a local pool of proliferating 
haematopoietic precursors seed the skin during embryonic development, which can 
give rise to LCs (Chang-Rodriguez et al., 2005). However, the development of LCs is 
differentially regulated in steady state and under inflammatory conditions. Following 
UV ablation of LCs, Gr-1high monocytes were shown to be specifically recruited into 
the epidermis, where they proliferated locally and differentiated into LCs, a process is 
critically dependent on CSF1R (Ginhoux et al., 2006). Similarly, following UV 
irradiation, the existence of two distinct populations of LCs was reported, short-term 
and long-term LCs, which transiently or stably reconstitute the epidermis respectively 
(Seré et al., 2012). Short-term LCs are derived from Gr-1high monocytes and are 
independent of the transcription factor Id2 (Seré et al., 2012, Chopin et al., 2013), 
which is critically required for the development of LCs and langerin+ dermal DCs 
(during ontogeny) (Hacker et al., 2003). Id2 is a critical mediator of TGF-β signalling, 
which is supported by an absence of LCs in both ID2- and TGF-β-deficient mice 
(Hacker et al., 2003). Conversely, the BM-precursors that give rise to long-term LCs 
are critically dependent on Id2. However, it is currently unclear whether long-term 
LCs contribute to the maintenance of LCs in the absence of an initial depletion of LCs, 
or whether LCs under steady state conditions are maintained exclusively by local self-
proliferation of embryonically-seeded precursors. 
Transcription factors play key roles in the development, maintenance, and function of 
myeloid cells. Recently, tissue-specific master regulators that control resident Mϕs 
have been identified, which control the development and specify the transcriptional 
programs of tissue-resident Mϕs, thereby enabling them to perform their niche-specific 
functions. For instance, the master regulator SpiC controls the development of red pulp 
Mϕs, which phagocytose senescent erythrocytes and recycle heme-associated iron 
(Kohyama et al., 2009). Interestingly, physiologic stimuli from the niche in which 
tissue-resident Mϕs reside can promote the expression of these master regulators. For 
instance, the expression of Spic is induced by heme, a metabolite of erythrocyte 
degradation (Haldar et al., 2014). Similarly, retinoic acid in the peritoneal cavity 
induces the expression of the transcription factor Gata6, the central regulator of murine 
peritoneal Mϕ phenotype (Okabe and Medzhitov, 2014, Rosas et al., 2014, Gautier et 
al., 2014). 
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In addition to Id2, the transcription factor PU.1 has been shown to be important for 
steady state LC homeostasis. PU.1 controls LC differentiation through the induction 
of RUNX3, a critical component of the TGF-β signalling cascade in LCs (Fainaru et 
al., 2004). Interestingly, PU.1 synergizes with TGF-β to promote the expression of 
RUNX3. Accordingly, several master transcription factors have been shown to 
synergize with TGF-β, orchestrating the cell-type specific effects of TGF-β signalling 
(Mullen et al., 2011). Given the similarities between LCs and tissue-resident Mϕs in 
their embryonic origin, capacity for self-renewal, longevity, and ligand-dependent 
development, we hypothesised that LCs are under the control of (tissue-specific) 
master regulators. 
The GATA family of transcription factors are critical regulators for a diverse array of 
immune cells. Having identified Gata6 as the master regulator of murine peritoneal 
Mϕ function and phenotype, our research group is interested in how transcription 
factors control the development and function of other immune populations. 
Preliminary analysis of immune cell microarray datasets from the Immunological 
Genome Project (ImmGen) indicated that Gata3 is selectively up-regulated in murine 
LCs. Furthermore, experiments in our lab performed by Dr Marcela Rosas showed 
GATA3 was highly-expressed in LCs derived in vitro from the hematopoietic cell line 
MUTZ-3 compared to the precursor cells (Data unpublished). 
The importance of GATA3 has been long established for developing and mature T 
cells, whereby it is required for the differentiation of T helper 2 cells, early T cell 
commitment CD4+ T cell development and β-selection (Zheng and Flavell, 1997). 
More recent studies have demonstrated that GATA3 is essential for the development 
and function of several immune subsets including the development, maintenance, and 
function of NK cells, NKT cells and ILC2 cells (Mjösberg et al., 2012, Samson et al., 
2003, Kim et al., 2006). 
Moreover, GATA3 is also expressed in many embryonic and adult tissues, including 
the kidneys, hair follicles, skin, and the central nervous system, in which several 
knockout and conditional knockout mouse models have demonstrated important 
functions (Kaufman et al., 2003, Grote et al., 2008). Given the role of GATA family 
members in the development, phenotype, and function of other immune cells, we 
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hypothesized that GATA3 may be important/synonymous in the LC-specific 
transcriptional program and the overarching function and phenotype thereof. 
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5.2 Chapter hypothesis and aims 
The hypothesis tested in this chapter is that the development, maintenance, or effector 
functions of LCs are dependent on the transcription factor GATA3. 
Aims 
• To determine whether GATA3 is selectively expressed in human LCs 
• To design and test the efficacy of lentiviral shRNA constructs on GATA3 
knockdown 
• To determine whether GATA3 knockdown effects LC differentiation 
• To determine whether loss of GATA3 changes the phenotype of naïve and 
mature LCs 
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5.3 Results 
5.3.1 GATA3 expression in murine and human LCs 
To examine whether GATA family members are important for the development of 
myeloid cell subsets, publicly available microarray data sets were analysed for the 
expression of GATA family members in various murine immune cell populations 
(Figure 5.1A-C). The murine microarray expression data indicated that GATA3 was 
selectively enriched in murine LCs, albeit at lower levels than T cell and NK cell 
subsets (Figure 5.1A-C). To determine whether GATA3 expression extends to human 
LCs, microarray expression data of human myeloid/DC populations from blood, skin, 
and in vitro derived DCs and LCs was analysed for GATA3 expression (Figure 5.1D). 
The expression of GATA3 was relatively low across all samples, but the expression 
was marginally higher in primary LCs and LCs derived in vitro from the MUTZ-3 cell 
line (MuLC) (Figure 5.1D). 
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Figure 5.1 | Gata3 is selectively expressed in murine LCs. 
(A-C) Microarray expression data across different murine immune cell populations. 
Data was assembled by the ImmGen consortium (Heng and Painter, 2008). (A) 
Heatmap showing the expression of Gata family members across different immune 
cell populations. (B) Expression values of Gata family members in murine LCs from 
Immgen consortium (C) The expression of Gata3 in select immune cell populations, 
which unless stated otherwise were isolated from the spleen. (D) Quantile normalised 
expression of GATA3 in human cells isolated from the blood, skin or generated in vitro 
from the MUTZ-3 cell line. Data was analysed from microarray data publicly available 
(GSE32400).  
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5.3.2 In vitro derived LCs upregulate GATA3 compared to 
precursors 
To examine whether GATA3 is important for LC development, the human CD34+ 
acute myeloid leukaemia cell line MUTZ-3 was used as an in vitro model of LC 
development. MUTZ-3 cells can be differentiated into MUTZ-3-derived LCs 
(hereafter referred to as MuLCs) after 10 days of cytokine stimulation, and they exhibit 
similarities to primary LCs including the expression of langerin and the presence of 
Birbeck granules (Santegoets et al., 2006, Masterson et al., 2002). To evaluate whether 
the GATA3 is important for LC differentiation, the expression of GATA3 was 
determined in MUTZ-3 precursors and MuLCs by qPCR and flow cytometry 
respectively (Figure 5.2). The expression of GATA3 was approximately 100-fold 
higher in MuLCs compared to MUTZ-3 precursors. However, no GATA3 protein was 
detectable by flow cytometry in CD1a+CD207+ MuLCs (Figure 5.2). The expression 
of GATA3 was also determined in monocyte-derived LCs (MoLCs), but was found to 
be lower than both monocytes and monocyte-derived DCs (MoDCs). 
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Figure 5.2 | MuLCs upregulate GATA3 compared to precursors, but no protein was detected. 
(A) Representative bivariate plots showing the cell surface expression of CD1a and CD207 in MUTZ-3 precursors and LCs derived from MUTZ-
3 (MuLCs). (B) Representative histogram showing isotype (empty histogram) and GATA3 (filled histogram) in MUTZ-3 precursors and 
CD1a+CD207+ MuLCs after 10 days of differentiation The MFI is indicated on each plot. (C) Scatter plots showing GATA3 MFI (minus isotype 
control) and percentage positive cells from two independent experiments. (D) The expression of GATA3 was determined by qPCR relative to the 
endogenous control gene YWHAZ in MUTZ-3 precursors and CD1a+ MuLCs (MACS enriched). Data is mean ± S.D from three independent 
experiments (E) Bar chart shows the expression of GATA3 in monocytes, monocyte-derived LCs (MoLC) and monocyte derived DCs (MoDC) 
determined by qPCR relative to the endogenous control YWHAZ. Error bars indicate the 95% confidence interval of three technical replicates. 
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5.3.3 GATA3 protein is not detected during differentiation 
The expression of GATA3 detected by qPCR showed that it was highly-expressed in 
MuLCs compared to MUTZ-3 precursors. However, GATA3 protein was undetectable 
in MuLCs after 10 days of differentiation by cytokine stimulation (Figure 5.2). To 
evaluate whether GATA3 protein expression was transient, the expression of GATA3 
in MUTZ-3 precursors undergoing differentiation at various time points was assessed 
by flow cytometry (Figure 5.3). The percentage of CD1a+CD207+ MuLCs on day 4 
was similar to MUTZ-3 precursors, but steadily increased to approximately 8% by day 
6 and over 50% by day 10 of differentiation. However, the expression of GATA3 was 
undetectable in MUTZ-3 precursors during differentiation at all time points analysed, 
in both CD207+ MuLCs and non-differentiated cells (Figure 5.3). 
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Figure 5.3 | The expression of GATA3 protein is undetectable in MuLCs during differentiation from MUTZ-3 precursors. 
(A, B) Bivariate plots showing the expression of (A) CD207 and CD1a and (B) isotype control or GATA3 in MUTZ-3 precursors and during 
their differentiation into MuLCs. Jurkat T cells were used as a positive control for GATA3 expression. n=1. 
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5.3.4 GATA3 protein is undetectable in mature MuLCs 
GATA3 protein was undetectable in MUTZ-3 precursors at different stages of 
differentiation into MuLCs (Figure 5.3). GATA3 is critical for T helper type 2 (TH2) 
cell differentiation. Whilst IL-4 induces the expression of GATA3 mRNA, the protein 
levels are insufficient to induce TH2 differentiation. Rather, simultaneous TCR-
activation is required, which has been reported to stabilize GATA3 protein and 
enhance the rate of translation of GATA3 (Cook and Miller, 2010). Therefore, GATA3 
protein levels in LCs may be dependent on specific extracellular stimuli that enhance 
its stability and translation. To determine whether GATA3 protein is detectable in 
MuLCs upon maturation, MuLCs were unstimulated or stimulated with LPS for 24 
hours and the expression of GATA3 determined by flow cytometry. The expression of 
GATA3 was comparable, and effectively undetected in both unstimulated and LPS-
stimulated MuLCs (Figure 5.4). 
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Figure 5.4 | The expression of GATA3 protein is undetectable in mature MuLCs. 
MuLCs were either unstimulated or stimulated with 1 µg ml-1 LPS for 24 hours. (A) 
Representative bivariate plots showing CD207and GATA3 expression in CD1a-
enriched MuLCs Experiment representative of two independent experiments. (B) 
Scatter plots show GATA3 MFI (minus isotype control) and percentage GATA3 
positive MuLCs. Each point represents data from independent experiments. (C) The 
expression of GATA3 in CD1a-enriched MuLCs was determined relative to the 
endogenous control YWHAZ. Each point represents expression relative to unstimulated 
MuLCs from two independent experiments. 
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5.3.5 GATA3 shRNA design and efficacy 
To investigate the role of GATA3 in LC development, maintenance, and function, 
lentiviral constructs expressing shRNA targeting GATA3 were designed. The efficacy 
of different shRNA constructs on the knockdown of GATA3 expression was 
determined in Jurkat T cells, which constitutively express GATA3. Jurkat T cells were 
transduced with two different lentiviral shRNA constructs targeting GATA3 and a 
non-silencing control (NSC) shRNA, and the expression of GATA3 determined by 
qPCR and flow cytometry (Figure 5.5). 
The knockdown of GATA3 expression in Jurkat T cells by shGATA-1 and shGATA-
2 constructs was approximately 53% and 75% respectively (Figure 5.5 C). In addition 
to transcriptional analysis, flow cytometry was used to determine the knockdown of 
GATA3 expression, which showed that the transcriptional data strongly correlated 
flow cytometry analysis, in which shGATA3-1 was less efficacious in the knockdown 
of GATA3 compared to the shGATA3-2 construct, with a reduction in GATA3 
expression of 45% and 70% respectively (Figure 5.5). 
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Figure 5.5 | shGATA3 design and efficacy. 
Jurkat T cells were either non-transduced (WT) or transduced with lentiviruses 
encoding NSC, GATA3-1 or GATA3-2 shRNA constructs. (A) Representative 
bivariate plot showing GATA3 and rCD2 expression 7 days post-transduction. Data 
representative of two independent experiments (B) Bar graph shows mean GATA3 
MFI (minus isotype control) ± S.D from three biological replicates. (C) The expression 
of GATA3 was determined by qPCR relative to the endogenous control gene YWHAZ. 
Error bars indicate the 95% confidence interval of three technical replicates. 
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5.3.6 GATA3 is not required for LC development. 
Having established that the shRNA targeting GATA3 was efficacious, the next aim 
was to knock-down GATA3 expression in MUTZ-3 precursors to determine whether 
this would affect their differentiation into MuLCs. To determine whether GATA3 was 
important for the development of LCs, MUTZ-3 precursors were either non-
transduced (WT) or transduced with lentiviral constructs expressing shNSC or 
shGATA3-2 (hereafter referred to as shGATA3) and subsequently differentiated into 
MuLCs. After 10 days, the differentiation of MUTZ-3 precursors was analysed by 
flow cytometry (Figure 5.6). 
The percentage of CD1a+CD207+ LCs after 10 days differentiation from MUTZ-3 
precursors was comparable between non-transduced and shNSC- or shGATA3-
expressing cells (p = 0.3488 and p = 0.7276 respectively) (Figure 5.6). The expression 
of GATA3 reduced by over 90% in MuLCs derived from precursors transduced with 
shGATA3 compared to non-transduced MuLCs. The expression of GATA3 was 
significantly reduced in MuLCs derived from precursors transduced with shGATA3 
compared to those transduced with shNSC (p = 0.0489), confirming that MuLCs could 
differentiate without GATA3 (Figure 5.6B). The MFI of CD207 and CD1a was not 
significantly different between WT MuLCs and shNSC- or shGATA3-MuLCs (Figure 
5.6E). However, the percentage of CD1a+CD207- cells was significantly higher in 
precursors transduced with shNSC compared to non-transduced and shGATA3 cells 
(p = 0.033 and p = 0.223 respectively). 
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Figure 5.6 | Loss of GATA3 does not affect the development of MuLCs. 
(A) Representative bivariate plots showing the cell surface expression of CD1a and 
CD207 in MuLC differentiated from MUTZ-3 precursors that were non-transduced 
(WT) or transduced with lentivirus expressing shNSC or shGATA3. (B) GATA3 
expression in CD1a+ MuLCs was determined by qPCR relative to the endogenous 
control YWHAZ. Data shows mean ± S.D from three independent experiments. (C) 
Bar chart shows percentage of CD1a+CD207+ and CD1a+CD207- LCs after 10 days of 
cytokine differentiation. Data are presented as mean ± S.D of three independent 
experiments. (D) Stacked bar chart shows percentage of cells that were CD1a-CD207-
, CD1a+CD207- or CD1a+CD207+ after 10 days of cytokine differentiation. (E) Bar 
charts shows mean CD207 and CD1a MFI ± S.D after 10 days of cytokine 
differentiation. Statistical significance was determined by (B) a one-tailed paired t-test 
or (C, E) repeated measures one-way ANOVA with Tukeys multiple comparison post-
test (*p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant). 
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5.3.7 GATA3 is not required for LC receptor expression. 
The loss of GATA3 had no significant effect on the differentiation of MUTZ-3 
precursors to MuLCs (Figure 5.6). In addition to their role in the development of 
immune cells, transcription factors impart specific transcriptional control on mature 
cells that specifies distinct functional effector phenotypes. LCs express numerous cell 
surface receptors that enable them to recognise invading pathogens, and capture, 
process, and present antigen to naïve T cells. 
The maturation of LCs has been functionally defined as the acquisition of potent 
immunogenic capacity (Banchereau and Steinman, 1998). This typically involves the 
upregulation of CD40, CD83, CD86 and HLA products, which are required for antigen 
presentation and co-stimulation of naïve T cells by LC. Therefore, to determine 
whether GATA3 is required for the maturation of LCs, cell surface receptor expression 
was determined by flow cytometry in unstimulated or LPS-stimulated MuLCs that 
were non-transduced (WT) or transduced with lentivirus expressing shNSC or 
shGATA (Figure 5.7). The percentage of cells expressing HLA-DR was comparable 
between MuLCs derived from precursors that were non-transduced or transduced with 
either shNSC or shGATA3 (p = 0.9980 and p = 0.9094 respectively) (Figure 5.7). 
Similarly, HLA-DR MFI was not significantly different (p = 0.7730 and 0.9079). 
Furthermore, stimulation with LPS did not significantly increase HLA-DR expression 
or percentage of positive cells. The percentage of cells expressing CD80 was not 
significantly different between WT MuLCs and shNSC- or shGATA3-MuLCs (p = 
0.8621 and p = 0.1819). Similarly, CD80 MFI was comparable (p = 0.8502 and p = 
0.1041). Stimulation with LPS did not significantly increase the percentage of CD80 
positive cells or CD80 MFI. The percentage of cells expressing CD83 was comparable 
between WT MuLCs and shNSC- or shGATA3-MuLCs (p > 0.9999 and 0.9403). 
Likewise, CD83 MFI was comparable (p > 0.9999 and p = 0.9999). Stimulation with 
LPS did not significantly increase the percentage of CD83 positive cells or CD83 MFI.  
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Figure 5.7 | LC cell surface receptor expression is unaffected by loss of GATA3. 
MuLCs were differentiated from MUTZ-3 precursors that were non-transduced or 
transduced with lentivirus expressing shNSC or shGATA. After differentiation, cells 
were either unstimulated or stimulated with 1 µg ml-1 LPS for 24 hours. (A) Cell 
surface receptor expression of CD1a-enriched MuLCs was determined by flow 
cytometry. (B) Scatter plots show MFI and percentage of cells expressing the indicated 
cell surface receptors. Each point represents data from independent experiments. 
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5.4 Discussion 
5.4.1 GATA3 is up-regulated in mouse and human LCs 
LCs are the tissue-resident myeloid cells of the epidermis that have long been 
described as the archetypal DC. However, unlike DCs which critically rely on 
Flt3/Flt3L and GM-CSF for their development, LC numbers are unaffected by 
deficiencies in either of these. Furthermore, DCs are short-lived and are derived from 
BM-precursors. Conversely, LCs have striking similarities with tissue-resident Mϕs 
with respect to their embryonic origin, capacity for self-renewal, cytokine dependency, 
and their longevity (Romani et al., 2010).  
Given the similarities between LCs and tissue-resident Mϕs, I sought to identify 
whether LC development and function was dependent on a master regulator. 
Preliminary work within our research group indicated that GATA3 was enriched in 
LCs. Analysis of microarray expression data from different murine immune cell 
populations suggested that Gata3 was upregulated in LCs, although this was lower 
than in T cells and NK cells, for which the importance of Gata3 has already been 
ascribed. Analysis of human microarray data suggested that GATA3 may also be up-
regulated in primary LCs and those derived from the MUTZ-3 cell line. However, the 
microarray dataset had a limited number of replicates, which restrained what 
conclusions could be made from this dataset. GATA family members are important 
for the development of many tissues. Gata3-deficient mice die at embryonic day 11, 
displaying severe abnormalities in the nervous system, aberrations in fetal liver 
haematopoiesis and massive internal bleeding (Pandolfi et al., 1995). GATA3 is 
expressed in both hematopoietic and non-hematopoietic tissues, including the central 
nervous system, the kidney, mammary glands, and of note for this study, skin (Grote 
et al., 2008, Kaufman et al., 2003, Kouros-Mehr et al., 2006). 
 
5.4.2 GATA3 expression is up-regulated in MuLCs compared 
to MUTZ-3 precursors 
To investigate whether GATA3 was important for LC development, the MUTZ-3 cell 
line was used as an in vitro source of LCs (MuLCs). LCs generated from MUTZ-3 
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precursors (MuLCs) have been shown to express langerin and contain Birkbeck 
granules.(Santegoets et al., 2006). Furthermore, extensive phenotypic and functional 
comparative studies have suggested that MuLCs show a close resemblance to primary 
LCs (Santegoets et al., 2008). The expression of GATA3 was highly up-regulated 
(~100 fold) in MuLCs compared to MUTZ-3 precursors, but no GATA3 protein was 
detectable (Figure 5.2). The expression of GATA3 in monocyte-derived LCs (MoLCs) 
was found to be ~10% of monocytes. The lack of detectable GATA3 protein in MuLCs 
did not exclude its requirement for the development or function of LCs. Poor 
correlation of mRNA and protein levels have been reported, which are generally 
ascribed to translational control and the stability of the protein, yet these remain poorly 
understood (Maier et al., 2009). Genes that are involved in constitutive cellular 
processes such as translation (ribosomal proteins), respiration and metabolism 
(Glycolysis, TCA cycle) generally have stable mRNAs and proteins. Conversely, 
genes that have unstable mRNAs and proteins are enriched for transcription factors, 
chromatin modifying enzymes, and signalling genes (Schwanhausser et al., 2011). 
Thus, in general, critical regulators of dynamic processes such as transcription factors 
are under greater transcriptional and/or translational regulation than housekeeping 
genes. The ubiquitin-proteasome pathway is one of the major mechanisms for the 
degradation of short-lived regulatory proteins such as transcription factors. In CD4+ T 
cells, the TCR-mediated activation of the Ras-ERK-MAPK cascade regulates GATA3 
stability through the ubiquitin-proteasome pathway (Yamashita et al., 2005, Hosokawa 
et al., 2006, Shinnakasu et al., 2008). Further studies have reported that TCR activation 
leads to an mTORC-1-dependent increase in the rate of GATA3 translation (Cook and 
Miller, 2010). Overall these studies show that the expression of master transcription 
factors in immune cells can be regulated at the level of translation and post-translation. 
Therefore, steady-state GATA3 protein levels in LCs may be undetectable in fully-
differentiated MuLCs, but transiently abundant during differentiation. To address this, 
the expression of GATA3 protein was determined in MUTZ-precursors undergoing 
differentiation at various time points. However, no GATA3 protein was detected at 
any of the time points analysed (Figure 5.3). Alternatively, like T cells which require 
TCR-activation for GATA3 protein stabilization, LCs may depend on specific 
extracellular stimuli such as microbial ligands to stabilise GATA3 protein levels. To 
address this, the expression of GATA3 was determined in MuLCs unstimulated or 
stimulated with LPS, which induces the maturation of MuLCs. However, the 
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expression of GATA3 was undetectable in both unstimulated and LPS-stimulated LCs 
(Figure 5.4). Overall, despite GATA3 mRNA being very highly expressed in MuLCs, 
GATA3 protein was undetectable in MuLCs both during the course of differentiation 
and upon maturation. 
 
5.4.3 GATA3 is not required for LC development or 
maturation 
To exclude the role of GATA3 in the development of LCs, lentiviral vectors expressing 
shRNAs targeting GATA3 were designed and the efficacy of GATA3 knockdown 
determined in Jurkat T cells, which abundantly express GATA3. Having determined 
the most efficacious shRNA construct, MUTZ-3 precursors were transduced and 
differentiated into MuLCs. The differentiation of MUTZ-3 into MuLCs was 
unaffected by the loss of GATA3 (Figure 5.6).  
In addition to their role in the development of specific immune cells, tissue-specific 
transcription factors are required for specifying effector functions, through the 
induction of specific transcriptional programs. LCs predominantly reside in the 
epidermis where they are traditionally considered as the first line of defence against 
invading pathogens (Merad et al., 2008). More recently, the function of LCs has 
become more controversial, with some studies suggesting that their main function in 
vivo is immunoregulation rather than immune stimulation (Kaplan, 2010). LCs 
continuously probe their environment for invading pathogens by extending and 
retracting their dendrites. LCs express a plethora of PRRs including the C-type lectin 
receptors, which recognise carbohydrate moieties expressed by pathogens. Langerin 
(CD207) is a C-type lectin receptor found almost exclusively on LCs, with DDCs the 
only other cell type reported to express langerin (Ginhoux et al., 2007, Poulin et al., 
2007, Bursch et al., 2007). The expression of both CD207 and CD1a, which are both 
highly expresses on LCs were unaffected by the loss of GATA3 (Figure 5.6E). 
The LC paradigm was largely established through studying LCs in vitro, which 
emphasized that LC have a unique capacity to induce/initiate primary immune 
responses. In peripheral tissues, they acquire antigens and subsequently migrate to 
lymph nodes where they present processed peptides to naïve T cells (Romani et al., 
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2010, Villadangos and Schnorrer, 2007). Upon microbial stimulation, MuLCs (and 
primary LCs) are described in the literature as having ‘matured’. Upon ‘maturation’, 
LCs up-regulate the expression of genes such as those encoding the co-receptors 
CD80, CD40. GATA3-deficiency did not affect the expression of these markers, 
suggesting that GATA3 is not required for the maturation of MuLCs. 
5.4.4 Conclusion 
The expression of GATA3 was highly upregulated in MuLCs compared to their 
MUTZ-3 precursors. Together with public microarray data, the expression of GATA3 
appeared to be selectively upregulated. Despite the high expression of GATA3, no 
detectable protein was present, either in differentiating MuLCs or in fully-
differentiated MuLCs. Furthermore, GATA3 was not required for the differentiation 
of MuLCs, nor was it required for their maturation. Based on these observations, I 
conclude that GATA3 is not required for the development, maintenance, or maturation 
of LCs from the MUTZ-3 cell line.  
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6 Chapter Six - General Discussion  
Chapter Six 
General Discussion 
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6.1 Introduction 
Tissue-resident macrophages are a highly heterogeneous cell type, present in virtually 
every mammalian tissue, where they play a fundamental role in development, 
homeostasis, tissue repair and host defence responses (Davies et al., 2013, Gordon and 
Taylor, 2005). Tissue-resident macrophages were long thought to be derived from BM 
precursors, although recent lineage-tracing studies challenged this long-held view and 
indicate that embryonic precursors give rise to many tissue-resident macrophage 
populations. In adulthood, different tissue-resident populations have differential 
requirements for BM-derived replenishment, but most consist of a mixture of 
embryonically-derived and monocyte-derived macrophages. Comprehensive 
transcriptional analysis of resident macrophage populations suggested macrophage 
populations from different organs exhibited considerable transcriptional diversity, as 
would be predicted from their phenotypic diversity (Gautier et al., 2012), indicating 
that environmental cues may condition different tissue-resident macrophage 
populations to perform their tissue-specific roles. Recent evidence suggests that 
distinct tissue-specific master regulators govern the phenotypic diversity and 
specialised functions of different tissue-specific macrophages. Our research group as 
well as other groups identified the transcription factor Gata6 as a critical regulator of 
a peritoneal macrophage-specific transcriptional program (Okabe and Medzhitov, 
2014, Gautier et al., 2014, Rosas et al., 2014). Interestingly, retinoic acid derived from 
peritoneal omental tissue was shown to drive induce the expression of Gata6 (Okabe 
and Medzhitov, 2014), suggesting that environmental factors have a critical role in 
specifying the tissue-specific functions of different tissue-resident macrophage 
populations. Analogous factors have been identified in other tissue-resident 
macrophage populations, such as Spi-C, which is essential for the development of 
splenic red pulp macrophages (Kohyama et al., 2009). However, genetic deletion of 
these tissue-specific transcriptional regulators typically results in the ablation of the 
specific macrophage populations, for instance the loss of splenic red pulp macrophages 
in mice deficient of Spi-C, and absence of metallophilic and marginal zone 
macrophages in mice deficient of LXRα (A-Gonzalez et al., 2013, Kohyama et al., 
2009). Conversely, genetic deletion of Gata6 in macrophages does not completely 
ablate the population of peritoneal macrophages, albeit it leaves them at reduced 
numbers. Thus, Gata6-deficient pMϕs provide a unique tool to investigate how tissue-
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specific transcription factors regulate macrophage function during homeostasis and in 
response to environmental stimuli, such as those encountered during inflammation. 
Lineage-specific transcription factors, such as PU.1, which is essential for the 
development of macrophages, are thought to co-ordinately regulate macrophage 
identity and function in tandem with tissue-specific transcription factors during the 
steady state. Furthermore, recent evidence suggests that the accessibility of 
macrophage-specific transcriptional regulatory elements (enhancers and promoters) is 
imparted by tissue- and lineage-specific transcription factors (Lavin et al., 2014, 
Gosselin et al., 2014). As such, the ability of stimulus-induced transcription factors 
such as NF-κB to elicit gene expression changes is thought to be dictated by the 
accessibility of enhancers and promoters specified by tissue- and lineage-specific 
transcription factors. However, it is largely unclear how transcriptional master 
regulators control tissue-specific macrophage phenotype during the initiation of the 
inflammatory response and the resolution thereof. 
 
Aims 
To date, limited studies have addressed how the loss of these tissue-specific 
transcriptional factors effects the inflammatory responses of tissue-resident 
macrophage populations. As such, the work presented in this thesis aimed to identify 
whether Gata6 was important for the regulation of the inflammatory response and its 
resolution, and whether analogous factors control the development of other tissue-
resident macrophages. 
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6.2 Gata6 regulates inflammatory responses of 
peritoneal macrophages 
Recent studies have identified a number of tissue-specific transcription factors that 
control the development and function of tissue-resident macrophage populations. 
However, our current understanding of how these transcription factors regulate 
inflammatory responses is unclear. To address this, pMϕs from Gata6-WT and Gata6-
KOmye were stimulated with an array of TLR ligands, as well as fungal ligands and the 
production of pro-inflammatory cytokines determined. 
 
6.2.1 Dysregulated TNF and IL-6 production in LPS-
stimulated Gata6-deficient pMϕs 
The production of TNF from LPS-stimulated pMϕs from Gata6-WT mice was 
transient, with peak production detected at 3 hours and undetectable in culture 
supernatants at 12 hours. Conversely, LPS-stimulated Gata6-deficient pMϕs produced 
significantly more TNF at 3 hours, which was sustained and detectable after 24 hours 
(Figure 4.3). Flow cytometric cytokine staining supported the significant increase in 
peak TNF production following stimulation with LPS for 3 hours. However, the 
production of IL-6 detected by flow cytometry was significantly lower in Gata6-
deficient pMϕs compared to those from Gata6-WT mice, whereas IL-6 detected by 
ELISA was comparable. These discrepancies may result from distinct differences in 
the composition of peritoneal cells in Gata6-WT and Gata6-KOmye, as ex vivo assays 
such as ELISAs were performed using pMϕs purified by adherence, termed APECs. 
Thus, it is possible that APECs from Gata6-KOmye contain a population of cells that 
are potent sources of IL-6. Alternatively, soluble factors released through the classical 
secretion pathway (inhibited by GolgiPlug™ in flow cytometric cytokine production 
assays) may modulate the production of IL-6. Preliminary experiments of MACS-
enriched pMϕs from Gata6-WT and Gata6-KOmye suggest that the production of IL-6 
is comparable at early and late time points, and the production of TNF and IL-1β reflect 
the other experimental observations in this thesis using APECs. 
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6.2.2 Gata6 regulates the activation of the NLRP3 
inflammasome  
The production and release of IL-1β from macrophages is tightly controlled through 
the combination of two distinct signals: transcription as well as maturation and release, 
commonly referred to as the two-signal model for IL-1β processing and release 
(Martinon et al., 2002). In macrophages, LPS stimulation alone fails to induce robust 
processing and release of mature IL-1β (Franchi et al., 2012). Strikingly, Gata6-
deficient pMϕs released mature IL-1β and IL-18 upon stimulation with LPS alone, 
whereas minimal IL-1β and IL-18 were detected in supernatants from LPS-stimulated 
pMϕs from Gata6-WT mice (Figure 3.1). The production of IL-18 from LPS-
stimulated Gata6-deficient pMϕs was significantly lower than that of IL-1β, which 
may reflect the differences in the intracellular pool of IL-18 and IL-1β. Supporting 
this, Gata6-deficient pMϕs primed with LPS and stimulated with nigericin secreted 
significantly more IL-1β than IL-18 (65 ng ml-1 and 1.5 ng ml-1 respectively). 
Inhibition of caspase-1 or NLRP3 inflammasome activation significantly reduced the 
production of IL-1β from LPS-stimulated Gata6-deficient pMϕs. Although the release 
of mature IL-1β in response to LPS alone (‘Priming’ signal) has been well described 
for murine BMDCs and human monocytes (Gaidt et al., 2016, He et al., 2013), 
secretion from macrophages is generally strictly dependent on two distinct signals. 
Conversely, genetic defects that lead to spontaneous IL-1β secretion by macrophages 
have been reported. BMDMs deficient of all three inhibitor of apoptosis proteins 
(cIAP1, cIAP2, and XIAP) exhibited spontaneous NLRP3 inflammasome activity and 
IL-1β secretion in response to LPS alone (Vince et al., 2012). Furthermore, another 
study suggested that BMDMs deficient of XIAP alone secreted IL-1β in response to 
LPS alone (Yabal et al., 2014). Similarly, ablation of Atg16l1 resulted in IL-1β 
secretion in response to LPS stimulation alone (Saitoh et al., 2008). More recently, 
LPS-stimulated BMDMs deficient of Tnfaip3 (which encodes the NF-κB inhibitor 
A20) were shown to spontaneously secrete IL-1β (Duong et al., 2015). However, the 
release of mature IL-1β from LPS-stimulated Gata6-deficient pMϕs is distinct from 
these previous studies. Firstly, macrophages deficient of all IAP proteins, A20 or 
Atg16L1 primed with LPS and activated with ATP secreted significantly more IL-1β 
compared to wild-type macrophages, suggesting that these factors control the 
magnitude of NLRP3 activation and subsequent IL-1β processing. Conversely, Gata6-
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deficient pMϕs primed with LPS and stimulated with soluble NLRP3 stimuli (ATP 
and nigericin) responded normally, secreting comparable levels of IL-1β as pMϕs from 
Gata6-WT mice (Figure 3.5), suggesting that Gata6 does not have a prominent role in 
regulating the magnitude of NLRP3 activation. Another distinguishing feature is the 
direct or indirect specificity of LPS to induce the secretion of IL-1β from Gata6-
deficient pMϕs, but not any of the other TLR ligands tested. However, for the studies 
carried out in this thesis, a dose-response curve for IL-1β and IL-18 release from 
Gata6-WT and Gata6-KOmye pMϕs was only performed with the TLR4 ligand LPS. 
As such, it is possible that the concentrations of TLR ligands used to stimulate pMϕs 
from Gata6-WT and Gata6-KOmye pMϕs were sub-optimal. As such, it is possible that 
the release of IL-1β and IL-18 from Gata6-deficient pMϕs may not be restricted to 
LPS stimulation alone and that the failure of other TLR ligands to induce the release 
of IL-1β and TNF from Gata6-KOmye is an experimental artefact. Conversely, a range 
of TLR ligands have been reported to induce IL-1β secretion from macrophages 
deficient of all IAP proteins or A20 secreted mature IL-1β in response to a range of 
TLR ligands. 
Having established that the secretion of mature IL-1β from LPS-stimulated Gata6-
deficient pMϕs, the underlying molecular mechanisms of NLRP3 inflammasome 
activation were investigated. A wide array of exogenous and endogenous stimuli have 
been reported to activate the NLRP3 inflammasome (Latz et al., 2013). Given the 
structural and molecular diversity of these stimuli, it is likely that they all bind directly 
to the NLRP3 inflammasome, as such, it has been suggested that inflammasomes most 
likely monitor cellular homeostasis which is perturbed by activatory stimuli. In 
addition to their role in metabolism, mitochondria are complex regulators of cellular 
homeostasis. Perturbation of ROS, intracellular K+ concentration or lysosomal damage 
have been reported to induce mitochondrial dysfunction (Tschopp, 2011), which are 
also implicated in the activation of the NLRP3 inflammasome. As such, mitochondrial 
dysfunction has been strongly linked to the activation of the NLRP3 inflammasome, 
predominantly through the generation of mtROS and the release of mtDNA and 
cardiolipin (Nakahira et al., 2011, Zhou et al., 2011, Iyer et al., 2013). However, the 
role of mitochondria in the activation of the NLRP3 inflammasome is contentious 
(Lawlor and Vince, 2014), which could reflect cell-type and stimulus-dependent 
divergence in the requirement for mitochondria in the activation of the inflammasome. 
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Naïve Gata6-deficient pMϕs had enhanced mtROS compared to pMϕs from Gata6-
WT mice. During OXPHOS, the leakage of electrons at complex I and III leads to the 
generation of superoxide, which is typically dismutated to hydrogen peroxide by the 
action of superoxide dismutase (SOD)-1 and -2. However, high levels of mtROS are 
implicated in the activation of the inflammasome. Consistent with increased mtROS, 
Gata6-deficient pMϕs had a higher basal rate of OXPHOS than pMϕs from Gata6-
WT mice (Figure 3.7). The release of IL-1β was significantly reduced in LPS-
stimulated Gata6-deficient pMϕs treated with the mitochondria-targeted antioxidant, 
MitoTEMPO, compared to LPS-stimulation alone. Dysfunctional mitochondria are 
ordinarily targeted and removed for degradation in autophagosomes, in a process 
termed mitophagy (Lazarou et al., 2015). Indeed, perturbations of mitophagy have 
been strongly linked to inflammasome activation and IL-1β release (Zhong et al., 
2016). The accumulation of dysfunctional mitochondria (non-respiring, as determined 
by MitoTracker Deep Red staining) was higher in both unstimulated and LPS-
stimulated Gata6-deficient pMϕs compared to those from Gata6-WT mice, suggesting 
that they may have defective mitophagy which can perpetuate the production of 
mtROS and release of mtDNA, which can thereby activate the NLRP3 inflammasome. 
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6.3 Wild-type macrophages restore 
inflammatory responses of Gata6-deficient 
macrophages 
The penetrance of Cre-mediated excision of Gata6 in peritoneal macrophages is 
approximately 95%, resulting in a Gata6+ population of pMϕs within Gata6-deficient 
mice. Gata6-deficient pMϕs from young mice can be identified by flow cytometry by 
Tim4+F4/80low, whereas the population of Gata6+ pMϕs within the Gata6-KOmye mice 
exhibit Tim4+F4/80high staining, comparable to pMϕs from Gata6-WT mice (Rosas et 
al., 2014). Intriguingly, the production of TNF and IL-6 in LPS-stimulated Gata6+ 
pMϕs from Gata6-KOmye mice was comparable to pMϕs from Gata6-WT mice, 
whereas the Tim4+F4/80lowGata6- pMϕs exhibited greatly enhanced TNF and reduced 
IL-6 production (Figure 4.5). These results suggest that the aberrant production of 
these cytokines is cell intrinsic, and that contact-dependent mechanisms and/or soluble 
factors released (such as cytokines, lipids, or DAMPs) from Gata6-deficient pMϕs 
have no effect on the inflammatory responses of Gata6+ pMϕs.  
Conversely, co-cultured pMϕs from Gata6-WT and Gata6-KOmye mice (1:1 culture 
ratio) had significantly reduced secretion of TNF and IL-1β compared to monocultured 
Gata6-deficient pMϕs (Figure 3.14 and Figure 4.6), suggesting that contact-dependent 
mechanisms and/or the release of soluble factors from pMϕs from Gata6-WT mice 
modulate the inflammatory responses of Gata6-deficient pMϕs. Given the relatively 
small population of Gata6+ pMϕs in Gata6-KOmye mice, it is perhaps not surprising 
that they are insufficient to significantly regulate the inflammatory responses of 
neighbouring Gata6-deficient pMϕs in monoculture experiments. Overall, these 
observations suggest that Gata6 expression regulates either contact-dependent 
mechanisms and/or the release of soluble factors that dampen inflammatory responses, 
rather than DAMPs released by Gata6-deficient pMϕs exacerbating inflammatory 
responses of neighbouring cells.  
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6.4 Soluble factors 
Having established that Gata6-deficient pMϕs have markedly perturbed inflammatory 
responses and that co-cultured pMϕs from Gata6-WT mice could restore the aberrant 
release of IL-1β and TNF, attention was directed to the identification of mechanisms 
by which Gata6 regulates the inflammatory response and resolution thereof. 
6.4.1 Cytokine and purinogenic signalling 
The differential response of Gata6-deficient pMϕs to different TLR ligands provided 
an insight into possible mechanisms underlying the release of IL-1β from Gata6-
deficient pMϕs stimulated with LPS but not any of the other TLR ligands tested. One 
of the most striking observations was that similar to the release of IL-1β, the prolonged 
release of TNF was restricted to stimulation with LPS (Figure 4.3). On the basis of 
these observations, I hypothesised that IL-1β released from LPS-stimulated Gata6-
deficient pMϕs was mediated through the enhanced and sustained release of TNF. To 
address this, TNF signalling was inhibited in LPS-stimulated pMϕs with etanercept. 
Whilst etanercept significantly reduced the release of IL-1β by over 30%, it did not 
completely prevent the release of IL-1β (Figure 3.15). TNF signalling in macrophages 
can lead to the activation of NF-κB, which induces the expression of genes including 
Il1b and Tnf (Yarilina et al., 2008). Accordingly, TNF signalling may enhance the 
transcription of Il1b, increasing the pool of pro-IL-1β in Gata6-deficient pMϕs, which 
can be subsequently processed and released. Thus, inhibition of TNF signalling might 
reduce the expression of pro-IL-1β, but not directly contribute to the activation of the 
inflammasome. Furthermore, the release of IL-1β from Gata6-deficient pMϕs 
stimulated with recombinant TNF was comparable to unstimulated pMϕs. However, 
the responses of pMϕs to co-stimulation with LPS and recombinant TNF were not 
investigated, which may synergize and result in the aberrant release of IL-1β. 
Similarly, LPS-stimulated pMϕs treated with rIL-1Ra (which blocks autocrine and/or 
paracrine IL-1β signalling) had no significant effects on the production of either IL-1β 
or TNF compared to LPS stimulation alone. 
Our group has previously reported that CD73 expression is greatly diminished in 
Gata6-deficient pMϕs (Rosas et al., 2014). This ectoenzyme along with CD39 is 
highly expressed in resident peritoneal macrophages, which mediate the conversion of 
extracellular ATP into adenosine (Zimmermann and Braun, 1999, Kaczmarek et al., 
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1996). Macrophages release ATP into the extracellular milieu following exposure to 
TLR ligands and its subsequent processing to adenosine is reported to suppress the 
production of proinflammatory cytokines including TNF, whilst enhancing the 
production of anti-inflammatory cytokines such as IL-10 (Cohen et al., 2013). As such, 
the release of ATP and the subsequent generation of adenosine represents a possible 
mechanism through which resident macrophages resolve inflammatory responses. As 
Gata6-deficient pMϕs have significantly reduced CD73 expression, I hypothesised 
that they would have a deficiency of adenosine generation, which is a potent anti-
inflammatory mediator that can down-regulate pro-inflammatory cytokine expression 
and up-regulate the expression of anti-inflammatory cytokines. The release of IL-10 
was significantly lower in LPS-stimulated Gata6-deficient pMϕs compared to those 
from Gata6-WT mice (Figure 3.16). Interestingly, LPS-stimulated pMϕs treated with 
adenosine had significantly reduced TNF production but the secretion of IL-1β was 
unaffected, further supporting a limited role for TNF signalling in the release of IL-
1β. However, the addition of exogenous adenosine might not reflect the concentration 
of endogenous adenosine produced from the hydrolysis of ATP. In support of this, 
attempts to inhibit CD73 did not enhance the production of TNF or IL-1β in LPS-
stimulated pMϕs from Gata6-WT or Gata6-KOmye mice. 
6.4.2 Gata6 regulates inflammatory responses through 
eicosanoid production 
One of the most down-regulated genes in Gata6-deficient pMϕs was the gene encoding 
prostacyclin synthase, a terminal prostanoid synthase that catalyses the generation of 
prostacyclin (PGI2) from prostaglandin H2. Previous studies have shown pMϕs 
predominantly produce PGI2, PGE2, and LTC4 after stimulation with LPS, TNF, and 
IL-1 as well as C. albicans- and zymosan (Brock et al., 1999, Norris et al., 2011, Suram 
et al., 2013). PGI2 analogues have been shown to reduce the production of pro-
inflammatory cytokines including TNF, IL-6, and IL-12 in BMDCs (Zhou et al., 
2007). More recently, PGI2 and PGE2 analogues were reported to enhance the 
transcription of anti-inflammatory mediators and attenuate the secretion of TNF from 
pMϕs stimulated with C. albicans (Suram et al., 2013). LPS-stimulated Gata6-
deficient pMϕs had significantly reduced production of both PGI2 and PGE2 and 
increased TXB2 (the stable metabolite of TXA2) compared to pMϕs from Gata6-WT 
mice (Supplementary Figure 4). 
253 
 
To examine whether the dysregulated production of TNF and IL-6 were a result of 
significantly reduced PGI2, LPS-stimulated pMϕs from Gata6-KOmye were treated 
with beraprost, a PGI2 analogue. Similar to previous studies, beraprost significantly 
reduced the production of TNF in Gata6-deficient pMϕs which was comparable to 
TNF production in LPS-stimulated pMϕs from Gata6-WT mice. Conversely, the 
production of TNF by LPS-stimulated Gata6-deficient pMϕs was unaffected when 
treated with the COX1/2 inhibitor indomethacin, whereas TNF production in LPS-
stimulated pMϕs from Gata6-WT mice were significantly enhanced. Similarly, 
beraprost treatment significantly reduced the release of IL-1β (60% reduction) from 
LPS-stimulated Gata6-deficient pMϕs (Figure 3.6). Given that the reduction of IL-1β 
by beraprost treatment is more pronounced than that of etanercept, it is unlikely that 
the suppression of IL-1β is solely a consequence of reduced TNF production. PGI2 
analogues have been reported to decrease the expression of pro-inflammatory 
cytokines including IL-1β and TNF, mediated through the elevation of intracellular 
cAMP, which culminates in the inhibition of NF-κB signalling. Additionally, cAMP 
has been suggested to modulate NLRP3 inflammasome activation through direct 
binding to NLRP3 (Lee et al., 2012). Thus, cAMP produced downstream of PGI2 can 
potentially downregulate IL-1β by suppressing the transcription of Il1b, and through 
the direct inhibition of NLRP3 inflammasome activation. However, treatment with DB 
or RP (a cAMP analogue or an inhibitor of the activation of cAMP-dependent protein 
kinases by cAMP, respectively) did not significantly affect the release of IL-1β from 
LPS-stimulated Gata6-deficient pMϕs (Figure 3.6). 
Gata6-deficient pMϕs stimulated with LPS secreted significantly more TXB2, less 
PGE2, and barely detectable levels of PGI2 compared to pMϕs from Gata6-WT mice 
(Supplementary Figure 4). TXB2 has been typically ascribed pro-inflammatory 
functions and has been reported to enhance TNF production by zymosan-stimulated 
human monocytes (Caughey et al., 1997). However, indomethacin treatment did not 
reduce the production of TNF from Gata6-deficient pMϕs stimulated with LPS, 
suggesting that the increase in TXB2 does not enhance TNF signalling in this context. 
PGE2 has generally been described as having anti-inflammatory effects, but further 
study is needed to determine whether endogenous PGE2 produced by LPS-stimulated 
Gata6-deficient pMϕs suppressed IL-1β release. Many of the ascribed functions of 
PGI2 have been established in studies utilising PGI2 analogues (Suram et al., 2013). 
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However, the use of these occlude the function of endogenous PGI2 in several ways. 
Firstly, many of the PGI2 analogues used in the literature (treprostinil and iloprost) 
exhibit comparably high binding affinity for IP receptor as other prostanoid receptors 
including DP1, EP1, and EP2 (Whittle et al., 2012, Hata and Breyer, 2004). In contrast, 
the PGI2 analogue beraprost is reported to have a much lower affinity for other 
prostanoid receptors and is therefore considered better pharmacologic tools to 
investigate IP receptor-mediated biological responses (Tanaka et al., 2004). 
Additionally, whilst the half-life of endogenous PGI2 is very short (< 2 minutes), the 
half-life of analogues is considerably longer, which undoubtedly prolong its biological 
effects and likely don’t reflect the function of endogenous PGI2.  
To investigate how endogenous PGI2 effected the production of pro-inflammatory 
cytokines, the gene encoding Ptgis was cloned into lentiviral constructs with the aim 
of reconstituting Ptgis expression in Gata6-deficient pMϕs and determine whether 
restoring endogenous PGI2 production would restore pro-inflammatory cytokine 
production to that of pMϕs from Gata6-WT mice. BMDMs transduced with the Ptgis-
expressing lentivirus simulated with LPS failed to modulate the production of TNF at 
both 3 and 6 hours. This is likely because the expression of Ptgs1 and Ptgs2 (which 
encode COX-1 and COX-2 respectively) was significantly lower in BMDMs than 
pMϕs, which are required for the generation of PGH2, the universal substrate for 
downstream prostanoid synthases (von Moltke et al., 2012, Norris et al., 2011). Indeed, 
LPS-stimulated BMDMs treated with indomethacin had comparable production of 
TNF to LPS treatment alone, suggesting that endogenous eicosanoids are not produced 
at these early time points by these cells. The transduction of Gata6-deficient pMϕs 
transduced in vivo with Ptgis-expressing transgene was significantly lower than those 
from Gata6-WT mice, which may result from increased migration away from the 
peritoneal cavity (such as to the omentum) or increased cell death. As such, the 
production of TNF from Ptgis-expressing pMϕs was comparable to the control 
lentivirus. Given the small population of positive Ptgis-expressing Gata6-deficient 
pMϕs, it is not surprising that the production of TNF was not significantly different, 
as the production of PGI2 from this population is likely not enough to significant effect 
the larger number of non-transduced cells, synonymous with the Gata6+ population in 
Gata6-KOmye being unable to modulate the inflammatory responses of the 
predominant Tim4+F4/80lowGata6- population. 
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To overcome the technical issues in transducing Gata6-deficient pMϕs, I designed 
shRNA constructs targeting Ptgis with the aim recapitulating the aberrant production 
of TNF and IL-6 of LPS-stimulated Gata6-deficient pMϕs. The production of TNF 
was comparable at both 3 hours and 6 hours between the cells transduced with shNSC 
(control virus) and shPtgis in wild-type pMϕs. Similarly, IL-6 production was 
comparable at 3 hours in transduced cells expressing shNSC and shPtgis lentiviral 
constructs. However, the production of IL-6 in LPS-stimulated pMϕs after 6 hours was 
significantly lower in pMϕs transduced with shPtgis compared to shNSC(Figure 4.16). 
However, the production of IL-6 from the non-transduced and shPtgis-transduced 
pMϕs was not significantly different, which could suggest that PGI2 produced from 
the transduced population are modulating the production of IL-6 in the non-transduced 
population. However, the transduction efficiency in these experiments was particularly 
low (~5%), which probably confounded the effect of Ptgis-knockdown. Our lentiviral 
production protocols have since been optimised in our group. Thus, further 
experimentation with a higher percentage of transduced pMϕs may help to delineate 
the role of PGI2 in TNF and IL-6 production from LPS-stimulated pMϕs.  
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6.5 LPS stimulation induces cell death in Gata6-
deficient pMϕs 
The release of mature IL-1β from macrophages is reported to be strictly dependent on 
pyroptosis, which is mediated by the caspase-1 or caspase-11-dependent cleavage of 
gasdermin D, which leads to the formation of membrane pores culminating in the loss 
of plasma membrane integrity and release of IL-1β (He et al., 2015, Shi et al., 2015, 
Kayagaki et al., 2015). A similar study suggested that all NLRP3 activatory stimuli 
induce necrosis, which was proposed to be the convergence point of various stimuli 
for the activation of the NLRP3 inflammasome activation and subsequent processing 
and release of IL-1β (Cullen et al., 2015). However, this study preceded the 
identification of the role of gasdermin D in mediating pyroptosis, so it is likely that the 
necrotic cell death reported in this study is pyroptosis mediated by gasdermin D 
cleavage. 
To investigate whether the release of mature IL-1β from LPS-stimulated Gata6-
deficient pMϕs was associated with an increase in cell death, unstimulated and LPS-
stimulated pMϕs were stained with propidium iodide (PI+), which is excluded by 
viable cells. The percentage of PI+ pMϕs was significantly higher in LPS-stimulated 
Gata6-deficient pMϕs, compared to unstimulated Gata6-deficient pMϕs and both 
unstimulated and LPS-stimulated pMϕs from Gata6-WT mice (Figure 3.8).  
The percentage of PI+ pMϕs is relatively small compared to that from pMϕs primed 
with LPS and stimulated with either ATP or nigericin, which is consistent with the 
comparatively smaller release of IL-1β from LPS-stimulated Gata6-deficient pMϕs 
(typically 1 – 2 ng ml-1) compared to release from LPS-primed stimulated with either 
ATP or nigericin (35 and 65 ng ml-1 respectively). Surprisingly, inhibition of either 
caspase-1 or NLRP3 inflammasome activation failed to attenuate LPS-induced cell 
death in Gata6-deficient pMϕs, but did prevent the release of mature IL-1β (Figure 3.4 
and Figure 3.9). Furthermore, the inhibitors exhibited no apparent toxicity in 
unstimulated Gata6-deficient pMϕs. Apart from caspase-1, pyroptosis has been 
reported to be mediated by the non-canonical inflammasome activation, mediated by 
caspase-11 (Kayagaki et al., 2015). Caspase-11 was recently identified to directly 
recognise and bind intracellular LPS (Hagar et al., 2013), and has been implicated in 
257 
 
protection against intracellular Gram-negative bacteria in the cytosol that have escaped 
vacuoles (Aachoui et al., 2013). Caspase-11 mediates the activation of the NLRP3 
inflammasome which in turn leads to the activation of caspase-1 and processing and 
release of IL-1β. Interestingly, caspase-11 has been shown to directly cleave 
gasdermin d and subsequent pyroptosis independently of caspase-1 activation. As 
such, it is possible that cell death in Gata6-deficient pMϕs stimulated with LPS is 
mediated by caspase-11, which accounts for the NLRP3- and capase-1-depedent 
release of IL-1β and independent cell death. However, further study is needed to 
establish whether gasdermin D is cleaved in LPS-stimulated Gata6-deficient pMϕs, 
which would implicate pyroptosis as the mechanism of cell death. If LPS-stimulated 
Gata6-deficient pMϕs undergo pyroptosis, inhibition of caspase-11 (or shRNA 
knockdown) may address the underlying mechanism driving pyroptosis.  
Interestingly, the percentage of PI+ Gata6-deficient pMϕs stimulated with Pam3CSK4 
was comparable to pMϕs from Gata6-WT mice, suggesting that the underlying 
mechanisms regulating the release of IL-1β may also induce cell death. TNF signalling 
can also induce pro-apoptotic and RIP3-dependent necroptosis signalling cascades in 
macrophages, culminating in the activation of the inflammasome and IL-1β secretion 
in macrophages deficient of XIAP (Yabal et al., 2014). However, etanercept treatment 
did not attenuate cell death in LPS-stimulated Gata6-deficient pMϕs (Figure 3.15), 
suggesting that TNF signalling does not contribute to LPS-induced cell death in Gata6-
deficient pMϕs. Supporting this, preliminary experiments suggest that treatment of 
LPS-stimulated Gata6-deficient pMϕs with beraprost does not significantly reduce 
cell death, despite reducing the production of both TNF and IL-1β (Figure 3.6 and 
Figure 4.8). 
Alternatively, LPS stimulation may induce cell death and the release of IL-1β by 
independent mechanisms. Dramatic reduction of peritoneal macrophages in Gata6-
KOmye mice has been attributed to increased apoptosis under homeostatic conditions 
(Gautier et al., 2014), whereas another study attributed the reduction to increased 
accumulation of pMϕs in the omentum (Okabe and Medzhitov, 2014). As such, LPS-
stimulation may induce apoptotic cell death in Gata6-deficient pMϕs as opposed to 
pyroptotic cell death. Gata6-deficient pMϕs stimulated with LPS had significantly 
more caspase-3+ pMϕs than unstimulated pMϕs and both unstimulated and LPS-
stimulated pMϕs from Gata6-WT mice (Figure 3.11). In contrast to the observations 
258 
 
of Gautier and colleagues, the percentage of caspase-3+ naïve pMϕs from Gata6-
deficient pMϕs was not significantly different from pMϕs from Gata6-WT mice, 
which was supported by comparable annexin V staining (Figure 3.10). The increase in 
apoptosis of Gata6-deficient pMϕs was attributed to the marked reduction in Aspa 
expression, although it is noteworthy that approximately 10% of pMϕs from Aspa-
deficient mice were apoptotic, compared to over 20% reported for Gata6-deficient 
pMϕs (Gautier et al., 2014). Furthermore, apoptotic cells in vivo are typically cleared 
rapidly, unless the phagocytes have an impairment in the phagocytosis of apoptotic 
cells (Taylor et al., 2000, O'Brien et al., 2006, Elliott and Ravichandran, 2016). 
Similarly, apoptotic cells are normally cleared in vitro with similarly rapid dynamics. 
Impaired clearance of apoptotic cells typically results in the accumulation of late 
apoptotic and secondary necrotic cells (PI+), which are thought to release endogenous 
danger signals that can exacerbate inflammatory responses, which has been implicated 
in the development of autoimmune diseases such as systemic lupus erythematosus 
(Kaplan, 2004, Elliott and Ravichandran, 2016). As caspase-3+ Gata6-deficient pMϕs 
are readily detectable after stimulation with LPS, it may suggest that Gata6-deficient 
pMϕs have impaired apoptotic clearance, which would be supported by the increase in 
PI+ pMϕs after stimulation with LPS, which may simply reflect secondary necrotic 
cells. 
Strikingly, the percentage of PI+ Gata6-deficient pMϕs was significantly reduced 
when co-cultured with pMϕs from Gata6-WT mice (Figure 3.14). The results from 
these experiments suggest that either Gata6-WT pMϕs attenuate cell death through 
contact-dependent mechanisms and/or the release of soluble factors, or that Gata6-WT 
pMϕs phagocytose early apoptotic Gata6-deficient pMϕs, which prevents the 
progression of apoptotic cells to secondary necrotic cells. The clearance of apoptotic 
cells is thought to be predominantly non-phlogistic, and is characterised by the 
suppression of pro-inflammatory cytokine production and the increased production 
and release of pro-inflammatory mediators such as TGF-β and IL-10 (Fadok et al., 
1998, Meagher et al., 1992). Furthermore, secondary necrotic cells may release 
endogenous signals, which can subsequently activate the inflammasome. One of the 
limitations of these experiments is they are predominantly end-point assays, which 
occlude the dynamics of apoptotic induction, as such, future experiments utilising real-
259 
 
time monitoring of caspase-3/7 activation may provide critical insights into the 
kinetics of caspase-3 activation.  
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6.6 Do other GATA factors regulate the 
development of Mϕs? 
The final hypothesis tested was that the development, maintenance, or effector 
functions of LCs are dependent on the transcription factor GATA3. LC development 
is strictly dependent on the transcription factor Id2 for their development (Chopin et 
al., 2013, Hacker et al., 2003). Microarray expression data from human and murine 
suggested that GATA3 was selectively up-regulated. The CD34+ MUTZ-3 cell line 
provides a valuable tool for the generation of in vitro human LCs, which share similar 
characteristics to primary LCs (Masterson et al., 2002, Santegoets et al., 2008, 
Santegoets et al., 2006). Consistent with public microarray data, GATA3 was highly 
expressed in MuLCs, whereas it was barely detectable in MUTZ-3 precursors. 
However, flow cytometric analysis of GATA3 showed that it was comparable between 
the precursors and MuLCs (and barely detectable). I hypothesized that GATA3 may 
be required for the differentiation of precursors into MuLCs and thus not-detectable in 
differentiated MuLCs. However, flow cytometric staining for GATA3 was comparable 
over the course of differentiation. Supporting this, the knockdown of GATA3 had no 
significant effect on the differentiation of precursors to MuLCs, despite the significant 
reduction in GATA3 expression (Figure 5.2). The high expression of GATA3 but no 
detectable protein may indicate that stimuli might be required for the transcription of 
GATA3. To test this, the expression of GATA3 was determined in naive MuLCs and 
those maturated through stimulation with LPS. However, GATA3 was undetectable 
and in both naïve and mature MuLCs, and knockdown of GATA3 did not affect the 
maturation of MuLCs, as determined by comparable expression of maturation markers 
and key LC genes. Based on these observations, I conclude that GATA3 is not required 
for the development, maintenance, or maturation of MUTZ-3 derived LCs. It will be 
interesting to analyse GATA3 expression in both primary mouse and human cells, 
which could be determined by immunofluorescent microscopy for GATA3 in skin 
biopsies.  
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6.7 Conclusions 
The work in this thesis establishes the importance of tissue-specific transcription 
factors on the control of macrophage inflammatory responses, which to date, is poorly 
understood. The mechanisms underlying the differential requirement of one- or two-
signals for the processing and release of IL-1β is poorly understood. This is the first 
report of LPS-stimulation alone inducing the release of mature IL-1β in macrophages 
deficient of a tissue-specific transcription factor, suggesting that tissue-specific 
transcription factors controlling tissue-resident macrophages exert tight regulatory 
control over the release of IL-1 family cytokines and other pro-inflammatory 
mediators including TNF and NO, which could have important indications for the field 
of macrophage biology and the regulation of inflammatory responses. 
 
6.8 Future perspectives 
RNA-sequencing of unstimulated and LPS-stimulated pMϕs from Gata6-WT and 
Gata6-KOmye will provide valuable information that may help to identify perturbed 
pathways that contribute to the abnormal pro-inflammatory cytokine production 
exhibited by Gata6-deficient pMϕs. Tissue-specific transcription factors can regulate 
enhancer landscapes, which in turn make the regulatory elements of genes more 
accessible to stimulus-dependent transcription factors such as NF-κB, induced 
downstream, of LPS signalling. The current data of unstimulated pMϕs from Gata6-
WT and Gata6-KOmye mice therefore this data doesn’t provide an accurate picture of 
the genes that are dysregulated during inflammation in Gata6-deficient pMϕs. 
Understanding this may aid in the identification of pathways that are contributing to 
the phenotypes shown in this thesis. 
The restoration of normal inflammatory responses of Gata6-deficient pMϕs when co-
cultured with pMϕs from Gata6-WT mice is striking. To determine whether soluble 
mediators such as cytokines mediate this restoration, further study should perform 
these co-culture experiments in trans well tissue culture plates, which will allow any 
soluble mediators to exert their effects. Similarly, the transfer of conditioned medium 
generated from LPS-stimulated Gata6-WT pMϕs to those from Gata6-KO mice should 
support any observations from the trans well studies. Following on from these studies, 
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BMDMs deficient of any candidate genes could be co-cultured with pMϕs from 
Gata6-KO mice. 
Currently, our understanding of the control of macrophage function during 
homeostasis and inflammation is limited. One of the pertinent questions to be resolved 
is whether BM-derived tissue-resident macrophages can fully adopt the phenotype and 
function of the embryonically-derived Mϕs they replace. Tissue-derived signals such 
as retinoic acid in the peritoneum induces the expression of Gata6, which in turn 
specifies the function and phenotype of peritoneal macrophages. Furthermore, more 
recent studies have shown that tissue-specific and lineage-specific transcription factors 
co-ordinately regulate enhancer landscapes in tissue-resident macrophages (Gosselin 
et al., 2014, Lavin et al., 2014), which in turn regulates the accessibility of regulatory 
elements to stimulus-dependent transcription factors, such as NF-κB. However, 
whether origin and ontogeny impacts the regulation of enhancer landscapes and 
subsequent gene expression of BM-derived compared to embryonically-derived 
tissue-resident macrophages remains to be addressed. Single-cell sequencing of 
embryonically-derived and BM-derived tissue-resident macrophage populations 
should greatly aid our understanding of how their origin and ontogeny effects their 
function and phenotype. Interestingly, different tissue-resident macrophage 
populations have differential requirements for BM-derived issue-resident macrophage 
input. Furthermore, the requirement of BM-derived input has been reported to be 
highly gender specific for peritoneal macrophages (Bain et al., 2014), although the 
underlying mechanisms governing this are yet to be determined. Interestingly, this 
study showed that BM-derived tissue-resident pMϕs did not express the phagocytic 
receptor Tim4, which is highly expressed on embryonic-derived pMϕs. This might 
indicate that BM-derived pMϕs may not acquire the complete transcriptional profile 
of the embryonic cells they gradually replace, which may impact the function of pMϕs. 
However, extensive transcriptional studies are needed to fully define whether BM-
derived pMϕs can adopt the phenotype of embryonically-derived pMϕs. Interestingly, 
another study showed that BM-precursors transplanted into irradiated mice acquired 
90% of the transcriptional profile of their embryonic-derived peritoneal and alveolar 
macrophages (Lavin et al., 2014), although this was tissue-specific, as BM-derived 
Kupffer cells acquired less than 50% of the tissue-specific enhancers of their 
embryonic counterparts. Similarly, Bruttger et al. showed that BM-derived microglia 
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that colonize irradiated brains (microglial depletion) had over 2, 000 genes that were 
differentially expressed compared to embryonic microglia (Bruttger et al., 2015). 
Collectively, these results suggest that either a substantial component of the 
transcriptional profile of microglia and Kupffer cells are determined by their 
embryonic origin, or alternatively, that irradiation disrupts brain and liver homeostasis, 
preventing normal imprinting of BM-derived cells. Consistent with the latter, upon 
conditional deletion of Kupffer cells, Scott and colleagues showed that BM-derived 
Kupffer cells acquired an almost identical transcriptional profile to their embryonic 
counterparts (Scott et al., 2016). Likewise, when lungs were protected from irradiation 
in BM chimeric animals, BM-derived alveolar macrophages were reported to have 
almost identical transcriptional profile as embryonic-derived alveolar macrophages 
(Gibbings et al., 2015). Collectively, these studies suggest that disruption of tissue-
homeostasis can have critical implications for the phenotype and function of tissue-
resident macrophage function. This is particularly relevant in an inflammatory context, 
in which a plethora of stimuli (cytokines, microbial ligands, DAMPs) can potentially 
dictate tissue programming and ultimately affect the function of tissue-resident 
macrophage populations. One recent study of zymosan-induced peritonitis reported 
that BM-derived pMϕs (that populated the peritoneum following inflammation) 
persisted in the peritoneum for at least 2 months post-resolution (Newson et al., 2014), 
congruent with the persistence of BM-derived pMϕs up to 2 months after 
thioglycolate-induced peritonitis (Yona et al., 2013). Furthermore, the phenotype of 
the resident pMϕs after 60 days post-zymosan was different to naïve pMϕs, suggesting 
that inflammatory contexts can re-programme tissue resident macrophage populations, 
which can ultimately affect their functional characteristics. Overall, the function and 
phenotype of tissue-resident macrophages following inflammation remains poorly 
characterised and further study is needed. 
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 Appe ndices 
Appendices 
Appendix A | Caspase-1 or NLRP3 inhibition does not induce cell death in 
unstimulated pMϕs 
 
Supplementary Figure 1 | Inhibition of caspase-1 or NLRP3 inflammasome 
activation does not induce cell death in unstimulated pMϕs. 
Total PECs from Gata6-WT or Gata6-KOmye mice were either unstimulated or 
stimulated with 100 ng ml-1 LPS in the presence of DMSO (vehicle), 40 µM YVAD, 
or 1 µM MCC950 ex vivo for 16 hours. The percentage positive PI+ pMϕs (gated by 
CD11b+F4/80+) was determined by flow cytometry. Data is from one experiment. 
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Appendix B | TLR expression in pMϕs from Gata6-WT and Gata6-KOmye mice 
 
Supplementary Figure 2 | TLR expression in pMϕs. 
Microarray expression of genes encoding TLR receptors in pMϕs from Gata6-WT and 
Gata6-KOmye mice. Data is expressed as mean ± S.D from three biological replicates. 
Statistical significance was determined using an empirical Bayesian statistic corrected 
for false discovery rate by the Benjamin-Hochberg procedure (*p < 0.05, **p < 0.01, 
***p < 0.001, ns = not significant). 
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Appendix C | IL-6 secretion from Gata6-WT pMϕs after stimulation with various 
TLR ligands at different concentrations 
 
Supplementary Figure 3 | IL-6 secretion from pMϕs from Gata6-WT mice in 
response to different TLR ligands.  
APECs from Gata6-WT mice were stimulated with the indicated TLR ligands at 
different concentrations for 24 hours. Supernatants were collected and analysed by 
ELISA for IL-6 release. Data is from one experiment. 
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Appendix D | Prostanoid production in Gata6-deficient pMϕs 
The loss of Ptgis expression in Gata6-deficient pMϕs is likely to affect the prostanoid 
profile produced in response to microbial ligands, which in turn will specify the 
inflammatory response. To address this, Dr Marcela Rosas analysed the major 
prostanoids produced by unstimulated and LPS-stimulated pMϕs from Gata6-WT and 
Gata6-KOmye mice by mass spectrometry, which showed significant changes in the 
lipid profile (Supplementary Figure 4 ). In accordance with the significant decrease 
in Ptgis expression, the production of PGI2 was significantly attenuated in LPS-
stimulated Gata6-deficient pMϕs (Supplementary Figure 4 ). Furthermore, the 
production of PGE2 was lower in Gata6-deficient pMϕs stimulated with LPS. 
Conversely, the production of TXB2 was significantly increased in LPS-stimulated 
Gata6-deficient pMϕs. 
 
Supplementary Figure 4 | PGI2 is significantly reduced in LPS-stimulated Gata6-
deficient pMϕs and TXB2 increased. 
pMϕs from Gata6-WT and Gata6-KOmye were either unstimulated or stimulated with 
100 ng ml-1 LPS. Supernatants were analysed by mass spectrometry for (A) 6-keto-
PGF1a, (B) TXB2, and (C) PGE2 release. This experiment was performed by Dr 
Marcela Rosas and is included because of its relevance. 
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Appendix E | Ptgs1 expression is significantly reduced in Gata6-deficient pMϕs 
 
Supplementary Figure 5 | Ptgs1 and Ptgs2 expression in pMϕs from Gata6-WT 
and Gata6-KOmye mice. 
Microarray expression of Ptgs1 and Ptgs2 in pMϕs from Gata6-WT and Gata6-KOmye 
mice. Data is expressed as mean ± S.D from three biological replicates. Statistical 
significance was determined using an empirical Bayesian statistic corrected for false 
discovery rate by the Benjamin-Hochberg procedure (*p < 0.05, **p < 0.01, ***p < 
0.001, ns = not significant). 
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